<SEC-DOCUMENT>0001193125-17-154107.txt : 20170502
<SEC-HEADER>0001193125-17-154107.hdr.sgml : 20170502
<ACCEPTANCE-DATETIME>20170502164554
ACCESSION NUMBER:		0001193125-17-154107
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		46
CONFORMED PERIOD OF REPORT:	20170331
FILED AS OF DATE:		20170502
DATE AS OF CHANGE:		20170502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Intellia Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001652130
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				364785571
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37766
		FILM NUMBER:		17805739

	BUSINESS ADDRESS:	
		STREET 1:		40 ERIE STREET
		STREET 2:		SUITE 130
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		857-285-6200

	MAIL ADDRESS:	
		STREET 1:		40 ERIE STREET
		STREET 2:		SUITE 130
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d378762d10q.htm
<DESCRIPTION>10-Q
<TEXT>
<HTML><HEAD>
<TITLE>10-Q</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">10-Q</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9746;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the quarterly period ended March&nbsp;31, 2017 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OR </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the transition period from
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> to
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-37766</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>INTELLIA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">36-4785571</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>40 Erie Street, Suite 130, Cambridge, Massachusetts</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>02139</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>(Zip code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">857-285-6200</FONT></FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90
days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the
registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> during the preceding
12 months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, smaller reporting company, or an emerging growth company. See definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company,&#148;
and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the
Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The number of shares outstanding
of the registrant&#146;s common stock as of April&nbsp;26, 2017: 36,028,677 shares. </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>&nbsp;&nbsp;&nbsp;&nbsp; </B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="97%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="4" ALIGN="center"><B><A HREF="#tx378762_1">PART I - FINANCIAL INFORMATION</A></B></TD>
<TD VALIGN="top"><B><A HREF="#tx378762_1"></A>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx378762_2"><B>Item 1.</B> <B>Financial Statements</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx378762_3">Consolidated Balance Sheets as of March 31, 2017 and December 31,
2016</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx378762_4">Consolidated Statements of Operations for the Three Months Ended March 31, 2017
 and 2016</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx378762_5">Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2017
 and 2016</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx378762_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx378762_7">Item 2. Management&#146;s Discussion and Analysis of Financial Condition and
 Results of Operations </A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx378762_8">Item 3. Quantitative and Qualitative Disclosures About Market Risk
</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx378762_9">Item 4. Controls and Procedures</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="4" ALIGN="center"><B><A HREF="#tx378762_10">PART II - OTHER INFORMATION</A></B></TD>
<TD VALIGN="top"><B><A HREF="#tx378762_10"></A>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx378762_11">Item 1A. Risk Factors</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx378762_12">Item 2. Unregistered Sales of Equity Securities and Use of
Proceeds</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx378762_13">Item 6. Exhibits</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx378762_14">Signatures</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx378762_1"></A>PART I &#150; FINANCIAL INFORMATION </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="tx378762_2"></A>Financial Statements </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx378762_3"></A>INTELLIA
THERAPEUTICS, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED BALANCE SHEETS (UNAUDITED) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="8" ALIGN="center"><B>ASSETS</B></TD>
<TD VALIGN="top"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">257,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">273,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">281,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">279,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">298,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="8" ALIGN="center"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY</B></TD>
<TD VALIGN="top"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; Equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value; 120,000,000 shares authorized, 36,025,676 shares and 36,018,540
shares issued and outstanding, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66,201</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,570</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">209,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Liabilities and Stockholders&#146; Equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">279,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">298,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx378762_4"></A>INTELLIA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,948</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,694</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,631</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,689</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9.89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx378762_5"></A>INTELLIA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CASH FLOWS FROM OPERATING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,631</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,689</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(954</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,893</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(134</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,278</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(778</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,823</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,398</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,421</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CASH FLOWS FROM INVESTING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,162</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,008</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,162</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,008</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CASH FLOWS FROM FINANCING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments to acquire <FONT STYLE="white-space:nowrap">in-process</FONT> research and
development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of preferred unit and preferred stock issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of common stock offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(895</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash provided by (used in) financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,195</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net decrease in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,513</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">257,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">64,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment unpaid at period end</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition of <FONT STYLE="white-space:nowrap">in-process</FONT> research and development unpaid
at period end</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing costs incurred but unpaid at period end</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx378762_6"></A>INTELLIA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Overview and Basis of Presentation </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intellia Therapeutics, Inc. (collectively referred to with its
wholly-owned, controlled subsidiary, Intellia Securities Corp., as &#147;Intellia&#148; or the &#147;Company&#148;) is a genome editing company focused on developing potentially curative therapeutics utilizing a biological tool known as CRISPR/Cas9.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the
Securities and Exchange Commission (&#147;SEC&#148;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America
(&#147;U.S.&#148;) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these consolidated financial statements should be read in conjunction with the financial statements and notes thereto
included in the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
unaudited consolidated financial statements include the accounts of Intellia Therapeutics, Inc. and its wholly-owned, controlled subsidiary. All intercompany balances and transactions have been eliminated in consolidation. In the opinion of
management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The Company considers events or transactions that
occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The three months ended March&nbsp;31, 2017 and
2016 are referred to as the first quarter of 2017 and 2016, respectively. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Summary of Significant Accounting Policies </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2014, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;) No. <FONT
STYLE="white-space:nowrap">2014-09,</FONT><I> Revenue from Contracts with Customers (Topic 606),</I><I></I> which supersedes existing revenue recognition guidance. The standard&#146;s core principle is that a company will recognize revenue when it
transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The standard defines a five-step process to achieve this principle
and will require companies to use more judgment and make more estimates than under the current guidance. The Company expects that these judgments and estimates will include identifying performance obligations in the customer contract, estimating the
amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU <FONT STYLE="white-space:nowrap">2014-09</FONT> also requires additional disclosure about the
nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. The FASB continues to address certain implementation issues and clarify certain core revenue recognition principles of ASU <FONT
STYLE="white-space:nowrap">2014-09.</FONT> In July 2015, the FASB voted to delay the effective date of this standard such that ASU <FONT STYLE="white-space:nowrap">2014-09,</FONT> as amended, will be effective for the Company for annual and interim
periods beginning after December&nbsp;15, 2017. Early adoption of the standard is permitted for annual periods beginning after December&nbsp;15, 2016. The Company continues to evaluate the impact that the adoption of these ASUs will have on its
consolidated financial statements; however, the Company does not expect that adoption of this standard will have a significant impact on the consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU No. <FONT STYLE="white-space:nowrap">2016-02,</FONT><I>&nbsp;Leases</I>. ASU
<FONT STYLE="white-space:nowrap">2016-02</FONT> amends ASC 840,<I>&nbsp;Leases</I>, by introducing a lessee model that requires balance sheet recognition of most leases. The Company is the lessee under certain leases that are accounted for as
operating leases. The proposed changes would require that substantially all of the Company&#146;s operating leases be recognized as assets and liabilities on the Company&#146;s balance sheet. ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> will
be effective for the Company for annual periods, and interim periods within those annual periods, beginning after December&nbsp;15, 2018. The Company is evaluating the impact that the adoption of ASU <FONT STYLE="white-space:nowrap">2016-02</FONT>
will have on its consolidated financial statements but expects that the Company will recognize a significant lease obligation upon adoption in connection with the Company&#146;s existing lease agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-09,</FONT> <I>Improvements to
Employee Share-Based Payment Accounting</I>. ASU <FONT STYLE="white-space:nowrap">2016-09</FONT> amends ASC 718, <I>Compensation &#150; Stock Compensation</I>, by simplifying certain aspects of the accounting for employee share-based payment
transactions, including the accounting for income taxes, forfeitures, statutory tax withholding requirements and the classification in the statement of cash flows. ASU <FONT STYLE="white-space:nowrap">2016-09</FONT> was adopted by the Company on
January&nbsp;1, 2017 and did not have a significant impact on its consolidated financial statements. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Fair Value Measurements </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company classifies fair value based measurements using a three-level
hierarchy that prioritizes the inputs used to measure fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as
follows: Level&nbsp;1, quoted market prices in active markets for identical assets or liabilities; Level&nbsp;2, observable inputs other than quoted market prices included in Level&nbsp;1, such as quoted market prices for markets that are not active
or other inputs that are observable or can be corroborated by observable market data; and Level&nbsp;3, unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities,
including certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s
financial instruments as of March&nbsp;31, 2017 and December&nbsp;31, 2016 consisted primarily of cash and cash equivalents, accounts receivable and accounts payable. As of March&nbsp;31, 2017 and December&nbsp;31, 2016, the Company&#146;s financial
assets recognized at fair value consisted of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value as of March&nbsp;31, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">255,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">255,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">255,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">255,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value as of December&nbsp;31, 2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">270,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">270,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">270,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">270,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Accrued Expenses </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee compensation and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development and professional expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Collaborations </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Novartis Institutes for BioMedical Research </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2014, the Company entered into a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. (&#147;Novartis&#148;)
primarily focused on the&nbsp;development of new<I> ex vivo</I>&nbsp;CRISPR/Cas9-based therapies using chimeric antigen receptor T cells <FONT STYLE="white-space:nowrap">(&#147;CAR-T</FONT> cells&#148;) and hematopoietic stem cells
(&#147;HSCs&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Agreement Structure </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the
terms of the collaboration, the Company and Novartis may research potential therapeutic, prophylactic and palliative <I>ex vivo</I> applications of the CRISPR/Cas9 technology in HSCs and <FONT STYLE="white-space:nowrap">CAR-T</FONT> cells. The
Company and Novartis agreed to conduct research of HSC targets under a research plan agreed upon by both parties. Within the HSC therapeutic space, Novartis may obtain exclusive rights to a limited number of these HSC targets, to be selected by
Novartis in a series of selection windows, the last of which closes 90 days before the fifth anniversary of the effective date of the collaboration agreement. The Company has the right to choose a limited number of HSC targets for its exclusive
development and commercialization per the specified selection schedule. Following these selections by Novartis and the Company, Novartis may obtain rights to research an additional limited number of HSC targets on a
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> basis. If Novartis does not exercise its selection rights within each selection window, any such rights will be deemed forfeited by Novartis. Novartis is required to use commercially reasonable
efforts to research, develop and commercialize a specified number of HSC products directed to each of their selected HSC targets. The Company also agreed to collaborate with Novartis on research activities for
<FONT STYLE="white-space:nowrap">CAR-T</FONT> cell targets pursuant to a <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell program research plan approved by the <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell subcommittee of the
collaboration&#146;s joint steering committee. After completion of the activities contemplated by the <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell program research plan, Novartis will assume sole responsibility for developing any products
arising from that research plan and will be responsible for additional costs and expenses of developing, manufacturing and commercializing its selected research targets. Novartis is required to use commercially reasonable efforts to research,
develop or commercialize at least one <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell product directed to at least one of its selected <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell targets. In the last two years of the five-year
collaboration term, Novartis will have the option to select a limited number of targets for research, development and commercialization of<I>&nbsp;in vivo</I>&nbsp;therapies using the Company&#146;s CRISPR/Cas9 platform, on a <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> basis. Following Novartis&#146; selection of each <I>in vivo</I> target, Novartis may offer the Company the right to participate in the research and development of such targets, in which case an <I>in
vivo</I> program research plan for such target will be entered into between the Company and Novartis. Novartis is required to use commercially reasonable efforts to research, develop or commercialize at least one<I>&nbsp;in vivo</I> product directed
to each of its selected targets. Novartis&#146;<I></I><I>&nbsp;in vivo</I>&nbsp;target selections are subject to certain restrictions, including that the targets, or all targets within a limited number of organs: (i)&nbsp;have not already been
reserved by the Company pursuant to our limited right to do so under the agreement; (ii)&nbsp;are not the subject of a collaboration or pending collaboration with a third party; and (iii)&nbsp;are not the subject of ongoing or planned research and
development by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company received an upfront technology access payment from Novartis of $10.0&nbsp;million in January&nbsp;2015 and is
entitled to additional technology access fees of $20.0&nbsp;million and quarterly research payments of $1.0&nbsp;million, or up to $20.0&nbsp;million in the aggregate, during the five-year research term. For each product under the collaboration,
subject to certain conditions, the Company may be eligible to receive (i)&nbsp;up to $30.3&nbsp;million in development milestones, including for the filing of an investigational new drug application and for the dosing of the first patient in each of
Phase IIa, Phase IIb and Phase III clinical trials, (ii)&nbsp;up to $50.0&nbsp;million in regulatory milestones for the product&#146;s first indication, including regulatory approvals in the U.S. and European Union (&#147;EU&#148;), (iii) up to
$50.0&nbsp;million in regulatory milestones for the product&#146;s second indication, if any, including U.S. and EU regulatory approvals, (iv)&nbsp;royalties on net sales in the <FONT STYLE="white-space:nowrap">mid-single</FONT> digits, and
(v)&nbsp;net sales milestone payments of up to $100.0&nbsp;million. The Company may also be eligible to receive payments for: (i)&nbsp;each additional HSC target selected by Novartis beyond its initial defined allocation, (ii)&nbsp;each<I>&nbsp;in
vivo</I>&nbsp;target that Novartis selects and (iii)&nbsp;any exercise by Novartis of certain license options under the agreement. Additionally, at the inception of the arrangement, Novartis invested $9.0&nbsp;million to purchase the Company&#146;s <FONT
STYLE="white-space:nowrap">Class&nbsp;A-1</FONT> and <FONT STYLE="white-space:nowrap">Class&nbsp;A-2</FONT> Preferred Units. The difference between the cash proceeds received from Novartis for the units and the $11.6&nbsp;million estimated fair
value of those units at the date of issuance was determined to be $2.6&nbsp;million. Accordingly, $2.6&nbsp;million of the upfront technology access payment was allocated to record the preferred units purchased by Novartis at fair value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration Revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through March&nbsp;31, 2017, excluding amounts allocated to Novartis&#146; purchase of the Company&#146;s
<FONT STYLE="white-space:nowrap">Class&nbsp;A-1</FONT> and <FONT STYLE="white-space:nowrap">Class&nbsp;A-2</FONT> Preferred Units, the Company had recorded a total of $26.4&nbsp;million in cash and accounts receivable under the Novartis agreement.
Through March&nbsp;31, 2017, the Company has recognized $16.0&nbsp;million of collaboration revenue, including $2.2&nbsp;million and $1.8&nbsp;million in the three months ended March&nbsp;31, 2017 and 2016, respectively, in the consolidated
statements of operations related to this agreement. As of March&nbsp;31, 2017 and December&nbsp;31, 2016, the Company had accounts receivable of $1.0&nbsp;million and $6.0&nbsp;million, respectively, related to this agreement. As of March&nbsp;31,
2017 and December&nbsp;31, 2016, the Company had deferred revenue of $10.4&nbsp;million and $11.6&nbsp;million, respectively, related to this agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regeneron Pharmaceuticals, Inc. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2016,
the Company entered into a license and collaboration agreement with Regeneron Pharmaceuticals, Inc. (&#147;Regeneron&#148;). The agreement includes a product component to research, develop and commercialize
<FONT STYLE="white-space:nowrap">CRISPR/Cas-based</FONT> therapeutic products primarily focused on gene editing in the liver as well as a technology collaboration component, pursuant to which the Company and Regeneron will engage in research and
development activities aimed at discovering and developing novel technologies and improvements to CRISPR/Cas technology to enhance the Company&#146;s gene editing platform. Under this agreement, the Company also may access the Regeneron Genetics
Center and proprietary mouse models to be provided by Regeneron for a limited number of the Company&#146;s liver programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Agreement Structure
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the collaboration, the Company and Regeneron have agreed to a target selection process, whereby Regeneron may obtain exclusive
rights for up to 10 targets to be chosen by Regeneron during the collaboration term, subject to various adjustments and limitations set forth in the agreement. Of these 10 total targets, Regeneron may select up to five
<FONT STYLE="white-space:nowrap">non-liver</FONT> targets, while the remaining targets must be focused in the liver. At the inception of the agreement, Regeneron selected the first of its 10 targets, which will be subject to a <FONT
STYLE="white-space:nowrap">co-development</FONT> and <FONT STYLE="white-space:nowrap">co-commercialization</FONT> arrangement between the Company and Regeneron. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company retains the exclusive right to solely develop products for certain indications. During the target selection process, the Company has the right to
choose additional liver targets for its own development using commercially reasonable efforts. Certain targets that either the Company or Regeneron select may be subject to further <FONT STYLE="white-space:nowrap">co-development</FONT> and <FONT
STYLE="white-space:nowrap">co-commercialization</FONT> arrangements at the Company&#146;s or Regeneron&#146;s option, as applicable, which either can exercise pursuant to defined conditions. In addition, subject to certain restrictions, Regeneron
will be able to replace a limited number of targets with substitute targets upon the payment of a specified replacement fee, in which case exclusive rights to the replaced target revert to the Company. Regeneron&#146;s target selections are subject
to certain additional restrictions, including that <FONT STYLE="white-space:nowrap">non-liver</FONT> targets are not the subject of ongoing or planned research and development by the Company or are not the subject of a collaboration or pending
collaboration with a third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research activities under the collaboration will be governed by evaluation and research and development plans that will
outline the parties&#146; responsibilities under, anticipated timelines of and budgets for, the various programs. The Company will assist Regeneron with the preliminary evaluation of liver targets, and Regeneron will be responsible for preclinical
research and the conduct of clinical development, manufacturing and commercialization of products directed to each of its exclusive targets under the oversight of a joint steering committee. The Company may assist, as requested by Regeneron, with
the later discovery and research of product candidates directed to any selected target. For each selected target, Regeneron is required to use commercially reasonable efforts to submit regulatory filings necessary to achieve initial investigational
new drug (&#147;IND&#148;) acceptance for at least one product directed to each applicable target, and following IND acceptance for at least one product, to develop and commercialize such product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this collaboration, Regeneron agreed to purchase $50.0&nbsp;million of the Company&#146;s common stock in a private placement concurrent
with the Company&#146;s initial public offering, and the Company received a nonrefundable upfront payment of $75.0&nbsp;million. In addition, the Company is eligible to earn, on a <FONT STYLE="white-space:nowrap">per-licensed</FONT> target basis,
(i)&nbsp;up to $25.0&nbsp;million in development milestones, including for the dosing of the first patient in each of Phase I, Phase II and Phase III clinical trials, (ii)&nbsp;up to $110.0&nbsp;million in regulatory milestones, including for the
acceptance of a regulatory filing in the U.S., and U.S. and <FONT STYLE="white-space:nowrap">ex-U.S.</FONT> regulatory approvals, and (iii)&nbsp;up to $185.0&nbsp;million in sales-based milestone payments. The Company is also eligible to earn
royalties ranging from the high single digits to low teens, in each case, on a <FONT STYLE="white-space:nowrap">per-product</FONT> basis, which royalties are potentially subject to various reductions and offsets and are further subject to the
Company&#146;s existing low single-digit royalty obligations under the Caribou license agreement. In addition, Regeneron is obligated to fund 50.0% of the agreed-upon research and development costs for the transthyretin amyloidosis program, the
first target selected by Regeneron, which will be subject to a <FONT STYLE="white-space:nowrap">co-development</FONT> and <FONT STYLE="white-space:nowrap">co-commercialization</FONT> arrangement between the Company and Regeneron. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fixed portion of consideration under the collaboration arrangement was determined to be the
$75.0&nbsp;million nonrefundable upfront payment, for which there are no contingent terms. The significant deliverables of this multiple-element revenue arrangement were determined to be licenses to targets, the associated research activities and
evaluation plans for these programs and the technology collaboration. The Company further determined that the licenses and associated research activities and evaluation plans did not have standalone value due to the specialized nature of the
services to be provided by the Company; therefore, these deliverables are not separable, and, accordingly, the license and services are treated as a single unit of accounting. The Company additionally concluded that the technology collaboration has
standalone value from the product development, as shared rights to technological advancements under the technology collaboration could be separately applied by Regeneron to other programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company allocated the $75.0&nbsp;million in fixed consideration to the two units of accounting based on the estimated relative selling price of each
deliverable. The Company estimated the selling price of each deliverable by taking into consideration internal estimates of research and development personnel needed to perform the research and development services, estimates of expected cash
outflows to third parties for services and supplies, selling prices of comparable transactions and typical gross profit margins. As a result of this evaluation, the Company allocated $63.8&nbsp;million to the licenses to targets and the associated
research activities and evaluation plans and $11.2&nbsp;million to the technology collaboration. The $63.8&nbsp;million allocated to the licenses to targets and the associated research activities and evaluation plans for these programs is being
recognized over the <FONT STYLE="white-space:nowrap">six-year</FONT> performance period of the arrangement. The $11.2&nbsp;million allocated to the technology collaboration is being recognized over a period beginning with the inception of the
technology collaboration in September 2016, through the end of the arrangement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration Revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through March&nbsp;31, 2017, the Company recorded a $75.0&nbsp;million upfront payment and $1.4&nbsp;million for research and development services under the
Regeneron agreement. Through March&nbsp;31, 2017, the Company recognized $12.8&nbsp;million of collaboration revenue, including $4.1&nbsp;million in the three months ended March&nbsp;31, 2017, in the consolidated statement of operations. As of
March&nbsp;31, 2017 and December&nbsp;31, 2016, the Company had deferred revenue of $63.6&nbsp;million and $66.7&nbsp;million, respectively, related to this agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Equity-Based Compensation </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equity-based compensation expense is classified in the consolidated
statements of operations as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#146;s restricted stock activity, including converted Founder Stock, for the three months ended March&nbsp;31, 2017:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average&nbsp;Grant</B><br><B>Date&nbsp;Fair&nbsp;Value</B><br><B>per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted stock as of January&nbsp;1, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,361,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(186,917</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted stock as of March&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,174,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2017, there was $2.7&nbsp;million of unrecognized equity-based compensation expense related to restricted
stock that is expected to vest. These costs are expected to be recognized over a weighted average remaining vesting period of 1.8 years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock
Options </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The weighted average grant date fair value of options, estimated as of the grant date using the Black-Scholes option pricing model, was
$10.38 per option and $4.98 per option for those options granted during the three months ended March&nbsp;31, 2017 and 2016, respectively. Key assumptions used to apply this pricing model were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended</B><br><B>March&nbsp;31, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended</B><br><B>March&nbsp;31, 2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life of options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.0&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.0&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility of underlying stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of stock option activity for the three months ended March&nbsp;31, 2017: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Exercise</B><br><B>Price per</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Remaining</B><br><B>Contractual</B><br><B>Term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Intrinsic</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(In years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(In&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at January&nbsp;1, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,040,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,343,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,136</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,284</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at March&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,373,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at March&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">780,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2017, there was $25.0&nbsp;million of unrecognized compensation cost related to stock options that are
expected to vest. These costs are expected to be recognized over a weighted average remaining vesting period of 3.2 years. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Loss Per Share </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company calculates basic (loss) earnings per share by dividing (loss) income
allocable to common stockholders by the weighted average number of common shares outstanding. The Company computes diluted (loss) earnings per share after giving consideration to the dilutive effect of preferred stock, common stock and restricted
common stock that are outstanding during the period, except where such <FONT STYLE="white-space:nowrap">non-participating</FONT> securities would be anti-dilutive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic and diluted loss per share attributable to common stockholders was calculated as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In&nbsp;thousands&nbsp;except&nbsp;per&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,631</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,689</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9.89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2016, the Company issued an additional 6,900,000 shares of common stock in connection with its initial public offering
(&#147;IPO&#148;) and 23,481,956 shares of common stock in connection with the automatic conversion of its convertible preferred stock upon the closing of the IPO. In addition, the Company issued a total of 3,055,554 shares of common stock in two
separate, concurrent private placements upon the closing of the IPO. The issuance of these shares resulted in a significant increase in the Company&#146;s weighted average shares outstanding and will impact the year-over-year comparability of the
Company&#146;s (loss) earnings per share calculations into 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following common stock equivalents were excluded from the calculation of diluted
loss per share because their inclusion would have been anti-dilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Related Party Transactions </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2014, the Company issued Caribou Therapeutics Holdco, LLC, a
wholly-owned subsidiary of Caribou Biosciences, Inc. (&#147;Caribou&#148;), 8,110,599 Junior Preferred Units. As a result of this and related transactions, Caribou owned 15.5% of the Company&#146;s voting interests as of March&nbsp;31, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognized research and development expense of $0.4&nbsp;million during the three months ended March&nbsp;31, 2016 and an insignificant amount
during the three months ended March&nbsp;31, 2017, related to license and service agreements entered into with Caribou. In addition, the Company recognized general and administrative expense of $0.2&nbsp;million during the three months ended
March&nbsp;31, 2016 and an insignificant amount during the three months ended March&nbsp;31, 2017, related to the Company&#146;s obligation to pay 30.0% of Caribou&#146;s patent prosecution, filing and maintenance costs under its intellectual
property license agreement with Caribou. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with its entry into the collaboration and license agreement and related equity transactions with
Novartis, the Company issued Novartis 4,761,905 <FONT STYLE="white-space:nowrap">Class&nbsp;A-1</FONT> Preferred Units and 2,666,666 <FONT STYLE="white-space:nowrap">Class&nbsp;A-2</FONT> Preferred Units. In August 2015, Novartis acquired 761,905
shares of the Company&#146;s Series B Preferred Stock, and in May 2016, Novartis acquired 277,777 shares of the Company&#146;s common stock in a private placement transaction concurrent with the Company&#146;s IPO. As a result of these and
subsequent transactions, Novartis collectively owned 15.7% of the Company&#146;s voting interests as of March&nbsp;31, 2017. Refer to Note 5, <I>Collaborations</I>, for additional information regarding this collaboration agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognized collaboration revenue of $2.2&nbsp;million and $1.8&nbsp;million in the three months ended March&nbsp;31, 2017 and 2016, respectively,
in the consolidated statements of operations related to this agreement. As of March&nbsp;31, 2017 and December&nbsp;31, 2016, the Company had recorded accounts receivable of $1.0&nbsp;million and $6.0&nbsp;million and deferred revenue of
$10.4&nbsp;million and $11.6&nbsp;million, respectively, related to this collaboration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B><A NAME="tx378762_7"></A>Item&nbsp;2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Forward-looking Information </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This Quarterly
Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> contains forward-looking statements which are made pursuant to the safe harbor provisions of Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the
Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). These statements may be identified by such forward-looking terminology as &#147;may,&#148; &#147;should,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;plans,&#148;
&#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148; &#147;continue&#148; or the negative of these terms or other comparable terminology. Our forward-looking statements are based on a
series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions or expectations
disclosed in our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Our business and our forward-looking statements involve
substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding: </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>the initiation, timing, progress and results of our research and development programs and future preclinical and clinical studies;</I> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>our ability to apply a risk-mitigated strategy to efficiently discover and develop product candidates, including by applying learnings from one program to other programs;</I> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>our ability to create a pipeline of product candidates;</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>our ability to advance any product candidates into, and successfully complete, clinical studies;</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>our ability to advance our therapeutic delivery capabilities;</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;</I> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>our ability to operate, including commercializing products, without infringing the proprietary rights of others;</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>the issuance of regulatory guidance regarding preclinical and clinical studies for gene editing products;</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>the timing or likelihood of regulatory filings and approvals;</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>the commercialization of our product candidates, if approved;</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>the pricing and reimbursement of our product candidates, if approved;</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>the implementation of our business model, strategic plans for our business, product candidates and technology;</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>estimates of our expenses, future revenues, capital requirements and our needs for additional financing;</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements;</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>our ability to maintain and establish collaborations and licenses or obtain additional funding;</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>our financial performance;</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>developments relating to our competitors and our industry; and</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>other risks and uncertainties, including those listed under the caption &#147;Risk Factors.&#148;</I> </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>All of our forward-looking statements are as of the date of this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> only. In each case,
actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of or any material adverse change in one or more of the
risk factors or risks and uncertainties referred to in this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or included in our other public disclosures or our other periodic reports or other documents or filings filed with or
furnished to the Securities and Exchange Commission (the SEC) could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise
any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q,</FONT> even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> that modify or impact any of the forward-looking statements contained in this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> will be deemed to modify or supersede such statements in this
Quarterly Report on Form 10-Q. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management Overview </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intellia Therapeutics, Inc. (&#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;Intellia,&#148; or the &#147;Company&#148;) is a leading genome editing
company focused on the development of proprietary, potentially curative therapeutics utilizing a biological tool known as CRISPR/Cas9. We believe that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing
disease-associated genes or genetic material in the human body with a single treatment course. We intend to leverage our leading scientific expertise, clinical development experience and intellectual property position to unlock broad therapeutic
applications of CRISPR/Cas9 genome editing and develop a potential new class of therapeutic products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management&#146;s discussion and analysis of
our financial condition and results of operations are based upon our unaudited consolidated financial statements included in this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> which have been prepared by us in accordance
with accounting principles generally accepted in the United States of America, (GAAP), for interim periods and with Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> promulgated under the Exchange Act. This discussion and analysis should be
read in conjunction with these unaudited consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> as well as in conjunction with the audited financial
statements and notes thereto included in the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016. The three months ended March&nbsp;31, 2017 and 2016 are referred to as the
first quarter of 2017 and 2016, respectively. Unless the context indicates otherwise, all references herein to our company include our wholly-owned subsidiary, Intellia Securities Corp. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We commenced active operations in <FONT STYLE="white-space:nowrap">mid-2014,</FONT> and our operations to date have been limited to organizing and staffing
our company, business planning, raising capital, developing our technology, identifying potential product candidates, undertaking preclinical research and studies and evaluating a clinical path for our pipeline programs. To date, we have financed
our operations primarily through our collaborations with Novartis Institutes for BioMedical Research, Inc., (Novartis), and Regeneron Pharmaceuticals, Inc., (Regeneron), our initial public offering and private placements of our common and preferred
stock. All of our revenue to date has been collaboration revenue. Since our inception and through March&nbsp;31, 2017, we have raised an aggregate of approximately $358.6&nbsp;million to fund our operations, of which $103.1&nbsp;million was through
our collaboration agreements, $170.5&nbsp;million was from our initial public offering and concurrent private placements and $85.0&nbsp;million was from the sale of convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe our product focus, therapeutic discovery and development strength, delivery expertise and intellectual property portfolio make us well-positioned
to translate the potential of the CRISPR/Cas9 system into clinically meaningful genome editing-based therapeutics. To maximize our opportunity to rapidly develop clinically successful products, we are applying a risk-mitigating approach with our
initial indications, which we refer to as our sentinel indications. Our approach is defined by four primary criteria: (i)&nbsp;the type of edit&#151;knockout, repair or insertion; (ii)&nbsp;the delivery modality for <I>in vivo</I> and <I>ex vivo</I>
applications; (iii)&nbsp;the presence of established therapeutic endpoints; and (iv)&nbsp;the potential for the CRISPR/Cas9 system to provide therapeutic benefits when compared to existing therapeutic modalities. Our sentinel indications include
<I>in vivo</I> programs focused on diseases attributable to genes expressed in the liver that have significant unmet medical needs &#150; transthyretin amyloidosis, which we are <FONT STYLE="white-space:nowrap">co-developing</FONT> with Regeneron,
chronic hepatitis B infection, <FONT STYLE="white-space:nowrap">alpha-1</FONT> antitrypsin deficiency and inborn errors of metabolism, including primary hyperoxaluria &#150; as well as <I>ex vivo</I> applications of the technology in chimeric
antigen receptor T cell <FONT STYLE="white-space:nowrap">(CAR-T</FONT> cell) and hematopoietic stem cell (HSC), product candidates which are selectively partnered with our collaborator Novartis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table illustrates our discovery programs and opportunities as of March&nbsp;31, 2017: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g378762g57k66.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaborations </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Novartis</I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In December 2014, we entered into a strategic collaboration agreement
with Novartis, primarily focused on the development of new<I>&nbsp;ex vivo</I> CRISPR/Cas9-based therapies using <FONT STYLE="white-space:nowrap">CAR-T</FONT> cells and HSCs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Agreement Structure</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Under the terms of the collaboration, we and Novartis may research potential therapeutic, prophylactic and palliative <I>ex vivo
</I>applications of our CRISPR/Cas9 technology in HSCs and <FONT STYLE="white-space:nowrap">CAR-T</FONT> cells. We and Novartis agreed to conduct research of HSC targets under a research plan agreed upon by both parties. Within the HSC therapeutic
space, Novartis may obtain exclusive rights to a limited number of these HSC targets, to be selected by Novartis in a series of selection windows. We have the right to choose a limited number of HSC targets for our exclusive development and
commercialization per the specified selection schedule. Following these selections by Novartis and us, Novartis may obtain rights to research an additional limited number of HSC targets on a <FONT STYLE="white-space:nowrap">non-exclusive</FONT>
basis. Novartis is required to use commercially reasonable efforts to research, develop, and commercialize a specified number of HSC products directed to each of their selected HSC targets. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">We have also agreed to collaborate with Novartis on research activities for <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell targets pursuant
to the <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell program research plan approved by the <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell subcommittee of the collaboration&#146;s joint steering committee. After completion of the activities
contemplated by the <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell program research plan, Novartis will assume sole responsibility for developing any products arising from that research plan and the costs and expenses of developing,
manufacturing and commercializing its selected research targets. Novartis is required to use commercially reasonable efforts to research, develop or commercialize at least one <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell product directed to
each of its selected <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell targets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In the last two years of the five-year collaboration term, Novartis will have the option to
select a limited number of targets for research, development and commercialization of<I>&nbsp;in vivo</I>&nbsp;therapies using our CRISPR/Cas9 platform, on a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> basis. Following Novartis&#146;
selection of each<I>&nbsp;in vivo</I>&nbsp;target, Novartis may offer us the right to participate in the research and development of such targets, in which case an<I>&nbsp;in vivo</I>&nbsp;program research plan for such target will be entered into
between us and Novartis. Novartis is required to use commercially reasonable efforts to research, develop and commercialize at least one<I>&nbsp;in vivo</I>&nbsp;product directed to each of its selected<I>&nbsp;in vivo</I>&nbsp;targets.
Novartis&#146;<I></I><I>&nbsp;in vivo</I>&nbsp;target selections are subject to certain restrictions, including that the targets, or all targets within a limited number of organs: (i)&nbsp;have not already been reserved by us pursuant to our limited
right to do so under the agreement; (ii)&nbsp;are not the subject of a collaboration or pending collaboration with a third party; and (iii)&nbsp;are not the subject of ongoing or planned research and development by us. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Under the agreement, we received an upfront technology access payment of $10.0&nbsp;million and are entitled to additional technology access
fees of $20.0&nbsp;million and quarterly research payments of $1.0&nbsp;million, or up to $20.0&nbsp;million in the aggregate, during the five-year research term. In addition, for each product under the collaboration, subject to certain conditions,
we may be eligible to receive (i)&nbsp;up to $30.3&nbsp;million in development milestones, including for the filing of an investigational new drug application and for the dosing of the first patient in each of Phase IIa, Phase IIb and Phase III
clinical trials, (ii)&nbsp;up to $50.0&nbsp;million in regulatory milestones for the product&#146;s first indication, including regulatory approvals in the United States, (U.S.), and the European Union (EU), (iii) up to $50.0&nbsp;million in
regulatory milestones for the product&#146;s second indication, if any, including U.S. and EU regulatory approvals, (iv)&nbsp;royalties on net sales in the <FONT STYLE="white-space:nowrap">mid-single</FONT> digits, and (v)&nbsp;net sales milestone
payments of up to $100.0&nbsp;million. We may also be eligible to receive payments for: (i)&nbsp;each additional HSC target selected by Novartis beyond its initial defined allocation, (ii)&nbsp;each<I>&nbsp;in vivo</I>&nbsp;target that Novartis
selects and (iii)&nbsp;any exercise by Novartis of certain license options under the agreement. Additionally, at the inception of the arrangement, Novartis invested $9.0&nbsp;million to purchase our
<FONT STYLE="white-space:nowrap">Class&nbsp;A-1</FONT> and <FONT STYLE="white-space:nowrap">Class&nbsp;A-2</FONT> Preferred Units. The difference between the cash proceeds received from Novartis for the units and the $11.6&nbsp;million estimated
fair value of those units at the date of issuance was determined to be $2.6&nbsp;million. Accordingly, $2.6&nbsp;million of the upfront technology access payment was allocated to record the preferred units purchased by Novartis at fair value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Collaboration Revenue</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Through March&nbsp;31, 2017, excluding amounts allocated to Novartis&#146; purchase of our
<FONT STYLE="white-space:nowrap">Class&nbsp;A-1</FONT> and <FONT STYLE="white-space:nowrap">Class&nbsp;A-2</FONT> Preferred Units, we had recorded a total of $26.4&nbsp;million in cash and accounts receivable under the Novartis agreement. Through
March&nbsp;31, 2017, we have recognized $16.0&nbsp;million of collaboration revenue, including $2.2&nbsp;million and $1.8&nbsp;million in the three months ended March&nbsp;31, 2017 and 2016, respectively, in the consolidated statements of operations
related to this agreement. As of March&nbsp;31, 2017 and December&nbsp;31, 2016, we had deferred revenue of $10.4&nbsp;million and $11.6&nbsp;million, respectively, related to this agreement. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Regeneron</I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In April 2016, we entered into a license and collaboration agreement
with Regeneron. The agreement includes a product component to research, develop and commercialize <FONT STYLE="white-space:nowrap">CRISPR/Cas-based</FONT> therapeutic products primarily focused on gene editing in the liver as well as a technology
collaboration component, pursuant to which we and Regeneron will engage in research and development activities aimed at discovering and developing novel technologies and improvements to CRISPR/Cas technology to enhance our gene editing platform.
Under this agreement, we also may access the Regeneron Genetics Center and proprietary mouse models to be provided by Regeneron for a limited number of our liver programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Agreement Structure</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Under the terms of our collaboration, we and Regeneron have agreed to a target selection process, whereby Regeneron may obtain exclusive rights
for up to 10 targets to be chosen by Regeneron during the collaboration term, subject to various adjustments and limitations set forth in the agreement. Of these 10 total targets, Regeneron may select up to five
<FONT STYLE="white-space:nowrap">non-liver</FONT> targets, while the remaining targets must be focused in the liver. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">At the inception of the agreement, Regeneron selected the first of its 10 targets, which will be
subject to a <FONT STYLE="white-space:nowrap">co-development</FONT> and <FONT STYLE="white-space:nowrap">co-commercialization</FONT> arrangement between us and Regeneron. We retain the exclusive right to solely develop products for certain
indications. During the target selection process, we have the right to choose additional liver targets for our own development using commercially reasonable efforts. Certain targets that either we or Regeneron select may be subject to further <FONT
STYLE="white-space:nowrap">co-development</FONT> and <FONT STYLE="white-space:nowrap">co-commercialization</FONT> arrangements at our or Regeneron&#146;s option, as applicable, which either can exercise pursuant to defined conditions. In addition,
subject to certain restrictions, Regeneron will be able to replace a limited number of targets with substitute targets upon the payment of a specified replacement fee, in which case exclusive rights to the replaced target revert to us.
Regeneron&#146;s target selections are subject to certain additional restrictions, including that <FONT STYLE="white-space:nowrap">non-liver</FONT> targets are not the subject of ongoing or planned research and development by us or are not the
subject of a collaboration or pending collaboration with a third party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Research activities under the collaboration will be governed by
evaluation and research and development plans that will outline the parties&#146; responsibilities under, anticipated timelines of and budgets for, the various programs. We will assist Regeneron with the preliminary evaluation of liver targets, and
Regeneron will be responsible for preclinical research and the conduct of clinical development, manufacturing and commercialization of products directed to each of its exclusive targets under the oversight of a joint steering committee. We may
assist, as requested by Regeneron, with the later discovery and research of product candidates directed to any selected target. For each selected target, Regeneron is required to use commercially reasonable efforts to submit regulatory filings
necessary to achieve initial investigational new drug (IND) acceptance for at least one product directed to each applicable target, and following IND acceptance for at least one product, to develop and commercialize such product. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In connection with this collaboration, Regeneron agreed to purchase $50.0&nbsp;million of our common stock in a private placement, concurrent
with our initial public offering, and we received a nonrefundable upfront payment of $75.0&nbsp;million. In addition, we are eligible to earn, on a <FONT STYLE="white-space:nowrap">per-licensed</FONT> target basis, up to $25.0&nbsp;million,
$110.0&nbsp;million and $185.0&nbsp;million in development, regulatory and sales-based milestone payments, respectively. We are also eligible to earn royalties ranging from the high single digits to low teens, in each case, on a <FONT
STYLE="white-space:nowrap">per-product</FONT> basis, which royalties are potentially subject to various reductions and offsets and are further subject to our existing low single-digit royalty obligations under a license agreement with Caribou
Biosciences, Inc. (&#147;Caribou&#148;). In addition, Regeneron is obligated to fund 50.0% of the agreed-upon research and development costs for the ATTR program, the first target selected by Regeneron, which will be subject to a <FONT
STYLE="white-space:nowrap">co-development</FONT> and <FONT STYLE="white-space:nowrap">co-commercialization</FONT> arrangement between us and Regeneron. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Collaboration Revenue</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Through March&nbsp;31, 2017, we have recorded a $75.0&nbsp;million upfront payment and $1.4&nbsp;million for research and development services
under the Regeneron agreement. Through March&nbsp;31, 2017, we recognized $12.8&nbsp;million of collaboration revenue, including $4.1&nbsp;million in the three months ended March&nbsp;31, 2017, in the consolidated statement of operations. As of
March&nbsp;31, 2017 and December&nbsp;31, 2016, we had deferred revenue of $63.6&nbsp;million and $66.7&nbsp;million, respectively, related to this agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Results of Operations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration Revenue
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a comparison of collaboration revenue for the three months ended March&nbsp;31, 2017 and 2016: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our revenue consists of collaboration revenue, including amounts recognized related to upfront technology access payments for
licenses, technology access fees, research funding and milestone payments earned under our collaboration and license agreement with Novartis and amounts recognized related to upfront payments and research and development services under our
collaboration and license agreement with Regeneron. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the three months ended March&nbsp;31, 2017, collaboration revenue consisted of amounts recognized from
deferred revenue related to upfront technology access payments for licenses, technology access fees and research funding under the Novartis collaboration as well as amounts recognized from deferred revenue related to an upfront payment received and
amounts for research and development services under the Regeneron collaboration. During the three months ended March&nbsp;31, 2016, collaboration revenue consisted of amounts recognized from deferred revenue related to upfront technology access
payments for licenses, technology access fees and research funding under the Novartis collaboration. The increase in collaboration revenue during the three months ended March&nbsp;31, 2017 is related to the recognition of amounts under the Regeneron
collaboration, which was entered into in April 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a comparison of research and development expenses for the three months ended March&nbsp;31, 2017 and 2016: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses consist of expenses incurred in performing research and development activities, including
compensation and benefits, which includes equity-based compensation, for full-time research and development employees, facility-related expenses, overhead expenses, lab supplies and contract research services including, in 2016, research services
provided to us by Caribou, pursuant to a services agreement that we entered into with Caribou in July 2014 and which expired in November 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research
and development expenses increased $8.2&nbsp;million to $13.4&nbsp;million during the three months ended March&nbsp;31, 2017, as compared to $5.2&nbsp;million in the three months ended March&nbsp;31, 2016. This increase is primarily driven by our
growth to 88 research and development employees as of March&nbsp;31, 2017 from 44 research and development employees as of March&nbsp;31, 2016, and the advancement of our early-stage research programs, collectively resulting in increases in salaries
and related compensation expenses as well as laboratory supplies and research materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through 2017, we expect research and development expenses to
increase as we continue to grow our research and development team and continue to advance our research plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a comparison of general and administrative expenses for the three months ended March&nbsp;31, 2017 and 2016: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of salaries and benefits, including equity-based compensation, for our
executive, finance, legal, business development and support functions. Other general and administrative expenses include allocated facility-related costs not otherwise included in research and development expenses, travel expenses and professional
fees for auditing, tax and legal services, including intellectual property-related legal services, and other consulting fees and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and
administrative expenses increased $2.5&nbsp;million to $5.7&nbsp;million during the three months ended March&nbsp;31, 2017, compared to $3.2&nbsp;million in the three months ended March&nbsp;31, 2016, primarily related to increased salary and
related headcount-based expenses, including equity-based compensation expense, as we grew to 31 general and administrative employees as of March&nbsp;31, 2017 from 17 general and administrative employees as of March&nbsp;31, 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest Income </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest income is income earned on our cash equivalents. The increase in interest income is due to the increase in interest-bearing money market accounts,
commercial paper and U.S. treasury securities, as compared to the same period in the prior year. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our inception through March&nbsp;31, 2017, we have raised an aggregate of $358.6&nbsp;million to fund our operations, of which $103.1&nbsp;million was
through our collaboration agreements, $170.5&nbsp;million was from our initial public offering and concurrent private placements and $85.0&nbsp;million was from the sale of convertible preferred stock. As of March&nbsp;31, 2017, we had
$257.6&nbsp;million in cash and cash equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we are entitled to receive technology access fees and research payments under our
collaboration with Novartis and are also eligible to earn a significant amount of milestone payments and royalties, in each case, on a <FONT STYLE="white-space:nowrap">per-product</FONT> basis under our collaboration with Novartis and on a <FONT
STYLE="white-space:nowrap">per-target</FONT> basis under our collaboration with Regeneron. Our ability to earn these milestones and the timing of achieving these milestones is dependent upon the outcome of our research and development activities and
is uncertain at this time. Our rights to payments under our collaboration agreements are our only committed external source of funds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding
Requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our primary uses of capital are, and we expect will continue to be, research and development services, compensation and related
expenses, laboratory and related supplies, legal and other regulatory expenses, patent prosecution filing and maintenance costs for our licensed intellectual property and general overhead costs. Through 2017, we expect our expenses to increase
compared to prior periods in connection with our ongoing activities, particularly as we continue research and development and preclinical activities and spend a full year occupying our new office and laboratory facility, which we began to occupy in
the fourth quarter of 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because our research programs are still in preclinical development and the outcome of these efforts is uncertain, we cannot
estimate the actual amounts necessary to successfully complete the development and commercialization of any future product candidates or whether, or when, we may achieve profitability. Until such time, as we can generate substantial product
revenues, if ever, we expect to finance our ongoing cash needs through equity financings and collaboration arrangements. We are entitled to technology access fees and research payments under our collaboration with Novartis. Additionally, we are
eligible to earn milestone payments and royalties, in each case, on a <FONT STYLE="white-space:nowrap">per-product</FONT> basis under our collaboration with Novartis and on a <FONT STYLE="white-space:nowrap">per-target</FONT> basis under our
collaboration with Regeneron. Except for these sources of funding, we will not have any committed external source of liquidity. To the extent that we raise additional capital through the future sale of equity, the ownership interest of our
stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders. If we raise additional funds through collaboration arrangements in the
future, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity financings when
needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Outlook </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on our research and development
plans and our timing expectations related to the progress of our programs, we expect that our cash and cash equivalents as of March&nbsp;31, 2017, as well as technology access and research funding that we expect to receive from Novartis, will enable
us to fund our ongoing operating expenses and capital expenditures through <FONT STYLE="white-space:nowrap">mid-2019,</FONT> without giving effect to any potential milestone payments or extension fees we may receive under our collaboration
agreements with Novartis and Regeneron. We have based this estimate on current assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to generate revenue and achieve profitability depends significantly on our success in many areas, including: developing our delivery technologies
and our CRISPR/Cas9 technology platform; selecting appropriate product candidates to develop; completing research and preclinical and clinical development of selected product candidates; obtaining regulatory approvals and marketing authorizations
for product candidates for which we complete clinical trials; developing a sustainable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and scalable manufacturing process for product candidates; launching and commercializing product candidates for which we obtain regulatory approvals and marketing authorizations, either directly
or with a collaborator or distributor; obtaining market acceptance of our product candidates; addressing any competing technological and market developments; negotiating favorable terms in any collaboration, licensing, or other arrangements into
which we may enter; maintaining good relationships with our collaborators and licensors; maintaining, protecting, and expanding our portfolio of intellectual property rights, including patents, trade secrets, and
<FONT STYLE="white-space:nowrap">know-how;</FONT> and attracting, hiring, and retaining qualified personnel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of cash flows for the three months ended March&nbsp;31, 2017 and 2016: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net cash used in operating activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities of $11.4&nbsp;million during the three months ended March&nbsp;31, 2017 primarily reflects increased spend in our
research and development and general and administrative activities, offset in part by the receipt of $6.0&nbsp;million in additional payments from Novartis. Net cash used in operating activities of $9.4&nbsp;million during the three months ended
March&nbsp;31, 2016 reflects spend in our research and development and general and administrative activities as well as the payment of a $2.2&nbsp;million security deposit for our new office and laboratory facilities in Cambridge, Massachusetts.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net cash used in investing activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used
in investing activities during the three months ended March&nbsp;31, 2017 and 2016 relate solely to purchases of property and equipment as we grow our operations and build out our office and laboratory facilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net cash provided by (used in) financing activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net
cash provided by financing activities in the three months ended March&nbsp;31, 2017 is made up of $47,000 in cash received from the exercise of stock options. Net cash used in financing activities of $1.2&nbsp;million during the three months ended
March&nbsp;31, 2016 includes the payment of public offering costs, preferred stock issuance costs from our Series B Preferred stock financing in 2015 and amounts paid that were allocated to the value of intellectual property licensed from Caribou.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our critical
accounting policies require the most significant judgments and estimates in the preparation of our consolidated financial statements. Management has determined that our most critical accounting policies are those relating to revenue recognition and
equity-based compensation. There have been no significant changes to our critical accounting policies discussed in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2014, the
Financial Accounting Standards Board (FASB), issued Accounting Standards Update (ASU) <FONT STYLE="white-space:nowrap">No.&nbsp;2014-09,</FONT><I>&nbsp;Revenue from Contracts with Customers (Topic 606),</I><I></I>&nbsp;which supersedes existing
revenue recognition guidance. The standard&#146;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be
entitled in exchange for those goods or services. The standard defines a five-step process to achieve this principle and will require companies to use more judgment and make more estimates than under the current guidance. We expect that these
judgments and estimates will include identifying performance obligations in the customer contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance
obligation. ASU <FONT STYLE="white-space:nowrap">2014-09</FONT> also requires additional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. The FASB continues to address certain implementation issues and clarify
certain core revenue recognition principles of ASU <FONT STYLE="white-space:nowrap">2014-09.</FONT> In July 2015, the FASB voted to delay the effective date of this standard such that ASU <FONT STYLE="white-space:nowrap">2014-09,</FONT> as amended
by ASU <FONT STYLE="white-space:nowrap">2016-10,</FONT> will be effective for us for annual and interim periods beginning after December&nbsp;15, 2017. Early adoption of the standard is permitted for annual periods beginning after December&nbsp;15,
2016. We continue to evaluate the impact that the adoption of these ASUs will have on our consolidated financial statements; however, we do not expect that adoption of this standard will have a significant impact on our consolidated financial
statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT><I>&nbsp;Leases</I>. ASU <FONT
STYLE="white-space:nowrap">2016-02</FONT> amends ASC 840,<I>&nbsp;Leases</I>, by introducing a lessee model that requires balance sheet recognition of most leases. We are the lessee under certain leases that are accounted for as operating leases.
The proposed changes would require that substantially all of our operating leases be recognized as assets and liabilities on our balance sheet. ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> will be effective for us for annual periods, and
interim periods within those annual periods, beginning after December&nbsp;15, 2018. We are evaluating the impact that the adoption of ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> will have on our consolidated financial statements but expect
that we will recognize a significant lease obligation upon adoption in connection with our existing lease agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2016, the FASB issued ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2016-09,</FONT> <I>Improvements to Employee Share-Based Payment Accounting</I>. ASU <FONT STYLE="white-space:nowrap">2016-09</FONT> amends ASC 718, <I>Compensation &#150; Stock Compensation</I>, by simplifying
certain aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, statutory tax withholding requirements and the classification in the statement of cash flows. ASU <FONT
STYLE="white-space:nowrap">2016-09</FONT> was adopted ASU <FONT STYLE="white-space:nowrap">2016-09</FONT> on January&nbsp;1, 2017 and did not have a material impact on our consolidated financial statements </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no material changes
to our contractual obligations during the three months ended March&nbsp;31, 2017. For a complete discussion of our contractual obligations, please refer to our <I>Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations</I> in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We did not have during the periods presented, and we do not currently have, any <FONT
STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements as defined under the rules and regulations of the Securities and Exchange Commission. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B><A NAME="tx378762_8"></A>Item&nbsp;3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Quantitative and Qualitative Disclosures About Market Risk </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market risk inherent in our financial
instruments and in our financial position represents the potential loss arising from adverse changes in interest rates. As of March&nbsp;31, 2017, we had cash equivalents of $255.7&nbsp;million consisting of interest-bearing money market accounts,
commercial paper and U.S. treasury securities. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term maturities of our cash equivalents and
the low risk profile of these investments, an immediate 100 basis point change in interest rates at levels as of March&nbsp;31, 2017 would not have a material effect on the fair market value of our cash equivalents. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B><A NAME="tx378762_9"></A>Item&nbsp;4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Controls and Procedures </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Disclosure Controls and Procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has established disclosure controls and procedures designed to ensure that information required to be disclosed in the reports that the Company
files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#146;s rules and forms and is accumulated and communicated to management, including the principal executive officer
(our Chief Executive Officer) and principal financial officer (our Chief Financial Officer), to allow timely decisions regarding required disclosure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules
<FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e)</FONT> under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Exchange Act) as of the end of the period covered by this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> Management recognizes that any disclosure controls and
procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives. Our disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives. Based
on such evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of March&nbsp;31, 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Changes in Internal Control over Financial Reporting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No
change in the Company&#146;s internal control over financial reporting (as defined in Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f)</FONT> under the Exchange Act) occurred during the three
months ended March&nbsp;31, 2017 that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx378762_10"></A>PART II - OTHER INFORMATION </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx378762_11"></A>Item&nbsp;1A.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Risk Factors </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investing in our common stock involves a high degree of risk. Careful consideration should
be given to the following risk factors, in addition to the other information set forth in this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year
ended December&nbsp;31, 2016 and in other documents that we file with the SEC, in evaluating the Company and our business. If any of the following risks and uncertainties actually occurs, our business, prospects, financial condition and results of
operations could be materially and adversely affected. The risks described below are not intended to be exhaustive and are not the only risks facing the Company. New risk factors can emerge from time to time, and it is not possible to predict the
impact that any factor or combination of factors may have on our business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to
Our Business, Technology and Industry </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>CRISPR/Cas9 genome editing technology is a novel technology that is not yet clinically validated for human
therapeutic use. The approaches we are taking to discover and develop novel therapeutics using CRISPR/Cas9 systems are unproven and may never lead to marketable products. If we are unable to develop viable product candidates, achieve regulatory
approval for any such product candidate or market and sell any product candidates, we may never achieve profitability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are focused on
developing potentially curative medicines utilizing the CRISPR/Cas9 genome editing technology. Although there have been significant advances in the field of gene therapy, which typically involves introducing a copy of a gene into a patient&#146;s
cell, and genome editing in recent years, CRISPR-based genome editing technologies are relatively new, and their therapeutic utility is largely unproven. The CRISPR/Cas9 technologies that we have licensed and that we intend to develop have not yet
been clinically tested by us, nor are we aware of any clinical trials for safety or efficacy having been completed by third parties involving these technologies. The scientific evidence to support the feasibility of developing products based on
these technologies is both preliminary and limited. Successful development of products by us will require solving a number of issues, including safely delivering a therapeutic into target cells within the human body or in an<I></I><I>&nbsp;ex
vivo</I>&nbsp;setting, optimizing the efficiency and specificity of such products, and ensuring the therapeutic selectivity and efficacy of such products. There can be no assurance we will be successful in solving any or all of these issues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have concentrated our research efforts to date on bringing CRISPR/Cas9 therapeutics to the clinic for our initial indications, which we call our sentinel
indications, and our future success is highly dependent on the successful development of CRISPR-based genome editing technologies, cellular delivery methods and therapeutic applications. Our sentinel indications are the focus of our initial
development efforts, and we may decide to alter or abandon these programs as new data become available and we gain experience in developing CRISPR/Cas9-based therapeutics. We cannot be sure that our CRISPR/Cas9 technologies will yield satisfactory
products that are safe and effective, scalable or profitable in our sentinel indications or any other indication we pursue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Public perception and related
media coverage of potential therapy-related safety issues, including adoption of new therapeutics or novel approaches to treatment, as well as ethical concerns related specifically to genome editing and CRISPR/Cas9, may adversely influence the
willingness of subjects to participate in clinical trials, or if any therapeutic is approved, of physicians and patients to subscribe to the novel treatment mechanics. Physicians, health care providers and third-party payors often are
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
slow to adopt new products, technologies and treatment practices that require additional upfront costs and training. Physicians may not be willing to undergo training to adopt this novel and
personalized therapy, may decide the therapy is too complex to adopt without appropriate training and may choose not to administer the therapy. In addition, responses by the U.S., state or foreign governments to negative public perception or ethical
concerns may result in new legislation or regulations that could limit our ability to develop or commercialize any product candidates, obtain or maintain regulatory approval or otherwise achieve profitability. Based on these and other factors,
health care providers and payors may decide that the benefits of this new therapy do not or will not outweigh its costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intellectual property owned by
third parties relating to CRISPR/Cas9 or other related technologies necessary to develop, manufacture and commercialize CRISPR/Cas9 therapeutics, such as delivery technologies, chemical modifications and manufacturing methods, could adversely impact
our ability to ultimately market and sell products. Currently, the Regents of the University of California and the University of Vienna (collectively, UC/Vienna) <FONT STYLE="white-space:nowrap">co-own</FONT> a worldwide patent portfolio with
Dr.&nbsp;Emmanuelle Charpentier, which covers methods of use and compositions relating to engineered CRISPR/Cas9 systems for, among other things, cleaving or editing DNA and altering gene product expression in various organisms, including eukaryotic
cells, which <FONT STYLE="white-space:nowrap">to-date</FONT> includes granted patents from the United Kingdom&#146;s Intellectual Property Office and a decision to grant from the European Patent Office. We refer to this <FONT
STYLE="white-space:nowrap">co-owned</FONT> worldwide patent portfolio as the UC/Vienna/Charpentier patent family. Through our 2014 license agreement with Caribou, we sublicense the UC/Vienna rights to these patents for human therapeutic,
prophylactic and palliative uses, including companion diagnostics, except for anti-fungal and anti-microbial uses. The Broad Institute, Massachusetts Institute of Technology and the President and Fellows of Harvard College <FONT
STYLE="white-space:nowrap">co-own</FONT> patents and patent applications that also claim aspects of CRISPR/Cas9 systems to edit genes in eukaryotic cells, including human cells (collectively, the Broad Institute patent family). Because the
respective owners of the UC/Vienna/Charpentier patent application and the Broad Institute patent family both allege owning intellectual property claiming aspects of CRISPR/Cas9 systems and methods to edit genes in eukaryotic cells, including human
cells, our ability to market and sell CRISPR/Cas9-based human therapeutics may be impacted. In January 2016, the Patent Trial and Appeal Board (PTAB) initiated an interference proceeding to determine which set of intellectual property was invented
first and, thus, entitled to the patents covering these inventions. On February&nbsp;15, 2017, the PTAB dismissed the proceeding finding that the respective patent claims involved in the interference were distinct such that they did not meet the
legal requirement to proceed with the interference. As a result of this proceeding&#146;s dismissal, the PTAB did not make a decision regarding which party actually first invented the use of CRISPR/Cas9 systems and methods to edit genes in
eukaryotic cells. In April 2017, UC/Vienna/Charpentier appealed to the U.S. Court of Appeals for the Federal Circuit seeking a review and reversal of the PTAB&#146;s decision to terminate the interference. For additional information regarding the
risks that may apply to our and our licensors&#146; intellectual property rights, see the section entitled &#147;Risks Related to Our Intellectual Property&#148; appearing elsewhere in this report for more information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to generate product revenue is dependent on the success of our application of CRISPR/Cas9 technology for human therapeutic use, which is at
an early stage of development and will require significant additional discovery efforts, preclinical testing and clinical studies, as well as applicable regulatory guidance for preclinical testing and clinical studies from the FDA and other
regulatory authorities, before we can seek regulatory approval and begin commercial sales of any potential product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to
generate product revenue is highly dependent on our ability to obtain regulatory approval of and successfully commercialize one or more of our product candidates. Any product candidates we discover will require preclinical, clinical and regulatory
review and approval in each jurisdiction in which we intend to market the products, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from product
sales. Before obtaining marketing approval from regulatory authorities for the sale of a product candidate, we must conduct extensive clinical trials to demonstrate the safety, purity and potency, as well as the effectiveness of the product
candidates in humans. We cannot be certain that any of our product candidates will be successful in clinical trials and even if successful, they may not receive regulatory approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our approach to developing therapies for genetic and viral-based diseases centers on using the CRISPR/Cas9 technology to introduce or remove genetic
information to treat various disorders. Because this is a new therapeutic approach, discovering, developing and commercializing our product candidates subject us to a number of challenges, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining regulatory approval from the FDA and other regulatory authorities that have very limited or no experience with the clinical development of CRISPR/Cas9 therapeutics; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seeking and obtaining regulatory approval from the FDA and other regulatory authorities in light of no guidance regarding potential regulatory pathways for this category of therapeutics, including preclinical and
clinical requirements for approval of an IND; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">educating medical personnel regarding the potential benefits and side effect profile of each of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developing processes for the safe administration of these products, including long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> for all patients who receive treatment with any of our product candidates;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sourcing clinical and, if approved, commercial supplies for the materials used to manufacture and process our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developing a manufacturing process and distribution network with a cost of goods that allows for an attractive return on investment; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing sales and marketing capabilities after obtaining any regulatory approval to gain market acceptance. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, because our technology involves gene editing across multiple cell and tissue types, we are subject to many of the challenges and risks that gene
therapies face, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory requirements governing gene and cell therapy products have changed frequently and may continue to change in the future. To date, no products that involve the genetic modification of patient cells have been
approved in the United States and a limited number have been approved in the EU; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">improper insertion of a gene sequence into a patient&#146;s chromosome could lead to cancer, other aberrantly functioning cells or other diseases, including death; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA recommends a <FONT STYLE="white-space:nowrap">follow-up</FONT> observation period of 15 years or longer for all patients who receive treatment using gene therapies, and we may need to adopt such an observation
period for our product candidates; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical trials using genetically modified cells conducted at institutions that receive funding for recombinant DNA research from the NIH, are subject to review by the RAC. Although the FDA decides whether individual
protocols may proceed, the RAC review process can impede the initiation of a clinical trial, even if the FDA has reviewed the study and it has become effective under an IND. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, although human clinical trials for other genome editing-based therapeutics have been authorized by the FDA, neither we nor any other company has
received regulatory approval in the U.S. or EU to commence human clinical trials utilizing CRISPR/Cas9 or to market therapeutics utilizing any genome editing technology, including CRISPR/Cas9. There is no certainty that the FDA or EMA will apply to
CRISPR/Cas9 product candidates the same regulatory pathway and requirements it is applying to other genome editing therapeutics; and the FDA and other regulatory authorities have not yet provided written guidance regarding preclinical or clinical
studies or regulatory approval pathways for gene editing therapeutics. In addition, if any product candidates encounter safety or efficacy problems, developmental delays, regulatory issues or other problems, our development plans and business could
be significantly harmed. Further, competitors that are developing products with similar technology may experience problems with their product candidates or programs that could in turn cause us to identify problems with our product candidates and
programs that would potentially harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, significant uncertainty exists regarding the future scope and effect of the FDA&#146;s
regulatory framework, in particular relating to the review and approval of human therapeutic products because the new U.S. administration and federal legislators have publicly declared their intention to significantly modify the current regulatory
framework. Any such changes to the FDA requirements could impact our ability to obtain approval for our products or sell them profitably. In addition, in the EU, the decision of the United Kingdom to withdraw from the European Union may require the
EMA to relocate to another country and recruit and retain new personnel to review and approve our submissions for regulatory approval in Europe. EMA&#146;s relocation could result in delays and other changes that may impact the timing and our
ability to obtain approval for our products. Also, the United Kingdom may enact legislation related to the approval and oversight of human therapeutics in that nation. Until any such legislation is enacted, we will be uncertain as to its effects on
our business, including our ability to seek and obtain approval for our products in the United Kingdom. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain regulatory approval of any product candidates, such candidates may not gain market
acceptance among physicians, patients, hospitals, third-party payors and others in the medical community. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The use of the CRISPR/Cas9 system as a
framework for developing gene editing therapies is a recent development and may not become broadly accepted by physicians, patients, hospitals, third-party payors and others in the medical community. A variety of factors will influence whether our
product candidates are accepted in the market, including, for example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the clinical indications for which our product candidates are approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential and perceived advantages of our product candidates over alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevalence and severity of any side effects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product labeling or product insert requirements of the FDA or other regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations or warnings contained in the labeling approved by the FDA or other regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of market introduction of our product candidates as well as competitive products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of treatment in relation to alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amount of upfront costs or training required for health care providers to administer our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of adequate coverage, reimbursement and pricing by third-party payors and government authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patients&#146; ability to access physicians and medical centers capable of delivering any therapies that we develop; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the willingness of patients to pay out of pocket in the absence of coverage and reimbursement by third-party payors and government authorities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any restrictions on the use of our product candidates together with other medications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">interactions of our product candidates with other medicines patients are taking; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential adverse events for any products developed, or negative interactions with regulatory agencies, by us or others in the gene therapy and gene editing fields; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of our sales and marketing efforts and distribution support. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if our products achieve
market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete. In
addition, adverse publicity due to the ethical and social controversies surrounding the therapeutic use of CRISPR/Cas9 or other therapeutics mediums, such as viral vectors that we anticipate using in our clinical trials may limit market acceptance
of our product candidates. If our product candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals, third-party payors or others in the medical community, we will not be able to generate significant
revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Negative public opinion and increased regulatory scrutiny of CRISPR/Cas9, gene editing or gene therapy generally may damage public
perception of the safety of any product candidates that we develop and adversely affect our ability to conduct our business or obtain regulatory approvals for such product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gene therapy in general, and gene editing in particular, remain novel technologies, with no gene therapy product approved to date in the United States and
only two gene therapy products approved to date in the EU. Public perception may be influenced by claims that gene therapy or gene editing, including through the use of CRISPR/Cas9, is unsafe or unethical, and gene therapy or gene editing may not
gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians who specialize in the treatment of diseases targeted by our product candidates prescribing treatments
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that involve the use of our product candidates in lieu of, or in addition to, existing treatments with which they are more familiar and for which greater clinical data may be available. In
addition, responses by the U.S., state or foreign governments to negative public perception or ethical concerns may result in new legislation or regulations that could limit our ability to develop or commercialize any product candidates, obtain or
maintain regulatory approval or otherwise achieve profitability. More restrictive statutory regimes, government regulations or negative public opinion would have an adverse effect on our business, financial condition, results of operations and
prospects and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. For example, earlier gene therapy trials led to several well-publicized adverse events, including cases of
leukemia and death, and the FDA recently initiated a clinical hold on a <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell therapy clinical trial due to patient deaths, and the company developing the therapy ultimately decided to stop the program.
Serious adverse events in our clinical trials, or other clinical trials involving gene therapy or gene editing products or our competitors&#146; products, even if not ultimately attributable to the relevant product candidates, and the resulting
publicity could result in increased government regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved
and a decrease in demand for any such product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and reimbursement may be limited or unavailable in certain market segments for
our product candidates, if approved, which could make it difficult for us to sell any product candidates or therapies profitably. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The success of
our product candidates, if approved, depends on the availability of adequate coverage and reimbursement from third-party payors, including government agencies. In addition, because our product candidates represent new approaches to the treatment of
genetic-based diseases, we cannot be sure that coverage and reimbursement will be available for, or accurately estimate the potential revenue from, our product candidates or assure that coverage and reimbursement will be available for any product
that we may develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of
the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors are critical to new product acceptance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs and treatments they
will cover and the amount of reimbursement. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#146;s determination that use of a product is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a covered benefit under its health plan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">safe, effective and medically necessary; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appropriate for the specific patient; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cost-effective; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">neither experimental nor investigational. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, no uniform policy of coverage and
reimbursement for products exists among third-party payors. As a result, obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide
to each payor supporting scientific, clinical and cost-effectiveness data for the use of our products on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">payor-by-payor</FONT></FONT> basis, with no assurance that coverage and
adequate reimbursement will be obtained. Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate for us to achieve or sustain profitability or may require
<FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. Additionally, third-party payors may not cover, or provide adequate reimbursement for, long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> evaluations
required following the use of our gene-modifying products. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Because
our product candidates may have a higher cost of goods than conventional therapies, and may require long-term follow up evaluations, the risk that coverage and reimbursement rates may be inadequate for us to achieve profitability may be greater.
There is significant uncertainty related to insurance coverage and reimbursement of newly approved products. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may
cause such organizations to limit both coverage and the level of reimbursement for newly approved </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
products and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product
candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, cost containment initiatives and additional legislative changes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or
more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in the EU, the pricing of pharmaceutical products, including biologics, is
subject to governmental control and other market regulations which could put pressure on the pricing and usage of our product candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after
obtaining marketing approval of a product candidate. In addition, market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our product
candidates and may be affected by existing and future health care reform measures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and development of biopharmaceutical products is
inherently risky. We may not be successful in our efforts to use and enhance our gene editing technology to create a pipeline of product candidates, obtain regulatory approval and develop commercially successful products, or we may expend our
limited resources on programs that do not yield a successful product candidate and fail to capitalize on potential product candidates or diseases that may be more profitable or for which there is a greater likelihood of success. If we fail to
develop product candidates, our commercial opportunity, if any, will be limited. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not currently have any product candidates. We are at an
early stage of development and our technology and approach has not yet led, and may never lead, to any product candidate or any approved or commercially successful products. Even if we are successful in building our pipeline of product candidates,
completing clinical development, obtaining regulatory approvals and commercializing product candidates will require substantial additional funding and are prone to the risks of failure inherent in therapeutic product development. Investment in
biopharmaceutical product development involves significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval, or become commercially viable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot provide any assurance that we will be able to successfully advance any product candidates that we discover through the research process. Our
research programs may initially show promise, yet fail to yield product candidates for clinical development or commercialization for many reasons, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our technology and approach may not be successful in identifying product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not be able or willing to assemble sufficient resources to acquire or discover product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our product candidates may not succeed in preclinical or clinical testing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our planned risk mitigation strategy for selecting our sentinel indications may fail or we may not be able to efficiently apply learnings from our initial development programs to future development programs;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be unable to optimize the therapeutic efficiency, specificity, or selectivity of our future product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our therapeutic delivery systems may fail so that even a product candidate with therapeutic activity might not demonstrate a clinically meaningful therapeutic effect; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may not demonstrate in patients the biological, chemical and pharmacological properties identified in laboratory and <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies, or they may interact
with human biological systems in unforeseen, ineffective or even harmful ways; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the therapeutic effect of a product candidate may not be permanent and may diminish over time; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a single treatment course may not be sufficient for a cure or therapeutic benefit; it may take several treatment courses for the product to be effective; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a well-defined and achievable pathway to regulatory approval may never materialize for a specific product candidate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competitors may develop alternatives that render our product candidates obsolete or less attractive; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product candidates we develop may be covered by third-party or other exclusive rights or may not receive desired regulatory exclusivity, and we may be unable to maintain, expand or protect our intellectual property
rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the market for a product candidate may change during our program so that the continued development of that product candidate is no longer reasonable; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be unable to successfully maintain existing collaborations or licensing arrangements or enter into new ones throughout the development process as appropriate; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may not be accepted as safe and effective by physicians, patients, hospitals, third-party payors and others in the medical community. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, or we may not be able to identify, discover,
develop or commercialize product candidates, which would have a material adverse effect on our business and could potentially cause us to cease operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we have limited financial and managerial resources, we focus on research programs that we identify as our sentinel indications. As a result, we may
fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases that may later prove to have greater commercial potential,
or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to retain sole development and commercialization rights. For additional
information regarding the factors that will affect our ability to achieve revenue from product sales, see the risk factor entitled &#147;We have never generated any revenue from product sales and our ability to generate revenue from product sales
and become profitable depends significantly on our success in a number of factors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we do not successfully develop and commercialize product
candidates based upon our approach, we will not be able to obtain product revenue in future periods, which likely would result in significant harm to our financial position and adversely affect our stock price. Further, our current focus on
CRISPR/Cas9 technology for developing products as opposed to multiple, more proven technologies for product development increases the risk associated with our business. If we are not successful in developing a product candidate using CRISPR/Cas9
technology, we may not be able to successfully implement an alternative product development strategy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical development involves a lengthy and
expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of any product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of our lead programs are still in the discovery stage, and their risk of failure is high. It is impossible to predict when or if any of our programs will
prove effective and safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical development and then conduct extensive
clinical trials to demonstrate the safety and efficacy of any of our future product candidates in humans. Preclinical and clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to
outcome. We may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful, and a clinical trial can fail at any stage of testing. The outcome of preclinical testing and early clinical
trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and
analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Successful completion of clinical trials is a prerequisite to submitting an NDA or BLA to the FDA, a Marketing Authorization Application to the EMA and
similar approval filings to comparable foreign regulatory authorities, for each product candidate and, consequently, the ultimate approval and commercial marketing of any product candidates. We do not know whether any of our clinical trials will
begin or be completed on schedule, if at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may experience delays in completing our preclinical studies and initiating or completing clinical trials. We
also may experience numerous unforeseen events during, or as a result of, any future clinical trials that we could conduct, which could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulators or institutional review boards (IRBs) or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective contract research organizations (CROs), the terms of which can be subject to extensive
negotiation and may vary significantly among different CROs and trial sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical trials of any product candidates may fail to show safety or efficacy, produce negative or inconclusive results and we may decide, or regulators may require us, to conduct additional preclinical studies or
clinical trials or we may decide to abandon product development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of patients required for clinical trials of any product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these
clinical trials or fail to return for post-treatment <FONT STYLE="white-space:nowrap">follow-up</FONT> at a higher rate than we anticipate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the
trial, which may require that we add new clinical trial sites or investigators; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may elect to, or regulators, IRBs or ethics committees may require that we or our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory
requirements or a finding that the participants are being exposed to unacceptable health risks; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of preclinical studies and clinical trials of any product candidates may be greater than we anticipate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators, IRBs or ethics committees to suspend or terminate the trials, or reports may
arise from preclinical or clinical testing of other gene therapies or gene editing based therapies that raise safety or efficacy concerns about our product candidates; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or other regulatory authorities may require us to submit additional data, such as long-term toxicology studies, or impose other requirements before permitting us to initiate a clinical trial. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs of the institutions in which such trials are being conducted,
the Data Safety Monitoring Board (DSMB) for such trial or FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance
with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side
effects, failure to demonstrate a benefit from using a product or treatment, failure to establish or achieve clinically meaningful trial endpoints, changes in governmental regulations or administrative actions or lack of adequate funding to continue
the clinical trial. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Further, the FDA or other
regulatory authorities may disagree with our clinical trial design and our interpretation of data from clinical trials, or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product development costs will increase if we experience delays in clinical testing or marketing approvals. We do not know whether any of our
preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical or clinical trial delays also could shorten any periods during which we may have the
exclusive right to commercialize our product candidates and may allow our competitors to bring products to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations. Any delays in our preclinical or
future clinical development programs may harm our business, financial condition and prospects significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inconclusive results, lack of
efficacy, adverse events or additional safety concerns in clinical trials that we or others conduct may impede the regulatory approval process or overall market acceptance of our future product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Therapeutic applications of gene editing technologies, and CRISPR/Cas9 in particular, are unproven and must undergo rigorous clinical trials and regulatory
review before receiving marketing authorization. If the results of our clinical studies or those of any other third parties, including with respect to gene editing technology, are inconclusive, fail to show efficacy or if such clinical trials give
rise to safety concerns or adverse events, we may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be delayed in obtaining marketing approval for our future product candidates, if at all; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain approval for indications or patient populations that are not as broad as intended or desired; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be subject to the addition of labeling statements, such as warnings or contraindications, or other types of regulatory restrictions or scrutiny; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be subject to changes in the way the product is administered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be required to perform additional clinical studies to support approval or be subject to additional post-marketing testing requirements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">have regulatory authorities modify or withdraw their written guidance, if any, regarding the applicable regulatory approval pathway or any approval of the product in question, or impose restrictions on its distribution
in the form of a modified REMS; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be sued; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">experience damage to our reputation. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, our future product candidates could potentially cause
other adverse events that have not yet been predicted and the potentially permanent nature of gene editing effects, including CRISPR/Cas9&#146;s effects, on genes may make these adverse events irreversible. The inclusion of critically ill patients
in our clinical studies or those of our competitors may result in deaths or other adverse medical events, including those due to other therapies or medications that such patients may be using. Any of these events could prevent us from achieving or
maintaining regulatory approval or market acceptance of our future product candidates and impair our ability to achieve profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have
never generated any revenue from product sales and our ability to generate revenue from product sales and become profitable depends significantly on our success in a number of factors. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have no products approved for commercial sale, have not generated any revenue from product sales, and do not anticipate generating any revenue from product
sales until sometime after we have received regulatory approval for the commercial sale of a product candidate that we discover. Our ability to generate revenue and achieve and retain profitability depends significantly on our success in many
factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">selecting commercially viable product candidates and effective delivery methods; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">completing research and nonclinical and clinical development of product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining regulatory approvals and marketing authorizations for product candidates for which we complete clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developing a sustainable and scalable manufacturing process for product candidates, including establishing and maintaining commercially viable supply relationships with third parties and potentially establishing our own
manufacturing capabilities and infrastructure; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launching and commercializing product candidates for which we obtain regulatory approvals and marketing authorizations, either directly or with a collaborator or distributor; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">accurately assessing the size and addressability of potential patient populations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining market acceptance of our product candidates as viable treatment options; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">addressing any competing technological and market developments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter or which may be necessary for us to develop, manufacture or commercialize our product candidates;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintaining good relationships with our collaborators and licensors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and <FONT STYLE="white-space:nowrap">know-how;</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">avoiding infringement of or obtaining licenses to any valid intellectual property owned or controlled by third parties; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attracting, hiring and retaining qualified personnel. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if one or more product candidates that we discover
and develop are approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate and the timing of such costs may be out of our control. Our expenses could increase beyond
expectations if we are required by the FDA or other regulatory agencies, domestic or foreign, to change our manufacturing processes or assays, or to perform clinical, nonclinical or other types of additional studies. If we are successful in
obtaining regulatory approvals to market one or more product candidates, our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability
to get reimbursement at any price and whether we own the commercial rights for that territory. If the number of our addressable disease patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than
we expect or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. If we are not able to generate
revenue from the sale of any approved products, we may never become profitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face significant competition in an environment of rapid
technological change. The possibility that our competitors may achieve regulatory approval before we do or develop therapies that are more advanced or effective than ours may harm our business and financial condition or our ability to successfully
market or commercialize our product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical industries, including the gene editing field, are
characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property. We face substantial competition from many different sources, including large and specialty pharmaceutical and biotechnology
companies, academic research institutions, government agencies and public and private research institutions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Competitors in our efforts to provide
genetic therapies to patients can be grouped into at least three sets based on their product discovery platforms: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">gene editing companies focused on CRISPR/Cas9 including: Casebia Therapeutics, CRISPR Therapeutics, Inc., Editas Medicine, Inc., ToolGen, Inc. and Tracr Hematology Limited; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">other gene editing companies including: bluebird bio, Inc., Cellectis S.A., Poseida, Inc., Precision BioSciences, Inc. and Sangamo BioSciences; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">gene therapy companies developing <I>ex vivo</I> therapies including: bluebird bio, Inc., Cellectis S.A., Juno Therapeutics, Inc. and Kite Pharma, Inc. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our competitors will also include companies that are or will be developing other gene editing methods as well as small molecules, biologics, <I>in vivo</I>
gene therapies and nucleic acid-based therapies for the same indications that we are targeting with our CRISPR/Cas9-based therapeutics. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any advances in gene therapy or gene editing technology made by a competitor may be used to develop therapies
that could compete against any of our product candidates. Many of these competitors have substantially greater research and development capabilities and financial, scientific, technical, intellectual property, manufacturing, marketing, distribution
and other resources than we do, and we may not be able to successfully compete with them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To become and remain profitable, we must discover, develop and
eventually commercialize product candidates with significant market potential, which will require us to be successful in a range of challenging activities. These activities can include completing preclinical studies and clinical trials of product
candidates, obtaining marketing approval for product candidates, manufacturing, marketing and selling products that are approved and satisfying any post-marketing requirements. Even if we are successful in selecting and developing any product
candidates, in order to compete successfully we may need to be <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-to-market</FONT></FONT> or demonstrate that our CRISPR/Cas9-based products are superior to therapies based on the
same or different treatment methods. If we are not <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-to-market</FONT></FONT> or are unable to demonstrate such superiority, any products for which we are able to obtain approval
may not be successful. Furthermore, in certain jurisdictions, if a competitor has orphan drug status for a product and if our product candidate is determined to be contained within the scope of a competitor&#146;s orphan drug exclusivity, then
approval of our product for that indication or disease could potentially be blocked, for example, for up to seven years in the United States and 10 years in the EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may never succeed in any or all of these activities and, even if we do, we may never generate revenues that are significant or large enough to achieve
profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability
to raise capital, maintain our research and development efforts, expand our business or continue our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a very limited operating
history, which may make it difficult to evaluate our current business and predict our future performance. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are very early in our development
efforts and all of our lead programs are still in the discovery stage. We were formed in May 2014, have no products approved for commercial sale and have not generated any revenue from product sales. Our ability to generate product revenue or
profits, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates, which may never occur. We may never be able to develop or commercialize a
marketable product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of our programs will require additional discovery research and then preclinical and clinical development, regulatory approval in
multiple jurisdictions, obtaining manufacturing supply, capacity and expertise, building of a commercial organization, substantial investment and significant marketing efforts before we generate any revenue from product sales. In addition, our
product candidates must be approved for marketing by the FDA or certain other foreign regulatory agencies, including the EMA, before we may commercialize any product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our limited operating history, particularly in light of the rapidly evolving gene editing field, may make it difficult to evaluate our current business and
predict our future performance. Our very short history as an operating company makes any assessment of our future success or viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by very early
stage companies in rapidly evolving fields. If we do not address these risks successfully, our business will suffer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred net losses in
each period since our inception, anticipate that we will continue to incur net losses in the future and may never achieve profitability. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are
not profitable and have incurred losses in each period since our inception. Our net loss was $12.6&nbsp;million for the quarter ended March&nbsp;31, 2017. As of March&nbsp;31, 2017, we had an accumulated deficit of $66.2&nbsp;million. We expect
these losses to increase as we continue to incur significant research and development and other expenses related to our ongoing operations, seek regulatory approvals for our future product candidates, <FONT STYLE="white-space:nowrap">scale-up</FONT>
manufacturing capabilities, maintain, expand and protect our intellectual property portfolio and hire additional personnel to support the development of our product candidates and to enhance our operational, financial and information management
systems. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A critical aspect of our strategy is to invest significantly in our technology to improve the efficacy and safety of potential product
candidates that we discover. Even if we succeed in discovering, developing and ultimately commercializing one or more of these product candidates, we will continue to incur losses for the foreseeable future relating to our substantial research
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and development expenditures to develop our technologies. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our
business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on
our stockholders&#146; equity and working capital. Further, the net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> comparison of our results of operations may not be a good indication of our future performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may need to raise substantial additional funding to fund our operations. If we fail to obtain additional financing, we may be unable to complete the
development and commercialization of any product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our operations have required substantial amounts of cash since inception, and we
expect to spend substantial amounts of our financial resources on our discovery programs going forward. If we are able to identify product candidates that are eventually approved, we will require significant additional amounts in order to launch and
commercialize our product candidates. For the foreseeable future, we expect to continue to rely on additional financing to achieve our business objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will require additional capital for the further development and commercialization of any product candidates and may need to raise additional funds sooner
if we choose to expand more rapidly than we presently anticipate or due to other unanticipated factors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot be certain that additional funding will
be available on acceptable terms, or at all. We have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or
discontinue the development or commercialization of our product candidates or other research and development initiatives. Our collaboration and license agreements may also be terminated if we are unable to meet the payment or other obligations under
the agreements. We could be required to seek collaborators for product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable
terms our rights to product candidates in markets where we otherwise would seek to pursue development or commercialization ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of the above
events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our stockholders and restrict our operations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will need additional capital in the future to continue our planned operations. To the extent that we raise additional capital through the sale of equity or
convertible debt securities, the ownership interest of our existing stockholders may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt
financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring
dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we experience delays or difficulties in the enrollment of patients in clinical trials, our ability to complete clinical trials or our
receipt of necessary regulatory approvals could be delayed or prevented. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be able to initiate or continue clinical trials for any
future product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. If patients are unwilling to
participate in our clinical studies because of concerns about, or negative publicity from, adverse events in the gene editing field, the novel nature of the CRISPR/Cas9 gene editing technology, the irreversibility of the effects of CRISPR/Cas9 or
for other reasons, including competitive clinical studies for similar patient populations, then the timeline for recruiting patients, conducting studies and obtaining regulatory approval of potential products may be delayed. These delays could
result in increased costs, delays in advancing our product development, delays in testing the effectiveness of our technology or termination of the clinical studies altogether. In addition, any patients who would otherwise be eligible for clinical
trials that we may hold may instead enroll in clinical trials of product candidates of our competitors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patient enrollment is affected by other factors
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the size, location and nature of the patient population; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the severity of the disease under investigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the patient eligibility criteria for the study in question; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the perceived risks and benefits of the product candidate under study; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the design of the clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our payments for conducting clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the patient referral practices of physicians; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ability to monitor patients adequately during and after treatment; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the proximity and availability of clinical trial sites for prospective patients. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our inability to enroll a
sufficient number of patients for clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in clinical trials may result in increased development costs for any of
our potential future product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing. Furthermore, we expect to rely on CROs and clinical trial sites to ensure the proper and timely
conduct of our clinical trials, and, while we expect to enter into agreements governing their committed activities, we will have limited influence over their actual performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to expand our research, development and regulatory capabilities, and, as a result, we may encounter difficulties in hiring capable personnel
and otherwise managing our growth, which could disrupt our operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to experience significant growth in the number of our employees
and the scope of our operations, particularly in the areas of technology research, product development, regulatory affairs and, if any product candidates are submitted for or receive marketing approval, sales, marketing and distribution. To manage
our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial
resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to recruit and train additional qualified personnel or to otherwise effectively manage the expansion of our
operations. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business and development plans or disrupt our
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are highly dependent on the research and development, clinical, legal and business development expertise of Nessan Bermingham, Ph.D., our
President and Chief Executive Officer, John M. Leonard, M.D., our Executive Vice President, Research&nbsp;&amp; Development, Graeme Bell, our Executive Vice President, Chief Financial Officer, and Jos&eacute; E. Rivera, our Executive Vice President,
General Counsel, as well as the other principal members of our management, scientific and clinical teams. Although we have entered into employment arrangements with our executive officers, each of them may terminate their employment with us at any
time. We do not maintain &#147;key person&#148; insurance for any of our executives or other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recruiting and retaining qualified scientific,
clinical, manufacturing and sales and marketing personnel will also be important for our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and
commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited
number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products using our technology. Competition to hire from this limited pool is intense, and
we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies, universities and research institutions for similar personnel. The market for
qualified personnel in the biotechnology space generally, and gene editing and gene therapy fields in particular, in and around the Cambridge, Massachusetts area is especially competitive. In addition, we rely on consultants and advisors, including
scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategies. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or
advisory contracts with other entities that may limit their availability to us. Further, some of the qualified personnel that we hire and recruit are not United States citizens, and there is uncertainty with regard to their future
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employment status due to the new U.S. administration&#146;s announced intention of modifying the legal framework for <FONT STYLE="white-space:nowrap">non-U.S.</FONT> citizens to be employed in
the United States. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If, in the future, we are unable to establish sales, marketing and distribution capabilities or enter into agreements with third parties to sell, market
and distribute products based on our technologies, we may not be successful in commercializing our products if and when any products candidates or therapies are approved and we may not be able to generate any revenue. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not currently have a sales, marketing or distribution infrastructure and, as a company, have no experience in the sale, marketing or distribution of
therapeutic products. To achieve commercial success for any approved product candidate for which we retain sales and marketing responsibilities, we must build our sales, marketing, managerial and other
<FONT STYLE="white-space:nowrap">non-technical</FONT> capabilities or make arrangements with third parties to perform these services. In the future, we may choose to build a focused sales and marketing infrastructure to sell, or participate in sales
activities with our collaborators for, some of our product candidates if they are approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are risks involved with both establishing our own sales
and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch
of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly and
our investment would be lost if we cannot retain or reposition our sales and marketing personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Factors that may inhibit our efforts to commercialize
our product candidates on our own include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future product candidates that we may develop; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the lack of complementary treatments to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the location of patients in need of our product candidates and the treating physicians who may prescribe the products; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unforeseen costs and expenses, as well as legal and regulatory requirements, associated with creating and operating a sales and marketing organization. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability to us from
these revenue streams is likely to be lower than if we were to market and sell any product candidates that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product
candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties and any of them may fail to devote the necessary resources and attention to sell and market our product candidates
effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we may not be successful in commercializing our product candidates. Further, our business, results of
operations, financial condition and prospects will be materially adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our technological advancements and any potential for revenue
may be derived in part from our collaborations with Novartis and Regeneron, and if either of these collaboration agreements were to be terminated, our business, financial condition, results of operations and prospects would be harmed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2014, we entered into a collaboration agreement with Novartis regarding the discovery of new CRISPR/Cas9-based therapies principally using <FONT
STYLE="white-space:nowrap">CAR-T</FONT> cells and HSCs. Under the Novartis collaboration agreement, we received a commitment to advance multiple programs. Pursuant to the Novartis agreement, we granted Novartis exclusive rights to further develop
and commercialize products arising out of the <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell program during the research term. Regarding HSCs, we plan to jointly advance multiple programs with Novartis and have agreed to a process for assigning
development and ownership rights, which will enable us to develop our own proprietary HSC pipeline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2016, we entered into a collaboration agreement with Regeneron that includes a product component to
research, develop and commercialize CRISPR/Cas-based therapeutic products primarily focused on gene editing in the liver as well as a technology collaboration component, pursuant to which we and Regeneron will engage in research and development
activities aimed at discovering and developing novel technologies and improvements to CRISPR/Cas technology to enhance our gene editing platform. Pursuant to the Regeneron collaboration agreement, we granted Regeneron exclusive rights to select up
to 10 targets, subject to certain restrictions, while we retain the rights to solely develop our sentinel indications, other than ATTR, which is subject to a <FONT STYLE="white-space:nowrap">co-development</FONT> and
<FONT STYLE="white-space:nowrap">co-commercialization</FONT> arrangement with Regeneron, and have the right to choose additional liver targets for our own development during the collaboration term. Certain other of the development targets under the
Regeneron agreement may also be subject to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">co-development/co-commercialization</FONT></FONT> arrangement with the other party at the other party&#146;s option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Either Novartis or Regeneron may change its strategic focus or pursue alternative technologies in a manner that results in reduced, delayed or no revenue to
us. Each of Novartis and Regeneron has a variety of marketed products and product candidates under collaboration with other companies, including some of our competitors, and the respective corporate objectives of Novartis or Regeneron may not be
consistent with our best interests. If either of our collaboration partners fails to develop, obtain regulatory approval for or ultimately commercialize any product candidate from the development programs governed by the respective collaboration
agreement in the applicable territories, or if either of our collaboration partners terminates our collaboration with it, our business, financial condition, results of operations and prospects could be harmed. In addition, any dispute or litigation
proceedings we may have with either Novartis or Regeneron in the future could delay development programs, create uncertainty as to ownership of or access to intellectual property rights, distract management from other business activities and
generate substantial expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our existing and future collaborations will be important to our business. If we are unable to maintain any of these
collaborations, or if these collaborations are not successful, our business could be adversely affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have limited capabilities for product
development and do not yet have any capability for sales, marketing or distribution. Accordingly, we have entered, and plan to enter, into collaborations with other companies, including our therapeutic-focused collaboration agreements with Novartis
and Regeneron, that we believe can provide such capabilities. These collaborations provide us with important technologies and funding for our programs and technology, and we expect to receive additional technologies and funding under these and other
collaborations in the future. Our existing therapeutic collaborations, and any future collaborations we enter into, may pose a number of risks, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators have significant discretion in determining the efforts and resources that they will apply; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not perform their obligations as expected; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs or license
arrangements based on clinical trial results, changes in the collaborators&#146; strategic focus or available funding, or external factors, such as a strategic transaction that may divert resources or create competing priorities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new
formulation of a product candidate for clinical testing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators could develop independently or with third parties products that compete directly or indirectly with our products and product candidates if the collaborators believe that the competitive products are more
likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the
development or commercialization of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may fail to comply with applicable legal and regulatory requirements regarding the development, manufacture, sale, distribution or marketing of a product candidate or product; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators with sale, marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the sale, marketing and distribution of such
product or products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, sales or marketing, might cause delays or terminations of the research,
development or commercialization of product candidates, might lead to additional and burdensome responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and
expensive; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not properly maintain or defend their or our relevant intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our
intellectual property or proprietary information or expose us to potential litigation and liability; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if a collaborator of ours is involved in a business combination or cessation, the collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborations may be terminated by the collaborator, and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our therapeutic collaborations do not result in the successful discovery, development and commercialization of products or if one of our
collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development and
commercialization of our technology and product candidates could be delayed and we may need additional resources to develop product candidates and our technology. All of the risks relating to product development, regulatory approval and
commercialization described in this report also apply to the activities of our therapeutic collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, if one of our collaborators
terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the business and financial communities could be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For some of our programs, we may in the future determine to collaborate with pharmaceutical and biotechnology companies for development and potential
commercialization of therapeutic products. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the
collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation of a number of factors. If we are unable to reach agreements with suitable collaborators on a timely
basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope
of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to
obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and
commercialization activities, we may not be able to further develop our product candidates, bring them to market or continue to develop our technology and our business may be materially and adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gene editing products are novel and may be complex and difficult to manufacture. We could experience manufacturing problems that result in delays in the
development or commercialization of our product candidates or otherwise harm our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The manufacturing process used to produce
CRISPR/Cas9-based product candidates may be complex, as they are novel and have not been validated for clinical and commercial production. Several factors could cause production interruptions, including equipment malfunctions; facility
unavailability or contamination; raw material cost, shortages or contamination; natural disasters; disruption in utility services; human error; insufficient personnel; inability to meet legal or regulatory requirements; or disruptions in the
operations of our suppliers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product candidates will require processing steps that are more complex than those required for most small
molecule drugs. Moreover, unlike small molecules, the physical and chemical properties of a complex product such as ours generally cannot be fully characterized. As a result, assays of the finished product or relevant components may not be
sufficient to ensure that the product will perform in the intended manner. Accordingly, we will employ multiple steps to control the manufacturing process to assure that the process works and the product candidate is made strictly and consistently
in compliance with the process. Problems with the manufacturing process, even minor deviations from the normal process, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims
and litigation, insufficient inventory or production interruption. We may encounter problems achieving adequate quantities and quality of clinical grade materials that meet FDA, EMA or other applicable standards or specifications with consistent and
acceptable production yields and costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the FDA, the EMA and other foreign regulatory authorities may require us to submit samples of any
lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other foreign regulatory authorities may require that we not distribute a lot until the
relevant agency authorizes its release. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures, product recalls
or production interruption. Lot failures, product recalls or production interruption could cause us to delay product launches or clinical trials, which could be costly to us and otherwise harm our business, financial condition, results of operations
and prospects. Problems in our manufacturing process could restrict our ability to meet market demand for our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also may encounter problems
hiring and retaining the experienced scientific, quality-control and manufacturing personnel needed to operate our manufacturing processes, which could result in delays in production or difficulties in maintaining compliance with applicable
regulatory requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any problems in our manufacturing process or facilities could make us a less attractive collaborator for potential partners,
including larger pharmaceutical companies and academic research institutions, which could limit our access to additional attractive development programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to rely on third parties to manufacture our clinical product supplies, and we intend to rely on third parties for at least a portion of the
manufacturing process of our product candidates, if approved. Our business could be harmed if the third parties fail to provide us with sufficient quantities of product inputs or fail to do so at acceptable quality levels or prices or fail to meet
legal and regulatory requirements. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not currently own any facility that may be used as our clinical-scale manufacturing and processing
facility and must eventually rely on outside vendors to manufacture supplies and process our product candidates. We have not yet caused any product candidates to be manufactured or processed on a commercial scale and may not be able to do so for any
of our product candidates. We will make changes as we work to optimize the manufacturing process, and we cannot be sure that even minor changes in the process will result in therapies that are safe, potent or effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA or other foreign regulatory agencies
pursuant to inspections that will be conducted after we submit an application to the FDA or other foreign regulatory agencies. We do not control the manufacturing process of, and will be completely dependent on, our contract manufacturing partners
for compliance with legal and regulatory requirements for manufacture, including cGMP, and in certain cases, cGTP, requirements of our product candidates. If our contract manufacturers cannot successfully manufacture material that conforms to our
specifications and the strict regulatory requirements of the FDA or other regulatory authorities, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have no control over the
ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product
candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if
approved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will rely on third parties to conduct our clinical trials. If these third parties do not successfully
carry out their contractual duties or meet expected deadlines or comply with legal and regulatory requirements, we may not be able to obtain regulatory approval of or commercialize any potential product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will depend upon third parties, including independent investigators, to conduct our clinical trials under agreements with universities, medical
institutions, CROs, strategic partners and others. We expect to have to negotiate budgets and contracts with CROs and trial sites, which may result in delays to our development timelines and increased costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will rely heavily on third parties over the course of our clinical trials, and, as a result, will have limited control over the clinical investigators and
limited visibility into their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, including with respect to their compliance with the approved clinical protocol and other legal, regulatory and
scientific standards. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on third parties does not relieve
us of our legal responsibilities. We and these third parties are required to comply with good clinical practice, or GCP, requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product
candidates in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, clinical investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP
requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to suspend or terminate these trials or perform additional preclinical studies or
clinical trials before approving our marketing applications. We cannot be certain that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP requirements. In addition, our clinical trials
must be conducted with product produced under cGMP, and in certain cases, cGTP, requirements and may require a large number of test patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our failure
or any failure by these third parties to comply with these requirements or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be
implicated if any of these third parties violates applicable federal, state or local, as well as foreign, laws and regulations, such as the fraud and abuse or false claims laws and regulations or privacy and security laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any third parties conducting our future clinical trials will not be our employees and, except for remedies that may be available to us under our agreements
with such third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing preclinical, clinical, and nonclinical programs. These third parties may also have relationships with other commercial entities,
including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual
duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for
other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and
the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
any of our relationships with these third-party CROs or others terminate, we may not be able to enter into arrangements with alternative CROs or other third parties or to do so on commercially reasonable terms. Switching or adding additional CROs
involves additional cost and requires management time and focus. In addition, the transition to a new CRO may result in delays, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage
our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and
prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unfavorable global economic conditions or political developments could adversely affect our business, financial condition or results of
operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial
markets. For example, recent political unrest and global financial crises caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, political unrest or additional global financial crises
could result in a variety of risks to our business, including weakened demand for our products, if approved, or our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our
suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate, further political developments and financial market conditions could
adversely impact our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our internal computer systems, or those of our collaborators or other contractors or consultants, may fail
or suffer security breaches, which could result in a material disruption of our product development programs. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our internal computer systems and
those of our current and any future collaborators and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we
have not experienced any such material system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a disruption of our development programs and our business
operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory
approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of
confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Government Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The
regulatory approval process for our potential product candidates in the United States, EU and other jurisdictions is currently uncertain and will be lengthy, time-consuming and inherently unpredictable and we may experience significant delays in the
clinical development and regulatory approval, if any, of our product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The research, testing, manufacturing, labeling, approval,
selling, import, export, marketing and distribution of drug products, including biologics, are subject to extensive regulation by the FDA in the United States and other regulatory authorities. We are not permitted to market any drug or biological
product in the United States until we receive regulatory approval from the FDA. We have not previously submitted an NDA or BLA to the FDA, or similar approval filings to comparable foreign authorities. An NDA or BLA must include extensive
preclinical and clinical data and supporting information to establish that the product candidate is safe and effective or, for biological products, safe, pure and potent for each desired indication. The application must also include significant
information regarding the chemistry, manufacturing and controls for the product, and the manufacturing facilities must complete a successful <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection by the FDA, or applicable foreign authority,
prior to the approval or licensure of the product. We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, the FDA currently has no experience evaluating CRISPR/Cas9-based
therapies for human therapeutic use. The FDA may also require a panel of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety and efficacy data to support approval. The opinion of the Advisory Committee,
although not binding, may have a significant impact on our ability to obtain approval of any product candidates that we develop based on the completed clinical trials. Moreover, while we are not aware of any specific genetic or biomarker diagnostic
tests for which regulatory approval would be necessary in order to advance any of our product candidates to clinical trials or potential commercialization, in the future regulatory agencies may require the development and approval of such tests.
Accordingly, the regulatory approval pathway for such product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, clinical trials can be delayed or terminated for a variety of reasons, including delays or failures related to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining and maintaining regulatory authorization to conduct a trial, if applicable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of financial resources to begin and complete the planned trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining approval at each clinical trial site by an independent IRB; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recruiting suitable patients to participate in a trial in a timely manner; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">having patients complete a trial or return for post-treatment <FONT STYLE="white-space:nowrap">follow-up;</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical trial sites deviating from trial protocol, not complying with GCP requirements or dropping out of a trial; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">addressing any patient safety concerns that arise during the course of a trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">addressing any conflicts with new or existing laws or regulations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adding new clinical trial sites; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacturing qualified materials under cGMP regulations for use in clinical trials. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patient enrollment is a
significant factor in the timing of clinical trials and is affected by many factors. Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such trials are being conducted, the DSMB for such trial or
the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by
the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or
administrative actions or lack of adequate funding to continue the clinical trial. If we experience termination of, or delays in the completion of, any clinical trial of product candidates, the commercial prospects for our product candidates will be
harmed, and our ability to generate product revenue will be impaired. In addition, any delays in completing any clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence
product sales and generate revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that
we will be successful in obtaining regulatory approval of product candidates in other jurisdictions. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Obtaining and maintaining regulatory
approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have
a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing
and sale of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or
clinical trials as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it
can be approved for sale in that jurisdiction. In some cases, the price that we are allowed to charge for our products is also subject to approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us
and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets or to receive applicable marketing approvals, our target market will be reduced and our
ability to realize the full market potential of our product candidates will be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive regulatory approval of any product
candidates or therapies, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or
experience unanticipated problems with our product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of our product candidates are approved, they will be subject to ongoing
regulatory requirements for manufacturing, labeling, packaging, distribution, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information,
including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. In addition, we will be subject to continued compliance with cGMP and GCP, and in certain cases, cGTP, requirements for
any clinical trials that we conduct post-approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Manufacturers and manufacturers&#146; facilities are required to comply with extensive FDA and
comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP and, in certain cases, cGTP requirements. As such, we and our contract manufacturers will be subject to
continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA or BLA, other marketing applications, and previous responses to inspection observations. Accordingly, we and others with whom we work must
continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production and quality control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved
indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase IV clinical trials and surveillance to monitor the safety and efficacy of
the product candidate. The FDA may also require a REMS program as a condition of approval of our product candidates, which could entail requirements for long-term patient <FONT STYLE="white-space:nowrap">follow-up,</FONT> a medication guide,
physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our
product candidates, we will have to comply with legal or regulatory requirements including submissions of safety and other post-marketing information and reports and registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may seek to impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems
occur after the product reaches the market. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing
processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of
distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fines, warning letters or holds on clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product seizure or detention or refusal to permit the import or export of our product candidates; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctions or the imposition of civil or criminal penalties. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates marketing, labeling,
advertising, and promotion of products that are placed on the U.S. market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws
and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant
liability. The policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the
likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of
new requirements or policies, or if we are not able to maintain regulatory and legal compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare cost control initiatives, including healthcare legislative reform measures, may have a material adverse effect on our business and results of
operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of
controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been, and are expected to continue to be, a number of legislative and regulatory changes to the health care system that could impact our ability to
sell our products profitably. In the United States, however, significant uncertainty exists regarding the provision and financing of health care because the new administration and federal legislators have publicly declared their intention to
significantly modify the current legal and regulatory framework for the health care system but details have not been agreed upon or disclosed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Current
legislation at the United States federal and state levels seeks to reduce healthcare costs and improve the quality of healthcare. In March 2010, the Affordable Care Act was enacted, which substantially changed the way health care is financed by both
governmental and private insurers, and significantly impacted the U.S. pharmaceutical and biotechnology industry. The Affordable Care Act, among other things, subjects biologic products to potential competition by lower-cost biosimilars, addresses a
new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increases the minimum Medicaid rebates owed by most manufacturers
under the Medicaid Drug Rebate Program, extends the Medicaid Drug Rebate program to utilization of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prescriptions of individuals&nbsp;enrolled in Medicaid managed care organizations, subjects manufacturers to new annual fees and taxes for certain branded prescription drugs and biologic agents
and provides incentives to programs that increase the federal government&#146;s comparative effectiveness research. At this time, the full effect that the Affordable Care Act would have on our business remains unclear. Further, significant
uncertainty exists regarding the future scope and effect of the Affordable Care Act because the new administration and federal legislators have publicly declared their intention to significantly modify or repeal the legislation. We cannot predict
the ultimate form or timing of any modification to, or repeal of, the Affordable Care Act or the effect that such modification or repeal would have on our business. Recent public announcements by the U.S. administration and members of the U.S.
Congress have emphasized the administration&#146;s significant interest in pursuing prompt healthcare reform. Such reform efforts and any resulting changes to the Affordable Care Act could impact our ability to sell our products profitably. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other legislative changes relevant to the health care system have been adopted in the United States since the Affordable Care Act was enacted. In
August&nbsp;2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2
trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of
2%&nbsp;per fiscal year, which went into effect in April&nbsp;2013, and will remain in effect through 2024 unless additional Congressional action is taken. In January&nbsp;2013, the American Taxpayer Relief Act of 2012, was signed into law, which,
among other things, further reduced Medicare payments to several providers, including hospitals and other treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five
years. These laws may result in additional reductions in Medicare, Medicaid and other healthcare funding, which could have a material adverse effect on our customers and, accordingly, our financial operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the
availability of healthcare and containing or lowering the cost of healthcare. As indicated previously, significant uncertainty exists regarding the future scope and effect of current health care legislation and regulations because the new
administration and federal legislators have publicly declared their intention to significantly modify or repeal the current legislative framework. We cannot predict the initiatives that may be adopted in the future, any of which could limit or
modify the amounts that foreign, federal and state governments as well as private payors, including patients, will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing
pressures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The continuing efforts of governments, insurance companies, managed care organizations and other payors of healthcare services to contain or
reduce costs of healthcare and/or impose price controls could harm our business, financial conditions and prospects and may adversely affect: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the demand for or utilization of our product candidates, if we obtain regulatory approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to set a price that we believe is fair for our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to generate revenue and achieve or maintain profitability; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the level of taxes, fees and rebates that we are required to pay; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of capital. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any denial in coverage or reduction in reimbursement from Medicare or other
government programs, including state and foreign programs, may result in a similar denial or reduction in payments from private payors, which may adversely affect our future profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, clinical investigators, CROs, consultants, commercial partners and vendors may engage in misconduct or other
improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of <FONT STYLE="white-space:nowrap">non-compliance,</FONT> fraud, misconduct or other illegal activity by our employees,
independent contractors, clinical investigators, CROs, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to: comply with federal and state laws and those
of other applicable jurisdictions; provide true, complete and accurate information to the FDA and other similar foreign regulatory bodies; comply with manufacturing standards; comply with federal and state data privacy, security, fraud and abuse and
other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
healthcare laws and regulations in the United States and similar foreign privacy or fraudulent misconduct laws; or report financial information or data accurately; or disclose unauthorized
activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws will increase significantly, and our costs associated with compliance
with such laws are also likely to increase. These laws may impact, among other things, our current activities with clinical investigators and research patients, as well as proposed and future sales, marketing and education programs. In particular,
the promotion, sales and marketing of healthcare products and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing
and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, including promotion and marketing of <FONT STYLE="white-space:nowrap">off-label</FONT> uses of our
products, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials or
creating fraudulent data in our preclinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third
parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a
failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not
successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, physician payment transparency laws,
health information privacy and security laws and anti-corruption laws. If we are unable to comply, or have not fully complied, with such laws or their relevant foreign counterparts, we could face substantial penalties. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations may be directly, or
indirectly through our customers and third-party payors, subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act, and physician sunshine laws and
regulations. These laws or their relevant foreign counterparts may impact, among other things, our proposed sales, marketing, and education programs and our relationships with healthcare providers, physicians and other parties through which we
market, sell and distribute our products for which we obtain marketing approval. In addition, we may be subject to patient privacy regulation by the federal government and the states in the United States as well as other jurisdictions. The laws that
may affect our ability to operate include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or
indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service, for which payment may be made, in whole
or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">federal civil and criminal false claims laws and civil monetary penalties laws, including the civil False Claims Act, which impose criminal and civil penalties on individuals or entities for, among other things,
knowingly presenting, or causing to be presented to the U.S. federal government, claims for payment or approval that are false or fraudulent or knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the
federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false of fraudulent claim for purposes of the False Claims Act;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which imposes criminal and civil liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any
healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g.,
public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or
services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and their respective implementing regulations, which impose requirements on certain covered healthcare providers,
health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and
transmission of individually identifiable health information without appropriate authorization; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the U.S. federal physician payment transparency requirements, sometimes referred to as the &#147;Physician Payments Sunshine Act,&#148; created under the Affordable Care Act, and their implementing regulations, which
require manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program to report annually to the Centers for Medicare and Medicaid Services,
information related to payments or other transfers of value made to physicians, other healthcare providers, and teaching hospitals, as well as ownership and investment interests held by physicians, other healthcare providers, and their immediate
family members; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Foreign Corrupt Practices Act (FCPA) and other laws which prohibit improper payments or offers of payments to foreign governments and their officials and political parties by U.S. persons and issuers as defined by
the statute for the purpose of obtaining or retaining business; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Federal Food, Drug and Cosmetic Act, which prohibits, among other things, the commercialization of adulterated or misbranded of drugs and medical devices. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we are subject to state and foreign equivalents of each of the healthcare laws described above, among others, some of which may be broader in
scope and may apply regardless of the payor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the limited statutory exceptions and safe harbors available, it is
possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has strengthened these laws. For example, the Affordable Care Act, among other things,
amends the intent requirement of the federal Anti-Kickback Statute and criminal healthcare fraud statutes. As a result of such amendment, a person or entity no longer needs to have actual knowledge of these statutes or specific intent to violate
them in order to have committed a violation. Moreover, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or
fraudulent claim for purposes of the False Claims Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The increasingly global nature of our business operations subjects us to domestic and foreign
anti-bribery and anti-corruption laws and regulations, such as the FCPA. Activities conducted in jurisdictions outside of the U.S. create the risk of unauthorized payments or offers of payments that are prohibited under the FCPA or comparable laws
and regulations. It is our policy to implement safeguards to discourage these practices by our employees. However, these safeguards may ultimately prove ineffective, and our employees, consultants, and agents may engage in conduct for which we might
be held responsible. Violations of the FCPA may result in severe criminal or civil sanctions, and we may be subject to other liabilities, which could negatively affect our business, operating results and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations as well as other domestic and
foreign legal requirements will involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting
applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our
business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other U.S. federal healthcare programs, contractual damages,
reputational harm, diminished profits and future earnings, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval and
commercialization of any of our product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with environmental, health and safety, and laboratory animal welfare laws and
regulations, we could become subject to fines or penalties or incur costs that could harm our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to numerous federal, state
and local environmental, health and safety, and laboratory animal welfare laws and regulations. These legal requirements include those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and
wastes as well as those which regulate the care and use of animals in research. Our operations will involve research using research animals and the use of hazardous and flammable materials, including chemicals and biological materials. Our
operations also may produce hazardous waste products. We generally anticipate contracting with third parties for the disposal of these materials and wastes. We will not be able to eliminate the risk of contamination or injury from these materials.
In the event of contamination or injury resulting from any use by us of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil
or criminal fines and penalties for failure to comply with such laws and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we maintain workers&#146; compensation insurance to cover
us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental
liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety, and laboratory animal welfare laws and
regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third-party claims of intellectual property infringement against us, our licensors or our collaborators may prevent or delay our product discovery and
development efforts. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on our avoiding infringement of the valid patents and proprietary rights of third
parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are developing
our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. We cannot guarantee
that our technology, future product candidates or the use of such product candidates do not infringe third-party patents. It is also possible that we have failed to identify relevant third-party patents or applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third parties may assert that we infringe their patents or that we are otherwise employing their proprietary technology without authorization, and may sue us.
There may be third-party patents of which we are currently unaware with claims to compositions, formulations, methods of manufacture or methods of use or treatment that cover product candidates we discover and develop. Because patent applications
can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our
technologies or the manufacture, use or sale of our product candidates infringes upon these patents. If any such third-party patents were held by a court of competent jurisdiction to cover our technologies or product candidates, the holders of any
such patents may be able to block our ability to commercialize the applicable product candidate unless we obtain a license under the applicable patents, or until such patents expire or are finally determined to be held invalid or unenforceable. Such
a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, our ability to commercialize our product candidates may be impaired
or delayed, which could in turn significantly harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third parties asserting their patent rights against us may seek and obtain injunctive or
other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. For example, the Broad Institute patent family includes issued patents in the U.S. and Europe that purport to cover
certain aspects of the CRISPR/Cas9 gene editing platform for use on eukaryotic cells, including human cells. In January 2016, an interference proceeding was declared in the USPTO between the claims from one UC/Vienna/Charpentier patent application
we license through Caribou and certain U.S. patents and one application of the Broad Institute patent family to determine which set of inventors invented first and, thus, is entitled to patents on the invention. In February 2017, the PTAB dismissed
the interference proceeding without making </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any decision regarding inventorship or priority between the patents and applications at issue. It is now possible that the Broad Institute could seek to assert its patent family against us based
on our CRISPR/Cas9-based activities, including commercialization. Defense of these or similar claims, regardless of their merit, would involve substantial litigation expense, would be a substantial diversion of management and other employee
resources from our business and may impact our reputation. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#146; fees for any adjudicated willful
infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. In that event, we may be unable to further develop and
commercialize our product candidates, which could harm our business significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are found to infringe a third party&#146;s valid intellectual
property rights, we could be required to obtain a license from such third party to continue developing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all.
Even if we were able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease
commercializing, manufacturing or importing the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#146; fees if we are found to have willfully infringed a patent. A
finding of infringement could prevent us from commercializing our product candidates, force us to redesign our infringing products or force us to cease some or all of our business operations, any of which could materially harm our business and could
prevent us from further developing and commercializing our proposed future product candidates thereby causing us significant harm. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a
similar negative impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Under our license agreement with Caribou, we sublicense a patent family from The Regents of the University
of California and the University of Vienna that is <FONT STYLE="white-space:nowrap">co-owned</FONT> by Dr.&nbsp;Emmanuel Charpentier. The outcome of recent proceedings related to this patent family may affect our ability to utilize the intellectual
property sublicensed under our license agreement with Caribou. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Broad Institute patent family includes issued patents in the U.S. and Europe
that purport to cover certain aspects of the CRISPR/Cas9 gene editing platform for use on eukaryotic cells, including human cells. On January&nbsp;11, 2016, the PTAB declared an interference proceeding between certain patents and a patent
application of the Broad Institute patent family and one UC/Vienna/Charpentier patent application to determine, based on priority of invention, whether the contested inventions belong either to UC/Vienna/Charpentier or to the Broad Institute. This
interference proceeding was discontinued by the PTAB in February 2017 without any finding regarding inventorship or priority. In discontinuing the interference proceeding, the PTAB found that the claim sets presented by the two parties were
&#147;patentably distinct&#148; from each other and, thus, did not meet the statutory requirements for continuing the proceeding. In April 2017, UC/Vienna/Charpentier appealed to the U.S. Court of Appeals for the Federal Circuit seeking a review and
reversal of the PTAB&#146;s decision to terminate the interference. In addition, UC/Vienna/Charpentier continue to prosecute other patent claims covering the CRISPR/Cas9 inventions, which could also result in allowable or issued patents in the
United States. Certain of the claims being prosecuted by UC/Vienna/Charpentier, if found allowable by the USPTO, could lead to interference proceedings against patents or patent applications owned by other parties, including the Broad Institute
patent family, with respect to certain claims relating to the use of CRISPR/Cas9 in eukaryotic cells. We cannot be certain which of these results, if any, will actually occur. Further, the effects that any such results may have on us and our
intellectual property position, including whether UC/Vienna/Charpentier will ultimately be successful in prosecuting to issuance a patent covering the CRISPR/Cas9 system that we are able to use under our license agreement with Caribou, are currently
unknown. The Broad could seek to assert its issued patents against us based on our CRISPR/Cas9-based activities, including commercialization. Defense of these claims, regardless of their merit, would involve substantial litigation expense, would be
a substantial diversion of management and other employee resources from our business and may impact our reputation. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and
attorneys&#146; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. In that event, we could
be unable to further develop and commercialize our product candidates, which could harm our business significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims
challenging the inventorship of our patents and other intellectual property. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may in the future be subject to claims that former employees,
collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor</FONT> or other claims challenging the inventorship of our patents or ownership of our
intellectual property (including patents and intellectual property that we <FONT STYLE="white-space:nowrap">in-license).</FONT> For example, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
UC/Vienna/Charpentier patent family that is covered by our license agreement with Caribou is <FONT STYLE="white-space:nowrap">co-owned</FONT> by UC/Vienna and Dr.&nbsp;Charpentier, and our
sublicense rights are derived from the first two <FONT STYLE="white-space:nowrap">co-owners</FONT> and not from Dr.&nbsp;Charpentier. Therefore, our rights to these patents are not exclusive and third parties, including competitors, may have access
to intellectual property that is important to our business. In addition, we may have inventorship disputes arise from conflicting obligations of collaborators, consultants or others who are involved in developing our technology and product
candidates. Litigation or other legal proceedings may be necessary to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual
property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could
result in substantial costs and be a distraction to management and other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend on intellectual property licensed from third parties
and termination of any of these licenses could result in the loss of significant rights, which would harm our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are dependent on
patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary technology, both our own and licensed from others, including Caribou and Novartis. Any termination of these licenses, or a finding that such intellectual property lacks legal
effect, could result in the loss of significant rights and could harm our ability to commercialize any product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disputes may also arise
between us and our licensors, our licensors and their licensors, or us and third parties that <FONT STYLE="white-space:nowrap">co-own</FONT> intellectual property with our licensors or their licensors, regarding intellectual property subject to a
license agreement, including those relating to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope of rights, if any, granted under the license agreement and other interpretation-related issues; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the license agreement; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether our licensor or its licensor had the right to grant the license agreement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether third parties are entitled to compensation or equitable relief, such as an injunction, for our use of the intellectual property without their authorization; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our right to sublicense patent and other rights to third parties under collaborative development relationships; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether we are complying with our obligations with respect to the use of the licensed technology in relation to our development and commercialization of product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our involvement in the prosecution, defense and enforcement of the licensed patents and our licensors&#146; overall patent strategy; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the allocation of ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint creation or use of intellectual property by our licensors and by us and our partners; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amounts of royalties, milestones or other payments due under the license agreement. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If disputes over
intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, or are insufficient to provide us the necessary rights to use the intellectual property, we may be unable
to successfully develop and commercialize the affected product candidates. If we or any such licensors fail to adequately protect this intellectual property, our ability to commercialize our products could suffer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend, in part, on our licensors to file, prosecute, maintain, defend and enforce patents and patent applications that are material to our business.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patents relating to our product candidates are controlled by certain of our licensors. Each of our licensors or their licensors generally has
rights to file, prosecute, maintain and defend the patents we have licensed from such licensor. If these licensors or any future licensees and in some cases, <FONT STYLE="white-space:nowrap">co-owners</FONT> from which we do not yet have licenses,
having rights to file, prosecute, maintain, and defend our patent rights fail to adequately conduct these activities for patents or patent applications covering any of our product candidates, our ability to develop and commercialize those product
candidates may be adversely affected and we may not be able to prevent competitors from making, using or selling competing products. We cannot be certain that such activities by our licensors have been or will be conducted in compliance with
applicable laws and regulations or in our best interests, or will result in valid and enforceable patents or other intellectual property rights. Pursuant to the terms of the license </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreements with our licensors, the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and, even if we
are permitted to pursue such enforcement or defense, we cannot ensure the cooperation of our licensors or, in some cases, other necessary parties, such as the <FONT STYLE="white-space:nowrap">co-owners</FONT> of the intellectual property from which
we have not yet obtained a license. We cannot be certain that our licensors, and in some cases, their <FONT STYLE="white-space:nowrap">co-owners,</FONT> will allocate sufficient resources or prioritize their or our enforcement of such patents or
defense of such claims to protect our interests in the licensed patents. For example, with respect to our sublicensed rights from Caribou to UC/Vienna/Charpentier intellectual property, UC retained the right to control the prosecution, enforcement
and defense of this intellectual property in its license agreement with Caribou and, pursuant to the Invention Management Agreement, shares these responsibilities with CRISPR Therapeutics and, under certain circumstances, ERS, as the designated
managers of the intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we are not a party to legal actions involving our licensed intellectual property, an adverse outcome could
harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business. In addition, even when we have the right to control patent prosecution of licensed patents and patent
applications, enforcement of licensed patents, or defense of claims asserting the invalidity of those patents, we may still be adversely affected or prejudiced by actions or inactions of our licensors and their counsel that took place prior to or
after our assuming control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in obtaining or maintaining necessary rights to product components and processes or other
technology for our product development pipeline. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The growth of our business will likely depend in part on our ability to acquire or <FONT
STYLE="white-space:nowrap">in-license</FONT> additional proprietary rights. For example, our programs may involve additional product candidates, delivery systems or technologies that may require the use of additional proprietary rights held by third
parties. Our ultimate product candidates may also require specific modifications or formulations to work effectively and efficiently. These modifications or formulations may be covered by intellectual property rights held by others. We may be unable
to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> any relevant third-party intellectual property rights that we identify as necessary or important to our business operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these
institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#146;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license
within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The licensing and acquisition of third-party intellectual property rights is a competitive practice and companies that may be more established, or have
greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies
may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and
ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to
successfully obtain rights to valid third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial condition could suffer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We could be unsuccessful in obtaining or maintaining adequate patent protection for one or more of our products or product candidates, or asserting and
defending our intellectual property rights that protect our products and technologies. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We anticipate that we will file additional patent
applications both in the United States and in other countries, as appropriate. However, we cannot predict: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if and when any patents will issue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the degree and range of protection any issued patents will afford us against competitors, including whether third parties will find ways to invalidate or otherwise circumvent our patents; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether others will apply for or obtain patents claiming aspects similar to those covered by our patents and patent applications; or </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether we will need to initiate litigation or administrative proceedings to assert or defend our patent rights, which may be costly whether we win or lose. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Composition of matter patents for biological and pharmaceutical products are generally considered to be the strongest form of intellectual property protection
for those types of products, as such patents provide protection without regard to any method of use. We cannot be certain, however, that any claims in our pending or future patent applications covering the composition of matter of our product
candidates will be considered patentable by the USPTO or by patent offices in foreign countries, or that the claims in any of our ultimately issued patents will be considered valid and enforceable by courts in the United States or foreign countries.
Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the
patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products <FONT STYLE="white-space:nowrap">&#147;off-label&#148;</FONT> for those uses that are covered
by our method of use patents. Although <FONT STYLE="white-space:nowrap">off-label</FONT> prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or
prosecute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The strength of patents in the biotechnology and pharmaceutical field can be uncertain, and evaluating the scope of such patents involves
complex legal and scientific analyses. The patent applications that we own or <FONT STYLE="white-space:nowrap">in-license</FONT> may fail to result in issued patents with claims that cover any product candidates or uses thereof in the United States
or in other foreign countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, the patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all
necessary or desirable patent applications at a reasonable cost, in a timely manner, or in all jurisdictions. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain
patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties. We may also
require the cooperation of our licensors or other necessary parties, such as the <FONT STYLE="white-space:nowrap">co-owners</FONT> of the intellectual property from which we have not yet obtained a license, in order to enforce the licensed patent
rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The laws of foreign countries may not protect our rights to the same extent as the laws of the United States and we may fail to seek or obtain patent
protection in all major markets. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. Publications of discoveries in the scientific literature often lag behind the
actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we will be unable to know with certainty whether we were the
first to make any inventions claimed in any patents or patent applications, or that we were the first to file for patent protection of such inventions, nor can we know whether those from whom we license patents were the first to make the inventions
claimed or were the first to file. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned
and licensed patents may be challenged in the courts or patent offices in the United States and abroad. There is a substantial amount of litigation as well as administrative proceedings for challenging patents, including interference, derivation,
and reexamination proceedings before the USPTO and oppositions and other comparable proceedings in foreign jurisdictions, involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, and we expect this
to be true for the CRISPR/Cas9 space as well. In addition, since the passage of the America Invents Act in 2013, U.S. law also provides for other procedures to challenge patents, including <I>inter partes</I> reviews and post-grant reviews, that add
uncertainty to the possibility of challenge to our developed or licensed patents and patent applications in the future. Furthermore, for U.S. applications in which all claims are entitled to a priority date before March&nbsp;16, 2013, an
interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in
part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the
development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us
with sufficient rights to exclude others from commercializing products similar or identical to ours. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our
intellectual property or prevent others from designing their products to avoid being covered by our claims. If the breadth or strength of protection provided by the patent applications we hold is threatened, this could dissuade companies from
collaborating with us to develop, and could threaten our ability to commercialize, product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market product candidates under patent protection
would be reduced. Because patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our pending and future patent applications or the patent applications that we obtain rights to through
<FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements may not result in patents being issued which protect our technology or future product candidates, in whole or in part, or which effectively prevent others from commercializing
competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United&nbsp;States and other countries may diminish the value of our patents or narrow the scope of our patent protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Litigation or other administrative proceedings challenging our intellectual property, including interferences, derivation, reexamination, <I>inter partes</I>
reviews and post-grant reviews, may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. Furthermore, there could be public announcement of the
results of hearings, motions or other interim proceedings or developments in any proceeding challenging the issuance, scope, validity and enforceability of our developed or licensed intellectual property. If securities analysts or investors perceive
these results to be negative, it could have a substantial adverse effect on the price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these potential negative developments
could impact the scope, validity, enforceability or commercial value of our patent rights and, as a result, have material adverse effect on our business, financial condition, results of operations or prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect
proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> that is not patentable or that we elect not to patent. We also utilize proprietary processes for which patents are difficult to enforce. In addition, other elements of our product
discovery and development processes involve proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information, or technology that is not covered by patents. Trade secrets, however, may be difficult to protect. We seek to protect our
proprietary processes, in part, by entering into confidentiality agreements with our employees, consultants, outside scientific advisors, contractors, and collaborators. Although we use reasonable efforts to protect our trade secrets, our employees,
consultants, outside scientific advisors, contractors, and collaborators might intentionally or inadvertently disclose our trade secret information to competitors. In addition, competitors may otherwise gain access to our trade secrets or
independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we
may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, or
misappropriation of our intellectual property by third parties, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results, and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have limited intellectual property rights outside the United States. Filing, prosecuting, maintaining and defending patents on product candidates in all
countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can have a different scope and strength than do those in the United States. In addition, the laws of
some foreign countries, such as China, Brazil, Russia, India, and South Africa, do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties
from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions
where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement rights are not as strong as those in the United States.
These products may compete with our products and our patents or other intellectual property rights may not be effective or adequate to prevent them from competing. Further, in jurisdictions outside the United States, a license may not be enforceable
unless all the owners of the intellectual property agree or consent to the license. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in
foreign jurisdictions. The legal systems of certain countries, such as China, Brazil, Russia, India, and South Africa, do not favor the enforcement of patents, trade secrets and other intellectual property, particularly those relating to
biopharmaceutical products, which could make it difficult in those jurisdictions for us to stop the infringement or misappropriation of our patents or other intellectual property rights, or the marketing of competing products in violation of our
proprietary rights. Proceedings to enforce our patent and other intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business. Furthermore, such
proceedings could put our patents at risk of being invalidated, held unenforceable, or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims of infringement or
misappropriation against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the
world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be involved
in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming, and unsuccessful. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Competitors may infringe our patents or the patents of our licensors. To cease such infringement or unauthorized use, we may be required to file patent
infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding or a declaratory judgment action against us, a court may decide that one or more of our patents is not valid or is unenforceable, or may
refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceeding could put one or more of our patents at risk of
being invalidated, held unenforceable or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial
diversion of employee resources from our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interference or derivation proceedings provoked by third parties or brought by the USPTO may be
necessary to determine the priority of inventions with respect to, or the correct inventorship of, our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could
require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation,
interference or derivation proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our
confidential information could be compromised by disclosure during this type of litigation or proceeding. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If
securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or before the USPTO or comparable foreign
authority. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering one of our
product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are
commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or other jurisdictions, even
outside the context of litigation. Such mechanisms include re-examination,<I></I><I>&nbsp;inter partes</I>&nbsp;review, post-grant review and equivalent proceedings in foreign jurisdictions, such as opposition or derivation proceedings. Such
proceedings could result in revocation or amendment to our patents in such a way that they no longer cover and protect our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect
to the validity of our patents, for example, we cannot be certain that there is no invalidating prior art of which we, our patent counsel, and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion
of invalidity, unpatentability and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that our employees, consultants, or independent contractors have wrongfully
used or disclosed confidential information of third parties. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have received confidential and proprietary information from third parties. In
addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies as well as academic research institutions. We may be subject to claims that we or our employees, consultants, or independent contractors
have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#146; former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against
these claims, litigation could result in substantial cost and be a distraction to our management and employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our
patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees on any issued patent are due to be paid to
the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions
during the patent application process. Although an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment
or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include failure to
respond to official actions within prescribed time limits, <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees, and failure to properly legalize and submit formal documents. In any such event, our competitors might be able to enter the
market, which would have a material adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be required to pay certain milestones and royalties under
our&nbsp;license&nbsp;agreements with&nbsp;third-party licensors. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our current and future license agreements, we may be required to pay
milestones and royalties based on our revenues from sales of our products utilizing the technologies licensed or sublicensed from third parties, including Caribou and Novartis, and these royalty payments could adversely affect the overall
profitability for us of any products that we may seek to commercialize. In order to maintain our&nbsp;license&nbsp;rights under these&nbsp;license&nbsp;agreements, we will need to meet certain specified milestones, subject to certain cure
provisions, in the development of our product candidates and in the raising of funding. In addition, these agreements contain diligence milestones and we may not be successful in meeting all of the milestones in the future on a timely basis or at
all. We will need to outsource and rely on&nbsp;third parties&nbsp;for many aspects of the clinical development, sales and marketing of our products covered under our&nbsp;license&nbsp;agreements. Delay or failure by these&nbsp;third
parties&nbsp;could adversely affect the continuation of our&nbsp;license&nbsp;agreements with their third-party licensors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and
trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business
may be adversely affected. Our unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and
trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity
and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our unregistered trademarks or
trade names. Over the long term, if we are unable to successfully register our trademarks and trade names and establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be
adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of
resources and could adversely impact our financial condition or results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>An active trading market for our common stock may not be sustained. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2016, we closed our initial public offering. Prior to this offering, there was no public market for our common stock. Although we have completed our
initial public offering and shares of our common stock are listed and trading on The NASDAQ Global Market, an active trading market for our shares may not be sustained. If an active market for our common stock does not continue, it may be difficult
for our stockholders to sell their shares without depressing the market price for the shares or sell their shares at or above the prices at which they acquired their shares or sell their shares at the time they would like to sell. Any inactive
trading market for our common stock may also impair our ability to raise capital to continue to fund our operations by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The price of our common stock may be volatile and fluctuate substantially. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our stock price is likely to be volatile. The stock market in general and the market for smaller biopharmaceutical companies in particular have experienced
extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the success of competing products or technologies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">results of clinical trials of our product candidates or those of our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments or disputes concerning patent applications, issued patents or other proprietary rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory or legal developments in the United States and other countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the recruitment or departure of key personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the level of expenses related to any of our product candidates or clinical development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results of our efforts to discover, develop, acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> additional product candidates or products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">variations in our financial results or the financial results of companies that are perceived to be similar to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the structure of healthcare payment systems; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">market conditions in the pharmaceutical and biotechnology sectors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general economic, industry and market conditions; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the other factors described in this <I>Risk Factors</I> section. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our principal stockholders and
management own a significant percentage of our stock and, if they choose to act together, will be able to control or exercise significant influence over matters subject to stockholder approval. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our executive officers, directors and principal stockholders, together with their respective affiliates, beneficially owned approximately 74.6% of our capital
stock as of March&nbsp;31, 2017. Accordingly, our executive officers, directors and principal stockholders, if they choose to act together, will be able to determine the composition of the board of directors, retain the voting power to approve all
matters requiring stockholder approval, including mergers and other business combinations, and continue to have significant influence over our operations. This concentration of ownership could have the effect of delaying or preventing a change in
our control or otherwise discouraging a potential acquirer from attempting to obtain control of us that may be in the best interests of our stockholders. This in turn could have a material adverse effect on our stock price and may prevent attempts
by our stockholders to replace or remove the board of directors or management. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion over the use of our cash and cash equivalents and may not use them effectively.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management has broad discretion to use our cash and cash equivalents to fund our operations and could spend these funds in ways that do not
improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of
our common stock to decline and delay the development of our product candidates. Pending our use to fund operations, we may invest our cash and cash equivalents in a manner that does not produce income or that loses value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us difficult, limit attempts by our stockholders
to replace or remove our current management and adversely affect our stock price. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provisions of our certificate of incorporation and <FONT
STYLE="white-space:nowrap">by-laws</FONT> may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for
their shares, or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our stock. Among other things, the certificate of incorporation and <FONT
STYLE="white-space:nowrap">by-laws</FONT> will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">permit the board of directors to issue up to 5,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that the authorized number of directors may be changed only by resolution of the board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">divide the board of directors into three classes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that a director may only be removed from the board of directors by the stockholders for cause; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders, and may not be taken by written consent; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner,
and meet specific requirements as to the form and content of a stockholder&#146;s notice; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prevent cumulative voting rights (therefore allowing the holders of a plurality of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they
should so choose); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require that, to the fullest extent permitted by law, a stockholder reimburse us for all fees, costs and expenses incurred by us in connection with a proceeding initiated by such stockholder in which such stockholder
does not obtain a judgment on the merits that substantially achieves the full remedy sought; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that special meetings of our stockholders may be called only by the chairman of the board, our chief executive officer (or president, in the absence of a chief executive officer) or by the board of directors;
and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that stockholders will be permitted to amend the bylaws only upon receiving at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the total votes entitled to be cast by holders of all outstanding shares
then entitled to vote generally in the election of directors, voting together as a single class. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, because we are incorporated
in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any
&#147;interested&#148; stockholder for a period of three years following the date on which the stockholder became an &#147;interested&#148; stockholder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the
exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding
brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or our
<FONT STYLE="white-space:nowrap">by-laws,</FONT> any action to interpret, apply, enforce, or determine the validity of our certificate of incorporation or bylaws, or any action asserting a claim against us that is governed by the internal affairs
doctrine. The choice of forum provision may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits
against us and our directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional
costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We incur
significant costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives and corporate governance practices. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a public company, and particularly after we are no longer an &#147;emerging growth company&#148; under applicable SEC regulations, we incur significant
legal, accounting and other expenses. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The NASDAQ Global Market and other applicable securities rules and regulations impose
various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time to these
compliance initiatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 (Section&nbsp;404), we are required to furnish a report by our
management on our internal control over financial reporting. However, while we remain an emerging growth company, we are not required to include an attestation report on internal control over financial reporting issued by our independent registered
public accounting firm. To achieve compliance with Section&nbsp;404 within the prescribed period, we are engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this
regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve
control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. If we identify one or more material
weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not continue to publish research reports about our business, or if they issue an adverse opinion about our
business, our stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading market for our common stock may be influenced, in part, by the research
and reports that industry or securities analysts publish about us or our business. If one or more of the analysts who cover us issues an adverse opinion about our company, our stock price would likely decline. If one or more of these analysts ceases
research coverage of us or fails to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B><A NAME="tx378762_12"></A>Item&nbsp;2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Unregistered Sales of Equity Securities and Use of Proceeds </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Proceeds from Initial Public
Offering of Common Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2016, we issued and sold 6,900,000 shares of our common stock, including 900,000 shares of common stock sold
pursuant to the underwriters&#146; full exercise of their option to purchase additional shares, in our initial public offering (IPO) at a public offering price of $18.00 per share, for aggregate gross proceeds of $124.2&nbsp;million. All of the
shares issued and sold in the IPO were registered under the Securities Act pursuant to a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-210689),</FONT> which was
declared effective by the SEC on May&nbsp;5, 2016. Credit Suisse Securities (USA) LLC, Jeffries LLC and Leerink Partners LLC acted as joint book-running managers of the offering and as representatives of the underwriters. Wedbush Securities Inc.
acted as manager for the offering. The offering commenced on May&nbsp;5, 2016 and did not terminate until the sale of all of the shares offered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The estimated net proceeds to us, after deducting underwriting discounts of $8.7&nbsp;million and offering
expenses of $3.4&nbsp;million, were approximately $112.1&nbsp;million. No offering expenses were paid directly or indirectly to any of our directors or officers, or their associates, or persons owning 10.0% or more of any class of our equity
securities or to any other affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2017, we have used approximately $58.1&nbsp;million of the net offering proceeds primarily to
advance the research and development of our product candidates for our sentinel indications, to progress additional <I>in vivo</I> and <I>ex vivo</I> pipeline product candidates, to further develop our delivery technologies and CRISPR/Cas9 gene
editing platform and for working capital and general corporate purposes. We are holding a significant portion of the balance of the net proceeds from the offering in interest-bearing money market accounts, commercial paper and U.S. treasury
securities. There has been no material change in our planned use of the balance of the net proceeds from what was described in our Prospectus that forms a part of our Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-210689),</FONT> which was filed with the SEC on May&nbsp;5, 2016, pursuant to Rule 424(b)(4) under the Securities Act. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B><A NAME="tx378762_13"></A>Item&nbsp;6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Exhibits </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Chief Executive Officer pursuant to Rules <FONT STYLE="white-space:nowrap">13a-14(a)</FONT> or <FONT STYLE="white-space:nowrap">15d-14(a)</FONT> of the Securities Exchange Act of 1934, as adopted pursuant to
Section&nbsp;302 of the Sarbanes-Oxley Act of 2002. (1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Chief Financial Officer pursuant to Rules <FONT STYLE="white-space:nowrap">13a-14(a)</FONT> or <FONT STYLE="white-space:nowrap">15d-14(a)</FONT> of the Securities Exchange Act of 1934, as adopted pursuant to
Section&nbsp;302 of the Sarbanes-Oxley Act of 2002. (1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certifications pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of The Sarbanes-Oxley Act of 2002, by Nessan Bermingham, Ph.D., President and Chief Executive Officer of the Company, and Graeme Bell,
Executive Vice President, Chief Financial Officer of the Company. (1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Instance Document.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema Document.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Calculation Linkbase Document.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Definition Linkbase Document.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Label Linkbase Document.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.&nbsp;PRE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Presentation Linkbase Document.</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Filed with this Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx378762_14"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: May&nbsp;2, 2017 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">INTELLIA THERAPEUTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Nessan Bermingham</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Nessan Bermingham, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(Principal Executive Officer)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Graeme Bell</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Graeme Bell</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Executive&nbsp;Vice&nbsp;President,&nbsp;Chief&nbsp;Financial&nbsp;Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(Principal Financial Officer)</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>d378762dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RULE <FONT STYLE="white-space:nowrap">13a-14(a)</FONT> / RULE <FONT STYLE="white-space:nowrap">15d-14(a)</FONT> OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Nessan Bermingham, Ph.D., certify that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. &nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of Intellia
Therapeutics, Inc.; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. &nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. &nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly
present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. &nbsp;&nbsp;&nbsp;&nbsp;The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> for the registrant and have: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed
under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;(Paragraph omitted pursuant to SEC Release Nos. <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">33-8238/34-47986</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">33-8392/34-49313);</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) &nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) &nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that
occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal
control over financial reporting; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. &nbsp;&nbsp;&nbsp;&nbsp;The registrant&#146;s other certifying officer and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) &nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the
registrant&#146;s internal control over financial reporting. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May&nbsp;2, 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Nessan Bermingham</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nessan Bermingham, Ph.D.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President and Chief
Executive Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Executive Officer)</P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>d378762dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RULE <FONT STYLE="white-space:nowrap">13a-14(a)</FONT> / RULE <FONT STYLE="white-space:nowrap">15d-14(a)</FONT> OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Graeme Bell, certify that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. &nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of Intellia
Therapeutics, Inc.; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. &nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. &nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly
present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. &nbsp;&nbsp;&nbsp;&nbsp;The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> for the registrant and have: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed
under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;(Paragraph omitted pursuant to SEC Release Nos. <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">33-8238/34-47986</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">33-8392/34-49313);</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) &nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) &nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that
occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal
control over financial reporting; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. &nbsp;&nbsp;&nbsp;&nbsp;The registrant&#146;s other certifying officer and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) &nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the
registrant&#146;s internal control over financial reporting. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May&nbsp;2, 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Graeme Bell</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Graeme Bell</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive Vice President, Chief
Financial Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Financial Officer)</P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>d378762dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATIONS OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS ADOPTED PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of Intellia Therapeutics, Inc. (the &#147;Company&#148;) for the
period ended March&nbsp;31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), each of the undersigned, Nessan Bermingham, Ph.D., President and Chief Executive Officer of the Company, and Graeme
Bell, Executive Vice President and Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. (section) 1350, as adopted pursuant to (section) 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: May&nbsp;2, 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Nessan Bermingham</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nessan Bermingham, Ph.D.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President and Chief
Executive Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Executive Officer)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Graeme Bell</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Graeme Bell</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive Vice President, Chief
Financial Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Financial Officer)</P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>ntla-20170331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFS Xcelerate Instance Document - http://www.dfsco.com/financial-services/ -->
<!-- Version:  6.23.6 -->
<!-- Round: 4 -->
<!-- Creation date: 2017-05-01T16:46:03Z -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:ntla="http://intelliatx.com/20170331" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="ntla-20170331.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <us-gaap:PreferredUnitsIssued contextRef="eol_PE974471--1710-Q0002_STD_0_20140731_0_2038452x2392037" unitRef="shares" decimals="INF" id="id_8787543_D35EEA4B-0EB0-4E29-8BFB-B0AA43757F79_1001_0">8110599</us-gaap:PreferredUnitsIssued>
  <ntla:ResearchFundingAggregateAmount contextRef="eol_PE974471--1710-Q0002_STD_0_20150131_0_2025578x2392029_2028497x2033371_2036820x2025359" unitRef="iso4217_USD" decimals="INF" id="id_8787543_72BEC4AB-B6FD-45B7-A117-FBADDBFA8677_5001_3">20000000</ntla:ResearchFundingAggregateAmount>
  <ntla:QuarterlyResearchPayments contextRef="eol_PE974471--1710-Q0002_STD_0_20150131_0_2025578x2392029_2036820x2025359" unitRef="iso4217_USD" decimals="-5" id="id_8787543_72BEC4AB-B6FD-45B7-A117-FBADDBFA8677_6001_2">1000000</ntla:QuarterlyResearchPayments>
  <ntla:TechnologyAccessFees contextRef="eol_PE974471--1710-Q0002_STD_0_20150131_0_2025578x2392029_2036820x2025359" unitRef="iso4217_USD" decimals="-5" id="id_8787543_72BEC4AB-B6FD-45B7-A117-FBADDBFA8677_6001_1">20000000</ntla:TechnologyAccessFees>
  <ntla:EstimatedFairValueOfPreferredStock contextRef="eol_PE974471--1710-Q0002_STD_0_20150131_0_2025578x2392029_2039549x2392030" unitRef="iso4217_USD" decimals="-5" id="id_8787543_72BEC4AB-B6FD-45B7-A117-FBADDBFA8677_7001_10">11600000</ntla:EstimatedFairValueOfPreferredStock>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE974471--1710-Q0002_STD_0_20170426_0" unitRef="shares" decimals="INF" id="id_8787543_FE8ECEBC-6257-40C8-A580-4CA101F4BD1B_2_5">36028677</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE974471--1710-Q0002_STD_0_20160531_0_2040137x2029877" unitRef="shares" decimals="INF" id="id_8787543_2030FB77-6D4D-4EDA-8AA5-32415AA49E15_3001_1">23481956</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE974471--1710-Q0002_STD_0_20150831_0_2036820x2025359_2038452x2392029_2039549x2037696" unitRef="shares" decimals="INF" id="id_8787543_228973BC-2A56-46E9-9229-AA79F595C42F_2003_1">761905</us-gaap:PreferredStockSharesIssued>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE974471--1710-Q0002_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_1002_25">64192000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_469F7756-1021-4119-9F80-27B842AEC701_1_0">1532000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_71965D42-C554-4D66-9C10-3BEB7D21F85E_1001_1">255735000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_1_20">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_71965D42-C554-4D66-9C10-3BEB7D21F85E_1001_2">255735000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" xsi:nil="true" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_1_17" />
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="shares" decimals="INF" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_1_23">36025676</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="shares" decimals="INF" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_1_22">36025676</us-gaap:CommonStockSharesIssued>
  <us-gaap:Assets contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_1_8">279263000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_1_5">261078000</us-gaap:AssetsCurrent>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="shares" decimals="INF" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_1_21">120000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-5" id="id_8787543_36ABA540-319E-456D-9281-15249ECA1570_2001_0">2700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_1_24">266080000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_1_2">257551000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_1_3">2443000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_1_19">4000</us-gaap:CommonStockValue>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_1_15">54092000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_1_11">1434000</us-gaap:AccountsPayableCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_1_13">19917000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_469F7756-1021-4119-9F80-27B842AEC701_1_1">2027000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_1_12">3559000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_1_27">279263000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_1_16">378000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_1_14">24910000</us-gaap:LiabilitiesCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_1_7">6767000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_8B4CF2BB-D7F8-4254-9E0F-7ACA85EC9F75_1001_1">17929000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_1_6">11418000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8787543_F9931F9E-76E9-48D6-8E50-FC5F464B9F71_3001_6">7.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:StockholdersEquity contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_1_26">199883000</us-gaap:StockholdersEquity>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-5" id="id_8787543_D4BAEB95-6F65-4413-89C8-9637CBE0C76B_2001_0">25000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8787543_F9931F9E-76E9-48D6-8E50-FC5F464B9F71_3001_5">9.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="shares" decimals="INF" id="id_8787543_24B262DB-AEF7-4923-B137-51AAAC035E90_3001_6">780588</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="shares" decimals="INF" id="id_8787543_36B85128-8AD9-46B7-8D04-1A6039FFDFE4_1001_2">1174938</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8787543_693CF83A-16DE-4D7D-A01D-F482158FDE69_1001_2">0.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_1_25">-66201000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_1_4">1084000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_8B4CF2BB-D7F8-4254-9E0F-7ACA85EC9F75_1001_2">5440000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0" unitRef="shares" decimals="INF" id="id_8787543_24B262DB-AEF7-4923-B137-51AAAC035E90_3001_5">4373222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0_2022410x2026970" unitRef="iso4217_USD" decimals="-3" id="id_8787543_71965D42-C554-4D66-9C10-3BEB7D21F85E_1002_1">255735000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0_2022410x2026970" unitRef="iso4217_USD" decimals="-3" id="id_8787543_71965D42-C554-4D66-9C10-3BEB7D21F85E_1002_2">255735000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AccountsReceivableRelatedParties contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0_2025578x2392029_2036820x2025359" unitRef="iso4217_USD" decimals="-5" id="id_8787543_224A7E6A-3CD1-4581-9CF1-8119E9D739A4_1004_3">1000000</us-gaap:AccountsReceivableRelatedParties>
  <us-gaap:DeferredRevenue contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0_2025578x2392029_2036820x2025359" unitRef="iso4217_USD" decimals="-5" id="id_8787543_224A7E6A-3CD1-4581-9CF1-8119E9D739A4_1004_2">10400000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0_2025578x2392033_2036820x2025359" unitRef="iso4217_USD" decimals="-5" id="id_8787543_761E26B0-8F65-4BF4-B9C3-E40BDD71B897_3003_4">63600000</us-gaap:DeferredRevenue>
  <us-gaap:AccountsReceivableRelatedPartiesCurrent contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0_2036820x2025359_2038452x2392029" unitRef="iso4217_USD" decimals="-5" id="id_8787543_2E3FD9FC-C678-4864-8AF5-ACE21177DB9C_1003_1">1000000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
  <us-gaap:DeferredRevenue contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0_2036820x2025359_2038452x2392029" unitRef="iso4217_USD" decimals="-5" id="id_8787543_2E3FD9FC-C678-4864-8AF5-ACE21177DB9C_1003_2">10400000</us-gaap:DeferredRevenue>
  <ntla:RelatedPartyOwnershipPercentage contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0_2036820x2025359_2038452x2392029" unitRef="pure" decimals="3" id="id_8787543_228973BC-2A56-46E9-9229-AA79F595C42F_1005_3">0.157</ntla:RelatedPartyOwnershipPercentage>
  <ntla:RelatedPartyOwnershipPercentage contextRef="eol_PE974471--1710-Q0002_STD_0_20170331_0_2038452x2392037" unitRef="pure" decimals="3" id="id_8787543_D35EEA4B-0EB0-4E29-8BFB-B0AA43757F79_1002_1">0.155</ntla:RelatedPartyOwnershipPercentage>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE974471--1710-Q0002_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_2001_24">75816000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PreferredUnitsIssued contextRef="eol_PE974471--1710-Q0002_STD_0_20151231_0_2036820x2025359_2038452x2392029_2039549x2392042" unitRef="shares" decimals="INF" id="id_8787543_228973BC-2A56-46E9-9229-AA79F595C42F_2001_0">4761905</us-gaap:PreferredUnitsIssued>
  <us-gaap:PreferredUnitsIssued contextRef="eol_PE974471--1710-Q0002_STD_0_20151231_0_2036820x2025359_2038452x2392029_2039549x2392043" unitRef="shares" decimals="INF" id="id_8787543_228973BC-2A56-46E9-9229-AA79F595C42F_2002_0">2666666</us-gaap:PreferredUnitsIssued>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_469F7756-1021-4119-9F80-27B842AEC701_2_0">2703000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_241FB279-F374-46DC-851D-A142A030A8D6_1001_1">270448000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_2_20">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_241FB279-F374-46DC-851D-A142A030A8D6_1001_2">270448000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_2_17" />
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_2_23">36018540</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_2_22">36018540</us-gaap:CommonStockSharesIssued>
  <us-gaap:Assets contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_2_8">298969000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_2_5">281306000</us-gaap:AssetsCurrent>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_2_21">120000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_2_24">263403000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_2_2">273064000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_2_3">6454000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_2_19">4000</us-gaap:CommonStockValue>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_2_15">58109000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_2_11">4652000</us-gaap:AccountsPayableCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_2_13">20178000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_469F7756-1021-4119-9F80-27B842AEC701_2_1">3197000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_2_12">5900000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_2_27">298969000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_2_16">293000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_2_14">30730000</us-gaap:LiabilitiesCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_2_7">7035000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_2_6">10628000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:StockholdersEquity contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_2_26">209837000</us-gaap:StockholdersEquity>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8787543_F9931F9E-76E9-48D6-8E50-FC5F464B9F71_1001_1">8.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_8787543_36B85128-8AD9-46B7-8D04-1A6039FFDFE4_2001_0">1361855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8787543_693CF83A-16DE-4D7D-A01D-F482158FDE69_2001_0">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_2_25">-53570000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_3A27181F-E33D-47E6-8D80-74D07F5DE584_2_4">1788000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_8787543_24B262DB-AEF7-4923-B137-51AAAC035E90_1001_1">3040214</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0_2022410x2026970" unitRef="iso4217_USD" decimals="-3" id="id_8787543_241FB279-F374-46DC-851D-A142A030A8D6_1002_1">270448000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0_2022410x2026970" unitRef="iso4217_USD" decimals="-3" id="id_8787543_241FB279-F374-46DC-851D-A142A030A8D6_1002_2">270448000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AccountsReceivableRelatedParties contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0_2025578x2392029_2036820x2025359" unitRef="iso4217_USD" decimals="-5" id="id_8787543_224A7E6A-3CD1-4581-9CF1-8119E9D739A4_1005_3">6000000</us-gaap:AccountsReceivableRelatedParties>
  <us-gaap:DeferredRevenue contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0_2025578x2392029_2036820x2025359" unitRef="iso4217_USD" decimals="-5" id="id_8787543_224A7E6A-3CD1-4581-9CF1-8119E9D739A4_1005_2">11600000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0_2025578x2392033_2036820x2025359" unitRef="iso4217_USD" decimals="-5" id="id_8787543_761E26B0-8F65-4BF4-B9C3-E40BDD71B897_3004_4">66700000</us-gaap:DeferredRevenue>
  <us-gaap:AccountsReceivableRelatedPartiesCurrent contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0_2036820x2025359_2038452x2392029" unitRef="iso4217_USD" decimals="-5" id="id_8787543_2E3FD9FC-C678-4864-8AF5-ACE21177DB9C_1004_1">6000000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
  <us-gaap:DeferredRevenue contextRef="eol_PE974471--1710-Q0002_STD_0_20161231_0_2036820x2025359_2038452x2392029" unitRef="iso4217_USD" decimals="-5" id="id_8787543_2E3FD9FC-C678-4864-8AF5-ACE21177DB9C_1004_2">11600000</us-gaap:DeferredRevenue>
  <ntla:RegulatoryBasedMilestonePaymentsUnderAgreement contextRef="eol_PE974471--1710-Q0002_STD_30_20160430_0_2025578x2392033_2028497x2033371_2036820x2025359" unitRef="iso4217_USD" decimals="INF" id="id_8787543_EFB35167-0985-4BD2-96CC-F5965523C7A8_1001_3">110000000</ntla:RegulatoryBasedMilestonePaymentsUnderAgreement>
  <ntla:DevelopmentBasedMilestonePaymentsUnderAgreement contextRef="eol_PE974471--1710-Q0002_STD_30_20160430_0_2025578x2392033_2028497x2033371_2036820x2025359" unitRef="iso4217_USD" decimals="INF" id="id_8787543_EFB35167-0985-4BD2-96CC-F5965523C7A8_1001_2">25000000</ntla:DevelopmentBasedMilestonePaymentsUnderAgreement>
  <ntla:SalesBasedMilestonePaymentsUnderAgreement contextRef="eol_PE974471--1710-Q0002_STD_30_20160430_0_2025578x2392033_2028497x2033371_2036820x2025359" unitRef="iso4217_USD" decimals="INF" id="id_8787543_EFB35167-0985-4BD2-96CC-F5965523C7A8_1001_4">185000000</ntla:SalesBasedMilestonePaymentsUnderAgreement>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE974471--1710-Q0002_STD_30_20160430_0_2025578x2392033_2036820x2025359" unitRef="iso4217_USD" decimals="-5" id="id_8787543_EFB35167-0985-4BD2-96CC-F5965523C7A8_2001_0">50000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <ntla:AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans contextRef="eol_PE974471--1710-Q0002_STD_30_20160430_0_2025578x2392033_2036820x2025359" unitRef="iso4217_USD" decimals="-5" id="id_8787543_CDE09141-7F7F-45DD-818F-F7E6BD8272AB_1001_1">63800000</ntla:AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans>
  <ntla:AmountAllocatedToTechnologyCollaboration contextRef="eol_PE974471--1710-Q0002_STD_30_20160430_0_2025578x2392033_2036820x2025359" unitRef="iso4217_USD" decimals="-5" id="id_8787543_CDE09141-7F7F-45DD-818F-F7E6BD8272AB_1001_3">11200000</ntla:AmountAllocatedToTechnologyCollaboration>
  <ntla:LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod contextRef="eol_PE974471--1710-Q0002_STD_30_20160430_0_2025578x2392033_2036820x2025359" id="id_8787543_CDE09141-7F7F-45DD-818F-F7E6BD8272AB_1001_2">P6Y</ntla:LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod>
  <ntla:RevenueRecognitionMultipleDeliverableArrangementsNumberOfUnitsOfAccounting contextRef="eol_PE974471--1710-Q0002_STD_30_20160430_0_2025578x2392033_2036820x2025359" unitRef="Unit" decimals="INF" id="id_8787543_CDE09141-7F7F-45DD-818F-F7E6BD8272AB_1001_0">2</ntla:RevenueRecognitionMultipleDeliverableArrangementsNumberOfUnitsOfAccounting>
  <ntla:CollaborativeArrangementObligationToFundPercentage contextRef="eol_PE974471--1710-Q0002_STD_30_20160430_0_2025578x2392033_2036820x2025359" unitRef="pure" decimals="3" id="id_8787543_86555C2F-EF70-491F-8D11-2A026A84056A_1_0">0.500</ntla:CollaborativeArrangementObligationToFundPercentage>
  <us-gaap:DeferredRevenueAdditions contextRef="eol_PE974471--1710-Q0002_STD_31_20150131_0_2025578x2392029_2027749x2040355_2036820x2025359" unitRef="iso4217_USD" decimals="-5" id="id_8787543_72BEC4AB-B6FD-45B7-A117-FBADDBFA8677_1001_0">10000000</us-gaap:DeferredRevenueAdditions>
  <ntla:DevelopmentBasedMilestonePaymentsUnderAgreement contextRef="eol_PE974471--1710-Q0002_STD_31_20150131_0_2025578x2392029_2028497x2033371" unitRef="iso4217_USD" decimals="INF" id="id_8787543_72BEC4AB-B6FD-45B7-A117-FBADDBFA8677_2001_5">30300000</ntla:DevelopmentBasedMilestonePaymentsUnderAgreement>
  <ntla:RegulatoryBasedMilestonePaymentsUnderCollaborationFirstIndication contextRef="eol_PE974471--1710-Q0002_STD_31_20150131_0_2025578x2392029_2028497x2033371" unitRef="iso4217_USD" decimals="INF" id="id_8787543_72BEC4AB-B6FD-45B7-A117-FBADDBFA8677_2001_6">50000000</ntla:RegulatoryBasedMilestonePaymentsUnderCollaborationFirstIndication>
  <ntla:RegulatoryBasedMilestonePaymentsUnderCollaborationSecondIndication contextRef="eol_PE974471--1710-Q0002_STD_31_20150131_0_2025578x2392029_2028497x2033371" unitRef="iso4217_USD" decimals="INF" id="id_8787543_72BEC4AB-B6FD-45B7-A117-FBADDBFA8677_2001_7">50000000</ntla:RegulatoryBasedMilestonePaymentsUnderCollaborationSecondIndication>
  <ntla:SalesBasedMilestonePaymentsUnderAgreement contextRef="eol_PE974471--1710-Q0002_STD_31_20150131_0_2025578x2392029_2028497x2033371" unitRef="iso4217_USD" decimals="INF" id="id_8787543_72BEC4AB-B6FD-45B7-A117-FBADDBFA8677_2001_8">100000000</ntla:SalesBasedMilestonePaymentsUnderAgreement>
  <ntla:CollaborationArrangementTermOfAgreement contextRef="eol_PE974471--1710-Q0002_STD_31_20150131_0_2025578x2392029_2036820x2025359" id="id_8787543_72BEC4AB-B6FD-45B7-A117-FBADDBFA8677_3001_4">P5Y</ntla:CollaborationArrangementTermOfAgreement>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="eol_PE974471--1710-Q0002_STD_31_20150131_0_2025578x2392029_2039549x2392030" unitRef="iso4217_USD" decimals="-5" id="id_8787543_72BEC4AB-B6FD-45B7-A117-FBADDBFA8677_4001_9">9000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <ntla:CollaborationConsiderationAllocatedToEquity contextRef="eol_PE974471--1710-Q0002_STD_31_20150131_0_2025578x2392029_2039549x2392030" unitRef="iso4217_USD" decimals="-5" id="id_8787543_72BEC4AB-B6FD-45B7-A117-FBADDBFA8677_4001_11">2600000</ntla:CollaborationConsiderationAllocatedToEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE974471--1710-Q0002_STD_31_20160531_0_2036820x2025359_2038452x2392029" unitRef="shares" decimals="INF" id="id_8787543_228973BC-2A56-46E9-9229-AA79F595C42F_1004_2">277777</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE974471--1710-Q0002_STD_31_20160531_0_2040137x2029877" unitRef="shares" decimals="INF" id="id_8787543_2030FB77-6D4D-4EDA-8AA5-32415AA49E15_1001_0">6900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE974471--1710-Q0002_STD_31_20160531_0_2040137x2032595" unitRef="shares" decimals="INF" id="id_8787543_2030FB77-6D4D-4EDA-8AA5-32415AA49E15_2001_2">3055554</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:DeferredRevenueAdditions contextRef="eol_PE974471--1710-Q0002_STD_852_20170331_0_2025578x2392029_2036820x2025359" unitRef="iso4217_USD" decimals="-5" id="id_8787543_224A7E6A-3CD1-4581-9CF1-8119E9D739A4_1001_0">26400000</us-gaap:DeferredRevenueAdditions>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE974471--1710-Q0002_STD_852_20170331_0_2025578x2392029_2036820x2025359" unitRef="iso4217_USD" decimals="-5" id="id_8787543_224A7E6A-3CD1-4581-9CF1-8119E9D739A4_1001_1">16000000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:DeferredRevenueAdditions contextRef="eol_PE974471--1710-Q0002_STD_852_20170331_0_2025578x2392033_2027749x2040355_2036820x2025359" unitRef="iso4217_USD" decimals="-5" id="id_8787543_761E26B0-8F65-4BF4-B9C3-E40BDD71B897_1001_0">75000000</us-gaap:DeferredRevenueAdditions>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE974471--1710-Q0002_STD_852_20170331_0_2025578x2392033_2027749x2255924_2036820x2025359" unitRef="iso4217_USD" decimals="-5" id="id_8787543_761E26B0-8F65-4BF4-B9C3-E40BDD71B897_2001_1">1400000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE974471--1710-Q0002_STD_852_20170331_0_2025578x2392033_2036820x2025359" unitRef="iso4217_USD" decimals="-5" id="id_8787543_761E26B0-8F65-4BF4-B9C3-E40BDD71B897_3001_2">12800000</us-gaap:LicenseAndServicesRevenue>
  <dei:EntityRegistrantName contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_FE8ECEBC-6257-40C8-A580-4CA101F4BD1B_1_1">INTELLIA THERAPEUTICS, INC.</dei:EntityRegistrantName>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="shares" decimals="-3" id="id_8787543_FAD477E8-3BE4-410B-8EF7-D7E634873938_1_2">5548000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <dei:DocumentType contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_3ACEBD14-AF22-4568-B31D-B40B05105B53_1_0">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_FE8ECEBC-6257-40C8-A580-4CA101F4BD1B_1_2">0001652130</dei:EntityCentralIndexKey>
  <dei:DocumentPeriodEndDate contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_3ACEBD14-AF22-4568-B31D-B40B05105B53_1_2">2017-03-31</dei:DocumentPeriodEndDate>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_1_23">-15513000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8787543_37162E35-0E85-4DCC-AA68-6B0D21AD907B_1_8">-0.36</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_1_27">378000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_3ACEBD14-AF22-4568-B31D-B40B05105B53_1_3">2017</dei:DocumentFiscalYearFocus>
  <dei:AmendmentFlag contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_3ACEBD14-AF22-4568-B31D-B40B05105B53_1_1">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_FE8ECEBC-6257-40C8-A580-4CA101F4BD1B_1_3">--12-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_37162E35-0E85-4DCC-AA68-6B0D21AD907B_1_3">5732000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:Depreciation contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_1_3">660000</us-gaap:Depreciation>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_D5D84565-9614-438F-BB56-4C299A3AA6EA_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="8%" align="left"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Equity-Based Compensation&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Equity-based compensation expense is classified in the consolidated
 statements of operations as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,503&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;454&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,127&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;358&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;812&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;Restricted Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The following table summarizes the Company&amp;#x2019;s restricted stock
 activity, including converted Founder Stock, for the three months
 ended March&amp;#xA0;31, 2017:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&amp;#xA0;Grant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Date&amp;#xA0;Fair&amp;#xA0;Value&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;per Share&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unvested restricted stock as of January&amp;#xA0;1, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,361,855&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.81&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Vested&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(186,917&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.73&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unvested restricted stock as of March&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,174,938&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.82&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 As of March&amp;#xA0;31, 2017, there was $2.7&amp;#xA0;million of
 unrecognized equity-based compensation expense related to
 restricted stock that is expected to vest. These costs are expected
 to be recognized over a weighted average remaining vesting period
 of 1.8 years.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The weighted average grant date fair value of options, estimated as
 of the grant date using the Black-Scholes option pricing model, was
 $10.38 per option and $4.98 per option for those options granted
 during the three months ended March&amp;#xA0;31, 2017 and 2016,
 respectively. Key assumptions used to apply this pricing model were
 as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;March&amp;#xA0;31, 2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;March&amp;#xA0;31, 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected life of options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.0&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.0&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility of underlying stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;92.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;87.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The following is a summary of stock option activity for the three
 months ended March&amp;#xA0;31, 2017:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="62%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Options&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Exercise&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Price per&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Share&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Remaining&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Contractual&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Term&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Intrinsic&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;(In
 years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at January&amp;#xA0;1, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,040,214&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.35&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,343,428&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13.71&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,136&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.56&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Forfeited&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,284&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16.03&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at March&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,373,222&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9.99&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,929&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercisable at March&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;780,588&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.12&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,440&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 As of March&amp;#xA0;31, 2017, there was $25.0&amp;#xA0;million of
 unrecognized compensation cost related to stock options that are
 expected to vest. These costs are expected to be recognized over a
 weighted average remaining vesting period of 3.2 years.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_3ACEBD14-AF22-4568-B31D-B40B05105B53_1_4">Q1</dei:DocumentFiscalPeriodFocus>
  <us-gaap:CostsAndExpenses contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_37162E35-0E85-4DCC-AA68-6B0D21AD907B_1_4">19163000</us-gaap:CostsAndExpenses>
  <dei:EntityFilerCategory contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_FE8ECEBC-6257-40C8-A580-4CA101F4BD1B_1_4">Non-accelerated Filer</dei:EntityFilerCategory>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_B6228142-F19F-4A56-AC11-7713BE4FC514_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="8%" align="left"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company classifies fair value based measurements using a
 three-level hierarchy that prioritizes the inputs used to measure
 fair value. This hierarchy requires entities to maximize the use of
 observable inputs and minimize the use of unobservable inputs. The
 three levels of inputs used to measure fair value are as follows:
 Level&amp;#xA0;1, quoted market prices in active markets for identical
 assets or liabilities; Level&amp;#xA0;2, observable inputs other than
 quoted market prices included in Level&amp;#xA0;1, such as quoted
 market prices for markets that are not active or other inputs that
 are observable or can be corroborated by observable market data;
 and Level&amp;#xA0;3, unobservable inputs that are supported by little
 or no market activity and that are significant to the fair value of
 the assets or liabilities, including certain pricing models,
 discounted cash flow methodologies and similar techniques that use
 significant unobservable inputs.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company&amp;#x2019;s financial instruments as of March&amp;#xA0;31, 2017
 and December&amp;#xA0;31, 2016 consisted primarily of cash and cash
 equivalents, accounts receivable and accounts payable. As of
 March&amp;#xA0;31, 2017 and December&amp;#xA0;31, 2016, the Company&amp;#x2019;s
 financial assets recognized at fair value consisted of the
 following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair Value as of March&amp;#xA0;31,
 2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;255,735&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;255,735&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;255,735&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;255,735&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair Value as of December&amp;#xA0;31,
 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;270,448&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;270,448&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;270,448&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;270,448&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_0235E640-0FD2-4554-93FD-82B2B9EE25F3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 As of March&amp;#xA0;31, 2017 and December&amp;#xA0;31, 2016, the
 Company&amp;#x2019;s financial assets recognized at fair value consisted
 of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair Value as of March&amp;#xA0;31,
 2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;255,735&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;255,735&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;255,735&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;255,735&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair Value as of December&amp;#xA0;31,
 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;270,448&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;270,448&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;270,448&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;270,448&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;


 &lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_0A9917E8-61DB-4828-965A-8727F267CA94_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="8%" align="left"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Loss Per Share&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company calculates basic (loss) earnings per share by dividing
 (loss) income allocable to common stockholders by the weighted
 average number of common shares outstanding. The Company computes
 diluted (loss) earnings per share after giving consideration to the
 dilutive effect of preferred stock, common stock and restricted
 common stock that are outstanding during the period, except where
 such&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-participating&lt;/font&gt;&amp;#xA0;securities would be
 anti-dilutive.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Basic and diluted loss per share attributable to common
 stockholders was calculated as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands&amp;#xA0;except&amp;#xA0;per&amp;#xA0;share&amp;#xA0;data)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12,631&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,689&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Weighted average shares outstanding, basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34,723&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;676&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss per share attributable to common stockholders, basic and
 diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.36&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(9.89&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In May 2016, the Company issued an additional 6,900,000 shares of
 common stock in connection with its initial public offering
 (&amp;#x201C;IPO&amp;#x201D;) and 23,481,956 shares of common stock in
 connection with the automatic conversion of its convertible
 preferred stock upon the closing of the IPO. In addition, the
 Company issued a total of 3,055,554 shares of common stock in two
 separate, concurrent private placements upon the closing of the
 IPO. The issuance of these shares resulted in a significant
 increase in the Company&amp;#x2019;s weighted average shares outstanding
 and will impact the year-over-year comparability of the
 Company&amp;#x2019;s (loss) earnings per share calculations into
 2017.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The following common stock equivalents were excluded from the
 calculation of diluted loss per share because their inclusion would
 have been anti-dilutive:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unvested restricted stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,175&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,774&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,373&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,618&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,548&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,392&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;


 &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_9D982668-60B8-4C12-9EA4-AF2F3AE13053_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="8%" align="left"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Accrued Expenses&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Accrued expenses consisted of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;March&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Employee compensation and benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,532&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,703&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Research and development and professional expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,027&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accrued expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,559&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,900&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_78D563F3-4D18-477E-AE21-75F8131886B8_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="8%" align="left"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Collaborations&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;Novartis Institutes for BioMedical Research&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In December 2014, the Company entered into a strategic
 collaboration agreement with Novartis Institutes for Biomedical
 Research, Inc. (&amp;#x201C;Novartis&amp;#x201D;) primarily focused on
 the&amp;#xA0;development of new&lt;i&gt;&amp;#xA0;ex
 vivo&lt;/i&gt;&amp;#xA0;CRISPR/Cas9-based therapies using chimeric antigen
 receptor T cells&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;(&amp;#x201C;CAR-T&lt;/font&gt;&amp;#xA0;cells&amp;#x201D;) and
 hematopoietic stem cells (&amp;#x201C;HSCs&amp;#x201D;).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;i&gt;Agreement Structure&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Under the terms of the collaboration, the Company and Novartis may
 research potential therapeutic, prophylactic and
 palliative&amp;#xA0;&lt;i&gt;ex
 vivo&lt;/i&gt;&amp;#xA0;applications of the
 CRISPR/Cas9 technology in HSCs and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;CAR-T&lt;/font&gt;&amp;#xA0;cells. The Company and
 Novartis agreed to conduct research of HSC targets under a research
 plan agreed upon by both parties. Within the HSC therapeutic space,
 Novartis may obtain exclusive rights to a limited number of these
 HSC targets, to be selected by Novartis in a series of selection
 windows, the last of which closes 90 days before the fifth
 anniversary of the effective date of the collaboration agreement.
 The Company has the right to choose a limited number of HSC targets
 for its exclusive development and commercialization per the
 specified selection schedule. Following these selections by
 Novartis and the Company, Novartis may obtain rights to research an
 additional limited number of HSC targets on a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-exclusive&lt;/font&gt;&amp;#xA0;basis. If Novartis does not
 exercise its selection rights within each selection window, any
 such rights will be deemed forfeited by Novartis. Novartis is
 required to use commercially reasonable efforts to research,
 develop and commercialize a specified number of HSC products
 directed to each of their selected HSC targets. The Company also
 agreed to collaborate with Novartis on research activities
 for&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;CAR-T&lt;/font&gt;&amp;#xA0;cell targets pursuant to
 a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;CAR-T&lt;/font&gt;&amp;#xA0;cell program research plan
 approved by the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;CAR-T&lt;/font&gt;&amp;#xA0;cell subcommittee of the
 collaboration&amp;#x2019;s joint steering committee. After completion of
 the activities contemplated by the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;CAR-T&lt;/font&gt;&amp;#xA0;cell program research plan,
 Novartis will assume sole responsibility for developing any
 products arising from that research plan and will be responsible
 for additional costs and expenses of developing, manufacturing and
 commercializing its selected research targets. Novartis is required
 to use commercially reasonable efforts to research, develop or
 commercialize at least one&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;CAR-T&lt;/font&gt;&amp;#xA0;cell product directed to at
 least one of its selected&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;CAR-T&lt;/font&gt;cell targets. In the last two
 years of the five-year&amp;#xA0; collaboration term, Novartis
 will have the option to select a limited number of targets for
 research, development and commercialization of&lt;i&gt;&amp;#xA0;in
 vivo&lt;/i&gt;&amp;#xA0;therapies using the Company&amp;#x2019;s CRISPR/Cas9
 platform, on a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-exclusive&lt;/font&gt;&amp;#xA0;basis. Following
 Novartis&amp;#x2019; selection of each&amp;#xA0;&lt;i&gt;in vivo&lt;/i&gt;&amp;#xA0;target, Novartis may offer the
 Company the right to participate in the research and development of
 such targets, in which case an&amp;#xA0;&lt;i&gt;in vivo&lt;/i&gt;&amp;#xA0;program research plan for such
 target will be entered into between the Company and Novartis.
 Novartis is required to use commercially reasonable efforts to
 research, develop or commercialize at least one&lt;i&gt;&amp;#xA0;in
 vivo&lt;/i&gt;&amp;#xA0;product
 directed to each of its selected targets.
 Novartis&amp;#x2019;&lt;i&gt;&amp;#xA0;in vivo&lt;/i&gt;&amp;#xA0;target selections are
 subject to certain restrictions, including that the targets, or all
 targets within a limited number of organs: (i)&amp;#xA0;have not
 already been reserved by the Company pursuant to our limited right
 to do so under the agreement; (ii)&amp;#xA0;are not the subject of a
 collaboration or pending collaboration with a third party; and
 (iii)&amp;#xA0;are not the subject of ongoing or planned research and
 development by the Company.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company received an upfront technology access payment from
 Novartis of $10.0&amp;#xA0;million in January&amp;#xA0;2015 and is entitled
 to additional technology access fees of $20.0&amp;#xA0;million and
 quarterly research payments of $1.0&amp;#xA0;million, or up to
 $20.0&amp;#xA0;million in the aggregate, during the five-year research
 term. For each product under the collaboration, subject to certain
 conditions, the Company may be eligible to receive (i)&amp;#xA0;up to
 $30.3&amp;#xA0;million in development milestones, including for the
 filing of an investigational new drug application and for the
 dosing of the first patient in each of Phase IIa, Phase IIb and
 Phase III clinical trials, (ii)&amp;#xA0;up to $50.0&amp;#xA0;million in
 regulatory milestones for the product&amp;#x2019;s first indication,
 including regulatory approvals in the U.S. and European Union
 (&amp;#x201C;EU&amp;#x201D;), (iii) up to $50.0&amp;#xA0;million in regulatory
 milestones for the product&amp;#x2019;s second indication, if any,
 including U.S. and EU regulatory approvals, (iv)&amp;#xA0;royalties on
 net sales in the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;mid-single&lt;/font&gt;&amp;#xA0;digits, and (v)&amp;#xA0;net sales
 milestone payments of up to $100.0&amp;#xA0;million. The Company may
 also be eligible to receive payments for: (i)&amp;#xA0;each additional
 HSC target selected by Novartis beyond its initial defined
 allocation, (ii)&amp;#xA0;each&lt;i&gt;&amp;#xA0;in vivo&lt;/i&gt;&amp;#xA0;target that
 Novartis selects and (iii)&amp;#xA0;any exercise by Novartis of certain
 license options under the agreement. Additionally, at the inception
 of the arrangement, Novartis invested $9.0&amp;#xA0;million to purchase
 the Company&amp;#x2019;s&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;Class&amp;#xA0;A-1&lt;/font&gt;&amp;#xA0;and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;Class&amp;#xA0;A-2&lt;/font&gt;Preferred Units. The
 difference between the cash proceeds received from Novartis for the
 units and the $11.6&amp;#xA0;million estimated fair&amp;#xA0; value of those units at the
 date of issuance was determined to be $2.6&amp;#xA0;million.
 Accordingly, $2.6&amp;#xA0;million of the upfront technology access
 payment was allocated to record the preferred units purchased by
 Novartis at fair value.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;i&gt;Collaboration Revenue&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Through March&amp;#xA0;31, 2017, excluding amounts allocated to
 Novartis&amp;#x2019; purchase of the Company&amp;#x2019;s&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;Class&amp;#xA0;A-1&lt;/font&gt;&amp;#xA0;and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;Class&amp;#xA0;A-2&lt;/font&gt;&amp;#xA0;Preferred Units, the Company
 had recorded a total of $26.4&amp;#xA0;million in cash and accounts
 receivable under the Novartis agreement. Through March&amp;#xA0;31,
 2017, the Company has recognized $16.0&amp;#xA0;million of
 collaboration revenue, including $2.2&amp;#xA0;million and
 $1.8&amp;#xA0;million in the three months ended March&amp;#xA0;31, 2017 and
 2016, respectively, in the consolidated statements of operations
 related to this agreement. As of March&amp;#xA0;31, 2017 and
 December&amp;#xA0;31, 2016, the Company had accounts receivable of
 $1.0&amp;#xA0;million and $6.0&amp;#xA0;million, respectively, related to
 this agreement. As of March&amp;#xA0;31, 2017 and December&amp;#xA0;31,
 2016, the Company had deferred revenue of $10.4&amp;#xA0;million and
 $11.6&amp;#xA0;million, respectively, related to this agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;Regeneron Pharmaceuticals, Inc.&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In April 2016, the Company entered into a license and collaboration
 agreement with Regeneron Pharmaceuticals, Inc.
 (&amp;#x201C;Regeneron&amp;#x201D;). The agreement includes a product
 component to research, develop and commercialize&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;CRISPR/Cas-based&lt;/font&gt;&amp;#xA0;therapeutic products primarily
 focused on gene editing in the liver as well as a technology
 collaboration component, pursuant to which the Company and
 Regeneron will engage in research and development activities aimed
 at discovering and developing novel technologies and improvements
 to CRISPR/Cas technology to enhance the Company&amp;#x2019;s gene
 editing platform. Under this agreement, the Company also may access
 the Regeneron Genetics Center and proprietary mouse models to be
 provided by Regeneron for a limited number of the Company&amp;#x2019;s
 liver programs.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;i&gt;Agreement Structure&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Under the terms of the collaboration, the Company and Regeneron
 have agreed to a target selection process, whereby Regeneron may
 obtain exclusive rights for up to 10 targets to be chosen by
 Regeneron during the collaboration term, subject to various
 adjustments and limitations set forth in the agreement. Of these 10
 total targets, Regeneron may select up to five&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-liver&lt;/font&gt;&amp;#xA0;targets, while the remaining
 targets must be focused in the liver. At the inception of the
 agreement, Regeneron selected the first of its 10 targets, which
 will be subject to a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;co-development&lt;/font&gt;&amp;#xA0;and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;co-commercialization&lt;/font&gt;&amp;#xA0;arrangement between the
 Company and Regeneron.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company retains the exclusive right to solely develop products
 for certain indications. During the target selection process, the
 Company has the right to choose additional liver targets for its
 own development using commercially reasonable efforts. Certain
 targets that either the Company or Regeneron select may be subject
 to further&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;co-development&lt;/font&gt;&amp;#xA0;and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;co-commercialization&lt;/font&gt;&amp;#xA0;arrangements at the
 Company&amp;#x2019;s or Regeneron&amp;#x2019;s option, as applicable, which
 either can exercise pursuant to defined conditions. In addition,
 subject to certain restrictions, Regeneron will be able to replace
 a limited number of targets with substitute targets upon the
 payment of a specified replacement fee, in which case exclusive
 rights to the replaced target revert to the Company.
 Regeneron&amp;#x2019;s target selections are subject to certain
 additional restrictions, including that&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-liver&lt;/font&gt;targets are not the subject
 of ongoing or planned research and development by the Company or
 are not the subject of a collaboration or pending&amp;#xA0; collaboration with a third
 party.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Research activities under the collaboration will be governed by
 evaluation and research and development plans that will outline the
 parties&amp;#x2019; responsibilities under, anticipated timelines of and
 budgets for, the various programs. The Company will assist
 Regeneron with the preliminary evaluation of liver targets, and
 Regeneron will be responsible for preclinical research and the
 conduct of clinical development, manufacturing and
 commercialization of products directed to each of its exclusive
 targets under the oversight of a joint steering committee. The
 Company may assist, as requested by Regeneron, with the later
 discovery and research of product candidates directed to any
 selected target. For each selected target, Regeneron is required to
 use commercially reasonable efforts to submit regulatory filings
 necessary to achieve initial investigational new drug
 (&amp;#x201C;IND&amp;#x201D;) acceptance for at least one product directed to
 each applicable target, and following IND acceptance for at least
 one product, to develop and commercialize such product.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In connection with this collaboration, Regeneron agreed to purchase
 $50.0&amp;#xA0;million of the Company&amp;#x2019;s common stock in a private
 placement concurrent with the Company&amp;#x2019;s initial public
 offering, and the Company received a nonrefundable upfront payment
 of $75.0&amp;#xA0;million. In addition, the Company is eligible to
 earn, on a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;per-licensed&lt;/font&gt;&amp;#xA0;target basis, (i)&amp;#xA0;up to
 $25.0&amp;#xA0;million in development milestones, including for the
 dosing of the first patient in each of Phase I, Phase II and Phase
 III clinical trials, (ii)&amp;#xA0;up to $110.0&amp;#xA0;million in
 regulatory milestones, including for the acceptance of a regulatory
 filing in the U.S., and U.S. and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ex-U.S.&lt;/font&gt;&amp;#xA0;regulatory approvals, and
 (iii)&amp;#xA0;up to $185.0&amp;#xA0;million in sales-based milestone
 payments. The Company is also eligible to earn royalties ranging
 from the high single digits to low teens, in each case, on
 a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;per-product&lt;/font&gt;&amp;#xA0;basis, which royalties are
 potentially subject to various reductions and offsets and are
 further subject to the Company&amp;#x2019;s existing low single-digit
 royalty obligations under the Caribou license agreement. In
 addition, Regeneron is obligated to fund 50.0% of the agreed-upon
 research and development costs for the transthyretin amyloidosis
 program, the first target selected by Regeneron, which will be
 subject to a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;co-development&lt;/font&gt;&amp;#xA0;and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;co-commercialization&lt;/font&gt;&amp;#xA0;arrangement between the
 Company and Regeneron.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The fixed portion of consideration under the collaboration
 arrangement was determined to be the $75.0&amp;#xA0;million
 nonrefundable upfront payment, for which there are no contingent
 terms. The significant deliverables of this multiple-element
 revenue arrangement were determined to be licenses to targets, the
 associated research activities and evaluation plans for these
 programs and the technology collaboration. The Company further
 determined that the licenses and associated research activities and
 evaluation plans did not have standalone value due to the
 specialized nature of the services to be provided by the Company;
 therefore, these deliverables are not separable, and, accordingly,
 the license and services are treated as a single unit of
 accounting. The Company additionally concluded that the technology
 collaboration has standalone value from the product development, as
 shared rights to technological advancements under the technology
 collaboration could be separately applied by Regeneron to other
 programs.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company allocated the $75.0&amp;#xA0;million in fixed consideration
 to the two units of accounting based on the estimated relative
 selling price of each deliverable. The Company estimated the
 selling price of each deliverable by taking into consideration
 internal estimates of research and development personnel needed to
 perform the research and development services, estimates of
 expected cash outflows to third parties for services and supplies,
 selling prices of comparable transactions and typical gross profit
 margins. As a result of this evaluation, the Company allocated
 $63.8&amp;#xA0;million to the licenses to targets and the associated
 research activities and evaluation plans and $11.2&amp;#xA0;million to
 the technology collaboration. The $63.8&amp;#xA0;million allocated to
 the licenses to targets and the associated research activities and
 evaluation plans for these programs is being recognized over
 the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-year&lt;/font&gt;&amp;#xA0;performance period of the
 arrangement. The $11.2&amp;#xA0;million allocated to the technology
 collaboration is being recognized over a period beginning with the
 inception of the technology collaboration in September 2016,
 through the end of the arrangement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;i&gt;Collaboration Revenue&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Through March&amp;#xA0;31, 2017, the Company recorded a
 $75.0&amp;#xA0;million upfront payment and $1.4&amp;#xA0;million for
 research and development services under the Regeneron agreement.
 Through March&amp;#xA0;31, 2017, the Company recognized
 $12.8&amp;#xA0;million of collaboration revenue, including
 $4.1&amp;#xA0;million in the three months ended March&amp;#xA0;31, 2017, in
 the consolidated statement of operations. As of March&amp;#xA0;31, 2017
 and December&amp;#xA0;31, 2016, the Company had deferred revenue of
 $63.6&amp;#xA0;million and $66.7&amp;#xA0;million, respectively, related to
 this agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;


 &lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_1_9">-1893000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:NetIncomeLoss contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_37162E35-0E85-4DCC-AA68-6B0D21AD907B_1_7">-12631000</us-gaap:NetIncomeLoss>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_1_16">-4162000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_1_6">-4011000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_37162E35-0E85-4DCC-AA68-6B0D21AD907B_1_0">6215000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_1_8">-954000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_1_7">-704000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_4DD36F5F-CFF0-4633-80F0-505A09C6062E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In May 2014, the Financial Accounting Standards Board
 (&amp;#x201C;FASB&amp;#x201D;) issued Accounting Standards Update
 (&amp;#x201C;ASU&amp;#x201D;) No.&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2014-09,&lt;/font&gt;&lt;i&gt;&amp;#xA0;Revenue from Contracts with
 Customers (Topic 606),&lt;/i&gt;&amp;#xA0;which supersedes existing
 revenue recognition guidance. The standard&amp;#x2019;s core principle
 is that a company will recognize revenue when it transfers promised
 goods or services to customers in an amount that reflects the
 consideration to which the company expects to be entitled in
 exchange for those goods or services. The standard defines a
 five-step process to achieve this principle and will require
 companies to use more judgment and make more estimates than under
 the current guidance. The Company expects that these judgments and
 estimates will include identifying performance obligations in the
 customer contract, estimating the amount of variable consideration
 to include in the transaction price and allocating the transaction
 price to each separate performance obligation. ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2014-09&lt;/font&gt;&amp;#xA0;also requires additional
 disclosure about the nature, amount, timing and uncertainty of
 revenue and cash flows arising from customer contracts. The FASB
 continues to address certain implementation issues and clarify
 certain core revenue recognition principles of ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2014-09.&lt;/font&gt;&amp;#xA0;In July 2015, the FASB voted
 to delay the effective date of this standard such that
 ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2014-09,&lt;/font&gt;&amp;#xA0;as amended, will be effective
 for the Company for annual and interim periods beginning after
 December&amp;#xA0;15, 2017. Early adoption of the standard is permitted
 for annual periods beginning after December&amp;#xA0;15, 2016. The
 Company continues to evaluate the impact that the adoption of these
 ASUs will have on its consolidated financial statements; however,
 the Company does not expect that adoption of this standard will
 have a significant impact on the consolidated financial
 statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In February 2016, the FASB issued ASU No.&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-02,&lt;/font&gt;&lt;i&gt;&amp;#xA0;Leases&lt;/i&gt;.
 ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-02&lt;/font&gt;&amp;#xA0;amends ASC
 840,&lt;i&gt;&amp;#xA0;Leases&lt;/i&gt;, by introducing a lessee model that
 requires balance sheet recognition of most leases. The Company is
 the lessee under certain leases that are accounted for as operating
 leases. The proposed changes would require that substantially all
 of the Company&amp;#x2019;s operating leases be recognized as assets and
 liabilities on the Company&amp;#x2019;s balance sheet. ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-02&lt;/font&gt;&amp;#xA0;will be effective for the
 Company for annual periods, and interim periods within those annual
 periods, beginning after December&amp;#xA0;15, 2018. The Company is
 evaluating the impact that the adoption of ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-02&lt;/font&gt;&amp;#xA0;will have on its consolidated
 financial statements but expects that the Company will recognize a
 significant lease obligation upon adoption in connection with the
 Company&amp;#x2019;s existing lease agreements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In March 2016, the FASB issued ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-09,&lt;/font&gt;&amp;#xA0;&lt;i&gt;Improvements to Employee
 Share-Based Payment Accounting&lt;/i&gt;. ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-09&lt;/font&gt;&amp;#xA0;amends ASC 718,&amp;#xA0;&lt;i&gt;Compensation &amp;#x2013; Stock
 Compensation&lt;/i&gt;, by simplifying certain aspects of the accounting
 for employee share-based payment transactions, including the
 accounting for income taxes, forfeitures, statutory tax withholding
 requirements and the classification in the statement of cash flows.
 ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-09&lt;/font&gt;&amp;#xA0;was adopted by the Company on
 January&amp;#xA0;1, 2017 and did not have a significant impact on its
 consolidated financial statements.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_1_11">-268000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_37162E35-0E85-4DCC-AA68-6B0D21AD907B_1_5">-12948000</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_1_12">85000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_1_22">47000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_1_10">-4278000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_37162E35-0E85-4DCC-AA68-6B0D21AD907B_1_6">317000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_8F66A4C6-0F11-4CDA-9EF7-6193EF91AD84_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="8%" align="left"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Overview and Basis of
 Presentation&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Intellia Therapeutics, Inc. (collectively referred to with its
 wholly-owned, controlled subsidiary, Intellia Securities Corp., as
 &amp;#x201C;Intellia&amp;#x201D; or the &amp;#x201C;Company&amp;#x201D;) is a genome
 editing company focused on developing potentially curative
 therapeutics utilizing a biological tool known as CRISPR/Cas9.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The consolidated financial statements of the Company included
 herein have been prepared, without audit, pursuant to the rules and
 regulations of the Securities and Exchange Commission
 (&amp;#x201C;SEC&amp;#x201D;). Certain information and footnote disclosures
 normally included in financial statements prepared in accordance
 with accounting principles generally accepted in the United States
 of America (&amp;#x201C;U.S.&amp;#x201D;) have been condensed or omitted from
 this report, as is permitted by such rules and regulations.
 Accordingly, these consolidated financial statements should be read
 in conjunction with the financial statements and notes thereto
 included in the Company&amp;#x2019;s Annual Report on Form&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;10-K&lt;/font&gt;&amp;#xA0;for the year ended
 December&amp;#xA0;31, 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The unaudited consolidated financial statements include the
 accounts of Intellia Therapeutics, Inc. and its wholly-owned,
 controlled subsidiary. All intercompany balances and transactions
 have been eliminated in consolidation. In the opinion of
 management, the information furnished reflects all adjustments, all
 of which are of a normal and recurring nature, necessary for a fair
 presentation of the results for the reported interim periods. The
 Company considers events or transactions that occur after the
 balance sheet date but before the financial statements are issued
 to provide additional evidence relative to certain estimates or to
 identify matters that require additional disclosure. The three
 months ended March&amp;#xA0;31, 2017 and 2016 are referred to as the
 first quarter of 2017 and 2016, respectively. The results of
 operations for interim periods are not necessarily indicative of
 results to be expected for the full year or any other interim
 period.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_1_13">-11398000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_1_15">4162000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="shares" decimals="INF" id="id_8787543_24B262DB-AEF7-4923-B137-51AAAC035E90_5001_3">7136</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_0DBA232D-F152-42AA-AB6A-C252679CBC10_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Key assumptions used to apply this pricing model were as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;March&amp;#xA0;31, 2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;March&amp;#xA0;31, 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected life of options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.0&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.0&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility of underlying stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;92.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;87.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_A4C655D8-7B08-4EB8-8FFE-129F5450047E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following common stock equivalents were excluded from the
 calculation of diluted loss per share because their inclusion would
 have been anti-dilutive:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unvested restricted stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,175&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,774&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,373&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,618&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,548&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,392&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_64CB04F1-A56F-4FA6-99F0-C7CD2AF7610F_2001_1">P9Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_7A1B0C8E-3631-4BB4-9B7A-1AA85858DCA6_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Basic and diluted loss per share attributable to common
 stockholders was calculated as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands&amp;#xA0;except&amp;#xA0;per&amp;#xA0;share&amp;#xA0;data)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12,631&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,689&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Weighted average shares outstanding, basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34,723&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;676&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss per share attributable to common stockholders, basic and
 diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.36&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(9.89&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_29A11EB1-0DE1-426A-9E42-014ECE8E6833_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Equity-based compensation expense is classified in the consolidated
 statements of operations as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,503&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;454&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,127&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;358&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;812&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="pure" decimals="3" id="id_8787543_7785A6DE-C06A-415D-8B18-3EA53C020F00_1_3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8787543_F9931F9E-76E9-48D6-8E50-FC5F464B9F71_5001_2">13.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="shares" decimals="INF" id="id_8787543_36B85128-8AD9-46B7-8D04-1A6039FFDFE4_1_1">186917</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_64CB04F1-A56F-4FA6-99F0-C7CD2AF7610F_2001_2">P8Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8787543_F9931F9E-76E9-48D6-8E50-FC5F464B9F71_5001_4">16.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8787543_693CF83A-16DE-4D7D-A01D-F482158FDE69_1_1">0.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8787543_F9931F9E-76E9-48D6-8E50-FC5F464B9F71_5001_3">6.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_D0A18120-F749-495D-9E74-A48DEA92F736_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="8%" align="left"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Summary of Significant Accounting
 Policies&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In May 2014, the Financial Accounting Standards Board
 (&amp;#x201C;FASB&amp;#x201D;) issued Accounting Standards Update
 (&amp;#x201C;ASU&amp;#x201D;) No.&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2014-09,&lt;/font&gt;&lt;i&gt;&amp;#xA0;Revenue from Contracts with
 Customers (Topic 606),&lt;/i&gt;&amp;#xA0;which supersedes existing
 revenue recognition guidance. The standard&amp;#x2019;s core principle
 is that a company will recognize revenue when it transfers promised
 goods or services to customers in an amount that reflects the
 consideration to which the company expects to be entitled in
 exchange for those goods or services. The standard defines a
 five-step process to achieve this principle and will require
 companies to use more judgment and make more estimates than under
 the current guidance. The Company expects that these judgments and
 estimates will include identifying performance obligations in the
 customer contract, estimating the amount of variable consideration
 to include in the transaction price and allocating the transaction
 price to each separate performance obligation. ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2014-09&lt;/font&gt;&amp;#xA0;also requires additional
 disclosure about the nature, amount, timing and uncertainty of
 revenue and cash flows arising from customer contracts. The FASB
 continues to address certain implementation issues and clarify
 certain core revenue recognition principles of ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2014-09.&lt;/font&gt;&amp;#xA0;In July 2015, the FASB voted
 to delay the effective date of this standard such that
 ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2014-09,&lt;/font&gt;&amp;#xA0;as amended, will be effective
 for the Company for annual and interim periods beginning after
 December&amp;#xA0;15, 2017. Early adoption of the standard is permitted
 for annual periods beginning after December&amp;#xA0;15, 2016. The
 Company continues to evaluate the impact that the adoption of these
 ASUs will have on its consolidated financial statements; however,
 the Company does not expect that adoption of this standard will
 have a significant impact on the consolidated financial
 statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In February 2016, the FASB issued ASU No.&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-02,&lt;/font&gt;&lt;i&gt;&amp;#xA0;Leases&lt;/i&gt;.
 ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-02&lt;/font&gt;&amp;#xA0;amends ASC
 840,&lt;i&gt;&amp;#xA0;Leases&lt;/i&gt;, by introducing a lessee model that
 requires balance sheet recognition of most leases. The Company is
 the lessee under certain leases that are accounted for as operating
 leases. The proposed changes would require that substantially all
 of the Company&amp;#x2019;s operating leases be recognized as assets and
 liabilities on the Company&amp;#x2019;s balance sheet. ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-02&lt;/font&gt;&amp;#xA0;will be effective for the
 Company for annual periods, and interim periods within those annual
 periods, beginning after December&amp;#xA0;15, 2018. The Company is
 evaluating the impact that the adoption of ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-02&lt;/font&gt;&amp;#xA0;will have on its consolidated
 financial statements but expects that the Company will recognize a
 significant lease obligation upon adoption in connection with the
 Company&amp;#x2019;s existing lease agreements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In March 2016, the FASB issued ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-09,&lt;/font&gt;&amp;#xA0;&lt;i&gt;Improvements to Employee
 Share-Based Payment Accounting&lt;/i&gt;. ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-09&lt;/font&gt;&amp;#xA0;amends ASC 718,&amp;#xA0;&lt;i&gt;Compensation &amp;#x2013; Stock
 Compensation&lt;/i&gt;, by simplifying certain aspects of the accounting
 for employee share-based payment transactions, including the
 accounting for income taxes, forfeitures, statutory tax withholding
 requirements and the classification in the statement of cash flows.
 ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-09&lt;/font&gt;&amp;#xA0;was adopted by the Company on
 January&amp;#xA0;1, 2017 and did not have a significant impact on its
 consolidated financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <dei:TradingSymbol contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_FE8ECEBC-6257-40C8-A580-4CA101F4BD1B_1_0">NTLA</dei:TradingSymbol>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_37162E35-0E85-4DCC-AA68-6B0D21AD907B_1_2">13431000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_1_20">47000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_E963966F-A7A9-4A20-86C9-4C7B6D46EE34_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Accrued expenses consisted of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;March&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Employee compensation and benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,532&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,703&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Research and development and professional expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,027&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accrued expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,559&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,900&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="pure" decimals="3" id="id_8787543_7785A6DE-C06A-415D-8B18-3EA53C020F00_1_2">0.926</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_9BCD9A72-AA1A-4C52-BD5B-8C6A7D0A87EF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The following is a summary of stock option activity for the three
 months ended March&amp;#xA0;31, 2017:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="62%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Options&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Exercise&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Price per&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Share&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Remaining&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Contractual&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Term&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Intrinsic&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;(In
 years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at January&amp;#xA0;1, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,040,214&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.35&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,343,428&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13.71&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,136&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.56&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Forfeited&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,284&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16.03&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at March&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,373,222&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9.99&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,929&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercisable at March&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;780,588&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.12&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,440&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="shares" decimals="INF" id="id_8787543_24B262DB-AEF7-4923-B137-51AAAC035E90_5001_2">1343428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8787543_477B8EBD-8E94-4405-9E94-99A4A15084E0_1_0">10.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_F4A62C7B-2813-4EBE-800C-D55D646FC06E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The following table summarizes the Company&amp;#x2019;s restricted stock
 activity, including converted Founder Stock, for the three months
 ended March&amp;#xA0;31, 2017:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&amp;#xA0;Grant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Date&amp;#xA0;Fair&amp;#xA0;Value&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;per Share&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unvested restricted stock as of January&amp;#xA0;1, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,361,855&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.81&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Vested&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(186,917&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.73&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unvested restricted stock as of March&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,174,938&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.82&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="pure" decimals="3" id="id_8787543_7785A6DE-C06A-415D-8B18-3EA53C020F00_1_0">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="shares" decimals="INF" id="id_8787543_24B262DB-AEF7-4923-B137-51AAAC035E90_5001_4">3284</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_1_4">2630000</us-gaap:ShareBasedCompensation>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_7785A6DE-C06A-415D-8B18-3EA53C020F00_1_1">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" unitRef="shares" decimals="-3" id="id_8787543_37162E35-0E85-4DCC-AA68-6B0D21AD907B_1_9">34723000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0" id="id_8787543_8867C9B7-09BF-4310-A401-D8B57D8A31C4_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="8%" align="left"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Related Party
 Transactions&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In July 2014, the Company issued Caribou Therapeutics Holdco, LLC,
 a wholly-owned subsidiary of Caribou Biosciences, Inc.
 (&amp;#x201C;Caribou&amp;#x201D;), 8,110,599 Junior Preferred Units. As a
 result of this and related transactions, Caribou owned 15.5% of the
 Company&amp;#x2019;s voting interests as of March&amp;#xA0;31, 2017.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company recognized research and development expense of
 $0.4&amp;#xA0;million during the three months ended March&amp;#xA0;31, 2016
 and an insignificant amount during the three months ended
 March&amp;#xA0;31, 2017, related to license and service agreements
 entered into with Caribou. In addition, the Company recognized
 general and administrative expense of $0.2&amp;#xA0;million during the
 three months ended March&amp;#xA0;31, 2016 and an insignificant amount
 during the three months ended March&amp;#xA0;31, 2017, related to the
 Company&amp;#x2019;s obligation to pay 30.0% of Caribou&amp;#x2019;s patent
 prosecution, filing and maintenance costs under its intellectual
 property license agreement with Caribou.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In connection with its entry into the collaboration and license
 agreement and related equity transactions with Novartis, the
 Company issued Novartis 4,761,905&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;Class&amp;#xA0;A-1&lt;/font&gt;&amp;#xA0;Preferred Units and
 2,666,666&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;Class&amp;#xA0;A-2&lt;/font&gt;&amp;#xA0;Preferred Units. In August
 2015, Novartis acquired 761,905 shares of the Company&amp;#x2019;s
 Series B Preferred Stock, and in May 2016, Novartis acquired
 277,777 shares of the Company&amp;#x2019;s common stock in a private
 placement transaction concurrent with the Company&amp;#x2019;s IPO. As a
 result of these and subsequent transactions, Novartis collectively
 owned 15.7% of the Company&amp;#x2019;s voting interests as of
 March&amp;#xA0;31, 2017. Refer to Note 5,&amp;#xA0;&lt;i&gt;Collaborations&lt;/i&gt;, for
 additional information regarding this collaboration agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company recognized collaboration revenue of $2.2&amp;#xA0;million
 and $1.8&amp;#xA0;million in the three months ended March&amp;#xA0;31, 2017
 and 2016, respectively, in the consolidated statements of
 operations related to this agreement. As of March&amp;#xA0;31, 2017 and
 December&amp;#xA0;31, 2016, the Company had recorded accounts
 receivable of $1.0&amp;#xA0;million and $6.0&amp;#xA0;million and deferred
 revenue of $10.4&amp;#xA0;million and $11.6&amp;#xA0;million, respectively,
 related to this collaboration.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0_2021628x2022619" unitRef="shares" decimals="-3" id="id_8787543_FAD477E8-3BE4-410B-8EF7-D7E634873938_1001_1">4373000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0_2021628x2039074" unitRef="shares" decimals="-3" id="id_8787543_FAD477E8-3BE4-410B-8EF7-D7E634873938_2001_0">1175000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0_2025317x2022619" id="id_8787543_D4BAEB95-6F65-4413-89C8-9637CBE0C76B_1001_1">P3Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0_2025317x2041099" id="id_8787543_36ABA540-319E-456D-9281-15249ECA1570_1001_1">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0_2025578x2392029_2036820x2025359" unitRef="iso4217_USD" decimals="-5" id="id_8787543_224A7E6A-3CD1-4581-9CF1-8119E9D739A4_1002_1">2200000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0_2025578x2392033_2036820x2025359" unitRef="iso4217_USD" decimals="-5" id="id_8787543_761E26B0-8F65-4BF4-B9C3-E40BDD71B897_3002_3">4100000</us-gaap:LicenseAndServicesRevenue>
  <ntla:RevenueRecognitionMultipleDeliverableArrangementsAllocationToSpecificUnitOfAccounting contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0_2025578x2392033_2036820x2025359" id="id_8787543_CDE09141-7F7F-45DD-818F-F7E6BD8272AB_1002_4">The Company allocated the $75.0 million in fixed consideration to the two units  of accounting based on the estimated relative selling price of each deliverable.</ntla:RevenueRecognitionMultipleDeliverableArrangementsAllocationToSpecificUnitOfAccounting>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0_2029841x2029413" unitRef="iso4217_USD" decimals="-3" id="id_8787543_E2FC826F-3AC3-4542-91CB-C804185FC749_1001_1">1127000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0_2029841x2035076" unitRef="iso4217_USD" decimals="-3" id="id_8787543_E2FC826F-3AC3-4542-91CB-C804185FC749_2001_0">1503000</us-gaap:ShareBasedCompensation>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE974471--1710-Q0002_STD_90_20170331_0_2036820x2025359_2038452x2392029" unitRef="iso4217_USD" decimals="-5" id="id_8787543_2E3FD9FC-C678-4864-8AF5-ACE21177DB9C_1001_0">2200000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="shares" decimals="-3" id="id_8787543_FAD477E8-3BE4-410B-8EF7-D7E634873938_2_2">4392000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_2_23">-11624000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8787543_37162E35-0E85-4DCC-AA68-6B0D21AD907B_2_8">-9.89</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_2_27">918000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_37162E35-0E85-4DCC-AA68-6B0D21AD907B_2_3">3246000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:Depreciation contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_2_3">187000</us-gaap:Depreciation>
  <us-gaap:CostsAndExpenses contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_37162E35-0E85-4DCC-AA68-6B0D21AD907B_2_4">8471000</us-gaap:CostsAndExpenses>
  <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_2_18">200000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_2_9">-134000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:NetIncomeLoss contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_37162E35-0E85-4DCC-AA68-6B0D21AD907B_2_7">-6689000</us-gaap:NetIncomeLoss>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_2_16">-1008000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_37162E35-0E85-4DCC-AA68-6B0D21AD907B_2_0">1777000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_2_8">-87000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_2_7">-65000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_2_11">2823000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_37162E35-0E85-4DCC-AA68-6B0D21AD907B_2_5">-6694000</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_2_12">26000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_2_22">-1195000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_2_10">-778000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_37162E35-0E85-4DCC-AA68-6B0D21AD907B_2_6">5000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_2_13">-9421000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_2_15">1008000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="pure" decimals="3" id="id_8787543_7785A6DE-C06A-415D-8B18-3EA53C020F00_2_3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_37162E35-0E85-4DCC-AA68-6B0D21AD907B_2_2">5225000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="pure" decimals="3" id="id_8787543_7785A6DE-C06A-415D-8B18-3EA53C020F00_2_2">0.877</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_2_21">895000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_8787543_477B8EBD-8E94-4405-9E94-99A4A15084E0_2_0">4.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="pure" decimals="3" id="id_8787543_7785A6DE-C06A-415D-8B18-3EA53C020F00_2_0">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_2_4">812000</us-gaap:ShareBasedCompensation>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" id="id_8787543_7785A6DE-C06A-415D-8B18-3EA53C020F00_2_1">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="shares" decimals="-3" id="id_8787543_37162E35-0E85-4DCC-AA68-6B0D21AD907B_2_9">676000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <ntla:InitialPublicOfferingCostsIncurredButNotYetPaid contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_2_29">454000</ntla:InitialPublicOfferingCostsIncurredButNotYetPaid>
  <ntla:PaymentsOfTemporaryEquityIssuanceCosts contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_2_19">100000</ntla:PaymentsOfTemporaryEquityIssuanceCosts>
  <ntla:InProcessResearchAndDevelopmentAcquiredButNotYetPaid contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_8787543_93DD4EA0-07D4-4449-B51D-3FC94C4451BD_2_28">400000</ntla:InProcessResearchAndDevelopmentAcquiredButNotYetPaid>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0_2021628x2022619" unitRef="shares" decimals="-3" id="id_8787543_FAD477E8-3BE4-410B-8EF7-D7E634873938_1002_1">2618000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0_2021628x2039074" unitRef="shares" decimals="-3" id="id_8787543_FAD477E8-3BE4-410B-8EF7-D7E634873938_2002_0">1774000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0_2025578x2392029_2036820x2025359" unitRef="iso4217_USD" decimals="-5" id="id_8787543_224A7E6A-3CD1-4581-9CF1-8119E9D739A4_1003_1">1800000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0_2029841x2029413" unitRef="iso4217_USD" decimals="-3" id="id_8787543_E2FC826F-3AC3-4542-91CB-C804185FC749_1002_1">358000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0_2029841x2035076" unitRef="iso4217_USD" decimals="-3" id="id_8787543_E2FC826F-3AC3-4542-91CB-C804185FC749_2002_0">454000</us-gaap:ShareBasedCompensation>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0_2036820x2025359_2038452x2392029" unitRef="iso4217_USD" decimals="-5" id="id_8787543_2E3FD9FC-C678-4864-8AF5-ACE21177DB9C_1002_0">1800000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0_2038452x2392037" unitRef="iso4217_USD" decimals="-5" id="id_8787543_271B8F03-EC8A-490F-AE73-D295D7DEE682_1001_1">200000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0_2038452x2392037" unitRef="iso4217_USD" decimals="-5" id="id_8787543_271B8F03-EC8A-490F-AE73-D295D7DEE682_1001_0">400000</us-gaap:ResearchAndDevelopmentExpense>
  <ntla:RelatedPartyCommitmentObligationPercentage contextRef="eol_PE974471--1710-Q0002_STD_91_20160331_0_2038452x2392037" unitRef="pure" decimals="INF" id="id_8787543_271B8F03-EC8A-490F-AE73-D295D7DEE682_1001_2">0.300</ntla:RelatedPartyCommitmentObligationPercentage>
  <context id="eol_PE974471--1710-Q0002_STD_91_20160331_0_2038452x2392037">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntla:CaribouMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_91_20160331_0_2036820x2025359_2038452x2392029">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntla:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_91_20160331_0_2029841x2035076">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_91_20160331_0_2029841x2029413">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_91_20160331_0_2025578x2392029_2036820x2025359">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ntla:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_91_20160331_0_2021628x2039074">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_91_20160331_0_2021628x2022619">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_91_20160331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_90_20170331_0_2036820x2025359_2038452x2392029">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntla:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_90_20170331_0_2029841x2035076">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_90_20170331_0_2029841x2029413">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_90_20170331_0_2025578x2392033_2036820x2025359">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ntla:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_90_20170331_0_2025578x2392029_2036820x2025359">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ntla:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_90_20170331_0_2025317x2041099">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_90_20170331_0_2025317x2022619">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_90_20170331_0_2021628x2039074">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_90_20170331_0_2021628x2022619">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_90_20170331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_852_20170331_0_2025578x2392033_2036820x2025359">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ntla:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-12-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_852_20170331_0_2025578x2392033_2027749x2255924_2036820x2025359">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ntla:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">ntla:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-12-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_852_20170331_0_2025578x2392033_2027749x2040355_2036820x2025359">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ntla:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-12-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_852_20170331_0_2025578x2392029_2036820x2025359">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ntla:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-12-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_31_20160531_0_2040137x2032595">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-05-01</startDate>
      <endDate>2016-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_31_20160531_0_2040137x2029877">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-05-01</startDate>
      <endDate>2016-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_31_20160531_0_2036820x2025359_2038452x2392029">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntla:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-05-01</startDate>
      <endDate>2016-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_31_20150131_0_2025578x2392029_2039549x2392030">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ntla:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ntla:ClassAPreferredUnitsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_31_20150131_0_2025578x2392029_2036820x2025359">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ntla:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_31_20150131_0_2025578x2392029_2028497x2033371">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ntla:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_31_20150131_0_2025578x2392029_2027749x2040355_2036820x2025359">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ntla:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_30_20160430_0_2025578x2392033_2036820x2025359">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ntla:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-04-30</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_30_20160430_0_2025578x2392033_2028497x2033371_2036820x2025359">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ntla:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-04-30</endDate>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_0_20161231_0_2036820x2025359_2038452x2392029">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntla:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_0_20161231_0_2025578x2392033_2036820x2025359">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ntla:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_0_20161231_0_2025578x2392029_2036820x2025359">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ntla:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_0_20161231_0_2022410x2026970">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_0_20161231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_0_20151231_0_2036820x2025359_2038452x2392029_2039549x2392043">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntla:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ntla:ClassA2PreferredUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_0_20151231_0_2036820x2025359_2038452x2392029_2039549x2392042">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntla:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ntla:ClassA1PreferredUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_0_20151231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_0_20170331_0_2038452x2392037">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntla:CaribouMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-03-31</instant>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_0_20170331_0_2036820x2025359_2038452x2392029">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntla:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-03-31</instant>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_0_20170331_0_2025578x2392033_2036820x2025359">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ntla:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-03-31</instant>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_0_20170331_0_2025578x2392029_2036820x2025359">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ntla:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-03-31</instant>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_0_20170331_0_2022410x2026970">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-03-31</instant>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_0_20170331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
    </entity>
    <period>
      <instant>2017-03-31</instant>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_0_20160331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_0_20150831_0_2036820x2025359_2038452x2392029_2039549x2037696">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntla:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-08-31</instant>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_0_20160531_0_2040137x2029877">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-05-31</instant>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_0_20170426_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
    </entity>
    <period>
      <instant>2017-04-26</instant>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_0_20150131_0_2025578x2392029_2039549x2392030">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ntla:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ntla:ClassAPreferredUnitsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-01-31</instant>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_0_20150131_0_2025578x2392029_2036820x2025359">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ntla:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-01-31</instant>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_0_20150131_0_2025578x2392029_2028497x2033371_2036820x2025359">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ntla:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-01-31</instant>
    </period>
  </context>
  <context id="eol_PE974471--1710-Q0002_STD_0_20140731_0_2038452x2392037">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntla:CaribouMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-07-31</instant>
    </period>
  </context>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="Unit">
    <measure>ntla:Unit</measure>
  </unit>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>ntla-20170331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFS Xcelerate Taxonomy Schema - http://www.dfsco.com/financial-services/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 4 -->
<!-- Creation date: 2017-05-01T16:46:03Z -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31"
  xmlns:us-types="http://fasb.org/us-types/2016-01-31"
  xmlns:ntla="http://intelliatx.com/20170331"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2016-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
  xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
  targetNamespace="http://intelliatx.com/20170331"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/DocumentandEntityInformation" id="DocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/StatementOfFinancialPositionClassified" id="Role_StatementOfFinancialPositionClassified">
        <link:definition>103 - Statement - Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="Role_StatementOfFinancialPositionClassifiedParen">
        <link:definition>104 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/StatementOfIncomeAlternative" id="Role_StatementOfIncomeAlternative">
        <link:definition>105 - Statement - Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/StatementOfCashFlowsIndirect" id="Role_StatementOfCashFlowsIndirect">
        <link:definition>106 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <link:definition>107 - Disclosure - Overview and Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
        <link:definition>108 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock" id="Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock">
        <link:definition>109 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
        <link:definition>110 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" id="Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
        <link:definition>111 - Disclosure - Collaborations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <link:definition>112 - Disclosure - Equity-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock" id="Role_NotesToFinancialStatementsEarningsPerShareTextBlock">
        <link:definition>113 - Disclosure - Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" id="Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
        <link:definition>114 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
        <link:definition>115 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" id="Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables">
        <link:definition>116 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables">
        <link:definition>117 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
        <link:definition>118 - Disclosure - Equity-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables" id="Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables">
        <link:definition>119 - Disclosure - Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsRecognizedAtFairValue" id="DisclosureFairValueMeasurementsSummaryOfFinancialAssetsRecognizedAtFairValue">
        <link:definition>120 - Disclosure - Fair Value Measurements - Summary of Financial Assets Recognized at Fair Value (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses" id="DisclosureAccruedExpensesScheduleOfAccruedExpenses">
        <link:definition>121 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/DisclosureCollaborationsAdditionalInformation" id="DisclosureCollaborationsAdditionalInformation">
        <link:definition>122 - Disclosure - Collaborations - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpense" id="DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpense">
        <link:definition>123 - Disclosure - Equity-Based Compensation - Schedule of Equity-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRestrictedStockActivityIncludingConvertedFounderStock" id="DisclosureEquityBasedCompensationSummaryOfRestrictedStockActivityIncludingConvertedFounderStock">
        <link:definition>124 - Disclosure - Equity-Based Compensation - Summary of Restricted Stock Activity, Including Converted Founder Stock (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationAdditionalInformation" id="DisclosureEquityBasedCompensationAdditionalInformation">
        <link:definition>125 - Disclosure - Equity-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToComputeFairValueOfOptionGranted" id="DisclosureEquityBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToComputeFairValueOfOptionGranted">
        <link:definition>126 - Disclosure - Equity-Based Compensation - Summary of Weighted Average Assumptions Used to Compute Fair Value of Option Granted (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivity" id="DisclosureEquityBasedCompensationSummaryOfStockOptionActivity">
        <link:definition>127 - Disclosure - Equity-Based Compensation - Summary of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/DisclosureLossPerShareScheduleOfBasicAndDilutedNetLossPerShare" id="DisclosureLossPerShareScheduleOfBasicAndDilutedNetLossPerShare">
        <link:definition>128 - Disclosure - Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/DisclosureLossPerShareAdditionalInformation" id="DisclosureLossPerShareAdditionalInformation">
        <link:definition>129 - Disclosure - Loss Per Share - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShare" id="DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShare">
        <link:definition>130 - Disclosure - Loss Per Share - Potential Dilutive Securities Excluded from Computation of Diluted Net Loss Per Common Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://intelliatx.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation" id="DisclosureRelatedPartyTransactionsAdditionalInformation">
        <link:definition>131 - Disclosure - Related Party Transactions - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="ntla-20170331_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="ntla-20170331_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="ntla-20170331_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="ntla-20170331_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2016-01-31" schemaLocation="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <element name="AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans" id="ntla_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmountAllocatedToTechnologyCollaboration" id="ntla_AmountAllocatedToTechnologyCollaboration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CaribouMember" id="ntla_CaribouMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassA1PreferredUnitsMember" id="ntla_ClassA1PreferredUnitsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassA2PreferredUnitsMember" id="ntla_ClassA2PreferredUnitsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassAPreferredUnitsMember" id="ntla_ClassAPreferredUnitsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborationArrangementTermOfAgreement" id="ntla_CollaborationArrangementTermOfAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborationConsiderationAllocatedToEquity" id="ntla_CollaborationConsiderationAllocatedToEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborativeArrangementObligationToFundPercentage" id="ntla_CollaborativeArrangementObligationToFundPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DevelopmentBasedMilestonePaymentsUnderAgreement" id="ntla_DevelopmentBasedMilestonePaymentsUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentAndEntityInformationAbstract" id="ntla_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EarningsLossPerShareLineItems" id="ntla_EarningsLossPerShareLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EarningsLossPerShareTable" id="ntla_EarningsLossPerShareTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="EstimatedFairValueOfPreferredStock" id="ntla_EstimatedFairValueOfPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="InitialPublicOfferingCostsIncurredButNotYetPaid" id="ntla_InitialPublicOfferingCostsIncurredButNotYetPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="InProcessResearchAndDevelopmentAcquiredButNotYetPaid" id="ntla_InProcessResearchAndDevelopmentAcquiredButNotYetPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod" id="ntla_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NovartisInstitutesForBioMedicalResearchIncMember" id="ntla_NovartisInstitutesForBioMedicalResearchIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PaymentsOfTemporaryEquityIssuanceCosts" id="ntla_PaymentsOfTemporaryEquityIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="QuarterlyResearchPayments" id="ntla_QuarterlyResearchPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RegeneronPharmaceuticalsIncMember" id="ntla_RegeneronPharmaceuticalsIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RegulatoryBasedMilestonePaymentsUnderAgreement" id="ntla_RegulatoryBasedMilestonePaymentsUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RegulatoryBasedMilestonePaymentsUnderCollaborationFirstIndication" id="ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationFirstIndication" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RegulatoryBasedMilestonePaymentsUnderCollaborationSecondIndication" id="ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationSecondIndication" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RelatedPartyCommitmentObligationPercentage" id="ntla_RelatedPartyCommitmentObligationPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RelatedPartyOwnershipPercentage" id="ntla_RelatedPartyOwnershipPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchAndDevelopmentServicesMember" id="ntla_ResearchAndDevelopmentServicesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchFundingAggregateAmount" id="ntla_ResearchFundingAggregateAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RevenueRecognitionMultipleDeliverableArrangementsAllocationToSpecificUnitOfAccounting" id="ntla_RevenueRecognitionMultipleDeliverableArrangementsAllocationToSpecificUnitOfAccounting" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RevenueRecognitionMultipleDeliverableArrangementsNumberOfUnitsOfAccounting" id="ntla_RevenueRecognitionMultipleDeliverableArrangementsNumberOfUnitsOfAccounting" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SalesBasedMilestonePaymentsUnderAgreement" id="ntla_SalesBasedMilestonePaymentsUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TechnologyAccessFees" id="ntla_TechnologyAccessFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>ntla-20170331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFS Xcelerate Taxonomy Calculation Linkbase - http://www.dfsco.com/financial-services/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 4 -->
<!-- Creation date: 2017-05-01T16:46:03Z -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DocumentandEntityInformation" roleURI="http://intelliatx.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://intelliatx.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://intelliatx.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_StatementOfIncomeAlternative" roleURI="http://intelliatx.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://intelliatx.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureFairValueMeasurementsSummaryOfFinancialAssetsRecognizedAtFairValue" roleURI="http://intelliatx.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsRecognizedAtFairValue"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureAccruedExpensesScheduleOfAccruedExpenses" roleURI="http://intelliatx.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureCollaborationsAdditionalInformation" roleURI="http://intelliatx.com/taxonomy/role/DisclosureCollaborationsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpense" roleURI="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureEquityBasedCompensationSummaryOfRestrictedStockActivityIncludingConvertedFounderStock" roleURI="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRestrictedStockActivityIncludingConvertedFounderStock"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureEquityBasedCompensationAdditionalInformation" roleURI="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureEquityBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToComputeFairValueOfOptionGranted" roleURI="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToComputeFairValueOfOptionGranted"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureEquityBasedCompensationSummaryOfStockOptionActivity" roleURI="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureLossPerShareScheduleOfBasicAndDilutedNetLossPerShare" roleURI="http://intelliatx.com/taxonomy/role/DisclosureLossPerShareScheduleOfBasicAndDilutedNetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureLossPerShareAdditionalInformation" roleURI="http://intelliatx.com/taxonomy/role/DisclosureLossPerShareAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShare" roleURI="http://intelliatx.com/taxonomy/role/DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShare"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureRelatedPartyTransactionsAdditionalInformation" roleURI="http://intelliatx.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.1600" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/StatementOfIncomeAlternative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_LicenseAndServicesRevenue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" order="1.0400" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_PaymentsOfTemporaryEquityIssuanceCosts" xlink:label="ntla_PaymentsOfTemporaryEquityIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" order="1.1400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ntla_PaymentsOfTemporaryEquityIssuanceCosts" order="1.1500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.1700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_Depreciation" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.0500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1.0900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="1.1000" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsRecognizedAtFairValue">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureCollaborationsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpense">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRestrictedStockActivityIncludingConvertedFounderStock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToComputeFairValueOfOptionGranted">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivity">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureLossPerShareScheduleOfBasicAndDilutedNetLossPerShare">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureLossPerShareAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShare">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>ntla-20170331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFS Xcelerate Taxonomy Definition Linkbase - http://www.dfsco.com/financial-services/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 4 -->
<!-- Creation date: 2017-05-01T16:46:03Z -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DocumentandEntityInformation" roleURI="http://intelliatx.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://intelliatx.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://intelliatx.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_StatementOfIncomeAlternative" roleURI="http://intelliatx.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://intelliatx.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureFairValueMeasurementsSummaryOfFinancialAssetsRecognizedAtFairValue" roleURI="http://intelliatx.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsRecognizedAtFairValue"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureAccruedExpensesScheduleOfAccruedExpenses" roleURI="http://intelliatx.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureCollaborationsAdditionalInformation" roleURI="http://intelliatx.com/taxonomy/role/DisclosureCollaborationsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpense" roleURI="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureEquityBasedCompensationSummaryOfRestrictedStockActivityIncludingConvertedFounderStock" roleURI="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRestrictedStockActivityIncludingConvertedFounderStock"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureEquityBasedCompensationAdditionalInformation" roleURI="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureEquityBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToComputeFairValueOfOptionGranted" roleURI="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToComputeFairValueOfOptionGranted"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureEquityBasedCompensationSummaryOfStockOptionActivity" roleURI="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureLossPerShareScheduleOfBasicAndDilutedNetLossPerShare" roleURI="http://intelliatx.com/taxonomy/role/DisclosureLossPerShareScheduleOfBasicAndDilutedNetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureLossPerShareAdditionalInformation" roleURI="http://intelliatx.com/taxonomy/role/DisclosureLossPerShareAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShare" roleURI="http://intelliatx.com/taxonomy/role/DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShare"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureRelatedPartyTransactionsAdditionalInformation" roleURI="http://intelliatx.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DocumentandEntityInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/StatementOfFinancialPositionClassified">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/StatementOfIncomeAlternative">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/StatementOfCashFlowsIndirect">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsRecognizedAtFairValue">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0100" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureCollaborationsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:label="us-gaap_AccountsReceivableRelatedParties"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans" xlink:label="ntla_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_AmountAllocatedToTechnologyCollaboration" xlink:label="ntla_AmountAllocatedToTechnologyCollaboration"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_ClassAPreferredUnitsMember" xlink:label="ntla_ClassAPreferredUnitsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_2"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_CollaborationArrangementTermOfAgreement" xlink:label="ntla_CollaborationArrangementTermOfAgreement"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_CollaborationConsiderationAllocatedToEquity" xlink:label="ntla_CollaborationConsiderationAllocatedToEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_CollaborativeArrangementObligationToFundPercentage" xlink:label="ntla_CollaborativeArrangementObligationToFundPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_DevelopmentBasedMilestonePaymentsUnderAgreement" xlink:label="ntla_DevelopmentBasedMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_EstimatedFairValueOfPreferredStock" xlink:label="ntla_EstimatedFairValueOfPreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod" xlink:label="ntla_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_NovartisInstitutesForBioMedicalResearchIncMember" xlink:label="ntla_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_QuarterlyResearchPayments" xlink:label="ntla_QuarterlyResearchPayments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_2"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_RegeneronPharmaceuticalsIncMember" xlink:label="ntla_RegeneronPharmaceuticalsIncMember"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_RegulatoryBasedMilestonePaymentsUnderAgreement" xlink:label="ntla_RegulatoryBasedMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationFirstIndication" xlink:label="ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationFirstIndication"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationSecondIndication" xlink:label="ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationSecondIndication"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_ResearchAndDevelopmentServicesMember" xlink:label="ntla_ResearchAndDevelopmentServicesMember"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_ResearchFundingAggregateAmount" xlink:label="ntla_ResearchFundingAggregateAmount"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_RevenueRecognitionMultipleDeliverableArrangementsAllocationToSpecificUnitOfAccounting" xlink:label="ntla_RevenueRecognitionMultipleDeliverableArrangementsAllocationToSpecificUnitOfAccounting"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_RevenueRecognitionMultipleDeliverableArrangementsNumberOfUnitsOfAccounting" xlink:label="ntla_RevenueRecognitionMultipleDeliverableArrangementsNumberOfUnitsOfAccounting"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_SalesBasedMilestonePaymentsUnderAgreement" xlink:label="ntla_SalesBasedMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_TechnologyAccessFees" xlink:label="ntla_TechnologyAccessFees"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ntla_ClassAPreferredUnitsMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueAdditions" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_TechnologyAccessFees" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_QuarterlyResearchPayments" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_ResearchFundingAggregateAmount" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_CollaborationArrangementTermOfAgreement" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_DevelopmentBasedMilestonePaymentsUnderAgreement" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationFirstIndication" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationSecondIndication" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_SalesBasedMilestonePaymentsUnderAgreement" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_EstimatedFairValueOfPreferredStock" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_CollaborationConsiderationAllocatedToEquity" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LicenseAndServicesRevenue" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableRelatedParties" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_RegulatoryBasedMilestonePaymentsUnderAgreement" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_CollaborativeArrangementObligationToFundPercentage" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_RevenueRecognitionMultipleDeliverableArrangementsNumberOfUnitsOfAccounting" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_AmountAllocatedToTechnologyCollaboration" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_RevenueRecognitionMultipleDeliverableArrangementsAllocationToSpecificUnitOfAccounting" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_UpFrontPaymentArrangementMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="ntla_ResearchAndDevelopmentServicesMember" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ntla_NovartisInstitutesForBioMedicalResearchIncMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ntla_RegeneronPharmaceuticalsIncMember" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RangeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRestrictedStockActivityIncludingConvertedFounderStock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0600" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToComputeFairValueOfOptionGranted">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivity">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureLossPerShareScheduleOfBasicAndDilutedNetLossPerShare">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureLossPerShareAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_EarningsLossPerShareLineItems" xlink:label="ntla_EarningsLossPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_EarningsLossPerShareTable" xlink:label="ntla_EarningsLossPerShareTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ntla_EarningsLossPerShareLineItems" xlink:to="ntla_EarningsLossPerShareTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntla_EarningsLossPerShareLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntla_EarningsLossPerShareLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntla_EarningsLossPerShareTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_CaribouMember" xlink:label="ntla_CaribouMember"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_ClassA1PreferredUnitsMember" xlink:label="ntla_ClassA1PreferredUnitsMember"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_ClassA2PreferredUnitsMember" xlink:label="ntla_ClassA2PreferredUnitsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_NovartisInstitutesForBioMedicalResearchIncMember" xlink:label="ntla_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredUnitsIssued" xlink:label="us-gaap_PreferredUnitsIssued"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_RelatedPartyCommitmentObligationPercentage" xlink:label="ntla_RelatedPartyCommitmentObligationPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_2"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_RelatedPartyOwnershipPercentage" xlink:label="ntla_RelatedPartyOwnershipPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ntla_ClassA1PreferredUnitsMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ntla_ClassA2PreferredUnitsMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ntla_CaribouMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ntla_NovartisInstitutesForBioMedicalResearchIncMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PreferredUnitsIssued" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ntla_RelatedPartyOwnershipPercentage" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ntla_RelatedPartyCommitmentObligationPercentage" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LicenseAndServicesRevenue" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>ntla-20170331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFS Xcelerate Taxonomy Labels Linkbase - http://www.dfsco.com/financial-services/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 4 -->
<!-- Creation date: 2017-05-01T16:46:03Z -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_8787543_2025283_1_1">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_8787543_2025283_2_1">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_8787543_2027886_1_1">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_8787543_2027886_2_1">Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_8787543_2026150_1_1">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_8787543_2026150_2_1">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="id_8787543_2025718_1_1">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="id_8787543_2025718_2_1">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:label="us-gaap_AccountsReceivableRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableRelatedParties_lbl" xml:lang="en-US" id="id_8787543_2025936_1_1">Accounts Receivable, Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableRelatedParties_lbl" xml:lang="en-US" id="id_8787543_2025936_2_1">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableRelatedParties" xlink:to="us-gaap_AccountsReceivableRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl" xml:lang="en-US" id="id_8787543_2023768_1_1">Accounts Receivable, Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl" xml:lang="en-US" id="id_8787543_2023768_2_1">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_8787543_2027889_1_1">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_8787543_2027889_2_1">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_8787543_2027889_6_1">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" id="id_8787543_2026587_1_1">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" id="id_8787543_2026587_2_1">Research and development and professional expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" id="id_8787543_2024642_1_1">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" id="id_8787543_2024642_2_1">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_8787543_2023126_1_1">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_8787543_2023126_2_1">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_8787543_2024215_1_1">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_8787543_2024215_2_1">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans" xlink:label="ntla_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans_lbl" xml:lang="en-US" id="id_8787543_2392100_3_1">Amount allocated to licenses to targets and associated research activities and evaluation plans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans_lbl" xml:lang="en-US" id="id_8787543_2392100_1_1">Amount Allocated To Licenses To Targets And Associated Research Activities And Evaluation Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans_lbl" xml:lang="en-US" id="id_8787543_2392100_2_1">Amount allocated to licenses to targets and associated research activities and evaluation plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans" xlink:to="ntla_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_AmountAllocatedToTechnologyCollaboration" xlink:label="ntla_AmountAllocatedToTechnologyCollaboration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_AmountAllocatedToTechnologyCollaboration_lbl" xml:lang="en-US" id="id_8787543_2392114_3_1">Amount allocated to technology collaboration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_AmountAllocatedToTechnologyCollaboration_lbl" xml:lang="en-US" id="id_8787543_2392114_1_1">Amount Allocated To Technology Collaboration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_AmountAllocatedToTechnologyCollaboration_lbl" xml:lang="en-US" id="id_8787543_2392114_2_1">Amount allocated to technology collaboration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_AmountAllocatedToTechnologyCollaboration" xlink:to="ntla_AmountAllocatedToTechnologyCollaboration_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_8787543_2022267_1_1">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_8787543_2022267_2_1">Potential dilutive securities excluded from computation of diluted net loss per common share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="id_8787543_2021628_1_1">Antidilutive Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="id_8787543_2021628_2_1">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_8787543_2024873_1_1">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_8787543_2024873_2_1">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="id_8787543_2021396_1_1">Antidilutive Securities, Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="id_8787543_2021396_2_1">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_8787543_2035280_1_1">Arrangements and Non-arrangement Transactions [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_8787543_2035280_2_1">Arrangements and Non-arrangement Transactions [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_8787543_2023136_1_1">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_8787543_2023136_6_1">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_8787543_2027910_1_1">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_8787543_2027910_2_1">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_8787543_2023790_1_1">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_8787543_2023790_6_1">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_8787543_2027691_1_1">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_8787543_2027691_2_1">Current Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="id_8787543_2022272_1_1">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="id_8787543_2022272_2_1">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="id_8787543_2025317_1_1">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="id_8787543_2025317_2_1">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" id="id_8787543_2024029_1_1">Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" id="id_8787543_2024029_2_1">Purchases of property and equipment unpaid at period end</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_CaribouMember" xlink:label="ntla_CaribouMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_CaribouMember_lbl" xml:lang="en-US" id="id_8787543_2392037_3_1">Caribou.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_CaribouMember_lbl" xml:lang="en-US" id="id_8787543_2392037_1_1">Caribou [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_CaribouMember_lbl" xml:lang="en-US" id="id_8787543_2392037_2_1">Caribou [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_CaribouMember" xlink:to="ntla_CaribouMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_8787543_2025118_1_1">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_8787543_2025118_4_1">Cash and cash equivalents, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_8787543_2025118_5_1">Cash and cash equivalents, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_8787543_2025118_2_1">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" id="id_8787543_2021652_1_1">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" id="id_8787543_2021652_2_1">Cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_8787543_2023171_1_1">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_8787543_2023171_6_1">Net decrease in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_ClassA1PreferredUnitsMember" xlink:label="ntla_ClassA1PreferredUnitsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_ClassA1PreferredUnitsMember_lbl" xml:lang="en-US" id="id_8787543_2392042_3_1">Class A1 Preferred Units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_ClassA1PreferredUnitsMember_lbl" xml:lang="en-US" id="id_8787543_2392042_1_1">Class A-1 Preferred Units [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_ClassA1PreferredUnitsMember_lbl" xml:lang="en-US" id="id_8787543_2392042_2_1">Class A-1 Preferred Units [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_ClassA1PreferredUnitsMember" xlink:to="ntla_ClassA1PreferredUnitsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_ClassA2PreferredUnitsMember" xlink:label="ntla_ClassA2PreferredUnitsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_ClassA2PreferredUnitsMember_lbl" xml:lang="en-US" id="id_8787543_2392043_3_1">Class A2 Preferred Units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_ClassA2PreferredUnitsMember_lbl" xml:lang="en-US" id="id_8787543_2392043_1_1">Class A-2 Preferred Units [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_ClassA2PreferredUnitsMember_lbl" xml:lang="en-US" id="id_8787543_2392043_2_1">Class A-2 Preferred Units [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_ClassA2PreferredUnitsMember" xlink:to="ntla_ClassA2PreferredUnitsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_ClassAPreferredUnitsMember" xlink:label="ntla_ClassAPreferredUnitsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_ClassAPreferredUnitsMember_lbl" xml:lang="en-US" id="id_8787543_2392030_3_1">Class A Preferred units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_ClassAPreferredUnitsMember_lbl" xml:lang="en-US" id="id_8787543_2392030_1_1">Class A Preferred Units [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_ClassAPreferredUnitsMember_lbl" xml:lang="en-US" id="id_8787543_2392030_2_1">Class A Preferred Units [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_ClassAPreferredUnitsMember" xlink:to="ntla_ClassAPreferredUnitsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="id_8787543_2027969_1_1">Class of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="id_8787543_2027969_2_1">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_CollaborationArrangementTermOfAgreement" xlink:label="ntla_CollaborationArrangementTermOfAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_CollaborationArrangementTermOfAgreement_lbl" xml:lang="en-US" id="id_8787543_2392041_3_1">Collaboration arrangement term of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_CollaborationArrangementTermOfAgreement_lbl" xml:lang="en-US" id="id_8787543_2392041_1_1">Collaboration Arrangement Term Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_CollaborationArrangementTermOfAgreement_lbl" xml:lang="en-US" id="id_8787543_2392041_2_1">Research term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_CollaborationArrangementTermOfAgreement" xlink:to="ntla_CollaborationArrangementTermOfAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_CollaborationConsiderationAllocatedToEquity" xlink:label="ntla_CollaborationConsiderationAllocatedToEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_CollaborationConsiderationAllocatedToEquity_lbl" xml:lang="en-US" id="id_8787543_2392055_3_1">The amount of collaboration consideration received that has been allocated to the value of equity units purchased by the collaboration partner.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_CollaborationConsiderationAllocatedToEquity_lbl" xml:lang="en-US" id="id_8787543_2392055_1_1">Collaboration Consideration Allocated To Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_CollaborationConsiderationAllocatedToEquity_lbl" xml:lang="en-US" id="id_8787543_2392055_2_1">Difference between cash proceeds received and estimated fair value of preferred units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_CollaborationConsiderationAllocatedToEquity" xlink:to="ntla_CollaborationConsiderationAllocatedToEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" id="id_8787543_2027973_1_1">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" id="id_8787543_2027973_2_1">Collaborations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xml:lang="en-US" id="id_8787543_2025359_1_1">Collaborative Arrangement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xml:lang="en-US" id="id_8787543_2025359_2_1">Collaborative Arrangement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_CollaborativeArrangementObligationToFundPercentage" xlink:label="ntla_CollaborativeArrangementObligationToFundPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_CollaborativeArrangementObligationToFundPercentage_lbl" xml:lang="en-US" id="id_8787543_2398924_3_1">Represents the percentage of obligated fund on research and development costs under collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_CollaborativeArrangementObligationToFundPercentage_lbl" xml:lang="en-US" id="id_8787543_2398924_1_1">Collaborative Arrangement Obligation to Fund Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_CollaborativeArrangementObligationToFundPercentage_lbl" xml:lang="en-US" id="id_8787543_2398924_2_1">Percentage of obligated fund on research and development costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_CollaborativeArrangementObligationToFundPercentage" xlink:to="ntla_CollaborativeArrangementObligationToFundPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" id="id_8787543_2023406_1_1">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" id="id_8787543_2023406_2_1">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="id_8787543_2022745_1_1">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="id_8787543_2022745_2_1">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_8787543_2021893_1_1">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_8787543_2021893_2_1">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_8787543_2024271_1_1">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_8787543_2024271_2_1">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_8787543_2022978_1_1">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_8787543_2022978_2_1">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_8787543_2022748_1_1">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_8787543_2022748_2_1">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_8787543_2025780_1_1">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_8787543_2025780_2_1">Common stock, $0.0001 par value; 120,000,000 shares authorized, 36,025,676 shares and 36,018,540 shares issued and outstanding, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsAbstract_lbl" xml:lang="en-US" id="id_8787543_2021435_1_1">Compensation Related Costs [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsAbstract_lbl" xml:lang="en-US" id="id_8787543_2021435_2_1">Compensation Related Costs [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_CompensationRelatedCostsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" id="id_8787543_2035329_1_1">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" id="id_8787543_2035329_2_1">Conversion of convertible preferred stock into common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" id="id_8787543_2025799_1_1">Costs and Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" id="id_8787543_2025799_6_1">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" id="id_8787543_2023629_1_1">Costs and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" id="id_8787543_2023629_2_1">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US" id="id_8787543_2025578_1_1">Counterparty Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US" id="id_8787543_2025578_2_1">Counterparty Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_8787543_2024507_1_1">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_8787543_2024507_2_1">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="id_8787543_2026678_1_1">Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="id_8787543_2026678_2_1">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueAdditions_lbl" xml:lang="en-US" id="id_8787543_2021694_1_1">Deferred Revenue, Additions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueAdditions_lbl" xml:lang="en-US" id="id_8787543_2021694_2_1">Collaboration revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueAdditions" xlink:to="us-gaap_DeferredRevenueAdditions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xml:lang="en-US" id="id_8787543_2027749_1_1">Deferred Revenue Arrangement Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xml:lang="en-US" id="id_8787543_2027749_2_1">Deferred Revenue Arrangement Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xml:lang="en-US" id="id_8787543_2026679_1_1">Deferred Revenue [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xml:lang="en-US" id="id_8787543_2026679_2_1">Deferred Revenue [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_8787543_2026240_1_1">Deferred Revenue, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_8787543_2026240_2_1">Current portion of deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="id_8787543_2025833_1_1">Deferred Revenue, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="id_8787543_2025833_2_1">Deferred revenue, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" id="id_8787543_2025421_1_1">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" id="id_8787543_2025421_2_1">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_DevelopmentBasedMilestonePaymentsUnderAgreement" xlink:label="ntla_DevelopmentBasedMilestonePaymentsUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_DevelopmentBasedMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_8787543_2392044_3_1">Aggregate potential clinical development milestone payments available to be earned under a collaboration arrangement for each available target selected by the collaborator.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_DevelopmentBasedMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_8787543_2392044_1_1">Development Based Milestone Payments Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_DevelopmentBasedMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_8787543_2392044_2_1">Development based milestone payments under agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_DevelopmentBasedMilestonePaymentsUnderAgreement" xlink:to="ntla_DevelopmentBasedMilestonePaymentsUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_8787543_2026720_1_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_8787543_2026720_2_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_8787543_2025443_1_1">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_8787543_2025443_2_1">Equity-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_DocumentAndEntityInformationAbstract" xlink:label="ntla_DocumentAndEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_8787543_2260742_3_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_8787543_2260742_1_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_8787543_2260742_2_1">Document And Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_DocumentAndEntityInformationAbstract" xlink:to="ntla_DocumentAndEntityInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_8787543_2025647_1_1">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_8787543_2025647_2_1">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_8787543_2024142_1_1">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_8787543_2024142_2_1">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_8787543_2023078_1_1">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_8787543_2023078_2_1">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_8787543_2022383_1_1">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_8787543_2022383_2_1">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_EarningsLossPerShareLineItems" xlink:label="ntla_EarningsLossPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_EarningsLossPerShareLineItems_lbl" xml:lang="en-US" id="id_8787543_2307886_3_1">Earnings loss per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_EarningsLossPerShareLineItems_lbl" xml:lang="en-US" id="id_8787543_2307886_1_1">Earnings Loss Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_EarningsLossPerShareLineItems_lbl" xml:lang="en-US" id="id_8787543_2307886_2_1">Earnings Loss Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_EarningsLossPerShareLineItems" xlink:to="ntla_EarningsLossPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_EarningsLossPerShareTable" xlink:label="ntla_EarningsLossPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_EarningsLossPerShareTable_lbl" xml:lang="en-US" id="id_8787543_2327655_3_1">Earnings Loss Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_EarningsLossPerShareTable_lbl" xml:lang="en-US" id="id_8787543_2327655_1_1">Earnings Loss Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_EarningsLossPerShareTable_lbl" xml:lang="en-US" id="id_8787543_2327655_2_1">Earnings Loss Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_EarningsLossPerShareTable" xlink:to="ntla_EarningsLossPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_8787543_2022611_1_1">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_8787543_2022611_2_1">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_8787543_2023257_1_1">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_8787543_2023257_2_1">Net loss per share attributable to common stockholders, basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_8787543_2027799_1_1">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_8787543_2027799_2_1">Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_8787543_2021517_1_1">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_8787543_2021517_2_1">Employee compensation and benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_8787543_2023675_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_8787543_2023675_2_1">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="id_8787543_2027807_1_1">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="id_8787543_2027807_2_1">Weighted average period of unrecognized compensation costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" id="id_8787543_2024351_1_1">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" id="id_8787543_2024351_2_1">Total unrecognized stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" id="id_8787543_2035400_1_1">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" id="id_8787543_2035400_2_1">Unrecognized compensation cost related to stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_8787543_2022619_1_1">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_8787543_2022619_2_1">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_8787543_2022397_1_1">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_8787543_2022397_2_1">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_8787543_2025882_1_1">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_8787543_2025882_2_1">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_8787543_2025883_1_1">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_8787543_2025883_2_1">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_8787543_2021744_1_1">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_8787543_2021744_2_1">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_EstimatedFairValueOfPreferredStock" xlink:label="ntla_EstimatedFairValueOfPreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_EstimatedFairValueOfPreferredStock_lbl" xml:lang="en-US" id="id_8787543_2392052_3_1">Estimated fair value of preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_EstimatedFairValueOfPreferredStock_lbl" xml:lang="en-US" id="id_8787543_2392052_1_1">Estimated Fair Value Of Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_EstimatedFairValueOfPreferredStock_lbl" xml:lang="en-US" id="id_8787543_2392052_2_1">Estimated fair value of units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_EstimatedFairValueOfPreferredStock" xlink:to="ntla_EstimatedFairValueOfPreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" xml:lang="en-US" id="id_8787543_2026126_1_1">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" xml:lang="en-US" id="id_8787543_2026126_2_1">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="id_8787543_2024160_1_1">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="id_8787543_2024160_2_1">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="id_8787543_2028078_1_1">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="id_8787543_2028078_2_1">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" id="id_8787543_2027611_1_1">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" id="id_8787543_2027611_2_1">Summary of Financial Assets Recognized at Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_8787543_2022410_1_1">Fair Value, Hierarchy [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_8787543_2022410_2_1">Fair Value, Hierarchy [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="id_8787543_2025479_1_1">Fair Value Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="id_8787543_2025479_2_1">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" id="id_8787543_2026318_1_1">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" id="id_8787543_2026318_2_1">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_8787543_2026970_1_1">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_8787543_2026970_2_1">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_8787543_2023956_1_1">Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_8787543_2023956_2_1">Fair Value Hierarchy [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_8787543_2024630_1_1">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_8787543_2024630_2_1">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_8787543_2024630_12_1">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_8787543_2029413_1_1">General and Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_8787543_2029413_2_1">General and Administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_8787543_2034283_1_1">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_8787543_2034283_2_1">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_8787543_2029841_1_1">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_8787543_2029841_2_1">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_8787543_2031134_1_1">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_8787543_2031134_2_1">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_8787543_2031782_1_1">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_8787543_2031782_2_1">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="id_8787543_2030925_1_1">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="id_8787543_2030925_14_1">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" id="id_8787543_2029195_1_1">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" id="id_8787543_2029195_2_1">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="id_8787543_2033278_1_1">Increase (Decrease) in Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="id_8787543_2033278_2_1">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_8787543_2032424_1_1">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_8787543_2032424_2_1">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US" id="id_8787543_2032425_1_1">Increase (Decrease) in Other Noncurrent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US" id="id_8787543_2032425_2_1">Other long-term liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US" id="id_8787543_2032258_1_1">Increase (Decrease) in Other Operating Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US" id="id_8787543_2032258_14_1">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="id_8787543_2031795_1_1">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="id_8787543_2031795_14_1">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_InitialPublicOfferingCostsIncurredButNotYetPaid" xlink:label="ntla_InitialPublicOfferingCostsIncurredButNotYetPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_InitialPublicOfferingCostsIncurredButNotYetPaid_lbl" xml:lang="en-US" id="id_8787543_2304994_3_1">Future cash outflow to pay costs incurred related to the entity's initial public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_InitialPublicOfferingCostsIncurredButNotYetPaid_lbl" xml:lang="en-US" id="id_8787543_2304994_1_1">Initial Public Offering Costs Incurred But Not Yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_InitialPublicOfferingCostsIncurredButNotYetPaid_lbl" xml:lang="en-US" id="id_8787543_2304994_2_1">Financing costs incurred but unpaid at period end</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_InitialPublicOfferingCostsIncurredButNotYetPaid" xlink:to="ntla_InitialPublicOfferingCostsIncurredButNotYetPaid_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_InProcessResearchAndDevelopmentAcquiredButNotYetPaid" xlink:label="ntla_InProcessResearchAndDevelopmentAcquiredButNotYetPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_InProcessResearchAndDevelopmentAcquiredButNotYetPaid_lbl" xml:lang="en-US" id="id_8787543_2392057_3_1">Future cash outflow to pay the remaining obligation for in-process research and development assets acquired.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_InProcessResearchAndDevelopmentAcquiredButNotYetPaid_lbl" xml:lang="en-US" id="id_8787543_2392057_1_1">In Process Research And Development Acquired But Not Yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_InProcessResearchAndDevelopmentAcquiredButNotYetPaid_lbl" xml:lang="en-US" id="id_8787543_2392057_2_1">Acquisition of in-process research and development unpaid at period end</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_InProcessResearchAndDevelopmentAcquiredButNotYetPaid" xlink:to="ntla_InProcessResearchAndDevelopmentAcquiredButNotYetPaid_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" id="id_8787543_2033310_1_1">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" id="id_8787543_2033310_2_1">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" id="id_8787543_2029877_1_1">IPO [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" id="id_8787543_2029877_2_1">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_8787543_2031178_1_1">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_8787543_2031178_6_1">Total Liabilities and Stockholders' Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_8787543_2034137_1_1">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_8787543_2034137_2_1">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_8787543_2031608_1_1">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_8787543_2031608_6_1">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_8787543_2028362_1_1">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_8787543_2028362_2_1">Current Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServicesRevenue_lbl" xml:lang="en-US" id="id_8787543_2031458_1_1">License and Services Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseAndServicesRevenue_lbl" xml:lang="en-US" id="id_8787543_2031458_2_1">Collaboration revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServicesRevenue" xlink:to="us-gaap_LicenseAndServicesRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod" xlink:label="ntla_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod_lbl" xml:lang="en-US" id="id_8787543_2392115_3_1">Licenses to targets and associated research activities and evaluation plans performance period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod_lbl" xml:lang="en-US" id="id_8787543_2392115_1_1">Licenses To Targets And Associated Research Activities And Evaluation Plans Performance Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod_lbl" xml:lang="en-US" id="id_8787543_2392115_2_1">Licenses to targets and associated research activities and evaluation plans performance period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod" xlink:to="ntla_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_8787543_2033371_1_1">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_8787543_2033371_2_1">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_8787543_2032942_1_1">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_8787543_2032942_6_1">Net cash provided by (used in) financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_8787543_2033388_1_1">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_8787543_2033388_2_1">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_8787543_2030371_1_1">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_8787543_2030371_2_1">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_8787543_2030817_1_1">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_8787543_2030817_2_1">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_8787543_2034376_1_1">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_8787543_2034376_6_1">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_8787543_2029047_1_1">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_8787543_2029047_2_1">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_8787543_2030161_1_1">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_8787543_2030161_2_1">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_8787543_2030161_6_1">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_8787543_2032113_1_1">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_8787543_2032113_2_1">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_NovartisInstitutesForBioMedicalResearchIncMember" xlink:label="ntla_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_NovartisInstitutesForBioMedicalResearchIncMember_lbl" xml:lang="en-US" id="id_8787543_2392029_3_1">Novartis Institutes for Bio Medical Research Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_NovartisInstitutesForBioMedicalResearchIncMember_lbl" xml:lang="en-US" id="id_8787543_2392029_1_1">Novartis Institutes For Bio Medical Research Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_NovartisInstitutesForBioMedicalResearchIncMember_lbl" xml:lang="en-US" id="id_8787543_2392029_2_1">Novartis [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_NovartisInstitutesForBioMedicalResearchIncMember" xlink:to="ntla_NovartisInstitutesForBioMedicalResearchIncMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_8787543_2032376_1_1">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_8787543_2032376_6_1">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_8787543_2032787_1_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_8787543_2032787_2_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_8787543_2034201_1_1">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_8787543_2034201_2_1">Overview and Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="id_8787543_2033988_1_1">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="id_8787543_2033988_2_1">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_8787543_2031520_1_1">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_8787543_2031520_2_1">Other long-term liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" id="id_8787543_2034226_1_1">Payables and Accruals [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" id="id_8787543_2034226_2_1">Payables and Accruals [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" id="id_8787543_2039222_1_1">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" id="id_8787543_2039222_14_1">Payment of common stock offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_PaymentsOfTemporaryEquityIssuanceCosts" xlink:label="ntla_PaymentsOfTemporaryEquityIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_PaymentsOfTemporaryEquityIssuanceCosts_lbl" xml:lang="en-US" id="id_8787543_2371413_3_1">The cash outflow for cost incurred directly with the issuance of temporary equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_PaymentsOfTemporaryEquityIssuanceCosts_lbl" xml:lang="en-US" id="id_8787543_2371413_1_1">Payments of Temporary Equity Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ntla_PaymentsOfTemporaryEquityIssuanceCosts_lbl" xml:lang="en-US" id="id_8787543_2371413_14_1">Payment of preferred unit and preferred stock issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_PaymentsOfTemporaryEquityIssuanceCosts" xlink:to="ntla_PaymentsOfTemporaryEquityIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xml:lang="en-US" id="id_8787543_2028458_1_1">Payments to Acquire in Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xml:lang="en-US" id="id_8787543_2028458_14_1">Payments to acquire in-process research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_8787543_2034791_1_1">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_8787543_2034791_14_1">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_8787543_2039242_1_1">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_8787543_2039242_2_1">Preferred stock, shares acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredUnitsIssued" xlink:label="us-gaap_PreferredUnitsIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredUnitsIssued_lbl" xml:lang="en-US" id="id_8787543_2030871_1_1">Preferred Units, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredUnitsIssued_lbl" xml:lang="en-US" id="id_8787543_2030871_2_1">Junior preferred units issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredUnitsIssued" xlink:to="us-gaap_PreferredUnitsIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="id_8787543_2037836_1_1">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="id_8787543_2037836_2_1">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" id="id_8787543_2032595_1_1">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" id="id_8787543_2032595_2_1">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" id="id_8787543_2030658_1_1">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" id="id_8787543_2030658_2_1">Proceeds from issuance of preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" id="id_8787543_2040231_1_1">Proceeds from Issuance of Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" id="id_8787543_2040231_2_1">Purchase of common stock through private placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" id="id_8787543_2039031_1_1">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" id="id_8787543_2039031_2_1">Proceeds from options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_8787543_2035024_1_1">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_8787543_2035024_2_1">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_QuarterlyResearchPayments" xlink:label="ntla_QuarterlyResearchPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_QuarterlyResearchPayments_lbl" xml:lang="en-US" id="id_8787543_2392038_3_1">Amount of quarterly research payment to which the Company is entitled to receive under the collaboration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_QuarterlyResearchPayments_lbl" xml:lang="en-US" id="id_8787543_2392038_1_1">Quarterly Research Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_QuarterlyResearchPayments_lbl" xml:lang="en-US" id="id_8787543_2392038_2_1">Quarterly research payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_QuarterlyResearchPayments" xlink:to="ntla_QuarterlyResearchPayments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_8787543_2028497_1_1">Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_8787543_2028497_2_1">Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_8787543_2030442_1_1">Range [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_8787543_2030442_2_1">Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_RegeneronPharmaceuticalsIncMember" xlink:label="ntla_RegeneronPharmaceuticalsIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_RegeneronPharmaceuticalsIncMember_lbl" xml:lang="en-US" id="id_8787543_2392033_3_1">Regeneron Pharmaceuticals Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_RegeneronPharmaceuticalsIncMember_lbl" xml:lang="en-US" id="id_8787543_2392033_1_1">Regeneron Pharmaceuticals Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_RegeneronPharmaceuticalsIncMember_lbl" xml:lang="en-US" id="id_8787543_2392033_2_1">Regeneron Pharmaceuticals Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_RegeneronPharmaceuticalsIncMember" xlink:to="ntla_RegeneronPharmaceuticalsIncMember_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_RegulatoryBasedMilestonePaymentsUnderAgreement" xlink:label="ntla_RegulatoryBasedMilestonePaymentsUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_RegulatoryBasedMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_8787543_2392034_3_1">Aggregate potential regulatory milestone payments available to be earned under a collaboration arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_RegulatoryBasedMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_8787543_2392034_1_1">Regulatory Based Milestone Payments Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_RegulatoryBasedMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_8787543_2392034_2_1">Regulatory based milestone payments under agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_RegulatoryBasedMilestonePaymentsUnderAgreement" xlink:to="ntla_RegulatoryBasedMilestonePaymentsUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationFirstIndication" xlink:label="ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationFirstIndication"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationFirstIndication_lbl" xml:lang="en-US" id="id_8787543_2392047_3_1">Aggregate potential regulatory milestone payments available to be earned under a collaboration arrangement for a product candidate's first indication.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationFirstIndication_lbl" xml:lang="en-US" id="id_8787543_2392047_1_1">Regulatory Based Milestone Payments Under Collaboration First Indication</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationFirstIndication_lbl" xml:lang="en-US" id="id_8787543_2392047_2_1">Regulatory based milestone payments for first indication</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationFirstIndication" xlink:to="ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationFirstIndication_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationSecondIndication" xlink:label="ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationSecondIndication"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationSecondIndication_lbl" xml:lang="en-US" id="id_8787543_2392048_3_1">Aggregate potential regulatory milestone payments available to be earned under a collaboration arrangement for a product candidate's second indication.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationSecondIndication_lbl" xml:lang="en-US" id="id_8787543_2392048_1_1">Regulatory Based Milestone Payments Under Collaboration Second Indication</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationSecondIndication_lbl" xml:lang="en-US" id="id_8787543_2392048_2_1">Regulatory based milestone payments for second indication</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationSecondIndication" xlink:to="ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationSecondIndication_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_RelatedPartyCommitmentObligationPercentage" xlink:label="ntla_RelatedPartyCommitmentObligationPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_RelatedPartyCommitmentObligationPercentage_lbl" xml:lang="en-US" id="id_8787543_2209883_3_1">The entity's obligation to fund intellectual property costs of the related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_RelatedPartyCommitmentObligationPercentage_lbl" xml:lang="en-US" id="id_8787543_2209883_1_1">Related Party Commitment Obligation Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_RelatedPartyCommitmentObligationPercentage_lbl" xml:lang="en-US" id="id_8787543_2209883_2_1">Percentage of related party obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_RelatedPartyCommitmentObligationPercentage" xlink:to="ntla_RelatedPartyCommitmentObligationPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="id_8787543_2030464_1_1">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="id_8787543_2030464_2_1">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_RelatedPartyOwnershipPercentage" xlink:label="ntla_RelatedPartyOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_RelatedPartyOwnershipPercentage_lbl" xml:lang="en-US" id="id_8787543_2264810_3_1">The related party's percentage of fully diluted equity participation in the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_RelatedPartyOwnershipPercentage_lbl" xml:lang="en-US" id="id_8787543_2264810_1_1">Related Party Ownership Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_RelatedPartyOwnershipPercentage_lbl" xml:lang="en-US" id="id_8787543_2264810_2_1">Percentage of shares owned</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_RelatedPartyOwnershipPercentage" xlink:to="ntla_RelatedPartyOwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" id="id_8787543_2039498_1_1">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" id="id_8787543_2039498_2_1">Related Party Transaction [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="id_8787543_2039282_1_1">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="id_8787543_2039282_2_1">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="id_8787543_2038452_1_1">Related Party [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="id_8787543_2038452_2_1">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_8787543_2040692_1_1">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_8787543_2040692_2_1">Related Party Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" id="id_8787543_2040439_1_1">Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" id="id_8787543_2040439_2_1">Counterparty Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_8787543_2038837_1_1">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_8787543_2038837_2_1">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_8787543_2038837_12_1">Research and development expense related to license and service agreements with related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_8787543_2035076_1_1">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_8787543_2035076_2_1">Research and Development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_ResearchAndDevelopmentServicesMember" xlink:label="ntla_ResearchAndDevelopmentServicesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_ResearchAndDevelopmentServicesMember_lbl" xml:lang="en-US" id="id_8787543_2255924_3_1">Research and development services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_ResearchAndDevelopmentServicesMember_lbl" xml:lang="en-US" id="id_8787543_2255924_1_1">Research And Development Services [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_ResearchAndDevelopmentServicesMember_lbl" xml:lang="en-US" id="id_8787543_2255924_2_1">Research and Development Services [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_ResearchAndDevelopmentServicesMember" xlink:to="ntla_ResearchAndDevelopmentServicesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_ResearchFundingAggregateAmount" xlink:label="ntla_ResearchFundingAggregateAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_ResearchFundingAggregateAmount_lbl" xml:lang="en-US" id="id_8787543_2392199_3_1">The aggregate amount of research payments the Company is entitled to received under the collaboration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_ResearchFundingAggregateAmount_lbl" xml:lang="en-US" id="id_8787543_2392199_1_1">Research Funding Aggregate Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_ResearchFundingAggregateAmount_lbl" xml:lang="en-US" id="id_8787543_2392199_2_1">Total research funding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_ResearchFundingAggregateAmount" xlink:to="ntla_ResearchFundingAggregateAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" id="id_8787543_2041099_1_1">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" id="id_8787543_2041099_2_1">Restricted Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" id="id_8787543_2039074_1_1">Restricted Stock Units (RSUs) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" id="id_8787543_2039074_2_1">Unvested Restricted Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_8787543_2037317_1_1">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_8787543_2037317_2_1">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_RevenueRecognitionMultipleDeliverableArrangementsAllocationToSpecificUnitOfAccounting" xlink:label="ntla_RevenueRecognitionMultipleDeliverableArrangementsAllocationToSpecificUnitOfAccounting"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_RevenueRecognitionMultipleDeliverableArrangementsAllocationToSpecificUnitOfAccounting_lbl" xml:lang="en-US" id="id_8787543_2393639_3_1">Describes the allocation of consideration to a specific unit of accounting at the inception of a multiple-deliverable arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_RevenueRecognitionMultipleDeliverableArrangementsAllocationToSpecificUnitOfAccounting_lbl" xml:lang="en-US" id="id_8787543_2393639_1_1">Revenue Recognition Multiple Deliverable Arrangements Allocation To Specific Unit Of Accounting</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_RevenueRecognitionMultipleDeliverableArrangementsAllocationToSpecificUnitOfAccounting_lbl" xml:lang="en-US" id="id_8787543_2393639_2_1">Revenue Recognition, Multiple-deliverable Arrangements, Allocation to Specific Unit of Accounting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_RevenueRecognitionMultipleDeliverableArrangementsAllocationToSpecificUnitOfAccounting" xlink:to="ntla_RevenueRecognitionMultipleDeliverableArrangementsAllocationToSpecificUnitOfAccounting_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_RevenueRecognitionMultipleDeliverableArrangementsNumberOfUnitsOfAccounting" xlink:label="ntla_RevenueRecognitionMultipleDeliverableArrangementsNumberOfUnitsOfAccounting"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_RevenueRecognitionMultipleDeliverableArrangementsNumberOfUnitsOfAccounting_lbl" xml:lang="en-US" id="id_8787543_2393103_3_1">The number of units of accounting identified in a multiple element arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_RevenueRecognitionMultipleDeliverableArrangementsNumberOfUnitsOfAccounting_lbl" xml:lang="en-US" id="id_8787543_2393103_1_1">Revenue Recognition Multiple Deliverable Arrangements Number of Units of Accounting</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_RevenueRecognitionMultipleDeliverableArrangementsNumberOfUnitsOfAccounting_lbl" xml:lang="en-US" id="id_8787543_2393103_2_1">Number of accounting based units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_RevenueRecognitionMultipleDeliverableArrangementsNumberOfUnitsOfAccounting" xlink:to="ntla_RevenueRecognitionMultipleDeliverableArrangementsNumberOfUnitsOfAccounting_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="id_8787543_2036416_1_1">Sale of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="id_8787543_2036416_2_1">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_SalesBasedMilestonePaymentsUnderAgreement" xlink:label="ntla_SalesBasedMilestonePaymentsUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_SalesBasedMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_8787543_2392049_3_1">Aggregate potential sales-based milestone payments available to be earned under a collaboration arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_SalesBasedMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_8787543_2392049_1_1">Sales Based Milestone Payments Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_SalesBasedMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_8787543_2392049_2_1">Sales based milestone payments under agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_SalesBasedMilestonePaymentsUnderAgreement" xlink:to="ntla_SalesBasedMilestonePaymentsUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_8787543_2039094_1_1">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_8787543_2039094_2_1">Schedule of Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_8787543_2035513_1_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_8787543_2035513_2_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_8787543_2036741_1_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_8787543_2036741_2_1">Potential Dilutive Securities Excluded from Computation of Diluted Net Loss Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" id="id_8787543_2039891_1_1">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" id="id_8787543_2039891_2_1">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" id="id_8787543_2036959_1_1">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" id="id_8787543_2036959_2_1">Schedule of Basic and Diluted Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_8787543_2037678_1_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_8787543_2037678_2_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="id_8787543_2036960_1_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="id_8787543_2036960_2_1">Schedule of Equity-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" id="id_8787543_2041130_1_1">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" id="id_8787543_2041130_2_1">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_8787543_2038480_1_1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_8787543_2038480_2_1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" id="id_8787543_2039715_1_1">Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" id="id_8787543_2039715_2_1">Summary of Restricted Stock Activity, Including Converted Founder Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_8787543_2039316_1_1">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_8787543_2039316_2_1">Summary of Stock Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_8787543_2036601_1_1">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_8787543_2036601_2_1">Summary of Weighted Average Assumptions Used to Compute Fair Value of Option Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" id="id_8787543_2037696_1_1">Series B Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" id="id_8787543_2037696_2_1">Series B Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_8787543_2039916_1_1">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_8787543_2039916_2_1">Equity-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_8787543_2039916_12_1">Equity-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="id_8787543_2036267_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="id_8787543_2036267_4_1">Number of Shares, Unvested, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="id_8787543_2036267_5_1">Number of Shares, Unvested, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_8787543_2036766_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_8787543_2036766_4_1">Weighted Average Grant Date Fair Value per Share, Unvested, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_8787543_2036766_5_1">Weighted Average Grant Date Fair Value per Share, Unvested, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" id="id_8787543_2037346_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" id="id_8787543_2037346_14_1">Number of Shares, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_8787543_2037932_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_8787543_2037932_2_1">Weighted Average Grant Date Fair Value per Share, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_8787543_2036986_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_8787543_2036986_2_1">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_8787543_2039919_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_8787543_2039919_2_1">Expected life of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_8787543_2039121_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_8787543_2039121_2_1">Expected volatility of underlying stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_8787543_2039734_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_8787543_2039734_2_1">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_8787543_2035719_1_1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_8787543_2035719_2_1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="id_8787543_2039921_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="id_8787543_2039921_2_1">Aggregate Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_8787543_2035721_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_8787543_2035721_2_1">Number of Options, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8787543_2035124_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8787543_2035124_2_1">Weighted Average Exercise Price per Share, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_8787543_2037513_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_8787543_2037513_2_1">Weighted Average Remaining Contractual Term, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" id="id_8787543_2039736_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" id="id_8787543_2039736_14_1">Number of options, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="id_8787543_2039326_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="id_8787543_2039326_2_1">Number of options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_8787543_2039536_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_8787543_2039536_2_1">Weighted average grant date fair value per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_8787543_2034501_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_8787543_2034501_2_1">Aggregate Intrinsic Value, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_8787543_2041150_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_8787543_2041150_4_1">Number of Options, Outstanding, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_8787543_2041150_5_1">Number of Options, Outstanding, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8787543_2035540_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8787543_2035540_4_1">Weighted Average Exercise Price per Share, Outstanding, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8787543_2035540_5_1">Weighted Average Exercise Price per Share, Outstanding, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="id_8787543_2036768_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="id_8787543_2036768_2_1">Weighted Average Remaining Contractual Term, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="id_8787543_2036771_1_1">Equity Award [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="id_8787543_2036771_2_1">Equity Award [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8787543_2038291_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8787543_2038291_2_1">Weighted Average Exercise Price per Share, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8787543_2037515_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8787543_2037515_2_1">Weighted Average Exercise Price per Share, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8787543_2036990_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_8787543_2036990_2_1">Weighted Average Exercise Price per Share, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_8787543_2038494_1_1">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_8787543_2038494_2_1">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="id_8787543_2039549_1_1">Class of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="id_8787543_2039549_2_1">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_8787543_2038498_1_1">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_8787543_2038498_2_1">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_8787543_2039336_1_1">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_8787543_2039336_2_1">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_8787543_2035141_1_1">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_8787543_2035141_6_1">Total stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_8787543_2035553_1_1">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_8787543_2035553_2_1">Stockholders' Equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_8787543_2038730_1_1">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_8787543_2038730_2_1">Common stock, shares acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_8787543_2038730_12_1">Number of common stock issued upon conversion of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_8787543_2035145_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_8787543_2035145_14_1">Number of options, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="id_8787543_2040137_1_1">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="id_8787543_2040137_2_1">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="id_8787543_2036634_1_1">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="id_8787543_2036634_2_1">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_TechnologyAccessFees" xlink:label="ntla_TechnologyAccessFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntla_TechnologyAccessFees_lbl" xml:lang="en-US" id="id_8787543_2392039_3_1">Additional technology access fees to which the company is entitled to receive.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntla_TechnologyAccessFees_lbl" xml:lang="en-US" id="id_8787543_2392039_1_1">Technology Access Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntla_TechnologyAccessFees_lbl" xml:lang="en-US" id="id_8787543_2392039_2_1">Technology access fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_TechnologyAccessFees" xlink:to="ntla_TechnologyAccessFees_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_8787543_2038518_1_1">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_8787543_2038518_2_1">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_8787543_2036820_1_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_8787543_2036820_2_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UpFrontPaymentArrangementMember_lbl" xml:lang="en-US" id="id_8787543_2040355_1_1">Up-front Payment Arrangement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UpFrontPaymentArrangementMember_lbl" xml:lang="en-US" id="id_8787543_2040355_2_1">Upfront Technology Access Payment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UpFrontPaymentArrangementMember" xlink:to="us-gaap_UpFrontPaymentArrangementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_8787543_2040369_1_1">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_8787543_2040369_2_1">Weighted average shares outstanding, basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>ntla-20170331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFS Xcelerate Taxonomy Presentation Linkbase - http://www.dfsco.com/financial-services/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 4 -->
<!-- Creation date: 2017-05-01T16:46:03Z -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DocumentandEntityInformation" roleURI="http://intelliatx.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://intelliatx.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://intelliatx.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_StatementOfIncomeAlternative" roleURI="http://intelliatx.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://intelliatx.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureFairValueMeasurementsSummaryOfFinancialAssetsRecognizedAtFairValue" roleURI="http://intelliatx.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsRecognizedAtFairValue"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureAccruedExpensesScheduleOfAccruedExpenses" roleURI="http://intelliatx.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureCollaborationsAdditionalInformation" roleURI="http://intelliatx.com/taxonomy/role/DisclosureCollaborationsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpense" roleURI="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureEquityBasedCompensationSummaryOfRestrictedStockActivityIncludingConvertedFounderStock" roleURI="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRestrictedStockActivityIncludingConvertedFounderStock"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureEquityBasedCompensationAdditionalInformation" roleURI="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureEquityBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToComputeFairValueOfOptionGranted" roleURI="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToComputeFairValueOfOptionGranted"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureEquityBasedCompensationSummaryOfStockOptionActivity" roleURI="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureLossPerShareScheduleOfBasicAndDilutedNetLossPerShare" roleURI="http://intelliatx.com/taxonomy/role/DisclosureLossPerShareScheduleOfBasicAndDilutedNetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureLossPerShareAdditionalInformation" roleURI="http://intelliatx.com/taxonomy/role/DisclosureLossPerShareAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShare" roleURI="http://intelliatx.com/taxonomy/role/DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShare"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#DisclosureRelatedPartyTransactionsAdditionalInformation" roleURI="http://intelliatx.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="ntla-20170331.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_DocumentAndEntityInformationAbstract" xlink:label="ntla_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ntla_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ntla_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ntla_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ntla_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ntla_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ntla_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ntla_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ntla_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ntla_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ntla_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ntla_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/StatementOfFinancialPositionClassified" xlink:title="104000 - Statement - Statement of Financial Position, Classified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/StatementOfIncomeAlternative" xlink:title="124100 - Statement - Statement of Income">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_LicenseAndServicesRevenue" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/StatementOfCashFlowsIndirect" xlink:title="152200 - Statement - Statement of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_InitialPublicOfferingCostsIncurredButNotYetPaid" xlink:label="ntla_InitialPublicOfferingCostsIncurredButNotYetPaid"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_InProcessResearchAndDevelopmentAcquiredButNotYetPaid" xlink:label="ntla_InProcessResearchAndDevelopmentAcquiredButNotYetPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_PaymentsOfTemporaryEquityIssuanceCosts" xlink:label="ntla_PaymentsOfTemporaryEquityIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1.0800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" order="1.1000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ntla_PaymentsOfTemporaryEquityIssuanceCosts" order="1.1100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.1300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.1500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="ntla_InProcessResearchAndDevelopmentAcquiredButNotYetPaid" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="ntla_InitialPublicOfferingCostsIncurredButNotYetPaid" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsRecognizedAtFairValue">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureCollaborationsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:label="us-gaap_AccountsReceivableRelatedParties"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans" xlink:label="ntla_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_AmountAllocatedToTechnologyCollaboration" xlink:label="ntla_AmountAllocatedToTechnologyCollaboration"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_ClassAPreferredUnitsMember" xlink:label="ntla_ClassAPreferredUnitsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_CollaborationArrangementTermOfAgreement" xlink:label="ntla_CollaborationArrangementTermOfAgreement"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_CollaborationConsiderationAllocatedToEquity" xlink:label="ntla_CollaborationConsiderationAllocatedToEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_CollaborativeArrangementObligationToFundPercentage" xlink:label="ntla_CollaborativeArrangementObligationToFundPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_DevelopmentBasedMilestonePaymentsUnderAgreement" xlink:label="ntla_DevelopmentBasedMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_EstimatedFairValueOfPreferredStock" xlink:label="ntla_EstimatedFairValueOfPreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod" xlink:label="ntla_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_NovartisInstitutesForBioMedicalResearchIncMember" xlink:label="ntla_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_QuarterlyResearchPayments" xlink:label="ntla_QuarterlyResearchPayments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_RegeneronPharmaceuticalsIncMember" xlink:label="ntla_RegeneronPharmaceuticalsIncMember"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_RegulatoryBasedMilestonePaymentsUnderAgreement" xlink:label="ntla_RegulatoryBasedMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationFirstIndication" xlink:label="ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationFirstIndication"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationSecondIndication" xlink:label="ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationSecondIndication"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_ResearchAndDevelopmentServicesMember" xlink:label="ntla_ResearchAndDevelopmentServicesMember"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_ResearchFundingAggregateAmount" xlink:label="ntla_ResearchFundingAggregateAmount"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_RevenueRecognitionMultipleDeliverableArrangementsAllocationToSpecificUnitOfAccounting" xlink:label="ntla_RevenueRecognitionMultipleDeliverableArrangementsAllocationToSpecificUnitOfAccounting"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_RevenueRecognitionMultipleDeliverableArrangementsNumberOfUnitsOfAccounting" xlink:label="ntla_RevenueRecognitionMultipleDeliverableArrangementsNumberOfUnitsOfAccounting"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_SalesBasedMilestonePaymentsUnderAgreement" xlink:label="ntla_SalesBasedMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_TechnologyAccessFees" xlink:label="ntla_TechnologyAccessFees"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ntla_ClassAPreferredUnitsMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueAdditions" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_TechnologyAccessFees" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_QuarterlyResearchPayments" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_ResearchFundingAggregateAmount" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_CollaborationArrangementTermOfAgreement" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_DevelopmentBasedMilestonePaymentsUnderAgreement" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationFirstIndication" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationSecondIndication" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_SalesBasedMilestonePaymentsUnderAgreement" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_EstimatedFairValueOfPreferredStock" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_CollaborationConsiderationAllocatedToEquity" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LicenseAndServicesRevenue" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableRelatedParties" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_RegulatoryBasedMilestonePaymentsUnderAgreement" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_CollaborativeArrangementObligationToFundPercentage" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_RevenueRecognitionMultipleDeliverableArrangementsNumberOfUnitsOfAccounting" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_AmountAllocatedToTechnologyCollaboration" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ntla_RevenueRecognitionMultipleDeliverableArrangementsAllocationToSpecificUnitOfAccounting" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_UpFrontPaymentArrangementMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="ntla_ResearchAndDevelopmentServicesMember" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ntla_NovartisInstitutesForBioMedicalResearchIncMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ntla_RegeneronPharmaceuticalsIncMember" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RangeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRestrictedStockActivityIncludingConvertedFounderStock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToComputeFairValueOfOptionGranted">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureLossPerShareScheduleOfBasicAndDilutedNetLossPerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureLossPerShareAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_EarningsLossPerShareLineItems" xlink:label="ntla_EarningsLossPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_EarningsLossPerShareTable" xlink:label="ntla_EarningsLossPerShareTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ntla_EarningsLossPerShareLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ntla_EarningsLossPerShareLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ntla_EarningsLossPerShareTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ntla_EarningsLossPerShareTable" xlink:to="ntla_EarningsLossPerShareLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="ntla_EarningsLossPerShareTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_CaribouMember" xlink:label="ntla_CaribouMember"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_ClassA1PreferredUnitsMember" xlink:label="ntla_ClassA1PreferredUnitsMember"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_ClassA2PreferredUnitsMember" xlink:label="ntla_ClassA2PreferredUnitsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_NovartisInstitutesForBioMedicalResearchIncMember" xlink:label="ntla_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredUnitsIssued" xlink:label="us-gaap_PreferredUnitsIssued"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_RelatedPartyCommitmentObligationPercentage" xlink:label="ntla_RelatedPartyCommitmentObligationPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="ntla-20170331.xsd#ntla_RelatedPartyOwnershipPercentage" xlink:label="ntla_RelatedPartyOwnershipPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ntla_ClassA1PreferredUnitsMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ntla_ClassA2PreferredUnitsMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ntla_CaribouMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ntla_NovartisInstitutesForBioMedicalResearchIncMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PreferredUnitsIssued" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ntla_RelatedPartyOwnershipPercentage" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ntla_RelatedPartyCommitmentObligationPercentage" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LicenseAndServicesRevenue" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g378762g57k66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g378762g57k66.jpg
M_]C_X1A"17AI9@  34T *@    @ # $   ,    !!#@   $!  ,    ! L0
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ #J8
M   G$  .I@   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q
M-SHP-3HP,B P-CHT,SHS,0     $D   !P    0P,C(QH $  P    '__P
MH ( !     $   ) H , !     $   %/          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
M 7X" @ $     0  %KP         2     $   !(     ?_8_^T #$%D;V)E
M7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,
M#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,
M# P,# P,# P,# P,# P,# P,# S_P  1" != * # 2(  A$! Q$!_]T !  *
M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M-)>=K21.]_JM]U;/W6^]=XPUWMQ;32VLNM<"TCP9<V=6M^EMW(INZ8'OK+Z
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MV QC1N>[<D,X_=O[/^]5+X9,[9S'^Z)_]UFD^?8^72^F<CJ613;N=HUSWC:
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MW/#3?4*7[1Q^C9^;_P )^>DI_]'HNCML=]8'L])A8X]3$/.CP<JO?O;Z;O\
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M/+# W[WC4EK&LVN=NW;G?V%(LQSH<1\>&UO??_*_X:W_ +<3D4EH8[%>YK1
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M8?5#OI.K\/I.L;Z3/])_T%F=#92/K1F.HM<^Z<K<Q]08T?IANBUM]KG;7?\
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M  ,;)4<< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1QP"   "
M.$))300E       0,A^Z_@ 5=:K+^PE26]NVT3A"24T$.@     !/P   !
M   !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E
M96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;
M   +<')I;G1E<DYA;65415A4    +@!< %P 4 !( %@ 1@!" %4 +0!- %<
M10 M $8 4  Q #  +@!F &D ;@!C &\ 80!D "X 8P!O &T 7 !! %H ,  Q
M #4 ,0 M %@ 10!2 $\ 6  M #$ .       #W!R:6YT4')O;V93971U<$]B
M:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M   !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L
M.$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,
M   7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B
M;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
M 0       %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O
M=6) ;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L
M=                $)L9"!5;G1&(U)L=                %)S;'15;G1&
M(U!X;$!8            "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0
M  !09U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P
M(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D            0
M8W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M       ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO
M;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 &
M   !  $ 8     $  3A"24T$)@      #@             _@   .$))30/R
M       *  #_______\  #A"24T$#0      !    !XX0DE-!!D       0
M   >.$))30/S       )           ! #A"24T$"@       0  .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #00    8              4\   )     !@!G #4 -P!K #8
M-@    $                          0             "0    4\
M                 0                         0     0       &YU
M;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   4\
M4F=H=&QO;F<   )     !G-L:6-E<U9L3',    !3V)J8P    $       5S
M;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M      9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A
M=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<   %/     %)G:'1L;VYG   "0
M  -U<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB
M;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0
M  ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E
M96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E
M=&QO;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S
M971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
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MUL<QN9-@N<YK/4])]CF,V/M]]/YB)CX_4G7L:XY]5._4V68SAM&YPW[-UO\
M)_PMFS^VDI+C8S\O!=3=56^O[1D.(]1[?<+[OW&?FI#H.* X#%9[RUSCZ]TR
MWZ!W0K?2_P"C/_\ #&3_ .?[E<24YN-TIF+=Z]&.QMFLN-UKIW?3D/:YON1\
MAV7Z%FYE8&TR0]W'_;:MH65_1K?ZI_(DI__2U^A%K?K9U%[VO>*_MSME<[S%
M[/;6UA;O=_)73LS<5\QAYH(#C!KM'T0YVV7.V[G[/9_86-T;I'5<3ZRYN;D8
MEC,6TY09:U]9W>K<VVHL;7:;F[JV_G,6W;T_#M?8\TY3'VDN>ZNU]9W'\_\
M1W-]RBP B)!%>J7YMKG9QEDB8D2'! ::[179DXKK&L.+EMW?G%ENT?%P*&<[
M&'ISA9T6-#A%=A@$D19M>[8_V[]CO^K4G=,Q7;3LS&ENFYMSP2W<;/3<[UOH
MMW?\8E^S,73V9HC4?I[>8C='K_2_.4K58#J&(6[OL6>-)@U73K/MY^DK%]>.
MQU-Q:\,#+'D%SPZ-NZ-KG?203TO!< U]&4]HG:'VO=MW!@=L<Z[>S^;_ #7(
MPI8RSV8]IKL<]UK701+V[3])_P">DI?U>FCESQJ0XS9 @/>XN=.W;^AL]R=K
ML)SAM#RPP-^]XU):QK-KG;MVYW]A2+,<Z'$?'AM;WW_RO^&M_P"W$Y%):&.Q
M7N:T0 X Z:'\Y_\ )2T5JP-6+:<:RHN<QUCA.YXX9<UWTG?O-5',R7XF8:+7
M8E;+/=1ZN596\L&UKG.:YCF.?ZKOH>I_ZCT/H>@VG'L:RIY<1 [ML$_3_.?8
MJN9CYV3:\ML+:71%-F/78! $^YUC?I>[Z22E=-<_,=N<,=]#6D/LQLE]WZ7V
M?H_HUM:W^<_\"5K$Q:75.)#I]6W\]W^DL_E(.#7FXSW>J]]U1&E8IKK]T_SC
MG5O]SO[*L8]ME=9:ZBR398[AO#GO>W\[]UR2D0NZ0<EN(+VG)?.VD6N+_;.[
MV;_Y*GD8M(LQX#C-ATWN[5V_RE-KJF/-C,5S7F9<&-!]QW/]V[\YR:VVQ[Z7
M"BR*WESM&\%EC/W_ -YZ2FDS+#MH_9^5)G=#I#8!=_IM_N_XM.S)!<QCNG9C
M7N.TP9:#K+O4]?Z'MW>_9_VY[$ATCI(K94.GNV5P&#PVM;4R/TGYE=;&J='3
MNF8]K;J<!S+&DN:Z),G\[5_TM4E,^FXU+L9Y(=ID9(^F[_N1?_*5K['1X._S
MW_\ DE7P76T4.9918'&Z]XC:?;9=;;7^?^=6]JL?:7?Z&S[A_P"224K['1X.
M_P ]_P#Y)#R,6EM%A =(:3]-W;^TB?:7?Z&S[A_Y)0NM?94]C:;)<"!(;W_M
MI*?_T^GZ9UC/MZ]G49>79]CQ_M+@QK6>T5VBJO;Z57K.V,<M4=9Z*0TCJ+H<
M8;J=3&[_ $?YL>_]Q9'3:JQUBX@FJS(_:+3=6'%XB]FQW?W,;^ZW^VMS'J91
M:+/MN5:)DLM#G B"-NE;4_)5Z"M U^5,CC/'(R/'/6[]/%Z1_@HAUGHI(#>H
MN)=Q!)_[XIGJ?2QD'%.=8+P_TMAD'=.SO7^\[Z?T%?&7C@0-T<1Z;_\ R"7V
MRC^5_F/_ /()C8:-74>FVY#<5F;9Z[]&UDD&8W099M:YS1N:URLV5/;?4P76
M[7[MVH[#3\U%^V8_\K_,?_Y!5,]]&4ZJDN>UC]P?#'@N: "^OZ/Y[4E+?:JP
M2'/O&U[F$@M(]KO3+O\ J/\ /2.36&BQUES:RW<TEPW'3=]&-O;;NWJ9M>73
M]JL#?;[12>P]\'9_A%$OM( ^V6#2"?0,D['LW?0_TKF7?];V(BB!T19[6E=6
MZ<<LOMVVN@ZCC998/S?Y*K6WY==[Z?L^6\ Q78RRDAS8;-FUSVV-8U[MGT/_
M $5ZA77@7TN?:^QIL.UIK<(]N0[]SW>Q[&?]:5'JN,<[(+W8V-?6T 5/N%[+
M&C0N]U5;OS]WT4"D-W%LR;[1793EXPV%SGVNJ(#O9^B_0NMW.]S_ /MM%QV>
MHU^[(LWM?8"-PD-:][&:;?W6JGTAKL'?4ZFBFAWN_5V7;G6&!N<VQGM;M_EI
M-P^CY)?=DT>I:;K#N+'S(>^MOYO^C&Q)3I?9C_IK?\X?^10K:G-?0&WV18^'
M:C4;+'_N_O-5/]D_5V2?L@]PVGV61$;/:V/;[5*K&Z3A7TV8='HN<_8\MK>"
M6BNW:SZ*2F\['V-+G7VPT2=0=!_95#]J=+BPMS+7^D6BS:'.C<=H^C7[O["T
M/ME'\K_,?_Y! S#CY5;6>M?06G<'TA[7<%L3Z;OWDE-4=6Z4YI?7F6V-:0'N
M8'.#9:ZS<_;7[6[6)_VKTK4G.L  )DAP$!OJ<^G^XF.'473]OSH)ES9< 1K[
M?;2-O]A'PVT8KG..3E9!< /TV]P$$F6M%;6[O<DI/36RZIEU=]IKL:'L,Q(<
M-S='-W)74NKJ>]MUDM!(U';^RI_;*/Y7^8__ ,@AY&70ZBP NDM(U8_O_924
M_P#_U.AZ9E,9US--;?3LQFY[W6. <#^G:^?T=?K^W]S]-_P2UCUG-;E,Q#D8
M/K.?LV'U0[Z3J_#Z3K&^DS_2?]!9G0V4CZT9CJ+7/NG*W,?4&-'Z8;HM;?:Y
MVUW_  /O_P"#75#[3K'I<Z\\I^0BQ78-?E(R&,B57QSV(EZ>+T_+_5<9W7LI
MUM=5-^&ZRUC3741<"YT.#V^H6AC6NM;^B]3_ -&UJW5?US(QF78[L0N+C+3Z
MH!; VM]S6V,L;^=^C5UGVC;^C]';_)F/P3M^U1[?2B3Q/,^[_I)C8:K#]8/6
M&\8@IW#=!L+MDC<1IMW[=R+GOO8^DX[0^X[FL#OH@D ;[/SO39_)1OUS_@_^
MD@V?:?M%,^GN]^T:P=$E,W9=H=M&-:=6P[VQ[A/[W^#_ #U%V;<&@C$N+B)C
MVZ>QUNV=W[S/1_XRQ%_7/^#_ .DE^N?\'_TD016HM!![HG7/?D4M=6Y@;88<
MZ(/MR&>W_MO?_4L8L_,ZSD8N;=0[)P:V,<W:RXV,>&N#/I<LL?N=^8M"[[3Z
ME&[TY]0[8G4^G9RB_KG_  ?_ $D$N?TGJM^;D^D^[$L#:M[FT&SU-TL'N9:U
MOIL_G/\ A/YM2KS\BAUE3<*Z]@MLVVU[2"2][]=[V>UKOT:N_K?_  ?G])"Q
M?M/INV;"/4MYD:^H_=_TDE(OVM=)!Z=ERT28;7&HW;6N];W)5YEN3?CBS%NQ
MMK]TV[()-=OL;Z=ECMS?ZJM_KG_!_P#20;OM/J8^[TP?4.V),GT[>?[*2FXJ
M?5,K[-C A[JG6.VMM96;BV ;'.]%ON?[&.1OUS_@_P#I)?KG_!_]))3C?M?*
M%@:[*;N)+0P8.3[B#N]GOW;O36ATK/.4QS+'FRT2\N%%E#-I<YM;&_:1N<]C
M6_I%9_7/^#_Z27ZY_P '_P!))29"ROZ-;_5/Y$WZY_P?_20[_M/HOW^F&[3N
M(DF/+A)3_]DX0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H
M &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
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M(" @(" @(" @(" @(" @(#P_>'!A8VME="!E;F0](G<B/S[_[@ .061O8F4
M9$     !_]L A  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0$! 0$" @$"
M @,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P/_P  1" %/ D # 1$  A$! Q$!_]T ! !(_\0!H@    8" P$
M        !P@&!00) PH" 0 + 0  !@,! 0$            &!00#!P(( 0D
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M?^D^]+?_ %C]^_UH.7O^4^Y_XSU[_DXI[N_],QLW_57KW_#IO\R;_O*>@_\
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MZ4(_VXP?OW^M!L'_ "G7/_&>M_\ )Q7W=_Z9;9O^JO7O^'3?YDO_ 'E10_\
MI/G2O_UC]^_UH-@_Y3KG_C/6O^3BGN[_ -,QLW_57KW_  Z;_,F_[RGH/_2?
M>EO_ *Q^]_ZT'+W_ "GW/_&>M_\ )Q3W=_Z9C9O^JO7O^'3?YDW_ 'E/0?\
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M_P"3BGN[_P!,QLW_ %5Z]_PZ;_,E_P"\IZ'_ -)\Z5_^L?O7^M!L'_*;<_\
M&>M?\G%/=W_IF-F_ZJ]=?\.G?S)>?^<J*'CZ_P#./G2O_P!8_?O]:#8/^4ZY
M_P",]6_Y.*>[O_3+;-_U5Z[_ .'3OYDG_>5%!]+_ /9/G2W_ -8_?O\ 6@V#
M_E.N?^,]:_Y.*>[W_3+[-_U5Z]_PZ;_,F_[RHH/_ $GWI7_ZQ>[?ZT'+W_*?
M<_\ &>O?\G%?=S_IE]F_ZJ]>_P"'3?YDW_>4]!_Z3[TM_P#6/WK_ %H.7O\
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M\.F_S)O^\IZ#_P!)]Z6_^L?O7^M!R]_RGW/_ !GKW_)Q3W=_Z9C9O^JO7O\
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MRS2,21"Y4VDIB+20+(Y5F9'\1$:7Z<A4F=7D5>B/;+_X^OO'\W[0PO\ L/\
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M?@NP\GG)NQNOZ;8\W7^Y:\8O#[XP^_JG<D>S\YM6:N#QR5=+62) T4@DTE&
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MPH@]OR<DWTN[7.XR7Z%&FOF4LK-*1=P/$B.^LKHM]0$:*H4H&)[FZ)XOO/\
M*=MRKL?+]ORK?120KL.N))X4LH6V:Y2:9K:!+=6$E_1YKB>:268RLJJQC7(:
M[0^:^V-KYG8V5?K7+U@V?OWYC[S>.',XI#5Q_*7#U&+QM+")J;1'/L_S@UDC
M<5H4B/3?W6XY'NI=NNK!+^-6DV6RL*Z30-:S^,TF#4(XP%^('.>BW;OO-['9
M\P<O;O+RO<M#9<R<P[FR^*FIEWFR^DAB^ C5 0&8FH9>VB])O>ORWVUNSXP8
MSH>?9>\-QYZ@PFS<)BL_V?N+:>],;UB=K2I)E,KU#GX]J8WM&@3=20K3_P *
MRN3JL;BZ1FAIU9 H]F4?*UY_6;]]K<QQ1>,TC&-6224,I3PIJ.8I$!.LRF,2
MN0NHUJ>@[O/OYL6Y^R]K[<2;%>WN[+:0VZ&]E@N+>Q,3AVN=O<VR7D+SA=!M
M3<O;0H[+&NA57HBS<$_ZY]CL&O6*9!!H>NO>^M=>]^Z]U[W[KW7O?NO=!YUK
M_P !>RO_ !.G97_0V']ENV_#N7_/=/\ \^]#+G7^VY*_\5;;?\$W0A^S+-*5
MZ!X8BM#UW<\<MP+<&W^W_K[T0#QZ]J;UZ/E\#/CWLSY";D[IQVZ]B;M[/KMA
M=4P;QV=L+9N_L1UIE=S;@DW3C,,:%]TYYX<)0QBAK))%-5*D6I;>IB%('YYW
MF]V3;[&XL)TB>2\CB9F0N CK(S-I&3I*K@ D^0ZRG^ZY[7\K>Y_,7.%ES/LU
MSN L=DFNH+>">.U::9)K9%3QI1X:525\N0M:5X4(Q=J?$#J?$[G[3P>R,'FL
M)NS:7Q=I.S,WU%NGLJDW1N3ICM[(;\P^U,7M;+[MVA%5X/=-7E,=E(:L456\
M<4$=2)&?28U]D6U\T;O=VT#O=)/ V[6UO%<)$42:.1',HTR&OZ3J5:0:B"**
M"0>I/YT]AN0+#F#F.PV;:YK3<[?DR[O[G;;B[%Q/MM[#/#';*9K5&222YBD6
M9()- "R!F=59!TV[5_E_[4HNQ=MX7<7<F+[%H]M_)#J[XZ]W['VIMS<FT,OM
M_=F^J"NK\G2X/=^5DDH\IB<.:)H$R-/"K5$T4P$405&D6GGB6[M!/:;:\5K<
MVM]+;3,RD,+6-FU-&.X$FC!2::2IU$EE4AL/NO;-M6_[5;[OSI#N4UES'M&V
M;K9PQ20F&7<92KQQ7+@I*L>AXC*$'ZBOV! CR<MG?!'JW,]J[,AR/=U5F^E-
M]GY*Q8W.[0V/GJ/<='N/X\+5U6>VC)1Y]ON:W%PT")-%ETC0Y04[PI#!),D@
M1/SUNB<OWUT=M5=W@V^VNAK8:'CN'6+Q2$-5*R'^RU'!!#$!AT:V'W7.2+GW
M-Y<V]^>9I>0=QW7>+/\ 0@?ZB&?:HFN6MU:4:9(WAH5NM(!*NGAH[(W0']F_
M#JKZYZ"V[WW!V=3;PQ&Y<;MO/8M,%UUNX;.K,/NS(5=%BJ"G[)IILIMS'[]Q
M4%,)\O@LHN/EH=?BCGJ95TD]L.;GN-_?E^;;O"G1BC5E0-K6,2,Z1FAEMR3I
M6:.NIOP 5(B[G#[O(Y:]L8/<JTYM-[M\\23Q>'9W#0&"6=H4BENT$D4%^H'B
M364XC,:F@FD:@)*[\DCZ_P!?S_OK>QP/^+ZQD)TMVG'70XO;\_[Q_B/Z>_4'
MIUHL2 #UR7]<?_!T_P"AQ[]Y_GU4_"_^E/\ @Z#3J_G&;UL/U=P]I7_Q/\;I
MO^*^RW:_["\_Y[)_^/#H<\\FE[RS_P"*[MG_ %8;JQ[JSO:NEVW\2^IMJU.#
MV%N[I/OO=O:5/V=OO<])@=@'^]<V%F%/FJP4TE1@Z*CH\/+%-)+K6H,P11<^
MR.]V2(;ONF]WH,NW2;9].\2J7=EUR&32!Q8K(0B<21Q'4O\ )?NE<-RG[9>W
MFQR0[?S%MG-+[E'?7-PL%JA9(!$)7*DQHLD ,DE2 C?#7B;O?'R+^-N_-S?/
M+%9R1!T3+UCU7U!TGL?9&9HMH9_=>V-G=CIN#,U/6\F>Q>4H#*^XZRMS(6II
MC'-2R*7"@W #LN7M^@V?E>::%VWR3=5N92XKH5('BA\;2115A6.)J$%"QH=5
M.LD]X]W_ &GW;F_WUM3N$,/M_;\LQ[;MT=K((6F(W"*ZG-D9$D!:2\>XND#1
MLLB:0RA2=*3QO\S)OONR*>MVEV1M+;F:WOMG>?7L74?8>WMO;HQE!L[K^AZV
MQ.R=\[HW-M+<L];A\CA\/2U53D<1%296*K#K$_B8 &L_M]</;;:?JX)MR3ZH
M2F5&\&MW+XSND:.C:HG+!%9BKJ:2"O0&VO[W>V6^X<V0ML>Z[?L,T^WR60L;
MJ)+P1[;9K8PVUQ<3V\ZZ+B%$::6)(YXI 3 ^DA05SIWY%[+V]M3<?7W=.P]U
M]@[/R'=FU_D9@Y=E[MQ^U]ST7:.T_O46DSN3S.*RE/EMJ;CI*YHJUD2*N@<&
M:G8.Q $VX[#=^+L=_LMQ#%N%A \*:T)B,<H75V*P(*.BR)0^J-VGJ'N0O>38
M+';N;N6?<#9+V]Y:W/=8=T!M[@17:7EN9E"O,\;K)#<0S212EE#(:31G7CIK
M[P^34O>/7-1MO-[63%;QR_R/[6^0.;SN/J(3@?\ C)F*P>,CVQBZ$Q?Q*,X6
M/"HK5,S_ .4* 2"U_;6S<I_N;<-GGBN@UM9[2+.C#ND?ZAIVEXT .H]OD>&.
MF_<;WT3W%Y3YBVN]V3P-ZW/G*XWIW5QX21S64%I';!=(+&,0@^(34K34"W=T
M9/O/YS=8=S;4RU-'M#Y,X'=U5MS9%'B<--\AZFIZ(H=Q[!HL%#A<E6]-T\8P
M-9B'KL%'4STJI>6=FD],IU GVGD_=MHW>.^CN;%XEO7GU/;AIP))&8J):Z@:
M,5!!&@<,"G4L<]_>6Y%YRY1GVEMKYGAWG]T6]HL:;JZ[9XMM!%$DC;?X?@LA
M:(2,C8=JL>XENI%1\\^K(MT9O?V%Z6WQC=Z]D?(GHGY&]L-6;\P&2V]5;AZA
M,QRFW=CT*X*EK\/B<Y)-)-32UT]3/$\I22T<:>Z1<C7MO#86*;C&=LLX]P6&
MJ-XE+V-DJY#:24J*Z54$+7XB>O;I]Z/DZ^O=PYACY/OTYEW;>-@W#<:W*-;A
M]GG\9XK1/!$B1S,7<-))(4:30 40$EA[T[\VEW+UQUSMT;,W#M_>/6>Z.WY<
M=ESFL15;;RNRNT=_9?L,4-;C4H4RT.Z\/D<BL#3I,:26-&;1J9=)YL/+EWLN
MXM<B[C>TDVVT@D4@ZO$M8A$KQFOP, 25;-2*<,Q+[H^[G+ON+REM>T)LEU:[
MS8\P;M=P,)$:%K7=;MKQDF70&,\4C!$=&"LE2REB*$0V4=6[.\_P/]*.%L/]
M4#UQM_DVXX]B.R_W*WK_ )Z5_P"K*]11S1_RK_M;_P!**;_NXW'0B_46'U((
M_P!N/P;BY]F!%:#R/0,X'JR;87S(Z(VQM'XX5VY_C_O+>O='Q<VA7X+K;<<_
M9=-B.MZC-G/Y;<F#SFXMI45#)D:^'#Y;(I,(Q(KR-"%)TD%8YW/E3?I]SY@E
MV[>(H++<5C26L>N156$0N8R6TZF34%)! U5H#QS1Y3^\+[6[5RC[7P<R>V]Y
MN7.7**SO9/\ 5B*U:9[M[N$S1B(L4CE9&8*X+: "2#0,V8^=^8W-\=8^J<\O
M:%)OBEV9N'KZ3(;4WIM_ ]6[JP^Y=UU^YZ_<&]MNR;7KM[9//+%E:FC?'092
M##U49CD=5=+&S<C0Q\P6^Y6P@-FKVS$2HSNAM41%6*C!1K"*2SJ6C:I7CTDD
M^]#/N/M/>\F;JNZKS&]K?VNNVNHX;6XCW"XEN));P&!YW:,SRQF&.98ITTF1
M5*T*BWQ_, H\YNG%;LVOUSE<)7XKY'['[P--E,WC,C29#;.WNEL;T[N38%7#
M#3('DW/CZ6H8SF\*0U 1E+ GWNRY+>("&^NEDMFM;^%U (8_6W)G%"#0>%V@
MG@6 /2C??O1V5S<C<-BY>FM[Y-_V2_C+2JRJFT[4NW2Q$>'E+GNK_#&Q4@U!
MZ?\ ;7\QF'$[P[LJ*K:G8>U-@]A;MV#NC8.,ZDW?M;:^\NOL5UAMX;4VSUX^
M8W#MC<V'&TJK HJSRT%-#7T50/+2OS;VBN.0IYMLV>*2ZAGW:WFN9)6D5O"E
M:[H79PC*Y9"%TD&C*-+X/1[LWWMMKL.:_<&X&P[AM_*FYC;Q:)8S11W5G'M:
M-%;6\;S0S1+#+&[*Y6-7A8^)$:]O0<['^2=9OG>7P^PU#6X3KO='27:W;&^\
M_P!F=I[UACVEF*'M3>HW?N!,SF9Z$5D<[;?6?'U$D\?ERM3*NE5+V]F1Y9BV
M\[[=W:>-ML^TV]H88HR'*0QO&VA%)RWB:HXP133QH.@ALOO1/S/N'M#LVTW"
M;3OFU\S[GN3WE]=CP-5]=1W:B>5T_"L)CEE8,9=? ,:= K\PNU=M]O?(#>F>
MV##2T?56VAC^N^H<;04LM#C\?UMLN%L=@/X?236EIJ+(SM45JJP#VJ1J -Q[
M,>2MKO-MV))-SU?OBZ<S7!8@MXC4"AB*C4D:HA ) (/4?_>.YYV'GGW,W23E
M!8UY)VR-+';5C4K&+6W+90'NTR2M+,NJC4DH0*=%??\ 0W_!6_WH^Q=U B_$
MOV](#:?_ !_?>G_A[;'_ /?;8WV76AK>;W_S7B_ZLKT,>8O^54]K/^E7??\
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M_!]P[WEYJ]^]P)W;8K&\V_;+6UFBFGE=A((Q+57AB>-D9)%(H:@X(J#T[?\
M#67\PO\ [QH/_HY^G/\ [*/<D?Z\/+E?]P;S_>4_Z"ZQ$_Y-Q>]7_37\L_\
M.2Y_[9^O?\-9?S"_^\9W_P#1S=-?_97[]_KQ<M_\H-[_ +RG_077O^3<7O5_
MTU_+/_.2Y_[9^O?\-9?S"_\ O&=__1S=-?\ V5^_?Z\7+?\ R@WO^\I_T%U[
M_DW%[U?]-?RS_P Y+G_MGZ]_PUE_,+_[QG?_ -'-TU_]E?OW^O%RW_R@WO\
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M 'C._P#Z.;IK_P"ROW[_ %XN6_\ E!O?]Y3_ *"Z]_R;B]ZO^FOY9_YR7/\
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MZX^IGZRVW50P">HW''%6ZZ:IC;7"61=6D^H'VDM_=KEZ&;<9#8WA6:8.O:F
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M /93[W_KQ<N?\H-Y_O*?]!=>_P"3<'O3_P!-=RS_ ,YKG_MGZ[_X:R_F%?\
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M??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T2;XY?\ 93/SO_\
M$E]0?^^3VO[]U[H[/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ(Y\8LOB=N[@^<&=S^3Q^$PF)^5.[LCE<QEZVEQF+QF/I.K.KI:NOR.0K98*
M2BHZ:*-GDED=41022![J[K&*LP"XXFG' X^IP/4]656=@B*2WH,_/HZE!D*+
M*4-'D\;5TN1Q^0I8*Z@KZ&IAK*.OHJJ))Z6LHJJG>2GJJ6I@=7CD1F1T8$$@
MW]V=6C>1)$(=2000001Q!!X=-)(DBAT8,A%00:@CR(/H>B==J?-S8W2_;%/L
M/LCKCM[;/7S97&;5J_D5DMKX^EZ5I-^9S:65WOA]HP9&?-IN_.M48+!U$=1D
M\=B*O$4.1:*BGJ4G=EC3BXC"7$DI\.-%E*ZN,IAC\64(HJU1&&*%@HE,<BQE
MF4!E$L,B+;-"AF9RFL)GPEEE$,;2$T6AD*A@I9HU='<!&J IE_FC_'_ ]5[P
M[3[%VIW)UJFTMR]1X3^XF>V$^8[ SV)^0612FZ.WCA\/L_)[CQ\6V=_4)DJ7
MDK:NDDPHI:F+)I22PE"O6VD:YV^R&GZZ>^%F4K_97)5',<C_   +'(LA<,4(
M)"%G[2C-PBQ7UQ0FVAL3>!AGQ;=2R:XE^-B9$,832&!*LP5&#=#3NGY83[/^
M3?7/QJS/1';<LW:]3N-=D]G8:HZZS&R9\3LW:E+NC=N[,]C:7?/]^ML[1P53
MD*3$R5]7B423,5U-3Q!_,K^TUD5O)[NVU>'<0P/,P;AX:2)$IJM0#*[@1*:%
MJ/PT-1ZY_P 6B@GIKBDE2,$4R[JSE0"03H1&9RH(4 9[EJ;]_P!)_P!A_O8]
M^;X33K?5<&\OYD766R>U?DWTYD=A;\?=OQIRGQXIJN33B*;"]E8CY Y_9FU_
MX[L/*SURPU'^B_,[VI$W)25 BJ:2.:GD172IB)I9CZ];&2+M\?>EVXU(JCN%
M,<U*ZFB<LR=H)#QLK4.FNMPU;<TPEC9M.U2WRT!(9(A(SQDG"R:8PRAF[E<,
M,*VF?AOYCO26<W5@-A40@?L+-?+3LKXGU'7D>]=C3[\PN4ZQ&^I<MV'DMH09
MQ\^NT:RCV.:B-!3_ '<<-?3O(BJ20W:SI=0;?<!'\*?;[R[.*^&+-)G>-OZ;
M^"54UTZF )&>O70>TFOH'7]2*YM8AD 2?5FWT.I/X5%P"U<D1OIK0=,OQ@_F
M&1_(+/;2Q&Y.ELGUG3]H=/;C[TZJJL7V-L_MFOSFQMHY;%8S.4F\MO['0Y?K
MW=@BW#CYJ2CG2J@K7EFIHZDU5++#[OXD9L=PN>XR6UG;W+JJEZQ7"%ET$8:1
M2-!C U$]R:E!(V#6\M;:.GA37D]JK,='ZL#LK%E;"QG2Q\351<!])=-2 VC_
M #6-IY;J3='?^Y.CMZX_I:CR>R,1M/=77N[]D=S9ZNSF_P#LS;/6>'V+V5UY
ML7(5&\NFNTZ2LWC09"OP63I9_L:/[B.:I2LIGIBI@A2239H)I3'/?30(A UQ
M'QD+ZEE6J-X*J?'"X4%=!D!)5NX<0G=FC4M%9PSR2U[)%%O756-L@2$,(37O
M()8(*$G%R'S1^+>+VOBMY9#NC:-+MG-[,[#[!Q&7<Y,097:75.YL9LO?^3QL
M2XYZFKGP&[<S28W[2-&K:JNJ(X:>*9V ]I3,JXRS^#;RT4%F9+L@6S(J@LYG
M) C5 S-7ATK^EN HD,1$?C2Q5. )(4:28,30*(T5F=FHH R>@-ZT_F8_&_L5
M^S\I)GEVAM+K#-;SPM3D=ST^X:3>.XY=E[KV=L>IJL!U:-M'?+_Q#>6\X,+!
MC9J:+/R9I/M(\?(TL;LZ0R0PRN#XKN$5%_4<L\US#& $U5,AMI'55U,%5M80
MH>F$#O+?1QJ3%;@%W/:@7Z:&X<DM32(UF0.6HIJI5B".AKV[\V?C#N[<NR=F
M[6[1@W%NG?\ 3QU6&P6&VIOG(Y'#)-F\CMF*+L2"EVO(>I*Q]SXBKQ@I]U?P
M:?\ B5++2Z/N(WC%D1I798Z,!&CZ@5*%9$:2,*]=+,Z*[*BDN55CIH.J-(B+
M5SI.IE*D$."C(C$I\856= 7*A!K7-".H_>QOW_\ "O\ \2EVE_[X#LC_ 'D7
M]^XY'5^O_]2P?^?'_P!ET]4_^*?C_P!_;E/>+OWE?^='_P!/=?\ '8>ND?\
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ML.?]B+>_9Q3KW7$R:=18A54$ECP  +EB2;:1_7WXFE2>'7NN,<JRJLJ,KQE
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M=?\ '8>ND?\ =Y</>7_2[;_QZXZIQ]XOG@>ND?6UE_PG\_[(Y[6_\6Y[K_\
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MT %3@ 8Z_]&P?^?'_P!ET]4_^*?C_P!_;E/>+OWE?^='_P!/=?\ '8>ND?\
M=Y</>7_2[;_QZXZIP/Z>#8W'YM<7Y^O!/]/\?>+_  S6AZZ0X.":=;''\D3=
MGR*PWQ7[9H^LND>NM\;=7Y:=RR1YW<?>%;L?(3RO0;-^XCEP-/U9N]:?PR*
MK?='6O.D?G//V9T?ZV'*FAB3X<M<4SX\E1\_M\\=<2_O?>(?O(^YWB1JOZMJ
M!1M1(%G!0G H2*&E,&HJ:=7'?Z1/FG_WC%TS_P"E09?_ .T%[D_K&_KW^D3Y
MI_\ >,73/_I4&7_^T%[]U[KW^D3YI_\ >,73/_I4&7_^T%[]U[KW^D3YI_\
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MO?WK_GD_\^/_ )67_I27RK_^YE]^Z]UP;=G\\H*Q7HW^5D[ $JG^S)_*I0S
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M9E/>+OWE*ZN1Q\[K_CL?72/^[R_\'-_I=M_PW'5-Y]XO@DFOX>ND1X=;6/\
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MLZ*9*4*-T=+B"T2U)'C;'$H+ KX;R27)$A'$31]KD#3('559PM.MK=?I:]R
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M[J0J)+MK@2(,H8IY5E"'\;%"M#5M,ITLR@H*W<I?DG\V/NHKY]6ZJ0_DP_\
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M@K:JH6!F^X?TQ"-.?I]/?IKB>X$0EDKH%!\NMPVT$!E:*.A<U;CD]8=F=/\
M7/7VW<YM+:>UZ+&[<W'7Y7*9O$22U>1H\G69M#'E'J4R515EHZU#9XP?';Z
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M?E0=:AV^SMVB>*$!T!H<USQ)-<D^=>AQ L+?Z_\ O?M-TMZ)S\-/^+1\B_\
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MO2=XT<0ZER@ KYL1 UJK.>+N+=C&':II0_$ W2M3X8=/4C[^&"R7;NTJ+?\
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M. .N9WWOPW_!(^YVJ=W)FM3FF ;. @"E*@< 2*T J2>KB?\ 9;>[/^\X^_\
M_P! _P"/7_VGO<H=8W]>_P!EM[L_[SC[_P#_ $#_ (]?_:>]^Z]U[_9;>[/^
M\X^__P#T#_CU_P#:>]^Z]U[_ &6WNS_O./O_ /\ 0/\ CU_]I[W[KW7O]EM[
ML_[SC[__ /0/^/7_ -I[W[KW7O\ 9;>[/^\X^_\ _P! _P"/7_VGO?NO=>_V
M6WNS_O./O_\ ] _X]?\ VGO?NO=>_P!EM[L_[SC[_P#_ $#_ (]?_:>]^Z]U
M[_9;>[/^\X^__P#T#_CU_P#:>]^Z]U[_ &6WNS_O./O_ /\ 0/\ CU_]I[W[
MKW7O]EM[L_[SC[__ /0/^/7_ -I[W[KW7O\ 9;>[/^\X^_\ _P! _P"/7_VG
MO?NO=>_V6WNS_O./O_\ ] _X]?\ VGO?NO=>_P!EM[L_[SC[_P#_ $#_ (]?
M_:>]^Z]U[_9;>[/^\X^__P#T#_CU_P#:>]^Z]U[_ &6WNS_O./O_ /\ 0/\
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MK!K&QL0WUXL;$V_V/O9J#0CK2NCUTL"1Z>763WKJW7O?NO=>]^Z]T3CX:?\
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M'B16B'3"EP8WF+EX_#,M\20O&+%%\,;?9M<Z0/%>W)F6=;8#"R("LMP]#-)
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M[<)W1#%1T 3<&-S%+-1UFJ&.1JBG8N-98D[O75Y()4"Z)+>!P5X-JAC;4/\
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MC[#[8ZYW5M;;O]S^H9]Q]V4_8-%NW8>0[,IMP=>Q4>T-K[MR%#M79N"RE7N
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M0T4796_L<F4VOL,XZ($9".)WBISF)$JV6)GD150-SZB5.C:I/>;E(^HQH35
M:%J_Y*]!8W<EO8;5'"$'B4[V%57Y_;GKGL3,RY+YT;%-;VA@>V<G2]9[GQ60
MW?MS;F'VUBVJ5@EJ7P4<V%JZRAW%/0KID>42.U.&6(V*V'IDIM,X2!XXRZD
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M2 S*LB1O(@%2Z1O(H9U[:GXM(+!NH\""[(/TT@%& P"RN45OX6;PV[31AIR
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MAKH+J'&YS'Y/LO%1YW>.U3C^QME+CZI\75T;2PXUGH9$CJ?,1(TR6^X27*W
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MO=>_V0GXI?\ /LJW_P!&1VM_]G'OW7NO?[(3\4O^?95O_HR.UO\ [./?NO=
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MT)(8VET'PPP4FG D$@'T- 3U36NI4U#402,\0" 2/D"0*]#5J_%F_P!M^/\
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M"@G4%M8>]@,4UZ3I]:8ZKK37HUC7Z5S^SITN+7_WKG_>K^]=6ZXE_P"@)/\
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MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%+[W_YG_\ "O\
M\2EVE_[X'LCW[KW7_]>P?^?'_P!ET]4_^*?C_P!_;E/>+OWE?^='_P!/=?\
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ME\GN*IZKW$NRM^96':V[J#:.-WS%04F1R^TL-O/-X'$8#=F5P$.0@^]7'2U
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M77$;5J\G!B*F*#[S&0RSPR.()A&E-ZG@\P3E2!MT2RN#@R(49W:(?C$0"B4
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MIU3_ #$]M=A_*#:OQ@DV%E(:C=FTLKE=O[YBW1@,S6OF]I[#VAOW<=-O?:.
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MU3!IN"L$31Q(Y%0VHMQ:L=8(YHXUHDLOB./630D>JO&NA%7% 0H-*CKSDRO
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MUEQ=/-%)'-&']V**8S"BZ%S1D[&4FX^JJC+1D;ZG]<,A5A(68'N-;(2EQ'=
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M[.SLHT"PQ:V)X%Y)7,DLC4_$S' X*H51\->O./$O+J\<G7($4#R5(T"(B_(
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MQ_\ V >_=>Z]_L^/Q:_Y^#G/_13]Q_\ V >_=>Z]_L^/Q:_Y^#G/_13]Q_\
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M -%/W'_]@'OW7NO?[/C\6O\ GX.<_P#13]Q__8![]U[KW^SX_%K_ )^#G/\
MT4_<?_V >_=>Z]_L^/Q:_P"?@YS_ -%/W'_]@'OW7NNO]GQ^+5P/](6;%R +
M]4=Q <W^I.P %'^)X]^Z]T6'XN?+SH'9>+[PCW-NK=&'DW)\G^]-V82.NZC[
MAADR&W,YN>.IPV9IXSL(L^.RM-:2GE_1,ANI-C;W7NC/_P"SX_%K_GX.<_\
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M-DX^IR6+;^X/^6T$&3IIJ5YH]48J('2]P+^Z]T:__9\?BU_S\'.?^BG[C_\
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M'.W+VV\U<K[G'>;#=JYAFC-5D5)&C+*?,%D.DC#"A&#T+?\ LXI_[Q7^9/\
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MF3_Z) ?_ &4>_=>Z]_LXI_[Q7^9/_HD!_P#91[]U[KW^SBG_ +Q7^9/_ *)
M?_91[]U[I*[5^?&V]ZKN5MM_&KYBY'^Z.\\]L//!.C7B-)N3;1I5RM+:3<J>
M2*)JM L@]+\V^GOW7NE5_LXI_P"\5_F3_P"B0'_V4>_=>Z]_LXI_[Q7^9/\
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M?_1(#_[*/?NO=>_V<4_]XK_,G_T2 _\ LH]^Z]U[_9Q3_P!XK_,G_P!$@/\
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M<4_]XK_,G_T2 _\ LH]^Z]U[_9Q3_P!XK_,G_P!$@/\ [*/?NO=>_P!G%/\
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M7,Y8$?2^&8O$6Z_WRR+-$[(>[0]0#1@*Q6TL^@6ZZS)(B0Z2#]0TGB"/Z?\
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M^GM1=LDT6VQ"-5\112E>P%N SP/SS\^DMDDMO/N<PN&;PB=0H/U#IK5C3B.
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MN+)1SY7'#5Q*\4BM,O#$^S[26MMV=W<R!E\Z5-<U Q_+H':]%SLT<:(J%6H
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M#G^O%EHQMRMI%-+7T,56KULRL.HN-M+DO:VTUP-)I6=KFU2-;^6H(:\MI%:
MUH'MA&\)25-)8G7QSNKQH(7N=#+3/@B"[,IM(Z$:;:[C/BL161+G6LIEB>O4
MVA_EN_,+'[=INGJG$=9;CV1V=NKXU[TWKNK)]J;AFPO2VT>E\_ON;(=$8O:V
M1PF1SO9F-P^V-U4>.P]2TE)05=)2R15*TZQTZNBN;5[L06\UT&:WDDD,S DW
M+S;6UB3HI5&694<M(6+1D/\ VP8=/%V N;F%3&\Q0+"* 0*FX_5@!Q@AH69=
M** DJZ5'A,"+D?A!U;N+H_XE= ].;KV/MKKK<75_7.#V+E]I[/R>/S&UZ*KV
MVDF*DR&"K\7B\+228_< IQD$3[6&6'[KQR@R*[$RN9A.UL^HEA;PJ0>*LD**
MRUX'21IU## 5 %:!):P?3"ZB [/J9F4X&I7E=U<@?"6#5*Y(-14\>C6>V.E7
M1'?BW_S/GYX?3_F?.S_J;?\ -&MB?Z_OW7NCP!PWT_WCG\D<V^GT]ZJ*D>?7
MNN7O?7NNKCC^IO8?ZWU_VWOW7NN_?NO=>]^Z]UT2 +GW[KW7K_\ $_[P;>_=
M>Z[]^Z]T2;XY?]E,_.__ ,27U!_[Y/:_OW7NCL^_=>Z][]U[KWOW7N@Y[=WG
M5=<]5=F]A4-#392MV'U]O/>='C*RHDI:3(56V-N9'-T]#55,*2S4]/5S40C=
MU5F16) )L/9=NUZ^W;9?WT<89X8F< F@)45H3Z'I7M]JM[?V5DSE5FF1"?34
MP%?RKT4G>_SVV)TQ\9.EOD?W#M;=--B>SNK<%V7N&'9$>#K<-LFAFV)BM\;H
MJ*W.;TW'LO&U5-AZ6O=:+'T\M1N#->,IC\?53))&IKNBP;;O%QMAE_268H'-
M.'BI$I*@F1B7D6HB21E!+L BE@6[:\U_MB7ZQC65KH!XG2[4#&B@41J%V12=
M*UU,H((_\.U]/[6D[1;MO8V\=D0;'[7[8VS@FI:_95;4;AZ5ZCP_7V1SWR!J
M*?-[MVU/'MN2I["I8%P=$E=NJ63TTV,J2DIC:3PVBV_QG\*YE\02@FHA*W\U
MC'JTU9A*\18%%8*H=GTHFLV$ADED%N/$@:.%H6':9O$LUO'5=>D*T2-1@Y6K
M%54EW"]"7\U?F3O'H+;O4^XNMJ385+L/?TF8JMW?(7M#!]D[GZ5ZKHZ;$8C(
M[0Q6_P"CZGH:W=NT_P#23)FE%)G<DM+A,3#23-5N9)8(G;87$&ZR;;<QQQZ(
MWH7D"+).DBH;=9=+QQD*6=I'J-*G0LA! >B,,^WK?0L\B,RDA%+.D31N_CF(
MZ7D6JJGAI1M3@L545*$IOYGN'VTW=U5VEU%F:/;O2^%Z,K9-Z]6;VZ^W[L+?
M%1VKT[E>X=RY79^^=P[EV!MJ?9NT\/BGCQ];7S4%3N&1DAQ]-/62)2&\[I#:
MW-U-;30&._NH&210'1+>&WE,CJ#5G/CE?"C#RL%#HA4MH:MQ)<2V<<#Q3":R
MBG5HVJC-+<SVP0.:*!6$-K<K&-5&<:067F2_F@_&[$U-#DZG&]K/U5/6XO"Y
M/OR'9,3=0;9W1ENF9>^X]I[ER39U-VXS.4?72PR5)&&DI(<C5PX\S_>LT"^F
M'TYOEG:G@M<J,$^,;4A)?"H/]^$Q1EQ&)75_#+!&(NA,L-C-&A/C);N5X-&M
MRVF-I :"@'ZDF@OX<95GH&%4IO'^9OL#)_$CY2?(3IO#";>?QLV;B=R9W8?:
M5?A::@Q2;MP>/W)LS.[FS?6.XNP,.-M9+;V1-?4145?+E*1*::FJH*6K1HEU
MN"7%A'!)(%4F^CM7J:B.0S01R@E:JYC6=7U1LT;5 5SW4=VOP-QNC!&7(-H]
MPE!F2,1S-&5U4*^(T+( X5U^(I0K5"=2?S0J-*NHP?<>)PN_Z"OWWEMN;,[T
M^,V#W!5](;@V[M+I^L[F[5W)FI>Q\Q0Y';E!TKMK&2+FZBFK,LE5-4TT%'&]
M8\E)&_*D45O/--KB:".ZED#CA!;/ GC*%JQ#RW"P! A;QHW()C[@S;++<LHB
M:.3Q&M4C"5U&:Y,M(.X!=2I$;@L64"!T+ ."&%G9O\T3H7L>EH:/K_9_;^]^
MP\QD</'MOIW:F)Z]S78NYMMY[963[$Q6^Z'[#LJ;9&.VO-M##SU,\>3S5!EJ
M"<1T57105TT-,]6AD$IA9"9HRXE %1#X8C+^(PJC9EC5?":3Q')2/4R.%JDJ
M.C2HP,)5&C;@)O$=T01@T8'L9V\18]$0\5]*%6*&P'\S[;U O8>4[,V-N;$4
M^T-^=E;0PNQME[1S>Y>Q-Q4>W>\>I>CMF2U-+D:_"T&#W=D=U=JTU-E,+*L@
MIF5ITJ_##)J26THN9-KM4I)?79A152FGQ)Y[^):.Q *%+(N2=/AFNNM119=6
M[6T=W<N=%G!&TKLP)(CCLK>[D!5 2'4SZ5IJ$@ I0GI<5'\RWIZASHH<KB^P
M-OUV+QG9^+W)U5D]@ODNUJ7M#K[LKK[K*FZ]H:O;6ZLOL>HSFY<[V'CEQD4%
M754=?#6QU'WU/#%/9=#;W$L22PV[RF58?#5=(8M+<36Y#:B!V20R!ZE0BH9-
M3(5/3<T0MD=[IQ B-)J:0T3PTMDN0ZTJ2&C=2H%69CHT!P1TJ-Y?S"^M.O-P
M]=;.[&ZT[EZOW5V9E<;M;$8_L/![+Q4>%W?N;.YW;&SL+DX\9V!F,KNRFW#F
M<&P;(;0I]RXW&TU1!/D:BCCF1O:5A)-.;2R DO&A=XQ72'=+>6X,9KW(1'$]
M6=5BU#0LA<A2VI5+>&\N$9+<S!3@%E4RQQ:Z T(U2J0@)D*U;1I4GH?/B=W+
MF?D+\;NF>[=PX#&[6SG9NQ<1NO*[=P]?4Y7&8:MR"N9J"AKZRGI:JKIX62P=
MXT8_T]F%_;):3QQ1N61H87J13^UB20C\B]!Z@5ZJI.NZ0BACGFC^WPI7CK^>
MFM/*M.C$>TG5NO>_=>Z][]U[KWOW7NO>_=>Z*7WO_P S_P#A7_XE+M+_ -\#
MV1[]U[K_U[,/YY'_ &6UUT3Q_P XF4'^V_TTYZ_^V]S9[*U^KYF%,>##_P ?
M;KF#_>8@G9?9<#_E.W#_ *L1=4^G_B1_O8]SU@]<G1UM*_R(./B9VV?_  ++
MMT\^D7_@6PAR?R/>)ON)CG3??3Q%_P".+U] WW-?_$9/:;_GBE_[29NC'O\
MR]/CUDNCNI?BQE=Z[GSNSNH^U]^]I1XRJSNW#N;=5?OE>T*C<^U]TFCQD%3_
M  2*A[NJBOVL=-50HE&[2FQ,D?M:0S1;=;S1^)#:[8;-16E8_IQ:AS2E'72K
MJ1V^*.Y2*J<I6O)A>;M> *LE[>K<,/(,)DN/#4>:/X>A@:L8BP!'$ SL;^7%
M\8NG9=F5&;^0%6,K5T_8O66P:J2?I/K=-P83>/5>3Z.&TJ.@VIM;;]/O+=>
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M@I(BL%42(KT;2"NAJL5LDSM!'&@"3*KIK7BT<GQ1R+E9 IJ4+ E2S*=2-HZ
M/?\ _*/Z<WU5)6)V+O7%38K?':6;VA+6[9ZTWK+LS8?>&.V?3=H]9X9M^[1W
M'%54M?E]F4^4Q.;K4JLYAZYWT5$T!,!<MR()/&()D?Q!,:*IE5[I[Q*T7L>&
M:20(\>FL3LC!CI94PCC5C) BK(#"R$U;2\5LMH203WI+ D>N-ZKK1773D$0X
M_P"65TU#0X[$TF^.T*+&8C%_++"XVB@RF"6"FQGR[VSAMJ[SIU7^ >/1M+'X
M..3"655AG=VF652%#LTYE@N;<BGB[>;0L/B$9O#>Z@22 _B'16A&B@I7/5X%
M2WG@N%6K1W<-PM?XH;8VH7%.QD.IAQU4((&.AO[%^)&T-_=0]-]94>[]X;,W
M'\=ZG8F:Z2[<V^^$FWSLC=_7FVGVEBMP&GS&(R.VL_39S;E35X_-8VLHI*')
M4%=/$40LDD=KJZN+G>'WQ7T7C/,Q RC+.")8F6O<C@\*AE*JRL&4'JEM#%!M
MZ[6^I[31&OQ%6K$5:-PR\'5E!K2A!96!5B"5C?\ _*EV!VI68+>?9'=_;.^N
MXXJ[?$>[>V-YXSK?>-;G-F=C_P "7<NP-H;+W7LW-;&ZEVYAUVW2G;O\ H::
M?#S>6:1JN6>5W3PB*TG\:V5DC9 L@+%FD(F,ZLTAJRE)"50(5186,2J!1A=V
MDFJ[,/%$@>,T[(_T? *B.NEE= 'DU L\RB1F.5+_ "?RO.JJ''[^I=L;_P!X
M4%1OG;N]-K3TF[-J=5]G[/@P6]^VZ#M[)X3*=>[^V/F=I;FP7\5QL= M/5TY
M*T/,<D4ZK,K]Q<-<VD-H441(T1X$EO"ENI1JJ3G7=,P9:,K)&P.&#4BC$5PU
MPC,K4D^$Z3^I%;PG/FNFV6JD%6U."*%:'$^,_0FW/C#TIL?H[:6X-V[GP.QJ
M*O@I,UO7,39K.5,N6S%?FZZ-)9---B\+2UV2DBQV,I4CHL50)#24Z)#"BC<]
MTUR;?4M/"ACB&26*QH$5I&/=)(P4%Y&)9FJ3QIUJ&(1>.X(K)*SD !5#.=1"
M(**B5)TJN!7S-21\]M=.]>]^Z]T0;XQ[NP>P]H_,7>>YZI\?MW;/R_\ D'E\
MYD$IIZH8[$T53M^6OR,L%+'-.U+0TP::8JK%(D9K&WM!NNYV>S[==[KN$FBP
MMXR\C4+:47+,0H)HHJS$ T4$^71QR_L.Y\T;WMG+NRPB7=[R98H4+*OB2OA(
MPS$+J=J(@)%6('GT*G5?R8QW:O?_ 'QTCB]HUU)1]([<Z<W-3=A_QG'Y#;^_
ML=W+MO([EQ$V HZ2,5-)#CJ/'E7DD=UF+@IP/8NNMCBAY2Y5YMMMUBGM=U\<
MHB@]JPLH#ZJZ660,&4KY= 6WWRY;G3G+DJ]V>:VOMF,*RM(0"SRARR:*!D:(
MH5<-G5Z=-]+\/NLJ;K[L/K9,MO)L'V9O--\9^I?+4AR4&7CKJ7()#C:@8\1T
M]#YZ504*.;7&KV7_ +TF,T$Y1-2)I&#3[>/2[]TVXMY[8.^B1]1SYUKC'#H5
M-R=-[8W/O+JW?&0K<S'E>I#DFVU#2UE/%15393'1XJI.7C>F>2JM3(-.AX[,
M;\^V$NWCBN(E44DXD\<&M!]O2I[6.2:VF9CKB!H*XR*9'27H_CIM7%]I;F[,
MQ.XMY8R'?254F_-@092GDV%O&OJL5+AFK\WB*FBFJ9)EHYCI6.9$\EVMS;VY
M]=(UM';,D9*_"U.X4-<&OK\NFDV^)+F6Y61P'^)*C2QI2I%,X^=.D=MCXC;3
MVOD<+3TG8O;%7U[MG+)G=M=3U>[V_N7B,A'/+54T8^VI:?-5V*HYYV>&CFJG
MIU)Y#"]W'W21D;5!&+AA0O0:B/\ !7U(%>F4VJ*-T N)3;J:K'J[00:_;0>0
MK3H9]R=<'=%/OK'Y#>6\J#%[WPJX-H-NY./;N2VRAC,4V0VSN#%P09G'9.6]
MQ,9F*-RMO93>(+RS>T\62(,""\3M'(!ZJZD%&'D5H>C[;+M]KW*WW)(()S$Z
ML(KB%)X&*YI)"X*2(?Q*X((X])*G^/>T8L]TUN27.[VR66Z0Q>4Q&UZW-[AF
MS5;F*?+XY<;5U.[<CDH9\CG*]X$OYFE5RW+7]NV+M961L%DDD0HHUR.TDA"^
M;.QJS5XDU)Z9W5QNV[/N\MM!!,79O#MXT@@35Q6.% $C3R"( !P'0:5GPJZW
MK,;N3;)W?V;!L'.Y6LW!1]?4NZ$BVKMK<==D!E)LUB*48\U,DT=?JDBAJI:B
MGC9R?&6LP,UW6<48QH9E%"U*L13A_P 4 >B8[-;D.GB2B$DD(&[02:U ]:^7
M"AX='!I(%I:6FI5D:04U/#3K)*0TKB*-8U>0@*"[A+G@7/LM))R>)Z-@*"G4
MFXYY^GU]^Z]T3GX:?\6CY%_^+@_(C_WK8_?NO='']^Z]UP8 *3_13:Y-AQ[8
MN&,<$TB$!@A()X8!I7Y=;'$=:KW2'\Q+Y#;<HN@.U-\;R^1.YJK-;=^:/;7;
MF%[8Q'3F*Z-[ZZGZ%3L^2GV=\2'VC@J+<V1[RQN7P>!EQN*^XAG3;D63K:^&
MHB3R(CL[IH=LMKRYC:2)=@@N94;$[7$XMECD4KV"%9)F-TP#)##)#50[H287
M]E&VYWEC$S12MOKP1,HUPI!$9?$CE&6UM&@6V74));E'"L4#J#1[0_FI_)_?
M=5L38N)Z2Z0V?OK?46Y=W4V\>VMW[UZ[ZQ396'Z,7O"/!X[&92BEWQF-X8RF
M'\+K:TQ4V'F@?^+4S/3QRTJF6Y%=N>_U-XHL;>XDG"D*TIMY8(R(%;X!()^W
MQ35=(8AD<$(-K5MTABEBC9'GDMEBJ"53ZE9R [ ?J,AAJ1& &U%:J5-4YG/Y
MT>X=S+C\SM#J:B/5F]ME[DQ%/EJ/<N5PNZ=A=M8WH&?O"+:NX-^Y;%)M2JW'
M##2S4=1A,+BLO68ZA-/E:FICCJ%I%N\44=])9M-75XSQ.,!EMI;=)5*DEF:D
MK"0K2.&1#"6=JD)Q,KVB3K4,C1),!1BDDRS4(H0%3]-&A+$O<1N9 B!>ZSOX
M7_(GL[Y)OW?N'<^V-B[6ZZZ\[<S/3W7D6&W!F=Q[[W!/LG&XB7<>Z=]5<]!C
M,!C#E:W+ 4E#1Q221)$7FE)D"(JN8$AB2:0CQYIKC2%%$$45S-;IQ).MO!+'
M\*A@H+$$],VUS'<:4@J42&'Q"W$RRV\,[::8T*)0H;BY!:BC'1Z  /I[1]+.
MN_?NO=4$_)_M[M#I;:OSGW-T_N7*;5WKGOG9\1^NX:[!5>S<5N"NPW8B]*;1
MW%@L!N#L#&9G9NU\QGL+E9J6GR>0II(*%Y/*0"H(22"63<^7+1%<Q3WZ(X5E
M4LFB1F&I@:#M!(%&(!4$$]+[:%9+#F*8 >/!MTTD9()"2+I"L0.-*G!J*Y((
M'4[N;Y=][?#"AVAO/=P[8W+B:'8_RI[!W%U!V/O?J/M#>6^I]FTW5.$ZS3';
MWZKVQ046W=JXK,;LEJJFGCCEKH(&E><S6C7WLW)^K%@GAF1[:W5:A@(YKG<4
MMUDE/XU6-B2$\B%IK[@E%N6B%P5<(L\S,:@ZXK>PFN&CC7\+O(H +>A;X,=/
M&T_YG/R)WGN"?JO'=/\ 2^UNT.N\+OWLGLK<?<^^-T=)]5;ZZQZ_S6S<550=
M63;EQ^2W3L_=V0EWF(ZI]TQ)18<42U,BU%-70/&KA>WDN%=I*;?'X2RY4R:I
M;B2W5H\Z"!X3.R%M8=DM\.P<IZ3>"H"GZJ9G\*BL4"QVXN&\3&JM66,$4#('
MG'8C*&387\QKY,;?J<Y3[]PG4?8>.Q&]OYB':6Z<O@9L_B\]A/CM\0]RX+'[
M4ZWV7M:CBEBW-VIN&+<*0ME*JJAQD$$0J2E3Y5'M+;SLNQ_O*[0L;7:/J9BH
MH99GOIK.(*N1$B^&'F+5***4U GI5-].V\0[=!56N]QCMX!\81!:17,SNP_M
M&.LB%8Q20D$&E!U)H/YG'R:S>]^LNE,9U]\3:;M#MC XWM/"[VRG<VYDZ;V[
MU=N7I3=7<N"V_FZJ##'/Y'L^@AVJ]#5) T-#4T$XS$(2GB>G+M\W[O?=HG_5
M?;(YVN-) $I@\ D6Y)- _CD4ES&%61M2N *V<8OH;>6-75KGP#$""2BSR2Q+
MXJCN9E,==* :V)B7N2I8HOYRN]LSUTWR#VWTML!>G17Q]8+L/</8F0QO>[=Q
MUO2-;W%0;B&-CPLF!_T)&:G2A6N$9R%3B6.<B7[9?MBY=$6HN$(;ZB87/TP(
MII-LJ,5NJY1G#&H34(?T]182K1-#('E2*:J+#]/X[ :E/CS/%_BYJ!*$TAE/
M^B]ZC2T9J_[^_FF]W=<[@Z[V1G.ONG]Q;IGVST)_IJDZ^RF\\AM_K/=WRD@R
MW^BU*G<VX(\3AL338204#Q8N4Y'.[P@-1-1TN.B16+.^Q-97&^V,$]'@GFLX
MY"M!]7#9M=,VDGO&% A4%HT9999 "$-[&YMIK+;-S==<<L45TT0;N%K+=) E
M6I1=0\3]9M*&1?"1&-7"=Z9_F,?(RNV=T7L;.T_4&[?D?W3UO\6*:GW]GMW9
M3;OQ]I=\=M[4[HWSN'.9#:V-PR;HQ4"X3K%J6EI*:M>7*Y2H6-!31T["1<D<
M=T8EMJ1AJLQDK2D.V6][*JLM0K2-+2-2* :Y22JZ.DDLS6SR>.KL0K:0B$@!
M]QDLXB]<J(U75(QI4Z8AW-KZ4G4W\VCM7LW<.QMQ2].=78#IVL^071'QCWM(
MO8V8S78$W8'>.,S6.CW3L.2DP<.V,AL/;^]L0GVDE4PFSV%JA41-32Q&.35K
M'!=_NFX61TLMQDN8[<$?J*\%DM\OC#AW)KB8+E2$E[D;3T_?2?10;B20\]DB
M/*1\#!KY[$B/)((*B7OQ\47Q#5U8+\<O^RF?G?\ ^)+Z@_\ ?)[7]L=.]'9]
M^Z]U[W[KW7O?NO=)?>FT\-OS9^Z]C[BBGGP&\MN9W:F<AIJF6CJ9L/N+&5&(
MRD5/60E9J6>2BK'"2(0R-8CD>TM[:0W]I<V5P"8)4*-0T-&%#0C@?3IZWGEM
M;B"ZA(\6-U9:\*J017\QU7KNC^5OT=OSK+:'5&_>T/D1O;;FPMH;GZVVC7[@
MW]MR3/X/K#>.R,5L#<G7]!E*#8M!X,9D,'@Z-DRBQC<=)44^NFR4(DF65ZZ!
MO;FXO)V;ZJ9=,K Z3)29)UK2FDI,@<&/16I5]:'3TU;?XGX @4!(75X@<B-E
M22*JZJUK'(RD/K HK(%<!NE%7?RU.@)LN=R8W/=L;?W,,YD<LNY,9NO#5F8A
MQVXMN[)P&]-K4L^X=K9V*CP6]ZKKW%Y:O>&-,G#F(7J*&KI/)(A>,I:X-QX2
MZF,A8 :0PDN6NPATT(6.=Y'BT%2JRR(69&"A-':QP0Q01.RK''&JFM2ICA\#
M6-506>$*DA8$-H1J!UU=!SV-'\#<;WA-U=MGO?._&/ORCWIC*'>D_1V=R.Q&
MW+NWMW$4.2PNV>W\EDMI[BZCW%NK?M%04L^+&<1\ZTBH*":-YW65BUA_>1:W
MAC$MH_C0F&@\)R*2RQJE /$4-5O *R:6()*FG2F>;Z2W5K@A7'AR^(<R*!JB
M1G85/A&A%)@8M2AJ!@#TIMP_RK/B?GU7'86+L#8V)Q^W=N;3IMM;)WC34^"Q
M.,P>P-Q=9R?9XG-X?/Q4&8W#UYNRHQ]57+IK846*IHI*2K7[AJSPK/%>(ZD0
M3&4%02 $EB@B>-#\2H%MX"M#K4H*-I9E-H'-O);2Q@">-UD#$ DR+-+,LC U
M5CXDTU004.L@J2J%0-R_\L7#T/8N)@W=O[$4WPWV%38_>>8ZOJ\_O.KR?9%9
MM#H*?HBOR?;>*R-7)M;)Y3^Y50DN0W+1/!5U1HJ5GHTK1)D)-/)&?WK=[NZO
M T=WVBJI&+@JS2(00T90AY2H+*9V,B")6DC?>B61-NLMOUB=7ME#DZY&\&1G
M$1J"LB.2(P&4,(0(W:30C*9_K;XE?';>WQ7SW4N"[%WWVYTC\@=J;;R]%N:M
MW?A5RF3Z_3%X+^Z0VAEMI;;VK2P86#%4-'XZLTLE;5!]=543RN7*Z_\ J6N(
M4OT/U<-S'.2<,TJR),KNHHH#/&K%554;/;W'IBST6P<VA @,,D  RJQE7B9%
M/$E0[ ,2S#MR0!T/_:GQVZC[GS.P=P=B8F7.1];X_LO;>%Q8R\U%M[(8OMK9
ME9UCOG![CQM))%#EZ;);>KI:98V*M#.=26<#VDF07!W#Q@6-U:O;R"I%8I98
MI6 (-0Q:%*.I# 5 X]/6\LEG':1P/H%O/'.IQVO"DBH36H("R-4$$&H-,=%R
MP_\ +KZ8VYM?:N%P79O=V#S'7NXXJKJKL;$;XVMB=]]742;6EZYEV1M+*8_9
M=-AZO;V1VG,<75Q9>ARF0K"D<LU2]7##/&])++))%+)*QN"'#M6AF60HT@D
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M/T#4Y'^FG/:C%&1ZI0E]*_VFL/<U^RP7ZOF+62$,<-2.(&LZB/L'EUS%_O+
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MRQW&(B6(*%-O):.[K!+"P&L,-)BG21B1(A9:JP/2@^&G_%H^1?\ XN#\B/\
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MB8_&8_$4=-C<50T6,QM%&(:/'X^EAHZ*EA6^F*FI*9(H((EU&RHH%S[WZ5X
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M(^I1;VVNX[@D=Y"E[((+D@RJ&(60@Z@7 -&H:D5!H<C/3O[ML&DL9FM(C-;
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M[?K<-DLMCXJJ!]O=?;LVF\-374_D_BE'*D].B$F-22_NBEC!<[>X*W3SI [
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MNY&IE(MP>./>JD +7'7J+4G2*GK$M%3HL2K# H@4)!I@B'A1+!$B 4")446
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MPN?EP5?+&]5C&S.)8TU28F7S0'0UUX]Z!92[*:,R%#\U+*Q4^H+(C4X553Q
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M.@H*^=,YZ7GMCI_KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HI?>_\ S/\
M^%?_ (E+M+_WP/9'OW7NO__7LO\ YXY_YS;Z[-_^Y3* _P#L:,][FWV5Q<\R
M^ABA_P"/MUS!_O,\[)[+?\]VX?\ 5B+JG_W/)\NN3RBM?LZVEOY#W_9)O;?_
M (MGV[_[H]@_[Q[Q,]PQ3G7F ?\ #5_XXO7T"?<V_P#$9/:7_GBE_P"TJ;J[
M/V#.LF^NK#^@_P!L/?NO==^_=>Z][]U[KWOW7NO>_=>Z][]U[KJP_H/]L/?N
MO==V'TMQ_3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T
M2[X8?YKY4_\ BZ/?G_N9M_W[KW1T??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=$X^&G_%H^1?_ (N#\B/_ 'K8_?NO='']^Z]U
M[W[KW7O?NO==6']!_MA[]U[KOW[KW7O?NO=>]^Z]U[W[KW1'OBW_ ,SY^=_]
M?]/.T./S_P R:V+:W^N/?NO='A]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW1)OCE_V4S\[_\ Q)?4'_OD]K^_=>Z.S[]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z*7WO_ ,S_ /A7_P")2[2_
M]\#V1[]U[K__T-AG^95\.>M>_P#Y([7W]O;YQ]%?&_*XWHW'[-H.N.R,9M"J
MW'D\-%V!F,[)OB"7<':6S*_^$U&4JOX>FBC>G66%OW2Y*@:<E;[S)LDFX'EW
M9OK'D11)^G))HH6I_9\*YKJ\^L8OO+^UWLI[GV7)<'O/[C_U=M[&XN&LV^LL
M[/ZAY(T69:WA4/X:A6I'4K4%J5Z(1_PV=T-S;^:Y\4#Q<VPG6HX%K_3O\ @_
MT]C[^O?N5_TQ0_[)[GK%#_@4_N/@X^\J?^YULW_0?5G/P4^-/='1G5.]-J_&
M;YH?%WNK869[AWAN_*;GHNIJK=,>$WCF,9MVGS^SY*[8??$V(CEQ*8ZGE,4S
M"LC%2/( I6\3\QWNX[COE_?;O9FWW&1P7CTLNDA0 -+C4,#@0,'K/_V<Y8Y)
MY+]LN4^5_;KF+][<F6<#+;7AFBN#.ID=BWC0$PO1V9:QDKBG$$='5_N?\\_^
M?Y_&?_TG[L#_ .WI[)>I-Z]_<_YY_P#/\_C/_P"D_=@?_;T]^Z]U[^Y_SS_Y
M_G\9_P#TG[L#_P"WI[]U[KW]S_GG_P _S^,__I/W8'_V]/?NO=>_N?\ //\
MY_G\9_\ TG[L#_[>GOW7NO?W/^>?_/\ /XS_ /I/W8'_ -O3W[KW7O[G_//_
M )_G\9__ $G[L#_[>GOW7NO?W/\ GG_S_/XS_P#I/W8'_P!O3W[KW7O[G_//
M_G^?QG_])^[ _P#MZ>_=>Z]_<_YY_P#/\_C/_P"D_=@?_;T]^Z]U[^Y_SS_Y
M_G\9_P#TG[L#_P"WI[]U[KW]S_GG_P _S^,__I/W8'_V]/?NO=>_N?\ //\
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:W"1_!</E:G)SI2T-1*T-*2X2-7<>Z]U__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749159136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Apr. 26, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NTLA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INTELLIA THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001652130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,028,677<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntla_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document And Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntla_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntla_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749470352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 257,551<span></span>
</td>
<td class="nump">$ 273,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">2,443<span></span>
</td>
<td class="nump">6,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,084<span></span>
</td>
<td class="nump">1,788<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">261,078<span></span>
</td>
<td class="nump">281,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">11,418<span></span>
</td>
<td class="nump">10,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">6,767<span></span>
</td>
<td class="nump">7,035<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">279,263<span></span>
</td>
<td class="nump">298,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,434<span></span>
</td>
<td class="nump">4,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,559<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">19,917<span></span>
</td>
<td class="nump">20,178<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">24,910<span></span>
</td>
<td class="nump">30,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">54,092<span></span>
</td>
<td class="nump">58,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">378<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 120,000,000 shares authorized, 36,025,676 shares and 36,018,540 shares issued and outstanding, respectively</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">266,080<span></span>
</td>
<td class="nump">263,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(66,201)<span></span>
</td>
<td class="num">(53,570)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">199,883<span></span>
</td>
<td class="nump">209,837<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 279,263<span></span>
</td>
<td class="nump">$ 298,969<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6909838720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">36,025,676<span></span>
</td>
<td class="nump">36,018,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">36,025,676<span></span>
</td>
<td class="nump">36,018,540<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749528336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Collaboration revenue</a></td>
<td class="nump">$ 6,215<span></span>
</td>
<td class="nump">$ 1,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">13,431<span></span>
</td>
<td class="nump">5,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,732<span></span>
</td>
<td class="nump">3,246<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">19,163<span></span>
</td>
<td class="nump">8,471<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(12,948)<span></span>
</td>
<td class="num">(6,694)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12,631)<span></span>
</td>
<td class="num">$ (6,689)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (9.89)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding, basic and diluted</a></td>
<td class="nump">34,723<span></span>
</td>
<td class="nump">676<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseAndServicesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752043008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12,631)<span></span>
</td>
<td class="num">$ (6,689)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">660<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">2,630<span></span>
</td>
<td class="nump">812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">4,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">704<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(954)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(1,893)<span></span>
</td>
<td class="num">(134)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(4,278)<span></span>
</td>
<td class="num">(778)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">268<span></span>
</td>
<td class="num">(2,823)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(11,398)<span></span>
</td>
<td class="num">(9,421)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(4,162)<span></span>
</td>
<td class="num">(1,008)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="num">(4,162)<span></span>
</td>
<td class="num">(1,008)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payments to acquire in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_PaymentsOfTemporaryEquityIssuanceCosts', window );">Payment of preferred unit and preferred stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from options exercised</a></td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of common stock offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(895)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">47<span></span>
</td>
<td class="num">(1,195)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(15,513)<span></span>
</td>
<td class="num">(11,624)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">273,064<span></span>
</td>
<td class="nump">75,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">257,551<span></span>
</td>
<td class="nump">64,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment unpaid at period end</a></td>
<td class="nump">$ 378<span></span>
</td>
<td class="nump">918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_InProcessResearchAndDevelopmentAcquiredButNotYetPaid', window );">Acquisition of in-process research and development unpaid at period end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_InitialPublicOfferingCostsIncurredButNotYetPaid', window );">Financing costs incurred but unpaid at period end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 454<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntla_InProcessResearchAndDevelopmentAcquiredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay the remaining obligation for in-process research and development assets acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntla_InProcessResearchAndDevelopmentAcquiredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntla_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntla_InitialPublicOfferingCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay costs incurred related to the entity's initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntla_InitialPublicOfferingCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntla_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntla_PaymentsOfTemporaryEquityIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntla_PaymentsOfTemporaryEquityIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntla_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6744922848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Overview and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Overview and Basis of Presentation</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="8%" align="left"><b>1.</b></td>
 <td valign="top" align="left"><b>Overview and Basis of
 Presentation</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Intellia Therapeutics, Inc. (collectively referred to with its
 wholly-owned, controlled subsidiary, Intellia Securities Corp., as
 &#x201C;Intellia&#x201D; or the &#x201C;Company&#x201D;) is a genome
 editing company focused on developing potentially curative
 therapeutics utilizing a biological tool known as CRISPR/Cas9.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The consolidated financial statements of the Company included
 herein have been prepared, without audit, pursuant to the rules and
 regulations of the Securities and Exchange Commission
 (&#x201C;SEC&#x201D;). Certain information and footnote disclosures
 normally included in financial statements prepared in accordance
 with accounting principles generally accepted in the United States
 of America (&#x201C;U.S.&#x201D;) have been condensed or omitted from
 this report, as is permitted by such rules and regulations.
 Accordingly, these consolidated financial statements should be read
 in conjunction with the financial statements and notes thereto
 included in the Company&#x2019;s Annual Report on Form&#xA0;<font style="WHITE-SPACE: nowrap">10-K</font>&#xA0;for the year ended
 December&#xA0;31, 2016.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The unaudited consolidated financial statements include the
 accounts of Intellia Therapeutics, Inc. and its wholly-owned,
 controlled subsidiary. All intercompany balances and transactions
 have been eliminated in consolidation. In the opinion of
 management, the information furnished reflects all adjustments, all
 of which are of a normal and recurring nature, necessary for a fair
 presentation of the results for the reported interim periods. The
 Company considers events or transactions that occur after the
 balance sheet date but before the financial statements are issued
 to provide additional evidence relative to certain estimates or to
 identify matters that require additional disclosure. The three
 months ended March&#xA0;31, 2017 and 2016 are referred to as the
 first quarter of 2017 and 2016, respectively. The results of
 operations for interim periods are not necessarily indicative of
 results to be expected for the full year or any other interim
 period.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6631023408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="8%" align="left"><b>2.</b></td>
 <td valign="top" align="left"><b>Summary of Significant Accounting
 Policies</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>Recent Accounting Pronouncements</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In May 2014, the Financial Accounting Standards Board
 (&#x201C;FASB&#x201D;) issued Accounting Standards Update
 (&#x201C;ASU&#x201D;) No.&#xA0;<font style="WHITE-SPACE: nowrap">2014-09,</font><i>&#xA0;Revenue from Contracts with
 Customers (Topic 606),</i>&#xA0;which supersedes existing
 revenue recognition guidance. The standard&#x2019;s core principle
 is that a company will recognize revenue when it transfers promised
 goods or services to customers in an amount that reflects the
 consideration to which the company expects to be entitled in
 exchange for those goods or services. The standard defines a
 five-step process to achieve this principle and will require
 companies to use more judgment and make more estimates than under
 the current guidance. The Company expects that these judgments and
 estimates will include identifying performance obligations in the
 customer contract, estimating the amount of variable consideration
 to include in the transaction price and allocating the transaction
 price to each separate performance obligation. ASU&#xA0;<font style="WHITE-SPACE: nowrap">2014-09</font>&#xA0;also requires additional
 disclosure about the nature, amount, timing and uncertainty of
 revenue and cash flows arising from customer contracts. The FASB
 continues to address certain implementation issues and clarify
 certain core revenue recognition principles of ASU&#xA0;<font style="WHITE-SPACE: nowrap">2014-09.</font>&#xA0;In July 2015, the FASB voted
 to delay the effective date of this standard such that
 ASU&#xA0;<font style="WHITE-SPACE: nowrap">2014-09,</font>&#xA0;as amended, will be effective
 for the Company for annual and interim periods beginning after
 December&#xA0;15, 2017. Early adoption of the standard is permitted
 for annual periods beginning after December&#xA0;15, 2016. The
 Company continues to evaluate the impact that the adoption of these
 ASUs will have on its consolidated financial statements; however,
 the Company does not expect that adoption of this standard will
 have a significant impact on the consolidated financial
 statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In February 2016, the FASB issued ASU No.&#xA0;<font style="WHITE-SPACE: nowrap">2016-02,</font><i>&#xA0;Leases</i>.
 ASU&#xA0;<font style="WHITE-SPACE: nowrap">2016-02</font>&#xA0;amends ASC
 840,<i>&#xA0;Leases</i>, by introducing a lessee model that
 requires balance sheet recognition of most leases. The Company is
 the lessee under certain leases that are accounted for as operating
 leases. The proposed changes would require that substantially all
 of the Company&#x2019;s operating leases be recognized as assets and
 liabilities on the Company&#x2019;s balance sheet. ASU&#xA0;<font style="WHITE-SPACE: nowrap">2016-02</font>&#xA0;will be effective for the
 Company for annual periods, and interim periods within those annual
 periods, beginning after December&#xA0;15, 2018. The Company is
 evaluating the impact that the adoption of ASU&#xA0;<font style="WHITE-SPACE: nowrap">2016-02</font>&#xA0;will have on its consolidated
 financial statements but expects that the Company will recognize a
 significant lease obligation upon adoption in connection with the
 Company&#x2019;s existing lease agreements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In March 2016, the FASB issued ASU&#xA0;<font style="WHITE-SPACE: nowrap">No.&#xA0;2016-09,</font>&#xA0;<i>Improvements to Employee
 Share-Based Payment Accounting</i>. ASU&#xA0;<font style="WHITE-SPACE: nowrap">2016-09</font>&#xA0;amends ASC 718,&#xA0;<i>Compensation &#x2013; Stock
 Compensation</i>, by simplifying certain aspects of the accounting
 for employee share-based payment transactions, including the
 accounting for income taxes, forfeitures, statutory tax withholding
 requirements and the classification in the statement of cash flows.
 ASU&#xA0;<font style="WHITE-SPACE: nowrap">2016-09</font>&#xA0;was adopted by the Company on
 January&#xA0;1, 2017 and did not have a significant impact on its
 consolidated financial statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6744910544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="8%" align="left"><b>3.</b></td>
 <td valign="top" align="left"><b>Fair Value Measurements</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company classifies fair value based measurements using a
 three-level hierarchy that prioritizes the inputs used to measure
 fair value. This hierarchy requires entities to maximize the use of
 observable inputs and minimize the use of unobservable inputs. The
 three levels of inputs used to measure fair value are as follows:
 Level&#xA0;1, quoted market prices in active markets for identical
 assets or liabilities; Level&#xA0;2, observable inputs other than
 quoted market prices included in Level&#xA0;1, such as quoted
 market prices for markets that are not active or other inputs that
 are observable or can be corroborated by observable market data;
 and Level&#xA0;3, unobservable inputs that are supported by little
 or no market activity and that are significant to the fair value of
 the assets or liabilities, including certain pricing models,
 discounted cash flow methodologies and similar techniques that use
 significant unobservable inputs.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company&#x2019;s financial instruments as of March&#xA0;31, 2017
 and December&#xA0;31, 2016 consisted primarily of cash and cash
 equivalents, accounts receivable and accounts payable. As of
 March&#xA0;31, 2017 and December&#xA0;31, 2016, the Company&#x2019;s
 financial assets recognized at fair value consisted of the
 following:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"><b>Fair Value as of March&#xA0;31,
 2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center"><b>(In
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">255,735</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">255,735</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">255,735</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">255,735</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="16"></td>
 <td height="16" colspan="16"></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"><b>Fair Value as of December&#xA0;31,
 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center"><b>(In
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">270,448</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">270,448</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">270,448</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">270,448</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13504-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6617375120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="8%" align="left"><b>4.</b></td>
 <td valign="top" align="left"><b>Accrued Expenses</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Accrued expenses consisted of the following:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>March&#xA0;31,</b><br />
 <b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(In
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Employee compensation and benefits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,532</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,703</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Research and development and professional expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,027</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,197</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accrued expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,559</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,900</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6628711696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborations</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="8%" align="left"><b>5.</b></td>
 <td valign="top" align="left"><b>Collaborations</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>Novartis Institutes for BioMedical Research</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In December 2014, the Company entered into a strategic
 collaboration agreement with Novartis Institutes for Biomedical
 Research, Inc. (&#x201C;Novartis&#x201D;) primarily focused on
 the&#xA0;development of new<i>&#xA0;ex
 vivo</i>&#xA0;CRISPR/Cas9-based therapies using chimeric antigen
 receptor T cells&#xA0;<font style="WHITE-SPACE: nowrap">(&#x201C;CAR-T</font>&#xA0;cells&#x201D;) and
 hematopoietic stem cells (&#x201C;HSCs&#x201D;).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <i>Agreement Structure</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Under the terms of the collaboration, the Company and Novartis may
 research potential therapeutic, prophylactic and
 palliative&#xA0;<i>ex
 vivo</i>&#xA0;applications of the
 CRISPR/Cas9 technology in HSCs and&#xA0;<font style="WHITE-SPACE: nowrap">CAR-T</font>&#xA0;cells. The Company and
 Novartis agreed to conduct research of HSC targets under a research
 plan agreed upon by both parties. Within the HSC therapeutic space,
 Novartis may obtain exclusive rights to a limited number of these
 HSC targets, to be selected by Novartis in a series of selection
 windows, the last of which closes 90 days before the fifth
 anniversary of the effective date of the collaboration agreement.
 The Company has the right to choose a limited number of HSC targets
 for its exclusive development and commercialization per the
 specified selection schedule. Following these selections by
 Novartis and the Company, Novartis may obtain rights to research an
 additional limited number of HSC targets on a&#xA0;<font style="WHITE-SPACE: nowrap">non-exclusive</font>&#xA0;basis. If Novartis does not
 exercise its selection rights within each selection window, any
 such rights will be deemed forfeited by Novartis. Novartis is
 required to use commercially reasonable efforts to research,
 develop and commercialize a specified number of HSC products
 directed to each of their selected HSC targets. The Company also
 agreed to collaborate with Novartis on research activities
 for&#xA0;<font style="WHITE-SPACE: nowrap">CAR-T</font>&#xA0;cell targets pursuant to
 a&#xA0;<font style="WHITE-SPACE: nowrap">CAR-T</font>&#xA0;cell program research plan
 approved by the&#xA0;<font style="WHITE-SPACE: nowrap">CAR-T</font>&#xA0;cell subcommittee of the
 collaboration&#x2019;s joint steering committee. After completion of
 the activities contemplated by the&#xA0;<font style="WHITE-SPACE: nowrap">CAR-T</font>&#xA0;cell program research plan,
 Novartis will assume sole responsibility for developing any
 products arising from that research plan and will be responsible
 for additional costs and expenses of developing, manufacturing and
 commercializing its selected research targets. Novartis is required
 to use commercially reasonable efforts to research, develop or
 commercialize at least one&#xA0;<font style="WHITE-SPACE: nowrap">CAR-T</font>&#xA0;cell product directed to at
 least one of its selected&#xA0;<font style="WHITE-SPACE: nowrap">CAR-T</font>cell targets. In the last two
 years of the five-year&#xA0; collaboration term, Novartis
 will have the option to select a limited number of targets for
 research, development and commercialization of<i>&#xA0;in
 vivo</i>&#xA0;therapies using the Company&#x2019;s CRISPR/Cas9
 platform, on a&#xA0;<font style="WHITE-SPACE: nowrap">non-exclusive</font>&#xA0;basis. Following
 Novartis&#x2019; selection of each&#xA0;<i>in vivo</i>&#xA0;target, Novartis may offer the
 Company the right to participate in the research and development of
 such targets, in which case an&#xA0;<i>in vivo</i>&#xA0;program research plan for such
 target will be entered into between the Company and Novartis.
 Novartis is required to use commercially reasonable efforts to
 research, develop or commercialize at least one<i>&#xA0;in
 vivo</i>&#xA0;product
 directed to each of its selected targets.
 Novartis&#x2019;<i>&#xA0;in vivo</i>&#xA0;target selections are
 subject to certain restrictions, including that the targets, or all
 targets within a limited number of organs: (i)&#xA0;have not
 already been reserved by the Company pursuant to our limited right
 to do so under the agreement; (ii)&#xA0;are not the subject of a
 collaboration or pending collaboration with a third party; and
 (iii)&#xA0;are not the subject of ongoing or planned research and
 development by the Company.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company received an upfront technology access payment from
 Novartis of $10.0&#xA0;million in January&#xA0;2015 and is entitled
 to additional technology access fees of $20.0&#xA0;million and
 quarterly research payments of $1.0&#xA0;million, or up to
 $20.0&#xA0;million in the aggregate, during the five-year research
 term. For each product under the collaboration, subject to certain
 conditions, the Company may be eligible to receive (i)&#xA0;up to
 $30.3&#xA0;million in development milestones, including for the
 filing of an investigational new drug application and for the
 dosing of the first patient in each of Phase IIa, Phase IIb and
 Phase III clinical trials, (ii)&#xA0;up to $50.0&#xA0;million in
 regulatory milestones for the product&#x2019;s first indication,
 including regulatory approvals in the U.S. and European Union
 (&#x201C;EU&#x201D;), (iii) up to $50.0&#xA0;million in regulatory
 milestones for the product&#x2019;s second indication, if any,
 including U.S. and EU regulatory approvals, (iv)&#xA0;royalties on
 net sales in the&#xA0;<font style="WHITE-SPACE: nowrap">mid-single</font>&#xA0;digits, and (v)&#xA0;net sales
 milestone payments of up to $100.0&#xA0;million. The Company may
 also be eligible to receive payments for: (i)&#xA0;each additional
 HSC target selected by Novartis beyond its initial defined
 allocation, (ii)&#xA0;each<i>&#xA0;in vivo</i>&#xA0;target that
 Novartis selects and (iii)&#xA0;any exercise by Novartis of certain
 license options under the agreement. Additionally, at the inception
 of the arrangement, Novartis invested $9.0&#xA0;million to purchase
 the Company&#x2019;s&#xA0;<font style="WHITE-SPACE: nowrap">Class&#xA0;A-1</font>&#xA0;and&#xA0;<font style="WHITE-SPACE: nowrap">Class&#xA0;A-2</font>Preferred Units. The
 difference between the cash proceeds received from Novartis for the
 units and the $11.6&#xA0;million estimated fair&#xA0; value of those units at the
 date of issuance was determined to be $2.6&#xA0;million.
 Accordingly, $2.6&#xA0;million of the upfront technology access
 payment was allocated to record the preferred units purchased by
 Novartis at fair value.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <i>Collaboration Revenue</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Through March&#xA0;31, 2017, excluding amounts allocated to
 Novartis&#x2019; purchase of the Company&#x2019;s&#xA0;<font style="WHITE-SPACE: nowrap">Class&#xA0;A-1</font>&#xA0;and&#xA0;<font style="WHITE-SPACE: nowrap">Class&#xA0;A-2</font>&#xA0;Preferred Units, the Company
 had recorded a total of $26.4&#xA0;million in cash and accounts
 receivable under the Novartis agreement. Through March&#xA0;31,
 2017, the Company has recognized $16.0&#xA0;million of
 collaboration revenue, including $2.2&#xA0;million and
 $1.8&#xA0;million in the three months ended March&#xA0;31, 2017 and
 2016, respectively, in the consolidated statements of operations
 related to this agreement. As of March&#xA0;31, 2017 and
 December&#xA0;31, 2016, the Company had accounts receivable of
 $1.0&#xA0;million and $6.0&#xA0;million, respectively, related to
 this agreement. As of March&#xA0;31, 2017 and December&#xA0;31,
 2016, the Company had deferred revenue of $10.4&#xA0;million and
 $11.6&#xA0;million, respectively, related to this agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>Regeneron Pharmaceuticals, Inc.</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In April 2016, the Company entered into a license and collaboration
 agreement with Regeneron Pharmaceuticals, Inc.
 (&#x201C;Regeneron&#x201D;). The agreement includes a product
 component to research, develop and commercialize&#xA0;<font style="WHITE-SPACE: nowrap">CRISPR/Cas-based</font>&#xA0;therapeutic products primarily
 focused on gene editing in the liver as well as a technology
 collaboration component, pursuant to which the Company and
 Regeneron will engage in research and development activities aimed
 at discovering and developing novel technologies and improvements
 to CRISPR/Cas technology to enhance the Company&#x2019;s gene
 editing platform. Under this agreement, the Company also may access
 the Regeneron Genetics Center and proprietary mouse models to be
 provided by Regeneron for a limited number of the Company&#x2019;s
 liver programs.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <i>Agreement Structure</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Under the terms of the collaboration, the Company and Regeneron
 have agreed to a target selection process, whereby Regeneron may
 obtain exclusive rights for up to 10 targets to be chosen by
 Regeneron during the collaboration term, subject to various
 adjustments and limitations set forth in the agreement. Of these 10
 total targets, Regeneron may select up to five&#xA0;<font style="WHITE-SPACE: nowrap">non-liver</font>&#xA0;targets, while the remaining
 targets must be focused in the liver. At the inception of the
 agreement, Regeneron selected the first of its 10 targets, which
 will be subject to a&#xA0;<font style="WHITE-SPACE: nowrap">co-development</font>&#xA0;and&#xA0;<font style="WHITE-SPACE: nowrap">co-commercialization</font>&#xA0;arrangement between the
 Company and Regeneron.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company retains the exclusive right to solely develop products
 for certain indications. During the target selection process, the
 Company has the right to choose additional liver targets for its
 own development using commercially reasonable efforts. Certain
 targets that either the Company or Regeneron select may be subject
 to further&#xA0;<font style="WHITE-SPACE: nowrap">co-development</font>&#xA0;and&#xA0;<font style="WHITE-SPACE: nowrap">co-commercialization</font>&#xA0;arrangements at the
 Company&#x2019;s or Regeneron&#x2019;s option, as applicable, which
 either can exercise pursuant to defined conditions. In addition,
 subject to certain restrictions, Regeneron will be able to replace
 a limited number of targets with substitute targets upon the
 payment of a specified replacement fee, in which case exclusive
 rights to the replaced target revert to the Company.
 Regeneron&#x2019;s target selections are subject to certain
 additional restrictions, including that&#xA0;<font style="WHITE-SPACE: nowrap">non-liver</font>targets are not the subject
 of ongoing or planned research and development by the Company or
 are not the subject of a collaboration or pending&#xA0; collaboration with a third
 party.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Research activities under the collaboration will be governed by
 evaluation and research and development plans that will outline the
 parties&#x2019; responsibilities under, anticipated timelines of and
 budgets for, the various programs. The Company will assist
 Regeneron with the preliminary evaluation of liver targets, and
 Regeneron will be responsible for preclinical research and the
 conduct of clinical development, manufacturing and
 commercialization of products directed to each of its exclusive
 targets under the oversight of a joint steering committee. The
 Company may assist, as requested by Regeneron, with the later
 discovery and research of product candidates directed to any
 selected target. For each selected target, Regeneron is required to
 use commercially reasonable efforts to submit regulatory filings
 necessary to achieve initial investigational new drug
 (&#x201C;IND&#x201D;) acceptance for at least one product directed to
 each applicable target, and following IND acceptance for at least
 one product, to develop and commercialize such product.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In connection with this collaboration, Regeneron agreed to purchase
 $50.0&#xA0;million of the Company&#x2019;s common stock in a private
 placement concurrent with the Company&#x2019;s initial public
 offering, and the Company received a nonrefundable upfront payment
 of $75.0&#xA0;million. In addition, the Company is eligible to
 earn, on a&#xA0;<font style="WHITE-SPACE: nowrap">per-licensed</font>&#xA0;target basis, (i)&#xA0;up to
 $25.0&#xA0;million in development milestones, including for the
 dosing of the first patient in each of Phase I, Phase II and Phase
 III clinical trials, (ii)&#xA0;up to $110.0&#xA0;million in
 regulatory milestones, including for the acceptance of a regulatory
 filing in the U.S., and U.S. and&#xA0;<font style="WHITE-SPACE: nowrap">ex-U.S.</font>&#xA0;regulatory approvals, and
 (iii)&#xA0;up to $185.0&#xA0;million in sales-based milestone
 payments. The Company is also eligible to earn royalties ranging
 from the high single digits to low teens, in each case, on
 a&#xA0;<font style="WHITE-SPACE: nowrap">per-product</font>&#xA0;basis, which royalties are
 potentially subject to various reductions and offsets and are
 further subject to the Company&#x2019;s existing low single-digit
 royalty obligations under the Caribou license agreement. In
 addition, Regeneron is obligated to fund 50.0% of the agreed-upon
 research and development costs for the transthyretin amyloidosis
 program, the first target selected by Regeneron, which will be
 subject to a&#xA0;<font style="WHITE-SPACE: nowrap">co-development</font>&#xA0;and&#xA0;<font style="WHITE-SPACE: nowrap">co-commercialization</font>&#xA0;arrangement between the
 Company and Regeneron.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The fixed portion of consideration under the collaboration
 arrangement was determined to be the $75.0&#xA0;million
 nonrefundable upfront payment, for which there are no contingent
 terms. The significant deliverables of this multiple-element
 revenue arrangement were determined to be licenses to targets, the
 associated research activities and evaluation plans for these
 programs and the technology collaboration. The Company further
 determined that the licenses and associated research activities and
 evaluation plans did not have standalone value due to the
 specialized nature of the services to be provided by the Company;
 therefore, these deliverables are not separable, and, accordingly,
 the license and services are treated as a single unit of
 accounting. The Company additionally concluded that the technology
 collaboration has standalone value from the product development, as
 shared rights to technological advancements under the technology
 collaboration could be separately applied by Regeneron to other
 programs.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company allocated the $75.0&#xA0;million in fixed consideration
 to the two units of accounting based on the estimated relative
 selling price of each deliverable. The Company estimated the
 selling price of each deliverable by taking into consideration
 internal estimates of research and development personnel needed to
 perform the research and development services, estimates of
 expected cash outflows to third parties for services and supplies,
 selling prices of comparable transactions and typical gross profit
 margins. As a result of this evaluation, the Company allocated
 $63.8&#xA0;million to the licenses to targets and the associated
 research activities and evaluation plans and $11.2&#xA0;million to
 the technology collaboration. The $63.8&#xA0;million allocated to
 the licenses to targets and the associated research activities and
 evaluation plans for these programs is being recognized over
 the&#xA0;<font style="WHITE-SPACE: nowrap">six-year</font>&#xA0;performance period of the
 arrangement. The $11.2&#xA0;million allocated to the technology
 collaboration is being recognized over a period beginning with the
 inception of the technology collaboration in September 2016,
 through the end of the arrangement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <i>Collaboration Revenue</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Through March&#xA0;31, 2017, the Company recorded a
 $75.0&#xA0;million upfront payment and $1.4&#xA0;million for
 research and development services under the Regeneron agreement.
 Through March&#xA0;31, 2017, the Company recognized
 $12.8&#xA0;million of collaboration revenue, including
 $4.1&#xA0;million in the three months ended March&#xA0;31, 2017, in
 the consolidated statement of operations. As of March&#xA0;31, 2017
 and December&#xA0;31, 2016, the Company had deferred revenue of
 $63.6&#xA0;million and $66.7&#xA0;million, respectively, related to
 this agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6619012608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity-Based Compensation</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="8%" align="left"><b>6.</b></td>
 <td valign="top" align="left"><b>Equity-Based Compensation</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Equity-based compensation expense is classified in the consolidated
 statements of operations as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Three&#xA0;Months&#xA0;Ended&#xA0;March&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(In
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,503</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">454</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,127</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">358</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,630</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">812</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>Restricted Stock</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The following table summarizes the Company&#x2019;s restricted stock
 activity, including converted Founder Stock, for the three months
 ended March&#xA0;31, 2017:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="72%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Number of</b><br />
 <b>Shares</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted</b><br />
 <b>Average&#xA0;Grant</b><br />
 <b>Date&#xA0;Fair&#xA0;Value</b><br />
 <b>per Share</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unvested restricted stock as of January&#xA0;1, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,361,855</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.81</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Vested</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(186,917</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.73</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unvested restricted stock as of March&#xA0;31, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,174,938</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.82</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 As of March&#xA0;31, 2017, there was $2.7&#xA0;million of
 unrecognized equity-based compensation expense related to
 restricted stock that is expected to vest. These costs are expected
 to be recognized over a weighted average remaining vesting period
 of 1.8 years.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>Stock Options</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The weighted average grant date fair value of options, estimated as
 of the grant date using the Black-Scholes option pricing model, was
 $10.38 per option and $4.98 per option for those options granted
 during the three months ended March&#xA0;31, 2017 and 2016,
 respectively. Key assumptions used to apply this pricing model were
 as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="60%"></td>
 <td valign="bottom" width="13%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="13%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">
 <b>Three&#xA0;Months&#xA0;Ended</b><br />
 <b>March&#xA0;31, 2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">
 <b>Three&#xA0;Months&#xA0;Ended</b><br />
 <b>March&#xA0;31, 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.3</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected life of options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.0&#xA0;years</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.0&#xA0;years</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected volatility of underlying stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">92.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">87.7</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The following is a summary of stock option activity for the three
 months ended March&#xA0;31, 2017:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="62%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Number of</b><br />
 <b>Options</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted</b><br />
 <b>Average</b><br />
 <b>Exercise</b><br />
 <b>Price per</b><br />
 <b>Share</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted</b><br />
 <b>Average</b><br />
 <b>Remaining</b><br />
 <b>Contractual</b><br />
 <b>Term</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Aggregate</b><br />
 <b>Intrinsic</b><br />
 <b>Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center"><b>(In
 years)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>(In&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at January&#xA0;1, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,040,214</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8.35</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,343,428</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13.71</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(7,136</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.56</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Forfeited</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,284</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">16.03</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at March&#xA0;31, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,373,222</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9.99</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9.1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">17,929</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercisable at March&#xA0;31, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">780,588</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7.12</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.8</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,440</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 As of March&#xA0;31, 2017, there was $25.0&#xA0;million of
 unrecognized compensation cost related to stock options that are
 expected to vest. These costs are expected to be recognized over a
 weighted average remaining vesting period of 3.2 years.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6624742176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Share</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="8%" align="left"><b>7.</b></td>
 <td valign="top" align="left"><b>Loss Per Share</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company calculates basic (loss) earnings per share by dividing
 (loss) income allocable to common stockholders by the weighted
 average number of common shares outstanding. The Company computes
 diluted (loss) earnings per share after giving consideration to the
 dilutive effect of preferred stock, common stock and restricted
 common stock that are outstanding during the period, except where
 such&#xA0;<font style="WHITE-SPACE: nowrap">non-participating</font>&#xA0;securities would be
 anti-dilutive.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Basic and diluted loss per share attributable to common
 stockholders was calculated as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Three&#xA0;Months&#xA0;Ended&#xA0;March&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b>(In&#xA0;thousands&#xA0;except&#xA0;per&#xA0;share&#xA0;data)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(12,631</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(6,689</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Weighted average shares outstanding, basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">34,723</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">676</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net loss per share attributable to common stockholders, basic and
 diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.36</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(9.89</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In May 2016, the Company issued an additional 6,900,000 shares of
 common stock in connection with its initial public offering
 (&#x201C;IPO&#x201D;) and 23,481,956 shares of common stock in
 connection with the automatic conversion of its convertible
 preferred stock upon the closing of the IPO. In addition, the
 Company issued a total of 3,055,554 shares of common stock in two
 separate, concurrent private placements upon the closing of the
 IPO. The issuance of these shares resulted in a significant
 increase in the Company&#x2019;s weighted average shares outstanding
 and will impact the year-over-year comparability of the
 Company&#x2019;s (loss) earnings per share calculations into
 2017.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The following common stock equivalents were excluded from the
 calculation of diluted loss per share because their inclusion would
 have been anti-dilutive:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Three&#xA0;Months&#xA0;Ended&#xA0;March&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(In
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unvested restricted stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,175</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,774</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Stock options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,373</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,618</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,548</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,392</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6744927344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="8%" align="left"><b>8.</b></td>
 <td valign="top" align="left"><b>Related Party
 Transactions</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In July 2014, the Company issued Caribou Therapeutics Holdco, LLC,
 a wholly-owned subsidiary of Caribou Biosciences, Inc.
 (&#x201C;Caribou&#x201D;), 8,110,599 Junior Preferred Units. As a
 result of this and related transactions, Caribou owned 15.5% of the
 Company&#x2019;s voting interests as of March&#xA0;31, 2017.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company recognized research and development expense of
 $0.4&#xA0;million during the three months ended March&#xA0;31, 2016
 and an insignificant amount during the three months ended
 March&#xA0;31, 2017, related to license and service agreements
 entered into with Caribou. In addition, the Company recognized
 general and administrative expense of $0.2&#xA0;million during the
 three months ended March&#xA0;31, 2016 and an insignificant amount
 during the three months ended March&#xA0;31, 2017, related to the
 Company&#x2019;s obligation to pay 30.0% of Caribou&#x2019;s patent
 prosecution, filing and maintenance costs under its intellectual
 property license agreement with Caribou.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In connection with its entry into the collaboration and license
 agreement and related equity transactions with Novartis, the
 Company issued Novartis 4,761,905&#xA0;<font style="WHITE-SPACE: nowrap">Class&#xA0;A-1</font>&#xA0;Preferred Units and
 2,666,666&#xA0;<font style="WHITE-SPACE: nowrap">Class&#xA0;A-2</font>&#xA0;Preferred Units. In August
 2015, Novartis acquired 761,905 shares of the Company&#x2019;s
 Series B Preferred Stock, and in May 2016, Novartis acquired
 277,777 shares of the Company&#x2019;s common stock in a private
 placement transaction concurrent with the Company&#x2019;s IPO. As a
 result of these and subsequent transactions, Novartis collectively
 owned 15.7% of the Company&#x2019;s voting interests as of
 March&#xA0;31, 2017. Refer to Note 5,&#xA0;<i>Collaborations</i>, for
 additional information regarding this collaboration agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company recognized collaboration revenue of $2.2&#xA0;million
 and $1.8&#xA0;million in the three months ended March&#xA0;31, 2017
 and 2016, respectively, in the consolidated statements of
 operations related to this agreement. As of March&#xA0;31, 2017 and
 December&#xA0;31, 2016, the Company had recorded accounts
 receivable of $1.0&#xA0;million and $6.0&#xA0;million and deferred
 revenue of $10.4&#xA0;million and $11.6&#xA0;million, respectively,
 related to this collaboration.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6744830080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>Recent Accounting Pronouncements</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In May 2014, the Financial Accounting Standards Board
 (&#x201C;FASB&#x201D;) issued Accounting Standards Update
 (&#x201C;ASU&#x201D;) No.&#xA0;<font style="WHITE-SPACE: nowrap">2014-09,</font><i>&#xA0;Revenue from Contracts with
 Customers (Topic 606),</i>&#xA0;which supersedes existing
 revenue recognition guidance. The standard&#x2019;s core principle
 is that a company will recognize revenue when it transfers promised
 goods or services to customers in an amount that reflects the
 consideration to which the company expects to be entitled in
 exchange for those goods or services. The standard defines a
 five-step process to achieve this principle and will require
 companies to use more judgment and make more estimates than under
 the current guidance. The Company expects that these judgments and
 estimates will include identifying performance obligations in the
 customer contract, estimating the amount of variable consideration
 to include in the transaction price and allocating the transaction
 price to each separate performance obligation. ASU&#xA0;<font style="WHITE-SPACE: nowrap">2014-09</font>&#xA0;also requires additional
 disclosure about the nature, amount, timing and uncertainty of
 revenue and cash flows arising from customer contracts. The FASB
 continues to address certain implementation issues and clarify
 certain core revenue recognition principles of ASU&#xA0;<font style="WHITE-SPACE: nowrap">2014-09.</font>&#xA0;In July 2015, the FASB voted
 to delay the effective date of this standard such that
 ASU&#xA0;<font style="WHITE-SPACE: nowrap">2014-09,</font>&#xA0;as amended, will be effective
 for the Company for annual and interim periods beginning after
 December&#xA0;15, 2017. Early adoption of the standard is permitted
 for annual periods beginning after December&#xA0;15, 2016. The
 Company continues to evaluate the impact that the adoption of these
 ASUs will have on its consolidated financial statements; however,
 the Company does not expect that adoption of this standard will
 have a significant impact on the consolidated financial
 statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In February 2016, the FASB issued ASU No.&#xA0;<font style="WHITE-SPACE: nowrap">2016-02,</font><i>&#xA0;Leases</i>.
 ASU&#xA0;<font style="WHITE-SPACE: nowrap">2016-02</font>&#xA0;amends ASC
 840,<i>&#xA0;Leases</i>, by introducing a lessee model that
 requires balance sheet recognition of most leases. The Company is
 the lessee under certain leases that are accounted for as operating
 leases. The proposed changes would require that substantially all
 of the Company&#x2019;s operating leases be recognized as assets and
 liabilities on the Company&#x2019;s balance sheet. ASU&#xA0;<font style="WHITE-SPACE: nowrap">2016-02</font>&#xA0;will be effective for the
 Company for annual periods, and interim periods within those annual
 periods, beginning after December&#xA0;15, 2018. The Company is
 evaluating the impact that the adoption of ASU&#xA0;<font style="WHITE-SPACE: nowrap">2016-02</font>&#xA0;will have on its consolidated
 financial statements but expects that the Company will recognize a
 significant lease obligation upon adoption in connection with the
 Company&#x2019;s existing lease agreements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In March 2016, the FASB issued ASU&#xA0;<font style="WHITE-SPACE: nowrap">No.&#xA0;2016-09,</font>&#xA0;<i>Improvements to Employee
 Share-Based Payment Accounting</i>. ASU&#xA0;<font style="WHITE-SPACE: nowrap">2016-09</font>&#xA0;amends ASC 718,&#xA0;<i>Compensation &#x2013; Stock
 Compensation</i>, by simplifying certain aspects of the accounting
 for employee share-based payment transactions, including the
 accounting for income taxes, forfeitures, statutory tax withholding
 requirements and the classification in the statement of cash flows.
 ASU&#xA0;<font style="WHITE-SPACE: nowrap">2016-09</font>&#xA0;was adopted by the Company on
 January&#xA0;1, 2017 and did not have a significant impact on its
 consolidated financial statements.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6744926656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of Financial Assets Recognized at Fair Value</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 As of March&#xA0;31, 2017 and December&#xA0;31, 2016, the
 Company&#x2019;s financial assets recognized at fair value consisted
 of the following:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"><b>Fair Value as of March&#xA0;31,
 2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center"><b>(In
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">255,735</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">255,735</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">255,735</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">255,735</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="16"></td>
 <td height="16" colspan="16"></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"><b>Fair Value as of December&#xA0;31,
 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center"><b>(In
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">270,448</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">270,448</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">270,448</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">270,448</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6744932160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Accrued expenses consisted of the following:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>March&#xA0;31,</b><br />
 <b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(In
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Employee compensation and benefits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,532</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,703</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Research and development and professional expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,027</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,197</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accrued expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,559</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,900</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6614243392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Equity-Based Compensation Expense</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Equity-based compensation expense is classified in the consolidated
 statements of operations as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Three&#xA0;Months&#xA0;Ended&#xA0;March&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(In
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,503</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">454</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,127</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">358</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,630</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">812</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Activity, Including Converted Founder Stock</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The following table summarizes the Company&#x2019;s restricted stock
 activity, including converted Founder Stock, for the three months
 ended March&#xA0;31, 2017:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="72%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Number of</b><br />
 <b>Shares</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted</b><br />
 <b>Average&#xA0;Grant</b><br />
 <b>Date&#xA0;Fair&#xA0;Value</b><br />
 <b>per Share</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unvested restricted stock as of January&#xA0;1, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,361,855</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.81</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Vested</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(186,917</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.73</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unvested restricted stock as of March&#xA0;31, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,174,938</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.82</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted Average Assumptions Used to Compute Fair Value of Option Granted</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Key assumptions used to apply this pricing model were as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="60%"></td>
 <td valign="bottom" width="13%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="13%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">
 <b>Three&#xA0;Months&#xA0;Ended</b><br />
 <b>March&#xA0;31, 2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">
 <b>Three&#xA0;Months&#xA0;Ended</b><br />
 <b>March&#xA0;31, 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.3</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected life of options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.0&#xA0;years</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.0&#xA0;years</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected volatility of underlying stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">92.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">87.7</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 </table>
 <br class="Apple-interchange-newline" /></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The following is a summary of stock option activity for the three
 months ended March&#xA0;31, 2017:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="62%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Number of</b><br />
 <b>Options</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted</b><br />
 <b>Average</b><br />
 <b>Exercise</b><br />
 <b>Price per</b><br />
 <b>Share</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted</b><br />
 <b>Average</b><br />
 <b>Remaining</b><br />
 <b>Contractual</b><br />
 <b>Term</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Aggregate</b><br />
 <b>Intrinsic</b><br />
 <b>Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center"><b>(In
 years)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>(In&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at January&#xA0;1, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,040,214</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8.35</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,343,428</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13.71</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(7,136</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.56</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Forfeited</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,284</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">16.03</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at March&#xA0;31, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,373,222</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9.99</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9.1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">17,929</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercisable at March&#xA0;31, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">780,588</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7.12</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.8</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,440</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6897893184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 Basic and diluted loss per share attributable to common
 stockholders was calculated as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Three&#xA0;Months&#xA0;Ended&#xA0;March&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b>(In&#xA0;thousands&#xA0;except&#xA0;per&#xA0;share&#xA0;data)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(12,631</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(6,689</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Weighted average shares outstanding, basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">34,723</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">676</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net loss per share attributable to common stockholders, basic and
 diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.36</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(9.89</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potential Dilutive Securities Excluded from Computation of Diluted Net Loss Per Common Share</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The following common stock equivalents were excluded from the
 calculation of diluted loss per share because their inclusion would
 have been anti-dilutive:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Three&#xA0;Months&#xA0;Ended&#xA0;March&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b>(In&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unvested restricted stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,175</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,774</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Stock options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,373</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,618</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,548</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,392</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755088608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Assets Recognized at Fair Value (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 255,735<span></span>
</td>
<td class="nump">$ 270,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">255,735<span></span>
</td>
<td class="nump">270,448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">255,735<span></span>
</td>
<td class="nump">270,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 255,735<span></span>
</td>
<td class="nump">$ 270,448<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6747879632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">$ 1,532<span></span>
</td>
<td class="nump">$ 2,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Research and development and professional expenses</a></td>
<td class="nump">2,027<span></span>
</td>
<td class="nump">3,197<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 3,559<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6756839408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">28 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2016 </div>
<div>USD ($) </div>
<div>Unit</div>
</th>
<th class="th">
<div>Jan. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,215,000<span></span>
</td>
<td class="nump">$ 1,777,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=ntla_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis [Member] | Class A Preferred Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_EstimatedFairValueOfPreferredStock', window );">Estimated fair value of units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_CollaborationConsiderationAllocatedToEquity', window );">Difference between cash proceeds received and estimated fair value of preferred units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=ntla_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_DevelopmentBasedMilestonePaymentsUnderAgreement', window );">Development based milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationFirstIndication', window );">Regulatory based milestone payments for first indication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationSecondIndication', window );">Regulatory based milestone payments for second indication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_SalesBasedMilestonePaymentsUnderAgreement', window );">Sales based milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=ntla_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis [Member] | Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_TechnologyAccessFees', window );">Technology access fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_QuarterlyResearchPayments', window );">Quarterly research payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_CollaborationArrangementTermOfAgreement', window );">Research term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,400,000<span></span>
</td>
<td class="nump">$ 11,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=ntla_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis [Member] | Collaborative Arrangement [Member] | Upfront Technology Access Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=ntla_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis [Member] | Collaborative Arrangement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_ResearchFundingAggregateAmount', window );">Total research funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=ntla_RegeneronPharmaceuticalsIncMember', window );">Regeneron Pharmaceuticals Inc. [Member] | Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,600,000<span></span>
</td>
<td class="nump">$ 66,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Purchase of common stock through private placement</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_CollaborativeArrangementObligationToFundPercentage', window );">Percentage of obligated fund on research and development costs</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_RevenueRecognitionMultipleDeliverableArrangementsNumberOfUnitsOfAccounting', window );">Number of accounting based units | Unit</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans', window );">Amount allocated to licenses to targets and associated research activities and evaluation plans</a></td>
<td class="nump">$ 63,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod', window );">Licenses to targets and associated research activities and evaluation plans performance period</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_AmountAllocatedToTechnologyCollaboration', window );">Amount allocated to technology collaboration</a></td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_RevenueRecognitionMultipleDeliverableArrangementsAllocationToSpecificUnitOfAccounting', window );">Revenue Recognition, Multiple-deliverable Arrangements, Allocation to Specific Unit of Accounting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company allocated the $75.0 million in fixed consideration to the two units  of accounting based on the estimated relative selling price of each deliverable.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=ntla_RegeneronPharmaceuticalsIncMember', window );">Regeneron Pharmaceuticals Inc. [Member] | Collaborative Arrangement [Member] | Upfront Technology Access Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=ntla_RegeneronPharmaceuticalsIncMember', window );">Regeneron Pharmaceuticals Inc. [Member] | Collaborative Arrangement [Member] | Research and Development Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=ntla_RegeneronPharmaceuticalsIncMember', window );">Regeneron Pharmaceuticals Inc. [Member] | Collaborative Arrangement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_DevelopmentBasedMilestonePaymentsUnderAgreement', window );">Development based milestone payments under agreement</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_SalesBasedMilestonePaymentsUnderAgreement', window );">Sales based milestone payments under agreement</a></td>
<td class="nump">185,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_RegulatoryBasedMilestonePaymentsUnderAgreement', window );">Regulatory based milestone payments under agreement</a></td>
<td class="nump">$ 110,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntla_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to licenses to targets and associated research activities and evaluation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntla_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntla_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntla_AmountAllocatedToTechnologyCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to technology collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntla_AmountAllocatedToTechnologyCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntla_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntla_CollaborationArrangementTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration arrangement term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntla_CollaborationArrangementTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntla_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntla_CollaborationConsiderationAllocatedToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of collaboration consideration received that has been allocated to the value of equity units purchased by the collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntla_CollaborationConsiderationAllocatedToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntla_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntla_CollaborativeArrangementObligationToFundPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of obligated fund on research and development costs under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntla_CollaborativeArrangementObligationToFundPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntla_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntla_DevelopmentBasedMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential clinical development milestone payments available to be earned under a collaboration arrangement for each available target selected by the collaborator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntla_DevelopmentBasedMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntla_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntla_EstimatedFairValueOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntla_EstimatedFairValueOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntla_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntla_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licenses to targets and associated research activities and evaluation plans performance period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntla_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntla_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntla_QuarterlyResearchPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of quarterly research payment to which the Company is entitled to receive under the collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntla_QuarterlyResearchPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntla_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntla_RegulatoryBasedMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential regulatory milestone payments available to be earned under a collaboration arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntla_RegulatoryBasedMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntla_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationFirstIndication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential regulatory milestone payments available to be earned under a collaboration arrangement for a product candidate's first indication.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationFirstIndication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntla_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationSecondIndication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential regulatory milestone payments available to be earned under a collaboration arrangement for a product candidate's second indication.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntla_RegulatoryBasedMilestonePaymentsUnderCollaborationSecondIndication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntla_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntla_ResearchFundingAggregateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of research payments the Company is entitled to received under the collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntla_ResearchFundingAggregateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntla_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntla_RevenueRecognitionMultipleDeliverableArrangementsAllocationToSpecificUnitOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the allocation of consideration to a specific unit of accounting at the inception of a multiple-deliverable arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntla_RevenueRecognitionMultipleDeliverableArrangementsAllocationToSpecificUnitOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntla_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntla_RevenueRecognitionMultipleDeliverableArrangementsNumberOfUnitsOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of units of accounting identified in a multiple element arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntla_RevenueRecognitionMultipleDeliverableArrangementsNumberOfUnitsOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntla_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntla_SalesBasedMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential sales-based milestone payments available to be earned under a collaboration arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntla_SalesBasedMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntla_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntla_TechnologyAccessFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional technology access fees to which the company is entitled to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntla_TechnologyAccessFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntla_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseAndServicesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=ntla_NovartisInstitutesForBioMedicalResearchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=ntla_NovartisInstitutesForBioMedicalResearchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ntla_ClassAPreferredUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ntla_ClassAPreferredUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=ntla_RegeneronPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=ntla_RegeneronPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=ntla_ResearchAndDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=ntla_ResearchAndDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6743936656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Schedule of Equity-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="nump">$ 2,630<span></span>
</td>
<td class="nump">$ 812<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="nump">1,503<span></span>
</td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="nump">$ 1,127<span></span>
</td>
<td class="nump">$ 358<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6909874608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Summary of Restricted Stock Activity, Including Converted Founder Stock (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested, Beginning balance | shares</a></td>
<td class="nump">1,361,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested | shares</a></td>
<td class="num">(186,917)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested, Ending balance | shares</a></td>
<td class="nump">1,174,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value per Share, Unvested, Beginning balance | $ / shares</a></td>
<td class="nump">$ 0.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value per Share, Vested | $ / shares</a></td>
<td class="nump">0.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value per Share, Unvested, Ending balance | $ / shares</a></td>
<td class="nump">$ 0.82<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6756865472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total unrecognized stock-based compensation expense</a></td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share</a></td>
<td class="nump">$ 10.38<span></span>
</td>
<td class="nump">$ 4.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to stock options</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of unrecognized compensation costs</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of unrecognized compensation costs</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6892920032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Summary of Weighted Average Assumptions Used to Compute Fair Value of Option Granted (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility of underlying stock</a></td>
<td class="nump">92.60%<span></span>
</td>
<td class="nump">87.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752096912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Summary of Stock Option Activity (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, Beginning Balance | shares</a></td>
<td class="nump">3,040,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted | shares</a></td>
<td class="nump">1,343,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, Exercised | shares</a></td>
<td class="num">(7,136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, Forfeited | shares</a></td>
<td class="num">(3,284)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, Ending Balance | shares</a></td>
<td class="nump">4,373,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable | shares</a></td>
<td class="nump">780,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Outstanding, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 8.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Granted | $ / shares</a></td>
<td class="nump">13.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Exercised | $ / shares</a></td>
<td class="nump">6.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Forfeited | $ / shares</a></td>
<td class="nump">16.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Outstanding, Ending Balance | $ / shares</a></td>
<td class="nump">9.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Exercisable | $ / shares</a></td>
<td class="nump">$ 7.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="nump">$ 17,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 5,440<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6889773344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Detail) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12,631)<span></span>
</td>
<td class="num">$ (6,689)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding, basic and diluted</a></td>
<td class="nump">34,723<span></span>
</td>
<td class="nump">676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (9.89)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6888249168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>May 31, 2016 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_EarningsLossPerShareLineItems', window );"><strong>Earnings Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock issued upon conversion of shares</a></td>
<td class="nump">6,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Conversion of convertible preferred stock into common stock</a></td>
<td class="nump">23,481,956<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_EarningsLossPerShareLineItems', window );"><strong>Earnings Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock issued upon conversion of shares</a></td>
<td class="nump">3,055,554<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntla_EarningsLossPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings loss per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntla_EarningsLossPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntla_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6909872192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share - Potential Dilutive Securities Excluded from Computation of Diluted Net Loss Per Common Share (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential dilutive securities excluded from computation of diluted net loss per common share</a></td>
<td class="nump">5,548<span></span>
</td>
<td class="nump">4,392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential dilutive securities excluded from computation of diluted net loss per common share</a></td>
<td class="nump">1,175<span></span>
</td>
<td class="nump">1,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential dilutive securities excluded from computation of diluted net loss per common share</a></td>
<td class="nump">4,373<span></span>
</td>
<td class="nump">2,618<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755729360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Aug. 31, 2015</div></th>
<th class="th"><div>Jul. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense related to license and service agreements with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,431<span></span>
</td>
<td class="nump">$ 5,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,732<span></span>
</td>
<td class="nump">3,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,215<span></span>
</td>
<td class="nump">1,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ntla_CaribouMember', window );">Caribou [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredUnitsIssued', window );">Junior preferred units issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,110,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_RelatedPartyOwnershipPercentage', window );">Percentage of shares owned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense related to license and service agreements with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_RelatedPartyCommitmentObligationPercentage', window );">Percentage of related party obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ntla_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis [Member] | Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntla_RelatedPartyOwnershipPercentage', window );">Percentage of shares owned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares acquired</a></td>
<td class="nump">277,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ntla_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis [Member] | Class A-1 Preferred Units [Member] | Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredUnitsIssued', window );">Junior preferred units issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,761,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ntla_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis [Member] | Class A-2 Preferred Units [Member] | Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredUnitsIssued', window );">Junior preferred units issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,666,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ntla_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis [Member] | Series B Preferred Stock [Member] | Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">761,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntla_RelatedPartyCommitmentObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entity's obligation to fund intellectual property costs of the related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntla_RelatedPartyCommitmentObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntla_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntla_RelatedPartyOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The related party's percentage of fully diluted equity participation in the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntla_RelatedPartyOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntla_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseAndServicesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredUnitsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of preferred units issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187171-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70434-108055<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredUnitsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ntla_CaribouMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ntla_CaribouMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ntla_NovartisInstitutesForBioMedicalResearchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ntla_NovartisInstitutesForBioMedicalResearchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ntla_ClassA1PreferredUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ntla_ClassA1PreferredUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ntla_ClassA2PreferredUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ntla_ClassA2PreferredUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>42
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M7'_X782MUV9G_K'Q6;!KX====%]02P,$%     @ U86B2IE<G",0!@  G"<
M !,   !X;"]T:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T
M$W-I=MNTF83M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY
M\^XN8NB&B)3R>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2
MP]R"BPA+>!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?
M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA
M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M
M&N#C\7@XMLO2BW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_K
MFVB<"HU;3]-K=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K
M>A(5M>5 TR  6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T
M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)
MI#-ZG7TZSFN4?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R
M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MS8-\84P2%5#\I$)I5(^>%I1<I)[F:LYMH[(+R8:Q"4?3/X'J#U!+ P04
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MC'- H59F^J#G8GP?QD#Q?GKZT/S^%G\ 4$L#!!0    ( -6%HDK5$PY%J0(
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M;G6V(1TY5TQK3%=:W5G?4:9)PX[*#(D>BZ%1#Q/%^_$2DDPWH>U?4$L#!!0
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MC2+]0_$>H]?R \_9-?+,*:<IA:]2]DL&0_*E M^J<.+_P/DV_+ I\)#@A[7
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MJJGW#:*'H&1W$\:G"Y]K,10T/A[OP]E.(S89'OOY][#E"Y>_ 5!+ P04
M" #5A:)*;X6& [4!  #/ P  &    'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;'U3VV[<(!#]%<0'!)MUTLW*MI1-%+52*ZU2-7UF[;&-PL4%O$[_OH =UTJL
MO  SG#-S9ACR49L7VP$X]"J%L@7NG.L/A-BJ \GLE>Y!^9M&&\F<-TU+;&^
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MN&!^]+:9MFQR'/;S V++*R[_ %!+ P04    " #5A:)*D7]29K4!  #2 P
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M\&RG,9L,;_KY!['E&Y>_ %!+ P04    " #5A:)*_BV<.+,!  #2 P  &0
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M:&5E=#$W+GAM;&U4;8^<(!#^*X0?<"C[XG6C)K?7-&W2)IMK>OW,ZOB2 [&
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M>SK)B;%777RM"^1K0T"ADEJ!J.$*!Z!4"RD;?ZPF6CZIB>OY3?VSR:ZRG(B
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M8:A1T @_&X1AN&@&YX>U#EC/ <<..'3 6P?\SH&(C 'I(+*%9"TDI/6P!<;
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M\WXF]@?)VF'>H_&GD_\%4$L#!!0    ( -6%HDK0>0]X&@(  .L%   9
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MO-."P$GJ::;FW/8?NY"L'ULKFOI[]0]02P,$%     @ U86B2F^Y>1\\ @
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MCE(/9VK,;6.V$\F:[M)!_<V7_0502P,$%     @ U86B2OH_9;D, @  _04
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M_2J&#:5A,.S^N[B(RIIWF5C&3E;:_0:[LS:R'J+85&K^T3_+QCVO0_R;&^Q
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MK,QTJ>?"=0>W4+P;&A\:NV_Y!U!+ P04    " #5A:)*-#>>3P "  !P!0
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MABWG@DF:_HTDN)>C\^4A9UO1W%)Y7W7S8_<@^$'-QMYE0)_]!U!+ P04
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M%*BMV .PN+N$A>@"%6HYY0$XWCKIN86 S44' :)]1YXT TFDC!_ D(F""/P
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M     %]R96QS+RYR96QS4$L! A0#%     @ U86B2F;S"V""    L0   !
M             ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #5
MA:)* X**D>\    K @  $0              @ &9 0  9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " #5A:)*F5R<(Q &  "<)P  $P
M@ &W @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( -6%HDK]#!;.
M9 (  !4(   8              "  ?@(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " #5A:)*=?-D)5P#  !0#@  &
M@ &2"P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ U86B
M2L9 -+[X 0  BP4  !@              ( !) \  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( -6%HDK5$PY%J0(  !4)   8
M      "  5(1  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M" #5A:)*C!5=NN(#  !9$0  &               @ $Q%   >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ U86B2IS,6>BO 0  S@,  !@
M             ( !21@  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( -6%HDH 1UL0M $  ,X#   8              "  2X:  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #5A:)*;X6& [4!  #/
M P  &               @ $8'   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ U86B2N;2Z+RS 0  T@,  !@              ( ! QX
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( -6%HDH\R+UG
ML $  -$#   9              "  >P?  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ U86B2I%_4F:U 0  T@,  !D
M ( !TR$  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #5
MA:)*_BV<.+,!  #2 P  &0              @ &_(P  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( -6%HDH'/.*CLP$  -(#   9
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M970Q-RYX;6Q02P$"% ,4    " #5A:)*O^T6O,$!   W!   &0
M    @ %M+P  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M -6%HDJ<E]?=\0$   4&   9              "  64Q  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ U86B2JI3<M_B 0  YP0  !D
M             ( !C3,  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    " #5A:)*:QGIKJ $  #?&   &0              @ &F-0  >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( -6%HDIVM/=P+0(
M ( &   9              "  7TZ  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ U86B2M!Y#W@: @  ZP4  !D              ( !
MX3P  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #5A:)*
M;[EY'SP"   %!P  &0              @ $R/P  >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( -6%HDKZ/V6Y# (  /T%   9
M      "  :5!  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ U86B2NSH=,;% @    H  !D              ( !Z$,  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #5A:)*.I7#R1@"  ")!0
M&0              @ 'D1@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( -6%HDHT-YY/  (  ' %   9              "  3-)  !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ U86B2E<2F 4K
M @  @P8  !D              ( !:DL  'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    " #5A:)*&8PD4(4#  "L#P  &0
M@ ',30  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( -6%
MHDKJ6#WENB$  #&*   4              "  8A1  !X;"]S:&%R9613=')I
M;F=S+GAM;%!+ 0(4 Q0    ( -6%HDHB?3!W40(  ",,   -
M  "  71S  !X;"]S='EL97,N>&UL4$L! A0#%     @ U86B2B6 <,'0 @
M$A0   \              ( !\'4  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( -6%HDI5H"SI; $  !\3   :              "  >UX  !X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( -6%HDIIAGLXB $  -03
M   3              "  9%Z  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0   G "< @PH  $I\      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.7.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>53</ContextCount>
  <ElementCount>141</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>21</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/StatementOfIncomeAlternative</Role>
      <ShortName>Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Disclosure - Overview and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</Role>
      <ShortName>Overview and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - Collaborations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock</Role>
      <ShortName>Collaborations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - Equity-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</Role>
      <ShortName>Equity-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock</Role>
      <ShortName>Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - Equity-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables</Role>
      <ShortName>Equity-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables</Role>
      <ShortName>Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://intelliatx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - Fair Value Measurements - Summary of Financial Assets Recognized at Fair Value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsRecognizedAtFairValue</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Assets Recognized at Fair Value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - Collaborations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/DisclosureCollaborationsAdditionalInformation</Role>
      <ShortName>Collaborations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - Equity-Based Compensation - Schedule of Equity-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpense</Role>
      <ShortName>Equity-Based Compensation - Schedule of Equity-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - Equity-Based Compensation - Summary of Restricted Stock Activity, Including Converted Founder Stock (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRestrictedStockActivityIncludingConvertedFounderStock</Role>
      <ShortName>Equity-Based Compensation - Summary of Restricted Stock Activity, Including Converted Founder Stock (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>125 - Disclosure - Equity-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationAdditionalInformation</Role>
      <ShortName>Equity-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>126 - Disclosure - Equity-Based Compensation - Summary of Weighted Average Assumptions Used to Compute Fair Value of Option Granted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToComputeFairValueOfOptionGranted</Role>
      <ShortName>Equity-Based Compensation - Summary of Weighted Average Assumptions Used to Compute Fair Value of Option Granted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>127 - Disclosure - Equity-Based Compensation - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivity</Role>
      <ShortName>Equity-Based Compensation - Summary of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>128 - Disclosure - Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/DisclosureLossPerShareScheduleOfBasicAndDilutedNetLossPerShare</Role>
      <ShortName>Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>129 - Disclosure - Loss Per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/DisclosureLossPerShareAdditionalInformation</Role>
      <ShortName>Loss Per Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>130 - Disclosure - Loss Per Share - Potential Dilutive Securities Excluded from Computation of Diluted Net Loss Per Common Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShare</Role>
      <ShortName>Loss Per Share - Potential Dilutive Securities Excluded from Computation of Diluted Net Loss Per Common Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ntla-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>131 - Disclosure - Related Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation</Role>
      <ShortName>Related Party Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ntla-20170331.xml</File>
    <File>ntla-20170331.xsd</File>
    <File>ntla-20170331_cal.xml</File>
    <File>ntla-20170331_def.xml</File>
    <File>ntla-20170331_lab.xml</File>
    <File>ntla-20170331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>48
<FILENAME>0001193125-17-154107-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-17-154107-xbrl.zip
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M5;$#H#5*<^&MK3>*E:G.LH"HJM+RQ@&]:MC&]@A3+-M4@8441S=$S>C9HJV
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MDN%=Z/][1CATP)8P2'F9RUA[]]/)2Y2_)W> +@E@SM-@H]D?8)/YH1<.?2\
M0L+$,R9Z5]YTQC>(2X8$6UTL/&"@K9CX] XUX$;@?C^@W9PH]^&K^ >>ID'L
M IOCC"W8'91)$SPR$Y_Q%CZ;?S_U'O'+-G,&P.NK[C6H7QSU%BS%!2J)'!M\
MOY7.[[ 52ANS )'= H$O9VVLFEY3YWI4KSMA[.I!>4$'C*>VFC)WN/O@&:\^
M:*8^R-2OIRW(7IK!R-K*7A>E4W.=QH8%[?_JAH:*>VSI<Q.E\]V.]I]&<&I
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ML:9RA^Z2<S8:"R%YR!FY>(C\@-?N_?NHQ+#YC]VOE]=77]]UO<06!Q[. A/
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M%)9)E)SM:3'14S#<KD$QJ(B_SP*J(W2N(P XX3YBU4P V(@$H$/P%S(>PPZ
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M,FP9A#U@$_VO?O)G/R;D$CV5L*H3:Z$O80M]2;8/U$)_&?3[S73@)>?(;%E
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MF<W-,%M,"F= 54(_(\HD*FC$\3$X%C#6"09JZN[A>'/6S7$C *43KFZ#8_(
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M=C #VYB%\^Y>#CMV9L\  H2]_P%02P,$%     @ U86B2IVW]E4^#   -&T
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MJ>8,OF)5_73RI%CLH:1G*>_B4P.5M%94-S(3"C*82D5$127=N&?Z&#S[>"0
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MB0AG>O";V#5V.-.^Z>$H#B?6S?'<)71*-LAM.&[0*"PE7E/C1PU,8U-E=4J
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M3XQ?1< K12D)-1C&( C9!:39RUEJQ&8!-H/4WA#&[[X04U+JJT ]=GEL'/L
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MT/ LKW(,;L.-$&L)M1P/<]WK';:%Y_I'ZVQ^H+@^_R71',GR3SO%LG(2A 3
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M3_S6HE%6F31OA3E@5USYH$V![88F'B>-F<)OQUZQ<J]$R;6*#N.C/(&8=-3
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M"!S4*=$W!E5FF?@(_GQ0&E^!1$/ (P9RE)ZJ20D@JF( I";8H6EXKNA)FH.
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M $D3?5C@[\0+!)07K_@BK@A;'F26V_FQ:B_O0G[I%V";(KP>N;4N[ F$\=T
M=\@U] ;#-B/5&A%F8<S52R:$ZT>N],Z0O)$^#F%5^8% F1KL!?[+*5)ES4*W
M9\AM#.P&[-9[K4?HS5B&'F*4BXORR^816])(/$:ML_I!+PW=O.NE\ONST*/
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M#?WG7J/B*R)GPR35('D?4 %Z8_E _2TQ_;N.76YHX)BM-M'$J!&?WUVLF.6
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M29?H*5JOK6!;&.TI0B!$C\#V5Q[\#3C3,*LHNY15=JT0B*EM!Q%P;MXVP$,
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MMV=#^A@JEQL+GY X#_Q7B-'ZLB5Y7N^\;']*TIW"1H-A+UWIB75$?6BH^N+
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M MN=Z=$EI%$35$%-#R'1JV8AL*J/[BJD9YB5;V3[M,D-SG 2K==6L"4@8?$
M[3!] 1L[U&[QG'8C$L3CRO?P3DQ></H1>6L1/]K4D=(@8XG8?>O51SHGG@FO
MZ?N0!F-+QT:'H_H7;(9?MGF1U,_LAQ4X\4P@W@5!1-F8A2\@6+Q8WHS.5?1
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MV$O-V(#/XBB)3$GSHS*+G(^:,#4^$KNP:E%<?04US_1X->T 8FF:QD>;;=*
M2C)< -K]K;]!F"7F/FXOA)9+[3+P%3P!&VM5(03HYLUV(]S5+08\CF=*29HM
M=^X&\->U[VF[(9AB!AQQ\G>D]-J//-9A5TW;.LX&'2G_LJUO@)=&LL<>#Q!!
MED5*>?/#P:8Q65)CM='^)4F[24G_OGDP1(]/WV22_U7JZ$T"V'%)BV4"5-*)
MU@1C_>],I?1,C:+*]#.7ZHVL&5UIY<OTZV?1_9*3X:(J'4VUS76!3"AKA9EV
M YG+>=4[END"M)\=7J$8Y>^)QAJH#V9\-)G!M9F8$J_>N16$VX*1#0W&"V9J
MVT3Q0(_ !O"5C'J!9#RR5U% )AWK&"M86\O)O/!V;>HY#QCL_)?B6'!/6;*M
M*/&AN;("^.Q'M835%%#3IVLA-+W(KD2IEL6A@%-<(3V7<O34%]<Q^R@]B8V=
M:PFJ*:B%7M_%A/F!101[8=)S%T=#)1U\7"?C_PA>@<<,VUHMI8/27X ' LO%
M0F7JK*$'B99*<"2)$#S$HKRIE@Y.[J%-^L8T)2DC$1]]=GDEDN/!?R6[#[KS
M4 C#* 3D;?(7Z'\%#K0M%Y\F =:H7NX\FRU.I-O0XU7'<E]A>M8Q*VBEGPIK
M,<J+197,EJ*&1N[O8$@DV.S9A2NJE&'-U28JXJK6@56BMAZ[<DX>=Q>J*:@<
MW=D/++K0"]R(0UI713>.!:6OZ6:KL=J >&E*U=)8;4B\?-D6OW"N:B4:T'0O
M1/<9\EX$;Y&NOR'BA:\A\.OHO1<2@UOL^D>F+2U<@P"?@+^4]URN.LVKH<=;
M',-()D_QC,+SJF:6'WW=U?%%,E?/EH73%F=$ZLMJO<QH9Y4I.W#SCZJF!T=A
MFQ8ROUJN,<?TJ"3"^#",2Z9'H.#C([1][2\LA!Z(V.>F? J5;;2= F:9@8B\
MW<7TP#NBQ\:R WN=4<1TMQ 9I,0,"Z9[A;296PW'R4Z>(8-^*=@%M$8[?:>G
M)<;!)FU4[106W-"%RK/LFQZ]NPU>\F^A6X37-A0[SNV=Z8&NV\ E[#!C>@SJ
M-N#MW,Z;'@1:]+*EWBE5REQNNN^I_%U/6?7=/;^:CEBG>Q<6>$W0'Y&/;4=4
M.=<K*8CCU&P"D7$;D@)X.0+8;FW?'U.\DL:+SM+U4XWYW/2=A'OG6-*.9:_W
MC TS\>"' "W\6^A9G@TM-YMC:!:L+ _^1CN\PE#X+G3BP?2<>8&8V;*F<OZT
M8(%I^^+B2:CCV4 G'AH\C=2TK>-J7OG(]@!073<Z18O2F5041>H'8W^7,(.1
M54]PY<$EM"TL\F/#!S&N82AMB&OHE$"[Y#2(%4X%+>Y)8L@RW)/$*FMU]&D<
MG])92!"-<0DRH$E_&)=BFYP./PH4!7A4(B^.'H<H?=OXOTV+4KJ9PUF>\@@=
MX4*]M6! \^;DRH/>+;*.H(:5R:VB8VWR015G8ABK3F1$BNNN@?MQD941H48N
M+5M@1M84(4!<22U"F3/S'DF,A"!)DB(^<T6;&<J25")6#FE!"H_S$:[1](I\
M;FW)@B2>4[8=1)AG:#U#ET8,&8@=JRVI7+U6NC4MCV]C&E%*I.4V+6)>#9UK
M6("3.@<.Z2$?5[(H5OKVX9YFM9X@FCM04UP;;4/B#1S0JI6!Y0@7*NM-W$"V
M61GRZF>U3 L'=_6SWPLQDRYYI";6$<H%X6S3Q4S=>JU6:A)D5P,^=6M42R2K
MCD/7$0A&JV:E3N^,\2A29#'3=S88!4M5E<ZB1,<//_)1*W(R=2DM='=^!+:_
MPALYYH0^L*'LB1](5/>G%[UZ\NN"E4]_6 $^Y6 =!2:>F.*8J>EEB$@58I,C
MI> (-#P4/!*!0(>N2#:Q,<>K :%H'?_6&IL.G9BUW?<H^4Q_H-_G8"@2I*:_
M^-_/$'212*:GEMC_(A#9(_>7VG(P9Y"== 4Z#18'G3:-":08\</0%&12OG X
M/L+#/!,-?<?T0UY.ZO*OB%_RJ>I(LRFBFLC'0M F<8KB'+N29Q^YU@Y%=+5&
MR_3#B9Z47SI.'H/9.%BOC@=RX7P,0<[%+\]E6AABB _>>I9"1[.&]_,9(9\<
M#O$?_P]02P$"% ,4    " #5A:)*UD,]4A]K  !9K00 $0
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M+3(P,3<P,S,Q7VQA8BYX;6Q02P$"% ,4    " #5A:)*R%?*WI\@   53P(
M%0              @ %JU   ;G1L82TR,#$W,#,S,5]P<F4N>&UL4$L%!@
0   &  8 B@$  #SU      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
